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ABSTRACT 
 
Background: Current diagnostic, prognostic and risk stratification tools are inadequate for 
effective ischaemic stroke management. Hypothesising that –omics approaches can be used to 
detect novel candidate biomarkers for ischaemic stroke, this thesis aimed to evaluate the 
current status of biomarkers for ischaemic stroke and develop strategies for biomarker 
discovery. 
 
Methods: Systematic literature review and individual patient data meta-analyses were 
performed to assess current candidate biomarkers associated with ischaemic stroke. Proteomic 
SELDI-TOF MS profiling was undertaken to identify novel blood-based protein biomarkers for 
the diagnosis of acute ischaemic stroke, consisting of a pilot study and a subsequent well-
powered discovery study of 104 patients. In an integrative genomics study, transcriptomics data 
from carotid endarterectomy samples was combined with a genome-wide association study 
meta-analysis and subjected to functional enrichment analysis to detect differential gene 
expression or alternative splicing profiles that may be under the control of a genetic variant. 
 
Results: Systematic review and meta-analysis concluded that no current candidate biomarkers 
could be recommended for routine clinical practice, supporting the pursuit of novel biomarkers 
for ischaemic stroke and informing the design of subsequent experimental studies. SELDI-TOF 
MS detected two plasma protein ions, m/z 3699 and m/z 6640, which could differentiate 
between acute cerebral ischaemia and stroke mimics. Protein ion m/z 6640, identified as 
ApoC-1, highlighted the role of lipid dysregulation and was postulated to be a novel candidate 
biomarker for acute cerebral ischaemia. Integrative genomics provided evidence for the genetic 
regulation of cytoskeletal organisation and extracellular matrix remodelling processes in 
carotid disease. The LTBP4 gene was found to be a candidate risk biomarker for ischaemic 
stroke by predicting plaque instability and rupture. 
 
Conclusions: This work provides workflows for successful biomarker discovery using 
innovative –omics approaches, highlights key pathogenic pathways and identifies novel 
candidate biomarkers for ischaemic stroke diagnosis and risk stratification.  
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1.1 The Burden of Vascular Disease and Stroke 
In 2001, the United Nations Millennium Development Goals were established to tackle many of 
our greatest global development challenges. However it took another 10 years, following a 
historic United Nations High-Level Meeting in September 2011, for non-communicable diseases 
(NCDs) to receive international recognition as major targets for future sustainable development 
goals. Four main NCDs - cardiovascular disease (CVD), cancer, chronic respiratory diseases and 
diabetes – were responsible for two-thirds of global deaths in 2008.  
 
The term ‘cardiovascular disease’ encompasses a family of vascular diseases, including 
cerebrovascular disease, coronary artery disease and peripheral artery disease. Stroke 
(cerebrovascular disease) is the second leading cause of death worldwide after ischaemic heart 
disease, and the major cause of disability in adults (Mukherjee & Patil 2011). With accelerating 
global trends in consumption, urbanisation and life expectancy, the burden of stroke is set to 
soar, and it is predicted that by 2030, the global prevalence of stroke will reach 77 million 
(Strong et al. 2007), with the financial cost of stroke projected to more than double (Ovbiagele 
et al. 2013). Contrary to common belief, CVDs are not only ‘diseases of affluence’, and over 85% 
of stroke deaths occurr in low and middle income countries; from 1970 to 2008, there has been 
a 42% decrease in stroke incidence in high-income countries, while low and middle income 
countries have experienced a 100% increase (Feigin et al. 2009). This population is more 
exposed to vascular disease risk factors, with less accessibility to treatment, diagnosis and 
prevention strategies than those in high income countries.  
 
In the UK, over 150,000 people suffer from a stroke every year. Studies report an incidence of 
around 1.62/1000/year (Rothwell et al., 2004), costing the NHS over £2.8 billion (National 
Audit Office 2005). Stroke has a greater disability impact than any other chronic disease, with 
20-30% of stroke patients dying within one month, another 30% left with a long-term disability, 
and 12% requiring institutional care within one year (Adamson et al. 2004). The Department of 
Health recognised the importance of developing better stroke services by launching the 
National Stroke Strategy in December 2007, with the aim of reducing the death rate from stroke, 
coronary heart disease and related diseases in people under 75 years of age by 40% by 2010 
(National Stroke Strategy Report 2007). Subsequent initiatives have seen stroke incidence and 
mortality fall in recent years; however, morbidity and prevalence rates have increased (Lee et 
al. 2011). Hence there is further scope to improve risk stratification of high risk individuals and 
develop patient management to enhance diagnosis and prognosis following stroke. 
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1.2 Stroke Aetiology and Classification 
According to the Multinational Monitoring of Trends and Determinants in Cardiovascular 
Disease (MONICA) project, stroke is defined as “rapidly developed clinical signs of focal or 
global disturbance of cerebral function lasting more than 24 hours (unless interrupted by 
surgery or death), with no apparent cause other than a vascular origin. It includes patients 
presenting with clinical signs and symptoms suggestive of subarachnoid haemorrhage, 
intracerebral haemorrhage or cerebral ischaemic necrosis. It does not include transient cerebral 
ischaemia or stroke events in cases of blood disease, brain tumour or brain metastases” (World 
Health Organisation MONICA Project 1990). 
 
Stroke is classified on the basis of its aetiology as either ischaemic (80%) or haemorrhagic 
(20%). Ischaemic stroke is caused by occlusion of a cerebral artery through thrombosis (50%) 
or embolism (25%), while haemorrhagic stroke (intracerebral and/or subarachnoid 
haemorrhage) is caused by spontaneous rupture of a cerebrospinal artery (Warlow et al. 2003). 
Despite the two types sharing similar risk profiles (Michel & Bogousslavsky 2006), they exhibit 
distinct molecular mechanisms in the acute phase (Kleinig & Vink 2009; Wang et al. 2007; Wang 
& Doré 2007; Xi et al. 2006). 
 
 
1.2.1 Ischaemic Stroke Subtypes 
Ischaemic stroke is not just one disease, but rather consists of a collection of entities with a 
common final outcome. The heterogeneity and diversity associated with this complex syndrome 
can be captured by various subtype classifications. Prognosis and risk of recurrence differs 
between different subtypes of ischaemic stroke, hence classification according to aetiology 
provides an insight into the mechanisms underlying the stroke and allows informed decisions to 
be made about patient treatment and management.  
 
A number of classification systems have been proposed for ischaemic stroke: the Oxford 
Community Stroke Project (OCSP) classification (Bamford et al. 1991), the Atherosclerosis, 
Small Vessel Disease, Cardiac Source, Other Cause (A-S-C-O) classification (Amarenco et al. 
2009), the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification (Adams et al. 
1993) and the Causative Classification of Stroke System (CCS) (Ay et al. 2007). These can be 
divided into systems focussing upon phenotyic subtyping (OCSP, A-S-C-O), causative subtyping 
(TOAST) or both (CCS).  
 
The OCSP system is based upon clinical symptoms alone (or in combination with Computed 
Tomography (CT) scan findings), and hence does not rely on the availability of imaging 
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modalities. The classification denotes four subtypes of acute cerebral infarction: Total Anterior 
Circulation Infarcts (TACI), Partial Anterior Circulation Infarcts (PACI), Posterior Circulation 
Infarcts (POCI) and Lacunar Circulation Infarcts (LACI). Stroke subtype is further coded by 
adding a final letter ‘I’ for infarct (e.g. TACI), ‘H’ for haemorrhage (e.g. TACH) or ‘S’ for 
syndrome, prior to imaging (e.g. TACS). The anterior cerebral circulation supplies blood to the 
anterior portion of the brain, and comprises the internal carotid arteries, anterior cerebral 
arteries, anterior communicating artery and middle cerebral arteries. The posterior cerebral 
circulation supplies blood to the posterior region of the brain, including occipital lobes, 
cerebellum and brainstem, and comprises the vertebral arteries, basilar artery, posterior 
cerebral artery and posterior communicating artery. Lacunar infarcts occur in the brain’s deep 
structures and are caused by occlusion of penetrating arteries arising from the Circle of Willis, 
cerebellar arteries and basilar artery (Figure 1.1). 
 
Due to its simplicity and ability to relate the infarct to anatomical and pathophysiological 
processes, the OCSP system is often used in clinical practice and large-scale observational 
studies, in particular for the rapid identification of patients eligible for thrombolysis treatment. 
The four subtypes can be used to determine the area of the brain affected by stroke, and predict 
the extent of the stroke consequent prognosis. However, the classifications are limited by their 
inability to investigate causes and potential risk factors of stroke (Chen et al. 2012).  
 
 
Figure 1.1: A schematic illustration of intra- and extra-cranial arterial circulation. The supra-aortic extracranial 
anatomy (internal and common carotid arteries) is depicted in (A), while the intracranial anatomy (anterior, middle 
and posterior cerebral arteries), containing the Circle of Willis, is depicted in (B), highlighting the anterior circulation 
derived from the internal carotid arteries and the posterior circulation derived from the vertebral arteries.  
Atherosclerosis of these major extracranial and intracranial arteries is the cause of Large Artery Atherosclerosis 
(LAA) ischaemic strokes. CCA, common carotid artery; ECA, external carotid artery; ICA, internal carotid artery. 
Image modified with permission from Dr. Joseph Shalhoub. 
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The OCSP exhibits a close relationship to the TOAST classification (Qui  2008), which has 
become the most widely accepted system to date. The five TOAST subtypes are based upon 
aetiology, as follows: 
 
Large-Artery Atherosclerosis (LAA): Approximately 20% of all ischaemic strokes are caused by 
atherosclerosis affecting the major extracranial (internal and common carotid arteries) and 
intracranial (anterior, middle and posterior cerebral arteries) blood vessels (Figure 1.1), with 
the ratio of extracranial to intracranial lesions being more than 2:1. Prolonged low bloodflow 
due to hypotension caused by stenosis, or acute plaque rupture in these arteries causes a 
decrease in cerebral perfusion, resulting in ischaemia and focal neurological deficits.  
  
Cardioembolism (CE): In a further 30% of ischaemic stroke cases, turbulent or stagnant 
bloodflow in the heart (e.g. due to atrial fibrillation) can result in the formation of thrombi that 
can dislodge and occlude blood vessels downstream, thus affecting the blood supply to the 
brain. 
 
Small Artery Occlusion (SAO): Alterations in the structure of small perforating arteries in the 
brain (exacerbated by e.g. chronic hypertension, hyperlipidaemia, smoking and diabetes) can 
lead to decreased compliance, intraluminal stenosis and eventual occlusion. These arterial 
modifications often lead to small lacunar infarcts (<15 mm3), typically located in deep brain 
structures such as the thalamus and brainstem. 
 
Stroke of Other Determined Cause (SOC): While the majority of ischaemic strokes can be 
classified into the three categories above, some cases require further investigation, especially in 
young patients and those who present with no apparent risk factors for ischaemic stroke. These 
rarer causes include genetic disorders (e.g. CADASIL), coagulopathies and metabolic disorders. 
 
Stroke of Undetermined Cause (SUC): In just under 40% of ischaemic stroke cases, there is no 
obvious cause for stroke, despite extensive investigation. Comprehensive diagnosis and 
classification of these so called ‘cryptogenic’ strokes would greatly aid clinical evaluation of 
their management and prognosis. 
 
The criteria used in TOAST have been recently upgraded in the CCS classification, in which 
cardioembolic, lacunar and cryptogenic strokes have been further subcategorised (Arsava et al. 
2010). CCS and TOAST classifications demonstrate very high agreement with each other, 
indicating that either system is valuable for stroke subtyping for epidemiological and genetic 
studies (Lanfranconi & Markus 2012). Nonetheless, CCS has the advantage of being able to 
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provide both phenotypic and causative information by relying on five sources of data: clinical 
evaluation, brain imaging, extracranial and intracranial vascular survey, heart evaluations, and 
work-up for uncommon causes of stroke. Thus, advances in technology and the availability of 
these technologies within a clinical environment have driven ever more precise and refined 
diagnosis and classifications of ischaemic stroke subytypes. 
 
 
1.2.2 Transient Ischaemic Attack 
Studies suggest that 7-40% of patients presenting with ischaemic stroke have a pre-warning in 
the form of a transient ischaemic attack (TIA). TIAs are acute episodes of neurological 
dysfunction resulting from focal cerebral ischemia, with symptoms lasting less than 24 hours 
(Easton et al. 2009). Accurate estimates of TIA prevalence and incidence are difficult to 
determine due to varying criteria used to identify TIA and a general lack of recognition due to 
challenges in diagnosis. TIAs are often mistaken as stroke mimics (e.g. focal seizures) and 
diagnosis depends largely on reliable patient history rather than symptoms or brain imaging 
(Warlow et al. 2003).  
 
TIAs are defined under the assumption that the ischaemic event occurs rapidly enough to cause 
only transient symptoms that resolve within 24 hours and leave no permanent brain injury. 
This 24-hour criterion was based on the fact that a syndrome lasting longer than this would be 
detectable by microscopy, in an era when almost no neuro-diagnostic techniques or treatment 
for brain ischaemia were available. However, subsequent clinical, experimental and imaging 
data have suggested that the 24-hour definition of TIA is outdated, does not consider the 
possibility of brain injury and fails to inform clinicians on appropriate patient management. In 
light of this a tissue-based, rather than time-based, definition has been proposed, with which the 
difference between TIA and ischaemic stroke becomes similar to the distinction made between 
angina (which may be brief or prolonged) and myocardial infarction (Albers  2002). 
Nonetheless, consensus for a new definition is still pending, and the detection and diagnosis of 
TIA remains unreliable. 
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1.3 Stroke Pathophysiology 
The brain’s response to acute ischaemia is dependent upon the severity and duration of cerebral 
blood flow (CBF) interruption. The region with CBF lower than 10ml/100g of tissue/min is 
referred to as the ischaemic core, and these cells are assumed to die within minutes of stroke 
onset. The region with CBF of up to 10ml/100g of tissue/min is termed the ischaemic 
penumbra. This area consists of marginal perfusion and potentially salvageable tissue, and is 
therefore the target for therapeutic reversal of the acute neurological symptomology arising 
from stroke.  
 
On the molecular level, decrease in CBF causes depletion of oxygen and glucose and subsequent 
energy failure, leading to dysregulation of membrane Na+, Ca2+, Cl- and K+ ion gradients and 
neuron depolarisation. The resulting increase in intracellular Ca2+ drives the upregulation of 
kinases, proteases and lipases. Subsequent release of glutamate, dopamine and free radicals 
causes lipid peroxidation, membrane disruption, DNA damage and inflammation, eventually 
leading to neuronal death (Muthaian et al. 2012; Dirnagl et al. 1999).  These processes are 
illustrated in Figure 1.2. 
 
 The blood brain barrier (BBB) plays a key role in stroke pathophysiology, and is considered by 
many to be an important therapeutic target (Borlongan et al. 2012). The neurovascular unit of 
the BBB, consisting of the basal lamina, endothelial cells, pericytes and astrocytic endfeet, 
contributes to the selective permeability of the barrier. During an acute ischaemic insult the 
neurovascular units (and endothelial tight junctions in particular) are disrupted through a 
number of mechanisms including oxidative stress and a cytokine-mediated inflammatory 
response (Ronaldson & Davis 2012), resulting in a release of brain-derived proteins across the 
BBB and into the bloodstream (Borlongan et al. 2012). 
 
Although the ischaemic penumbra can be observed for up to 16 hours after stroke onset (Furlan 
et al. 1996), safe and effective thrombolysis treatment is still limited to a 4.5 hour time window 
(Del Zoppo et al. 2009). Given that loss of BBB integrity can be considered a precursor to 
haemorrhagic transformation (Kastrup et al. 2008), understanding BBB damage occurring 
within the approved thrombolysis time window can carry substantial prognostic information 
and help determine the decision to treat or not (Liu et al. 2012).  
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Figure 1.2: Flow-chart depicting the pathophysiology of ischaemic stroke. Energy failure and dysregulation of 
ion gradients leads to neuronal depolarisation, oedema and inflammation, eventually causing cell death.  
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1.4 Risk Factors for Stroke 
A number of factors have been shown to be associated with an increased risk of ischaemic 
stroke, supported by many epidemiological and experimental studies. The INTERSTROKE study, 
consisting of 3000 stroke cases and 3000 controls from 22 countries worldwide, reported that 5 
factors (hypertension, current smoking, abdominal obesity, diet, and physical activity) 
accounted for more than 80% of the global risk of stroke (ischaemic and haemorrhagic). The 
addition of another five factors (diabetes, heart disease, alcohol consumption, high cholesterol 
and stress or depressive symptoms) increased the population-attributable risk to 90.3% 
(O’Donnell et al. 2010). It is also important to appreciate the complex interaction between 
classic risk factors and socioeconomic factors, which can account for as much as 68% of the 
variation in standardised stroke mortality rates (Asplund 2005). 
 
Risk factors are often classified as non-modifiable (e.g. age, gender, race, family history) or 
modifiable (e.g. diet, exercise). Additionally, some clinical conditions have been linked to a 
higher risk of stroke.  
 
 
1.4.1 Non-Modifiable Risk Factors 
Age, gender, race and family history are non-modifiable factors that have become important for 
identifying individuals at greater risk at stroke, thus allowing a more targeted approach for 
addressing modifiable risk factors in this high risk population.  
 
1.4.1.1 Age and Gender 
Approximately a quarter of stroke victims in the UK are under the age of 65 (Intercollegiate 
Stroke Working Party 2012). However, stroke incidence rises rapidly with increasing age, and 
the Framingham Study found that stroke rate more than doubles in both men and women for 
each successive decade after age 55 (Brown et al. 1996). Stroke incidence is approximately 25% 
higher in men than in women. Nonetheless, stroke mortality rate is higher in women than men 
(10% compared to 7%) (Townsend 2012). 
  
1.4.1.2 Genetics and Family History 
Stroke is sometimes overlooked as a genetic disease, often considered to be a sporadic event. 
Clinical practice traditionally focuses upon modifiable risk factors, which account for a 
substantial proportion of stroke risk. However, much of stroke risk remains unexplained and it 
is still unclear why some individuals with risk factors develop stroke while others with a similar 
risk profile do not.  Thus it is likely that there is an intricate network of interaction between 
these clinical aspects and genetic risk factors.  
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The heritability of a trait refers to the proportion of total phenotypic variation within a 
population that can be attributed to genetic factors. Using genome-wide complex  trait analysis 
(GCTA) to estimate heritability by assessing the proportion of variation in case–control status 
explained by genotyped single nucleotide polymorphisms (SNPs), the genetic heritability of 
ischaemic stroke has been recently estimated to be 37.9%, with heritability varying by stroke 
subtype (40.3% for large-vessel disease, 16.1% for small-vessel disease) (Bevan et al. 2012). 
Intermediate phenotypes of ischaemic stroke also exhibit substantial heritability: the 
heritability of carotid intima-media thicknening (cIMT) is thought to be greater than for carotid 
stenosis (h2=0.61 versus h2=0.47 respectively), and considering cIMT as a covariate for stenosis 
results in a heritability estimate of h2=0.26, suggesting that genes affecting stenosis and cIMT 
regulate about half of the heritability of stenosis, while independent genes may regulate the 
other half (Moskau et al. 2005). 
 
A small proportion of ischaemic strokes are monogenic, and identifying mutations in these 
causal genes (e.g. the NOTCH3 gene in CADASIL disease) provides diagnostic and prognostic 
information, specific treatment and enables counselling of other family members (Markus 
2011). The vast majority of ischaemic strokes seem to be polygenic, with multiple genes 
conferring small risk of disease. Identification of these genetic factors could improve risk 
profiling in a non-symptomatic population. An integrated model combining common genetic 
variants and traditional risk factors could more effectively discriminate patients likely to 
develop ischaemic events (Pezzini et al. 2009). 
 
A five-fold increase in stroke prevalence between monozygotic and dizygotic twins (Brass et al. 
1992) and the impact of parental history on progeny developing stroke (Seshadri et al. 2010) 
lends convincing evidence for the role of genetic susceptibility in stroke onset (Markus 2011). 
Linkage analysis has been a very popular method for detecting genes of major effect in 
monogenic disorders, with these genes being relatively rare, relatively isolated to the disease 
population, and inherited in a Mendelian fashion. Linkage studies commonly examine large 
families where the disease affects individuals in several generations, with the aim of identifying 
a genetic marker that is always inherited by family members with the disease but not by those 
who do not have the disease.  
 
In complex traits, linkage analysis can be more problematic because it may be difficult to 
develop a model that adequately explains the inheritance pattern. In these situations, the 
inheritance patterns of groups of loci (rather than individual loci) can be examined, and linkage 
can be established on a subset of a pedigree (rather than a pedigree as a whole)(Lander & 
Schork 1994). Factors such as complex inheritance, incomplete penetrance, locus heterogeneity 
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can be incorporated into an optimised model to improve statistical power and the quality of a 
study (Bush & Haines 2010). Linkage studies investigating the co-segregation of ischaemic 
stroke with genetic markers within family members have largely been unsuccessful for 
elucidating the genetic determinants of complex traits such as ischaemic stroke. Geneological 
data available from the deCODE group in Iceland implicated two genes for ischaemic stroke 
susceptibility: STRK1, coding for phosphodiesterase 4D, and ALOX5P, encoding 5-lipoqxygenase 
activating protein (Gretarsdottir et al. 2003; Helgadottir et al. 2004). However, these findings 
have failed to be replicated independently (Markus 2011). Importantly, they also indicate that 
the ischaemic stroke is a complex genetic disorder, rather than a monogenic disease (although 
monogenic forms e.g. CADASIL, Fabry Disease, do exist), requiring the examination of many 
genes that make small contributions to disease aetiology. 
 
Given the limited success of linkage studies, until recently the mainstay for stroke genetics 
research, as with many complex diseases, has been the candidate gene association approach.  
These association studies test whether a particular genetic marker and trait occur more often 
than expected by chance alone, and are ideal for investigating complex disorders such as 
ischaemic stroke, which do not have a clear pattern of inheritance and are therefore not 
amenable to linkage analysis to determine their genetic basis. Therefore a number of genetic 
loci, each with small overall effect, can be explored. Association studies also have the advantage 
of relying on historical recombination events which can be examined in whole populations, as 
compared to linkage studies that are dependent upon pedigree information. As association 
analysis assumes that individuals are unrelated or have little population structure, any 
significant marker-trait associations can be mapped to fine genetic resolution within the 
kilobase range, rather than in the centimorgan range, as with linkage analysis. 
 
To date, candidate genes have been investigated in pathways involved primarily in 
inflammation, endothelial function, homocysteine metabolism, hyperlidaemia and coagulation 
pathways. The most consistent associations found include methylenetetrahydrofolate reductase 
(MTHFR), angiotensin-converting enzyme (ACE), prothrombin and factor V Leiden (Bentley et 
al. 2010), but results from most candidate gene studies have been difficult to replicate due to 
small sample sizes, phenotype heterogeneity and publication bias in literature-based meta-
analyses. Genome wide association studies (GWAS) represent a hypothesis-free approach that 
uses markers across the entire genome to examine association. Compared to linkage studies and 
candidate gene-based association studies, GWAS provide a more powerful strategy for detecting 
common variants with relatively small effects sizes by investigating very large population 
cohorts. The GWAS strategy is discussed in more detail in Section 1.10. 
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1.4.2 Modifiable Risk Factors 
Modifiable lifestyle risk factors have become key targets for primary and secondary stroke 
prevention. 
 
Smoking doubles the risk of stroke, and is particularly dangerous in combination with 
hypertension. It has been shown that smoking causes an immediate rise in blood pressure, 
while nicotine and other toxic by-products found in tobacco cause irreversible blood vessel 
damage (Shinton & Beevers 1989). 
 
High-lipid diets can increase blood cholesterol levels and obesity can increase risk of stroke by 
64% (Strazzullo et al. 2010), with central obesity (abdominal deposition of fat) being 
particularly related to the occurrence of atherosclerotic disease. Low density lipoproteins (LDL) 
and triglycerides can cause atherosclerotic plaque build-up, while high-density lipoproteins 
(HDL) can have a protective influence on extracranial carotid atherosclerosis (Heiss et al. 1991). 
Additionally, the INTERSTROKE study recently examined the association of apolipoproteins 
with stroke risk, concluding that the reduction in risk of ischaemic stroke conferred by HDL and 
apolipoprotein A-1 (ApoA-1) was larger than the risk associated with increased levels of 
apolipoprotein B (ApoB) or non-HDL cholesterol (O’Donnell et al. 2010). Exercise exerts a 
beneficial influence on risk factors for the atherosclerotic disease by raising HDL cholesterol 
and lowering LDL cholesterol and reducing blood pressure and weight. It has also been shown 
to delay the onset of diabetes by altering DNA methylation and increasing the expression of 
genes involved in glucose regulation (Barres et al. 2012). 
 
 
1.4.3 Clinical Risk Factors 
 
1.4.3.1 Diabetes and Hypertension 
Diabetics have double the risk of stroke than non-diabetics, in part due to the fact that diabetes 
is also associated with the presence of other risk factors such as obesity, high cholesterol levels 
and hypertension (Emerging Risk Factors Collaboration et al. 2010). Hypertension is the most 
common modifiable risk factor for stroke, and both incidence and mortality increase at a blood 
pressure of >100/75mmHg. Furthermore, visit-to-visit variability in systolic blood pressure is a 
strong predictor of ischemic stroke independent of mean blood pressure (Rothwell 2010). The 
presence of hypertension has been found to predict the severity of carotid atherosclerosis 
through mechanisms including endothelial dysfunction, shear stress and increased smooth 
muscle proliferation, as well as exposing plaques to a greater risk of rupture (Beaussier et al. 
CHAPTER ONE: INTRODUCTION 
31 
2008). Patients with well controlled blood pressure (<120/80 mm Hg) have approximately half 
the lifetime risk for stroke in comparison to patients with hypertension (Mancia 2010).  
 
1.4.3.2 Transient Ischaemic Attack 
Population studies and randomised trials have demonstrated that 17% of TIAs occur on the day 
of stroke, 9% on the previous day and 43% at some point 7 days prior to stroke presentation 
(Rothwell & Warlow 2005). Given the high early risk of ischaemic stroke associated with TIA, 
tools such as the ABCD and subsequent ABCD2 score have been developed for use in primary 
and emergency care settings to aid the prediction of stroke risk in the acute phase of TIA. The 
ABCD2 score assesses patients based upon the following criteria: age (≥60yrs), blood pressure 
(≥140/90mm Hg on first evaluation), clinical symptoms (speech disturbance with/without 
unilateral weakness), duration (10 to 59 minutes, >60 minutes) and presence of diabetes. 
Incorporation of brain imaging findings into this model, in an updated ABCD2I score, increases 
its predictive power, improving the area under the curve (AUC) from 0.66 with the ABCD2 score 
alone to 0.78 in the combined model (Giles et al. 2010). Thus there is growing appreciation that 
effective diagnosis and management of TIA offers valuable opportunity to initiate treatment and 
stall the probable onset of ischaemic stroke and the associated brain injury and disability. 
 
1.4.3.3 Heart Disease 
Atherosclerosis is typically a systematic disease, and similar mechanisms underlie the 
formation of atheromatous lesions throughout the arterial tree. Stroke and myocardial 
infarction (MI) share a number of risk factors, and it has been shown that a family of stroke or 
MI is associated with a considerably increased prevalence of many risk factors in the proband 
(Kennedy et al. 2012). Subsequently, the same nine risk factors assessed in the INTERHEART 
study for risk of MI also predict risk of stroke in the INTERSTROKE study, despite a few 
differences (e.g. the ratio of apolipoprotein B to apolipoprotein A-1 was found to be the most 
important risk factor for MI, while hypertension was found to be the most important cause of 
stroke; Yusuf et al. 2004; O’Donnell et al. 2010).  
 
1.4.3.4 Carotid Stenosis  
Large artery stenosis accounts for around 20% of all ischaemic strokes (Grau et al. 2001). 
Carotid atherosclerosis leading to amaurosis fugax, TIA or ischaemic stroke is termed 
symptomatic, whereas atherosclerotic arterial narrowing without an ischaemic event is termed 
asymptomatic carotid stenosis. 
 
Carotid artery atherosclerosis is a chronic process that shares similar risk factors to ischaemic 
stroke, including age, diabetes, hyperlipidaemia, hypertension and history of smoking. Meta-
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analysis on the prevalence of carotid artery stenosis in the general population established that 
around 2% of individuals aged 60-69 years have asymptomatic carotid stenosis in which the 
degree of lumen narrowing exceeds 50%; this proportion increases to 7.5% in men and 5.0% in 
women aged of 80 years or older (de Weerd et al. 2010). In asymptomatic patients with >50% 
carotid artery stenosis, the annual risk of stroke has been estimated to be 1-4.3% (Inzitari et al. 
2000; Nicolaides et al. 2005). Risk of stroke increases in those with progressive carotid artery 
stenosis (Inzitari et al. 2000), and progression to 80-99% stenosis or occlusion is more likely in 
patients whose initial stenosis is >50% (Johnson et al. 1995). 
 
Pathophysiology of Carotid Atherosclerosis 
The carotid artery is composed of three layers: the tunica intima, tunica media and tunica 
adventitia (Figure 1.3). The endothelial cells of the tunica intima play a key role in vascular 
permeability, platelet aggregation and resistance to thrombosis, and the ability of the 
endothelium to adapt and repair itself has a substantial impact upon the development of 
atherosclerosis. In response to physical or metabolic stress, changes in the expression of cell 
adhesion molecules (e.g. VCAM-1, ICAM-1) and other surface receptors causes endothelial 
cytoskeletal rearrangement and an increase in cell permeability. Subsequent platelet adhesion 
and migration of circulating cells beyond the endothelium induces smooth muscle cell 
proliferation within the tunica media as well as alterations of the extracellular matrix 
composition and organisation within this layer. The secretion of pro-inflammatory cytokines 
from the endothelium and formerly circulating cells attracts monocytes, T cells and 
macrophages (Hall & Bassiouny 2012). In particular, the aggregation of foam cells (lipoprotein-
rich macrophages) beneath the endothelial layer results in ‘fatty streaks’, which are the first 
visible lesions in the development of atherosclerosis. Further thickening of the tunica intima 
and tunica media is termed carotid intima-media thickening (cIMT), and mean cIMT (although 
not cIMT progression) has been shown to be associated with an increased risk of MI and 
ischaemic stroke (Lorenz et al. 2012). 
 
The progression of these early stages of carotid atherosclerosis into atheromatous plaque 
depends upon a number of metabolic, haemodynamic, environmental and genetic risk factors. 
Smooth muscle cell migration into the tunica intima and perpetuation of an immunological 
response within the arterial wall leads to the formation of a fibrous cap and the development of 
an atheroma, which is an active lesion producing cytokines and undergoing constant 
remodelling. Growth of the atheroma into the lumen initially leads to dilation of the artery to 
compensate for the reduction in luminal diameter (Glagovian remodelling) (Hall & Bassiouny 
2012). However, this adaptation fails with continued encroachment of the lumen beyond 40-
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50%, and further progression of the plaque can lead to focal arterial stenosis and potential 
occlusion.  
 
The Vulnerable Plaque 
It has been shown that incidence of cerebral ischaemic events is correlated with plaque 
morphology and composition, regardless of the degree of luminal stenosis (Yuan et al. 2001; 
Rothwell et al. 1996), thus promoting the concept of the ‘vulnerable’ or ‘high-risk’ plaque. 
Plaque vulnerability was first mentioned by Muller & Tofler (1992) to describe an 
atherosclerotic plaque that is vulnerable to rupture and subsequently cause an ischaemic event. 
Following the pioneering works of Virmani et al. (2000), Redgrave et al. (2008) and Naghavi et 
al. (2003a, 2003b), vulnerable carotid plaques are commonly characterised as follows: a thin 
fibrous cap of <200µm with an extensive loss of smooth muscle cells and extracellular matrix 
within the cap, overlying a large necrotic/lipid core that often comprises intraplaque 
haemorrhage, calcification and neovasculisation (Pelisek et al. 2012). 
 
Inflammation has been noted as a crucial driving force behind plaque progression and 
instability. The majority of plaques are vascularised by a network of small vessels originating 
from the vaso vasorum of the tunica adventitia (Figure 1.3). Along with the formation of these 
neovessels (angiogenesis), the growth and widening of existing vessels (arteriogenesis) and 
progressive permeability of these vessels can allow inflammatory cells to pass the endothelium 
and accumulate within the plaque. A developing plaque contains mainly monocytes and 
macrophages, as well as other inflammatory cells such as T and B cells that secrete a plethora of 
inflammatory cytokines. Additionally, the presence of neutrophils within unstable lesions has 
been correlated with the site of plaque rupture. The secretion of proteolytic enzymes from these 
cells degrades the extracellular matrix and modulates inflammatory responses within the 
plaque (Naruko et al. 2002). Degradation of the extracellular matrix, in particular in the fibrous 
area overlying the lipid core (precipitating a thin fibrous cap), is the key mechanism 
propagating plaque destabilisation and lesion vulnerability. The process is largely mediated by 
matrix metalloproteinases (MMPs), which at first instigate intimal thickening but later lead to 
the production of new extracellular matrix products and extracellular matrix degradation 
(Pelisek et al. 2012).  
 
While local factors such as sheer stress and vessel or plaque anatomy play an important role in 
plaque stability, there is strong evidence to suggest that systemic processes such as infection, 
autoimmunity and genetics are involved. Examination of patients with symptomatic carotid 
stenosis in the European Carotid Surgery trial (ECST) found that patients with plaque surface 
irregularity in one carotid artery were more likely than would be expected by chance to have an 
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irregular plaque in the other carotid artery and more likely than patients with smooth plaques 
to die as a consequence of myocardial infarction and other non-stroke vascular disorders 
(Rothwell et al. 2000). The grouping of unstable plaques within certain individuals reinforces 
the hypothesis that genetic factors can influence plaque progression and instability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Schematic illustration of the various layers of the carotid arterial wall. The tunica intima is 
comprised of a monolayer of endothelial cells. Smooth muscle cells are found in the tunica media, and a network of 
small blood vessels comprising the vaso vasorum are located in the tunica adventitia. 
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1.5 Clinical Evaluation of Ischaemic Stroke 
Risk prediction for stroke and other cardiovascular diseases has recently become a priority in 
public health policy, and future screening strategies will play an important role for primary 
prevention (discussed in Hasan 2013). Furthermore, a correct diagnosis of stroke impacts the 
admittance of a patient to a medical ward or stroke unit and the decision to administer 
thrombolysis, while assessment of prognosis is important for deciding whether to start the 
patient on medication to reduce the risk of future CVD events, and whether to consider nursing 
home care or a period of rehabilitation. 
 
The clinical evaluation of ischaemic stroke risk, diagnosis and prognosis, and the associated 
challenges, are outlined below. 
 
 
1.5.1 Risk Stratification 
Risk stratification and prevention can be implemented on either a primary or secondary level. 
Primary prevention aims to prevent a first event of stroke or TIA by detecting and managing 
people with risk factors but no recognised disease. For those with known cerebrovascular 
disease, secondary prevention aims to reduce the risk for subsequent vascular events by 
treating CVD and the associated risk factors. 
 
A recent statement from the American Heart Association and American Stroke Association 
emphasised the necessity for new policies for stroke to focus on primary prevention (Ovbiagele 
et al. 2013). In the UK, the NHS Health Check Putting Prevention First programme was 
introduced in 2009 as a high-risk screening policy for preventing CVD. This specified that all 
adults aged 40-74 years old should be screened for CVD risk, and those individuals found to 
exceed a 20% risk of a vascular event within the next decade should be treated with education 
on lifestyle choices as well as medication (anti-platelets such as aspirin, anti-coagulants such as 
warfarin, cholesterol reducing drugs such as statins or anti-hypertensives to lower blood 
pressure) as appropriate.. 
 
1.5.1.1 Assessment of Carotid Stenosis and Plaque Stability 
In addition to age, life expectancy and quality of life, both primary and secondary risk 
stratification of ischaemic stroke has focussed upon the assessment of carotid artery disease.  
 
A multicentre natural history study, the Asymptomatic Carotid Stenosis and Risk of Stroke 
(ACRS) study, was conducted to identify patients with asymptomatic carotid stenosis at high 
risk of stroke, and confirmed the relationship between cerebral ischaemic events and the degree 
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of carotid stenosis (Nicolaides et al. 2005). While treatment of carotid artery stenosis by 
stenting or endarterectomy (CEA) substantially reduces stroke risk, it is also accompanied by 
surgery-related morbidity and mortality (Doig & Brown 2012). As the Asymptomatic Carotid 
Surgery Trial (ACST) highlighted, there is a need to identify a high-risk subgroup of 
asymptomatic individuals that would benefit from intervention (Halliday et al. 2010).  
 
The identification of vulnerable carotid plaques that can predict symptomatic cerebrovascular 
events has been the subject of much research and accurate, non-invasive methods that predict 
plaque progression and instability remain an unmet clinical need. Effective prediction of 
individuals at high risk of ischaemic stroke or TIA could offer personalised patient management, 
aid in the decision to intervene via carotid stenting or endarterectomy (Doig & Brown 2012) 
and provide a new surrogate endpoint for plaque stabilising therapies. Risk stratification will 
most likely rely on a combination of clinical parameters, carotid artery imaging and molecular 
tests to provide comprehensive assessment of both stenosis and plaque stability. 
 
The main structural predictor of ischaemic stroke is the degree of luminal stenosis, as assessed 
in the ECST and NASCET trials (European Carotid Surgery Trialists’ Collaborative Group [ECST] 
1991; North American Symptomatic Carotid Endarterectomy Trial Collaborators [NASCET] 
1991). Both trials imaged carotid arteries using conventional angiography, first with 
conventional radiographic film and later with digital subtraction angiography. However, 
substantial differences have been reported between the NASCET and ECST angiographic 
methods, such that 50% stenosis by NASCET is equivalent to approximately 70% stenosis by 
ECST. Less invasive carotid-imaging techniques, such as CT and MR angiography, and Doppler 
ultrasound are now more commonly used. Doppler ultrasound records sound waves to assess 
speed of blood flow through the artery. Peak systolic velocity and the ratio between internal 
carotid artery peak systolic velocity and common carotid artery end diastolic velocity are used 
to estimate % stenosis per NASCET method, although Doppler velocity measurements are 
known to overestimate or underestimate stenosis in certain situations (Oates et al. 2009).  
 
The lack of reliable correlation between the widely used non-invasive carotid artery imaging 
modalities and the invasive catheter angiography used in NASCET and ECST upon which 
degrees of stenosis are defined makes assessment of carotid stenosis alone inadequate for 
determining surgical intervention. Furthermore, it belittles the role of plaque characteristics 
and stability in causing the ischaemic event (Ahmed et al. 2010). Plaque imaging techniques 
including ultrasound, positron emission tomography, MRI and multidetector CT angiography 
can characterise vulnerable carotid plaque features (inflammation, intraplaque haemorrhage, 
fibrous cap thickness, large lipid-rich necrotic core) as well as luminal stenosis. In addition, 
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diagnostic methods such as thermography, spectroscopy or molecular imaging, capable of 
detecting plaque physiology, would help to identify lesions of instability based upon activity, 
rather than morphology and stenosis alone (Naghavi et al. 2003a). However, at present the 
efficacy and reliability of these modalities remains unclear. 
 
 
1.5.2 Diagnosis 
Stroke diagnosis and its likely prognosis are commonly determined by clinicians with an 
assessment of the clinical features of the presenting syndrome, the patient’s history and brain 
imaging. The rapid development of pathophysiology means that prompt diagnosis of ischaemic 
stroke is critical for preventing large-scale brain damage. Early intervention is crucial, with 
approximately 2 million neurons lost per minute after stroke onset (Saver 2006). 
 
A diagnosis of ischaemic, rather than haemorrhagic, stroke appropriates the administration of 
thrombolysis, anticoagulants such as heparin to prevent recurrent cardiac embolism in patients 
with atrial fibrillation, anti-platelets such as aspirin to prevent recurrent vascular events and 
carotid artery imaging to examine stenosis. In an age of interventional stroke therapies, 
identifying stroke mimics (disorders that have a presentation resembling AIS or TIA) is also 
necessary to avoid potential adverse effects. Common stroke mimics include seizures, sepsis, 
syncope, brain tumours and metabolic disorders, and can account for up to a third of patients 
with stroke-like symptoms (Hand et al. 2006). Differentiating between stroke mimics and 
ischaemic events is becoming increasingly important, especially between stroke mimics and 
TIAs, which carry their own diagnostic challenges, as discussed earlier 
 
1.5.2.1 Clinical Scales 
At present, stroke diagnosis is made upon probability rather than certainty, and initial 
assessment of stroke patients is mostly performed by paramedics or triage nurses rather than 
stroke specialists who could make a more accurate analysis of symptoms and imaging results. 
With this in mind, a number of clinical scales have been developed to aid non-specialists. In the 
UK, the Stroke Association’s Act FAST (Face Arm Speech Test) is reported to have a positive 
predictive value (the likelihood that a patient testing positive actually has stroke) of 78% when 
used by ambulance staff (Harbison et al. 2003). The ROSIER (Recognition of Stroke in the 
Emergency Room Scale) scale, designed for emergency department staff, consists of a 7 item 
scoring system based on asymmetrical facial, arm or leg weakness, speech disturbance, visual 
field defect, evidence of syncope and seizure.  
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1.5.2.2 Brain Imaging 
Brain imaging has become a fundamental tool in stroke diagnosis. Due to its accessibility and 
speed, CT has been the mainstay of stroke imaging. Although CT imaging is able to exclude 
haemorrhagic stroke with near 100% sensitivity, less experienced observers are liable to 
overlook haemorrhage or mistake non-pathological calcification as blood (Schriger et al. 1998). 
Furthermore, CT imaging can often present as normal in acute stages of AIS, and 50% of infarcts 
never become visible on CT (Warlow et al. 2003). Thus it is assumed by deduction, rather than 
certainty, that if a stroke symptom is not caused by haemorrhage it is likely to be caused by 
ischaemic stroke, even if the CT does not detect a lesion. A recent meta-analysis of seven studies 
estimated that CT had a sensitivity of 39% (95% CI, 16% - 69%) and specificity of 100% (95% 
CI, 94% – 100%) for AIS. In contrast, the summary estimates for diffusion weighted magnetic 
resonance imaging (DW-MRI) showed a sensitivity of 99% (95% CI, 23% – 100%) and 
specificity of 92% (95% CI, 83% – 97%) (Brazzelli et al. 2009). Thus DW-MRI is a more reliable 
tool for diagnosis, but has the disadvantage of being expensive and unavailable in most 
emergency departments. Furthermore, there are many cases where the clinical diagnosis is 
certain and the MRI is negative, as well as the converse, so MRI is an inadequate diagnostic gold 
standard for acute ischaemic stroke (Jensen et al. 2008). Both CT and MRI are disadvantaged by 
the fact that their implementation and interpretation expends considerable time and effort. 
Whichever imaging method is used, radiologists require knowledge of the time and date of 
stroke in order to interpret the images correctly. 
 
1.5.2.3 Laboratory Tests 
In patients presenting with sudden onset focal neurological deficit, point of care testing consists 
of a basic metabolic panel test (glucose, calcium, sodium, potassium, chloride, bicarbonate, 
blood urea nitrogen and creatinine), complete blood count, cardiac enzymes and coagulation 
studies. Once the patient has stablilised, lipid panel and haemoglobin A1C testing can be used to 
identify risk factors. Further testing e.g. to assess for a hypercoagulable state or genetic, 
metabolic or inflammatory disturbances may be performed if aetiology remains uncertain. 
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1.5.3 Prognosis 
Around 30% of stroke patients die within a year of stroke, and nearly half of survivors are left 
dependent (Warlow et al. 2003). Reliable predictions about stroke outcome can guide decisions 
about medical treatment and patient management as well as allowing assessment of the 
performance of stroke services.  
 
Just as cardiologists have learnt that the most important criteria for determining the prognosis 
of myocardial infarction are the nature, location and severity of coronary artery disease, so the 
cause of brain ischaemia (cardiac, small or large vessel) determines stroke outcome and 
treatment. In clinical practice, the evaluation of stroke prognosis is usually based upon the 
judgement of the assessing doctor. However, evidence has shown that clinicians are often over-
optimistic about recovery, with only 65% of patients who are predicted to recover gaining 
independence by one year after stroke (Counsell et al. 2004). 
 
1.5.3.1 Outcome Scales 
In order to provide clinicians with more accurate prognostic information, a number of outcome 
scales have been devised. The most widely used clinical scale is the National Institute of Health 
Stroke Scale (NIHSS), consisting of a 15-item assessment of consciousness, gaze, vision, facial 
palsy, arm and leg strength, limb ataxia, sensory loss, neglect, dysarthria, and aphasia. The 
modified Rankin Scale (mRS) is commonly used to assess disability and dependence in the 
months following stroke, consisting of a 6-point scale from 0-5: patients with no impairment 
receive a score of 0, while patients with severe disability who are bed ridden and require 
constant nursing care and attention receive a score of 5 and death is rated as 6. Similarly, the 
Barthel index scale measures performance in activities of daily living, using 10 items including 
feeding, bathing and dressing and mobility to score a patient’s independence out of a total of 
100 points. Models based upon a number of variables such as age, arm power, independence 
before stroke, verbal ability and mobility can also provide reliable estimates of stroke prognosis 
(Counsell et al. 2002). 
 
1.5.4 Prognosis after Thrombolysis 
Prognostic tools can also be used to identify patients most likely to benefit from early 
therapeutic intervention. The aim of thrombolytic therapy is to break down the thrombus 
associated with AIS, providing reperfusion before permanent tissue damage. Intravenous 
recombinant tissue plasminogen activator (rt-PA) has revolutionised acute stroke management 
since approval by the US Food and Drug Administration (FDA) in 1996, and is the standard 
thrombolysing agent used in the US, Canada, Australia and European Union. Its arrival has 
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demonstrated that acute ischaemic stroke is treatable, and furthermore that reperfusion can 
dramatically improve patient prognosis.  
 
Although rt-PA is the only FDA-approved therapy specifically directed at acute ischemic stroke, 
there are a number of issues and controversies surrounding its use (Riggs 1996). Whilst 50% of 
patients receiving intravenous rt-PA achieve complete or partial recanalisation of the middle 
cerebral artery, a third of these patients also experience neurological worsening or delayed 
ischaemic injury (Grotta et al. 2001; Kidwell et al. 2002; Moldes et al. 2008). Additionally, intra-
cerebral haemorrhage (ICH) represents one of the most dangerous complications associated 
with thrombolytic therapy. These risks have greatly narrowed the number of patients being 
administered rtPA, therefore prediction of outcome following thrombolysis will aid clinicians to 
administer therapy successfully and greatly improve the number of patients receiving 
treatment.  
 
 
 
 
1.6 Use of Biomarkers for Improving Patient Management 
A biomarker has been formally defined as “a biological characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (Biomarkers Definitions Working 
Group 2001). The FDA states that an ideal biomarker should be highly sensitive (very few false 
negatives) and specific (very few false positives), predictive, able to bridge preclinical and 
clinical trials and be easily measurable. The interest in the applications of biomarkers has 
increased greatly in recent years and they are now considered to be one of the cornerstones of 
the modern drug discovery process in both preclinical and clinical studies (Feuerstein & Chavez 
2009).  
 
In several disorders, the delineation of biomarkers from normal biology causes them to be 
either newly expressed or increase or decrease in response to pathological stimuli. Thus, 
biomarkers can be effective indicators of disease mechanisms and progression. They have the 
potential to serve as diagnostic tools, prognostic aids for risk stratification and therapeutic 
intervention targets (Figure 1.4). 
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Figure 1.4: Pathway of disease progression and potential impact of biomarkers. Biomarkers can be utilised at 
many different stages of disease progression, to aid with risk stratification, diagnosis and prognosis. Image modified 
from Mayeux (2004). 
 
 
 
1.6.1 Specimen Selection  
Biomarker measurements can be made directly on biological samples (e.g. blood, tissue, urine) 
or via imaging to detect changes in the brain. Specimen selection is a critical process in 
biomarker discovery and is largely dependent upon the aim of the study in question. If the aim 
is to discover circulating biomarkers of disease, blood samples can be studied; if the aim is to 
elucidate biomarkers for the mechanisms of disease progression, tissue extracts may be 
preferred. Microdialysis for continuous sampling of the interstitial fluid of tissues is another 
technique that has predominantly been used in neurointensive care for monitoring the progress 
of brain ischaemia. 
 
Plasma and serum profiles are very interesting from a clinical point of view as they are able 
provide data about the physiological state of different tissues within the body, their relative 
merits being subject to debate (Rai et al. 2005). Plasma is obtained from the centrifugation of 
blood collected in an anticoagulant solution. On the contrary, serum is obtained after 
coagulation. The formation of a clot of activated leukocytes and platelets causes the release of 
proteins that can lead to considerable differences between plasma and serum profiles (Blanco-
Colio et al. 2006). The complexity and large concentration ranges of proteins within these 
samples present substantial analytical challenges. 
 
Disruption of the blood-brain barrier during stroke causes the release of brain-derived 
molecules into the bloodstream, but the variability of perfusion through the disrupted area 
could mean that biomarker levels become substantially altered in plasma and serum levels long 
after management decisions need to be made. The cerebral spinal fluid (CSF) is derived from the 
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choroid plexus, blood vessels of the arachnoid and the ependymal lining of the ventricular 
system and glial membrane (You et al. 2005), and is therefore a good reflection of biochemical 
changes occurring within the nervous system.  
 
However, CSF sample collection by lumbar puncture is invasive and entails a number of 
complications, with potential blood contamination during collection altering protein profiles 
and hindering the accurate identification of biomarkers (You et al. 2005). Furthermore, the 
composition of normal CSF differs considerably from the composition of extracellular fluids in 
the brain, including microdialysate (Hamberger et al. 1990). A number of studies have shown a 
lack of correlation between biomarker levels in the CSF and serum (Petzold et al. 2008). This 
could be due to the time taken for molecules to enter the blood following stroke onset, or 
differences in the biological half-life of some proteins and metabolites between CSF and blood. 
CSF proteins are generally less abundant than their corresponding plasma and serum 
counterparts, necessitating the use of more sensitive analytical techniques. Consequently, 
potential biomarkers identified from either fluid need to be treated with caution until their 
validity can be confirmed in the other.  
 
In the context of stroke biomarker research, brain tissue or atherosclerotic plaque samples 
arguably have the advantage of being the most useful for preliminary detection of potential 
disease-specific markers (Blanco-Colio et al. 2006). Tissue samples represent an ideal medium 
for investigating the tissue-specific mechanisms underlying ischaemic stroke e.g. for risk 
biomarkers of carotid plaque rupture, or mechanistic biomarkers of ischaemia-related changes 
within the brain. However the collection of these samples is difficult and obtaining samples 
from a healthy comparison group is often impractical. In contrast, plasma and serum samples 
are more convenient to collect and can be used practically for non-invasive, point-of-care 
diagnostic biomarker tests.  
 
 
1.6.2 Multi-Marker Tests 
The clinical utility of a biomarker is defined by its ability for classification, namely its sensitivity 
and specificity. Disorders such as stroke are complex and multi-factorial, therefore a single 
biomarker is may not have adequate sensitivity and specificity for a clinical test. Combination of 
markers in a ‘signature fingerprint’ for disease, constituting a multi-marker test, has shown to 
increase the power of discrimination between study populations (Gillette et al. 2005; Woolas et 
al. 1995). A number of studies have attempted this approach in stroke biomarker research (e.g. 
Laskowitz et al. 2005; Montaner et al. 2005; Reynolds et al. 2003; Tuttolomondo et al. 2008), but 
thus far none have been suitably successful.  
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1.7 Approaches for Biomarker Discovery 
Biomedical research to date has been largely candidate-driven, with experiments being 
designed to test whether a hypothesis is true or false. These hypothesis-based, directed studies 
have been successful in identifying a number of important biomarkers for disease, for example 
troponins for the detection of cardiac injury (Babuin & Jaffe 2005), and CD340 as a prognostic 
biomarker and anti-cancer therapy target in breast cancer (Luftner et al. 2003; Baselga et al. 
1998). The majority of biomarkers implicated in stroke thus far have also been identified using 
these candidate-based approaches.  
 
Although candidate-based approaches have yielded much information about individual 
components of a system, they have been less successful at providing an integrated 
understanding of the structure and dynamics of the complete gene or protein system being 
studied, and the compensatory responses of the system to perturbations (Alawieh et al. 2012). 
In 1928, the physicist Niels Bohr suggested that a particular experiment can only reveal a 
certain kind of information; other information that is equally important cannot be measured 
simultaneously and is lost. His student Max Delbrück applied this ‘principle of complementarity’ 
to biology, proposing that the function of molecules such as proteins can only be fully 
understood when they are studied at a whole system level, taking into account their interaction 
with other biological molecules.  
 
The sequencing of the human genome and recent advances in high-throughput technology have 
created a paradigm shift in molecular biology and laid the foundations for the development 
of -omics approaches that can interrogate entire gene, RNA or protein systems. This new 
approach aims to better map the functionality of complex biological systems for insights into the 
pathophysiology of disease, increasing diagnostic, prognostic and disease-monitoring potential 
for clinical applications (Dominiczak et al. 2010). Thus proteomic, transcriptomic and genomic 
technologies provide new platforms for unbiased hypothesis testing in biomarker discovery 
(Figure 1.5). 
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1.7.1 Data Handling for Biomarker Discovery 
While –omics-based approaches have significant scientific potential, the difficulty lies in 
extracting valuable biological information from the mass of data generated, and translating this 
into clinically useful biomarker tests. The experiments collect large amounts of data in the 
absence of hypotheses concerning particular candidate molecules, therefore, they must be well 
designed in order to take advantage of statistics for data interpretation and maximise the 
likelihood of new discoveries and new testable hypotheses. Indeed, the results of any -omics 
study is largely dependent upon the quality of the data used for analysis and the statistical 
approaches employed (Tworoger & Hankinson 2006). 
 
Dimensionality reduction is often performed in order to reduce ‘noise’ that can confuse 
downstream analysis, and facilitates the use of conventional statistical approaches that are 
often limited by the number of variables that can be examined. This can be performed by 
selecting variables that provide the most statistically significant differences between study 
groups (through use of e.g. Student’s t-test or analysis of variance), or by clustering variables 
that correlate with each other (through use of e.g. principal components analysis).  
 
The association between a biomarker and disease is traditionally assessed by epidemiologists 
using regression analysis to calculate effect size (e.g. odds ratio or standardised mean 
difference). While individual primary studies provide information about the research question 
being studied, results may be conflicting and therefore it becomes difficult to draw firm 
conclusions about the scientific progress made. A systematic literature review (qualitative 
analysis) can be conducted to gather all empirical evidence fitting pre-specified eligibility 
criteria in order to answer a specific research question e.g. the association of a biomarker with 
disease. Subsequent meta-analysis can be conducted to statistically combine results from two or 
more independent studies by calculating pooled effect sizes (e.g. pooled odds ratio, pooled 
standardised mean difference) to obtain a quantitative association between a biomarker and 
disease phenotype. Thus meta-analysis can establish the direction and size of the effect of 
association through increasing power and precision by combining all primary studies, answer 
questions not posed by individual primary studies, address controversies arising from 
conflicting  results of individual studies and generate new hypotheses. By using clear, 
systematic methods to minimise bias, literature review and meta-analysis therefore present a 
balanced summary of results to inform clinical practice and policy development (Higgins & 
Green 2011).  
 
While measures of association using odds ratios and standardised mean differences are useful, 
biomarkers proposed for discrimination of individual subjects can also be assessed for their 
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sensitivity and specificity. An ideal biomarker classification model yields 100% discrimination 
between study groups, but this is often unachievable in reality. The receiver operating 
characteristic (ROC) curve is able to describe the whole set of potential combinations of 
sensitivity and specificity for a continuous biomarker, thus enabling the selection of an optimum 
threshold value for discrimination between groups. While effect sizes calculated via regression 
analysis are interpreted per unit increase in the biomarker and therefore may not be 
comparable between biomarkers measured in different units, the ROC curve provides a natural 
common scale for comparing different biomarkers, regardless of the units of measurement 
(Cook 2007). The area under the curve (AUC) generated by ROC analysis is often used to assess 
the accuracy of a biomarker model, where an AUC of 1 represents 100% discrimination and 
values of 0.8 and above are deemed good (Pepe 2004). 
 
 
 
 
 
     
 
 
Figure 1.5: Summary of the main disciplines in systems biology. The genetic information contained within a 
genome can be investigated using genomics approaches e.g. GWAS. DNA sequences are converted into RNA via a 
process of transcription, with introns being spliced out and exons retained, in various combinations (alternative 
splicing). RNA gene expression and alternative splicing profiles can be interrogated using transcriptomics 
approaches. RNA sequences are converted into proteins via a process of translation. Quantification and 
characterisation of proteins can be achieved by proteomics approaches e.g. SELDI-TOF MS. GWAS, genome wide 
association study; SELDI-TOF MS, surface enhanced laser desorption ionisation time of flight mass spectrometry. 
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1.8 Proteomics  
The completion of the Human Genome Project showed that given the relatively small increase in 
genes through evolution, diversity in organisms is largely determined by protein regulation. 
While genomic and transcriptomic techniques have been successful in the discovery of 
countless biomarkers, they are limited in the amount of information they can provide about the 
molecular dynamics associated with acute neurological insults.  
 
The proteome can be defined as all the proteins present in a cell or organism at a given time, 
including those translated directly from genetic material as well as a spectrum of proteins 
arising from alternative splicing of RNA transcripts and post-translational processing (Arrell et 
al. 2001). Thus the major advantage of proteomics over gene based technologies is that it 
directly investigates the functional molecules and not the source code. Proteins commonly have 
short half-lives and are constantly synthesised and degraded as required, altering physiology 
via their interactions with protein and non-protein substrates and thus can providing 
information about the molecular dynamics associated with acute insults.  
 
Due to the dynamic nature of protein regulation, the study of the proteome can be technically 
very challenging. Proteomics aims to identify, characterise and understand these protein 
changes. Proteomic investigations can be divided into three distinct categories, depending upon 
the aim of the study. Structural proteomics aims to provide 3-dimensional information for all 
proteins within a cell or organelle. Expressional proteomics compares relative protein 
quantities between samples from different physiological states e.g. normal versus diseased, 
while functional proteomics aims to classify protein changes such as post-translational 
modification or protein-protein interaction occurring during certain biological conditions 
(Karvunidis et al. 2009).  
 
The presence of a large number of proteins in blood makes human plasma an excellent material 
for discovering biomarkers for potential clinical diagnostics and therapeutics. However, the 
complexity and large concentration ranges of proteins within plasma samples present major 
challenges for their analysis. A handful of highly abundant proteins, such as albumin, represent 
over 90% of the plasma proteome and can mask the detection of low-abundance proteins that 
are likely to be more valuable as clinical biomarkers (Anderson & Anderson 2002). 
Furthermore, the complete measured dynamic range of proteins spans more than 10 logs of 
molar abundance (Hortin & Sviridov 2010). As a result, affinity chromatography or membrane 
filtration is often performed before sample analysis, in order to deplete high-abundance 
proteins. Additionally, samples can undergo multiple fractionation steps in order to simplify the 
proteome and maximise protein separation and resolution. Physicochemical approaches to 
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fractionation include alcohol precipitation and ultracentrifugation, while methods exploiting 
specific protein characteristics, such as their inherent chemical properties e.g biospecificity, 
hydrophobicity or charge can also be utilised. Sample preparation is critical for accurate 
proteomics analysis (Tam et al. 2004). 
 
 
1.8.1 Methods for Proteomic Analysis 
With recent advances in separation techniques and mass spectrometry (MS), proteomic 
approaches have flourished and have allowed the unequivocal identification and quantification 
of molecules that could not have been detected by classical techniques such as immunoassays, 
making proteomics a promising approach for biomarker identification. 
 
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) has played an invaluable role 
in proteomics and has been a key method of protein identification in the majority of early 
proteomics investigations. Samples are spotted on separate gels, and proteins are resolved in 
two sequential steps: in the first dimension separation involves isoelectric focusing (IEF), by 
which proteins are focused by relative charge according to their inherent charge, or by 
isoelectric point (pI). Proteins are then resolved in the second dimension by their molecular 
weight. After separation, staining (e.g by Coomassie, zinc, silver staining, radiolabelling or 
fluorescence via 2D-DIGE) is carried out to analyse protein expression. Protein levels are 
compared between samples, then spots of interest can be excised, enzymatically digested, and 
the peptides are analysed using MS. Although 2D-PAGE technology has greatly improved in 
recent years, limitations of the technique still include a lack of sensitivity and dynamic detection 
range, slow throughput and low reproducibility.  
The substitution of 2D-PAGE with liquid chromatography based high-resolution MS has made 
proteomics a convincing approach to biomarker eludcidation. Mass spectrometry is now at the 
heart of nearly all proteomics experiments and offers unparalleled sensitivity for the 
investigation of protein profiles and provides the possibility of rapid detection of conditions 
such as acute ischaemic stroke, in which early diagnosis and intervention determines the 
prognosis of clinical outcome (White et al. 2006).  
MS consists of an ion source, a mass analyser that measures the mass to charge ratio (m/z) of 
the ionised analytes, and a detector that registers the number of ions at each m/z value. Gel-free 
techniques, unlike 2D-PAGE, allow the direct coupling of the LC system to the mass 
spectrometer so that the effluent from the column (separated species) can be detected and 
characterized by MS/MS. In the ‘top-down’ approach, intact protein isoforms can be isolated 
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before MS identification; in the ‘bottom-up’ approach, protein mixtures are enzymatically 
digested into complex peptide mixtures before being subjected to tandem MS. Electron spray 
ionisation (ESI) ionises the analytes out of a solution and is therefore easily coupled to liquid-
based separation tools such as high pressure liquid chromatography (HPLC), in which peptides 
are separated according to hydrophobicity. Subsequently, within the MS, ions with specific m/z 
ratios can be selected in a ‘trap’ for collision induced fragmentation. Fragmentation of the 
peptide ion, commonly at the peptide bond, produces the tandem mass spectrum from which an 
amino acid sequence for the peptide can be deduced (Guerrera & Kleiner 2005). 
Four basic types of mass analyser are currently used in proteomic research, each with their own 
advantages and disadvantages: the ion trap, the quadrupole, the Fourier transform and the 
time-of-flight (TOF) analysers (Aebersold & Mann 2003). Matrix-assisted laser 
desorption/ionisation (MALDI) and surface-enhanced laser desorption/ionisation (SELDI) 
technologies are both typically coupled to TOF analysers.  
 
1.8.1.1 SELDI-TOF Mass Spectrometry 
SELDI-TOF MS is an affinity-based technology first described by Hutchens and Yip in 1993 and 
developed into the ProteinChip system by Ciphergen Biosystem Inc (Fremont, CA, USA). It 
couples chromatographic separation using reactive surfaces with high-throughput mass 
spectrometry, encompassing two key subsets of MS technology: surface enhanced neat 
desorption and surface enhanced affinity capture (Hutchens & Yip 1993).  
 
The ProteinChip array distinguishes SELDI-TOF technology from other proteomics platforms, 
with chromatographic capture of proteins occurring on the same support as that used for laser 
desorption, hence simplifying the SELDI-TOF procedure and assisting automated analysis to 
increase reproducibility (Ciphergen Biosystems).  
SELDI-TOF MS is a variation of MALDI-TOF MS, with target surfaces to which the proteins and 
matrices are applied to being modified for various conditions such as anion exchange, cation 
exchange and pH. Thus classes of proteins can be fractionated on the chip prior to analysis. The 
combination of selective protein binding with quantitative mass detection makes SELDI-TOF MS 
a simple and attractive method for comparative protein analysis.  
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1.8.2 Proteomics and SELDI-TOF MS for Ischaemic Stroke Biomarker Discovery 
While several studies have employed immunoassays for the detection of diagnostic biomarkers 
for acute ischaemic stroke (Reynolds et al. 2003; Lynch et al. 2004; Laskowitz et al. 2009; 
Montaner et al. 2012), the use of proteomics technology in stroke research is relatively 
uncommon. To date, proteomics technology has been used in ischaemic stroke research to 
investigate brain tissue and cells (Cuadrado et al. 2009; Cuadrado et al. 2010; Brea et al. 2011), 
urine (Dawson et al. 2012), CSF (Zimmermann-Ivol et al. 2004; Lescuyer et al. 2004; Dayon et al. 
2008; Allard et al. 2005), microdialysate (Maurer et al. 2003; Dayon et al. 2011), plasma (Ning et 
al. 2010; Lopez et al. 2012) and serum (Huang et al. 2009). These studies have predominantly 
focussed upon diagnosis of acute ischaemic stroke against haemorrhagic stroke or healthy 
controls. Many investigations for stroke biomarkers have focussed upon CSF and microdialysate 
as these biofluids are considered to be less complex to work with; studies investigating blood 
have commonly employed have typically employed technically demanding methods of analysis, 
based upon fractionation, multiple stages of separation and mass spectrometry in order to 
expose meaningful proteomic data from the plasma or serum samples (Kodali et al. 2012; Lopez 
et al. 2012; Brea et al. 2009).  
 
Preliminary investigations into acute and chronic pathologies by the Lescuyer group identified 
13 potential proteins in post-mortem CSF for the diagnosis of ischaemia and neurodegeneration 
(Lescuyer et al. 2004). Subsequent studies confirmed that levels of PARK7, Nucleoside 
Diphosphate Kinase A (Allard et al. 2005) and Brain-Type and Heart-Type Fatty-Acid Binding 
Proteins (Wunderlich et al. 2005) are elevated in early serum and plasma samples from patients 
with stroke. Plasma validation of proteins expressed in post-mortem CSF demonstrated that 
ubiquitin fusion degradation protein, RNA-binding protein and nucleoside diphosphate kinase A 
have high specificity and sensitivity for ischaemic stroke in a cohort of over 600 patients (Allard 
2004). 
 
The data obtained from these studies demonstrate that proteins involved in ischaemic stroke 
pathogenesis can be detected using proteomic techniques. However, they are largely limited to 
media that are invasive and not amenable to rapid point of care testing (e.g. CSF, 
microdialysate), and complicated experimental techniques that can result in loss of proteomic 
information at each level of fractionation, separation and analysis. 
 
By combining fractionation and mass spectrometry in one platform, SELDI-TOF MS provides an 
ideal method for high-throughput analysis of complex plasma samples. Employing a proteomic 
approach using SELDI-TOF, 1D gel electrophoresis, nano LC-ESI-MS/MS and subsequent ELISA, 
Allard et al. (2004) categorised plasma proteins that could distinguish between acute ischaemic 
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and haemorrhagic stroke. The aim of the study was to identify a biomarker which could 
improve stroke management, and ideally fulfill the following criteria: be a) brain-specific, b) a 
plasmatic marker as these samples are easiest to obtain c) detectable as early as possible after 
symptom onset d) expressed proportionally to the extent of the lesion e) beneficial for 
prognosis f) able to distinguish ischaemic from haemorrhagic stroke. Analysis revealed that 
apolipoprotein C1 (ApoC-I) and apolipoprotein CIII (ApoC-III) could provide good predictive 
information of ischaemic versus haemorrhagic stroke (94% sensitivity and 73% specificity for 
ApoC-I and 94% sensitivity and 87% specificity for ApoC-III). Using SELDI-TOF MS and CM10 
ProteinChips to analyse plasma samples from acute ischaemic stroke patients and hospitalised 
controls, Zhang et al. (2008) detected 13 protein ions of significance, 10 of which were down-
regulated and 3 up-regulated in patients with acute ischaemic stroke. The authors concluded 
that a diagnostic test for would likely consist of a combination of biomarkers in a multi-marker 
model, reflecting the multi-factorial roles of inflammation, atherosclerosis, thrombosis, 
ischaemia and neurodegeneration in the pathogenesis of ischaemic stroke. In another study, 
Staals et al. (2008) investigated protein profiles of lacunar stroke patients with a single 
symptomatic lacunar lesion compared with those with multiple ‘silent’ lacunar lesions and 
extensive white matter lesions. They found that a 16kDa protein ion upon SELDI-TOF MS, 
identified as the alpha-2-chain of haptoglobin, was over-expressed in single symptomatic 
lacunar strokes, and speculated that the differences in alpha-1 or alpha-2 protein expression 
could be due to polymorphic differences between the study groups. Table 1.1 summarises the 
findings from these studies. 
 
To date none of the candidate biomarkers identified through SELDI-TOF MS analysis of blood 
samples have entered clinical practice for the diagnosis of ischaemic stroke. Nonetheless, the 
studies demonstrate that SELDI-TOF MS is an effective strategy for high-throughput blood 
proteome analysis.  
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Table 1.1: Summary of SELDI-TOF MS proteomics investigations of acute ischaemic stroke.  
 
 
 
 
1.9 Transcriptomics 
While most cells in the body contain the same genome, regardless of cell type or environmental 
conditions, the transcriptome (the complete set of RNA transcripts produced by the genome at 
any one time) is highly dynamic and varies under disease conditions or environmental stress. 
Transcriptomics, the study of the whole transcriptome, provides a strategy for exploring gene 
expression and the genetic mechanisms underlying disease pathogenesis.  
 
Transcription describes the creation of a complementary RNA molecule from a DNA sequence, 
and transcription of genes to produce messenger RNA (mRNA) is a primary step in gene 
expression. RNA is synthesised in a 5’ to 3’ direction by the enzyme RNA polymerase. The 
process is naturally modulated by the binding of regulatory proteins to DNA binding sites, as 
well as epigenetic regulation e.g. via DNA methylation, which affects chromatin folding and thus 
the accessibility of genes for transcription. There is also growing evidence that a vast proportion 
of the RNA manufactured from the human genome does not code for proteins; rather, many 
types of RNA molecules exist that are not intermediates between DNA and protein, as classically 
thought. In particular, microRNAs are non-coding RNAs known to control transcription and 
translation to decide a tissue-specific protein repertoire to actively regulate homeostasis, and 
have been implicated in plaque instability and stroke pathogenesis (Bidzhekov et al. 2012; 
Haver et al. 2010; Vemuganti 2010). 
 
Study Disease State Biological Sample Differentially Expressed Protein Ions 
Staals et al 2008 
First-Ever Lacunar Stroke: 
Single Symptomatic Lacunar 
vs. Multiple Additional ‘Silent’ 
Lacunar Lesions 
Serum Alpha-2-chain of Haptoglobin 
Zhang et al 2008 
AIS vs. Hospitalised Controls 
(Otorhinolaryngology 
Department) 
Plasma 
2.71kDa, 3.42kDa, 4.29kDa, 4.36kDa, 
6.71kDa, 6.99kDa, 8.46kDa, 8.53kDa, 
8.56kDa, 8.64kDa, 9.13kDa, 22.80kDa, 
24.36kDa 
Allard et al 2004 
AIS vs. ICH and Hospitalised 
Controls (Orthopedic 
Department) 
Plasma 
Apolipoprotein CI, Apolipoprotein CIII, 
Serum Amyloid A, Antithrombin-III 
Fragment 
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Following transcription and prior to being capped with a poly(A) tail at the 3’ end, eukaryotic 
RNA is commonly spliced to remove non-protein coding introns and stitch together exons in 
various combinations, creating splice variants that code for diverse protein isoforms (Figure 
1.5). While early estimates stated that around 100,000 genes were required to code a 
mammalian genome, the actual number is less than a quarter of this. Alternative splicing is now 
known to account for a much of this ‘missing information’ and plays a key role in regulating 
gene expression (Nilsen & Graveley 2010). It is estimated that over 90% of human genes 
express multiple RNA transcripts due to alternative RNA splicing (Wang et al. 2008), and these 
transcriptional isoforms can alter protein products associated with the manifestation of disease 
(Cline et al. 2005). 
 
 
1.9.1 Methods for Transcriptomic Analysis 
Gene expression can be measured by quantifying mRNA abundance. Northern blotting was first 
used to directly quantify steady-state levels of mRNA by electrophoresis and subsequent 
incubation with specific probes. Real-time quantitative polymerase chain reaction (qPCR) 
remains the most accurate method for quantifying specific nucleic acid targets and is commonly 
employed following reverse transcription of mRNA to complementary DNA (cDNA).  
 
Following the development of DNA microarrays in the mid-1990s, it is now possible to examine 
the genes spanning the entire human genome at once and investigate global gene expression 
patterns. A range of microarrays are available, including oligonucleotide and cDNA arrays, 
which predominantly utilise a 3’ hybridisation method.  
 
1.9.1.1 Affymetrix Human Exon Array 1.0 ST 
While standard 3’ microarrays measure only gene expression, recently introduced exon arrays 
can measure the expression of single exons within genes. The Affymetrix Human Exon 1.0 ST 
array allows the highest resolution of expression analysis, consisting of ~5.5 million probes 
clustered into 1.4 million probe sets and  covering around 80% of exons within the human 
genome. Approximately 4 probes per exon enable ‘exon-level’ analysis to distinguish between 
different isoforms of a gene and detection of alterations in exon usage (alternative splicing 
events). Additionally, the summarisation of probes (around 40 per gene) into an expression 
value for all transcripts allows ‘gene-level’ expression analysis. 
 
Input sequences and annotations to design the probes for exon arrays are selected from a 
variety of sources including the high quality human genome assembly, annotations inferred 
from human cDNAs and from a number of publicly available gene prediction sets e.g. Ensembl, 
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GENSCAN and Vega. This information is consolidated onto the genome and divided into probe 
selection regions that are contiguous and do not overlap in genomic space (Affymetrix 2006). 
Probes on the array are divided into three categories, according to their reliability: 1) ‘core’ 
probes derived from RefSeq transcripts or full-length mRNAs 2) ‘extended’ probes, derived from 
expressed sequence tag evidence and 3) ‘full’ probes, derived from computationally predicted 
exons.  
 
To estimate a reliable background signal, the exon array design consists of 40,000 mismatch 
probes (MM) for comparison with perfect match (PM) probes, binned according to their GC 
content in order to account for the effects of GC-richness on hybridization strengths. The 
background signal for a PM probe is estimated by calculating the median intensity of all 
background probes with the same GC content as the PM probe (Zimmermann & Leser 2010).  
 
The Affymetrix exon array differs from 3’ expression arrays in a number of ways to allow 
enhanced gene expression profiling. A higher coverage of more evenly distributed probes 
provides a more accurate measure of gene expression. While 3’ array probes hybridise to an 
anti-sense strand (commonly RNA), the Affymetrix exon array consists of a ‘Sense Target’ (ST) 
hybridisation design using random primers that attach to a cDNA sense strand. This avoids 
hybridisation bias resulting from targeting only the 3’ end of transcripts, many of which may 
lack poly-A tails and therefore do not bind to a 3’ array (Zimmermann & Leser 2010).  
 
 
1.9.2 Transcriptomics for Ischaemic Stroke Biomarker Discovery 
Several studies have employed large-scale gene expression platforms to determine genes 
associated with carotid stenosis and plaque instability (summarised in Table 1.2), and have 
implicated the involvement of inflammation, angiogenesis, deranged extracellular matrix and 
lipid metabolism, and iron haemostasis in carotid disease progression, as well as RNA splicing 
and processing factors.  Hence tissue-derived biomarkers based upon gene expression data can 
provide novel insights into the molecular mechanisms underlying carotid disease and plaque 
rupture. 
 
Comparing carotid plaques from the Biobank of Karolinska Endarterectomies (BiKE) to normal 
iliac artery tissue, Wang et al. (2012) found an up-regulation of IGFBP-1 and down-regulation of 
IGF-1, IGF-2 and IGFBP-3 to IGFBP-6 in carotid plaque samples. The expression IGFBP-1, 
involved in cell migration and proliferation, was co-localised with smooth muscle cells and 
macrophages and correlated with a number of inflammatory genes.  Di Taranto et al. (2012) 
also demonstrated a key role for inflammation, showing that genes involved in the eicosanoid 
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synthesis pathway were differentially expressed in carotid plaques as compared to normal 
artery samples. Investigating gene expression differences between unstable carotid plaques and 
normal mammary arteries, Martinet et al. (2002) used microarray analysis, 
immunohistochemistry and cell culture and found that LDL aggregation in unstable carotid 
plaques caused overexpression of DAP, a mediator of apoptotic cell death, in smooth muscle 
cells. This demonstrates the role of lipid-induced changes within the carotid plaque, causing 
instability and rupture. Korol et al. (2011) further implicated role of expression differences in 
genes involved with extracellular matrix remodelling in the loss of plaque stability.  
 
The studies above have investigated gene expression differences between carotid plaques and 
normal artery tissue. A number of studies have also explored differences between 
asymptomatic (stable) and symptomatic (unstable) carotid plaques, and have also found 
differential gene expression of genes involved in lipid metabolism, inflammation, extra-cellular 
matrix remodelling and RNA splicing (Vemuganti & Dempsey 2006; Saksi et al. 2011). Taking 
four symptomatic and four asymptomatic carotid plaque specimens, Dahl et al. (2007) revealed 
significant differential expression of 137 genes with fold difference of >2, and in a replication 
cohort of 21 more plaque samples the investigators demonstrate an increase in visfatin RNA 
and protein levels in symptomatic plaques, a finding that was further replicated at the site of 
coronary plaque rupture in samples from patients with acute coronary artery disease. More 
recently, Perisic et al. (2013) have used a novel approach using transcriptomic and tissue 
microarray profiling to demonstrate an increased expression of PCSK6 (proprotein convertase) 
in symptomatic carotid plaques that could be associated with inflammatory and extracellular 
matrix remodelling processes that lead to plaque rupture. In order to minimise inter-patient 
gene expression differences, studies have also investigated paired stable and unstable carotid 
plaque regions taken from the same patient. For example, Papaspyridonos et al. (2006) took 
paired stable and unstable plaque regions from 3 symptomatic individuals, and replicated 27 
genes found to be differentially expressed through microarray in a further set of 46 unstable 
and stable plaque regions. These investigations establish the utility of gene microarray 
technology for hypothesis-free interrogation of carotid plaque gene expression. Such studies are 
making progress at uncovering a ‘genetic fingerprint’ of vulnerable plaques, which can comprise 
a multi-marker risk-stratifying test for ischaemic stroke. 
 
Alternative splicing mechanisms have previously been implicated in carotid artery disease. 
Berglund et al. (2012) found that splicing of the AIF-1 gene results in the expression of two 
different proteins – AIF-1, whose overexpression leads to proliferation of vascular smooth 
muscle cells and a pro-inflammatory, unstable carotid plaque profile, and IRT-1, which plays an 
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opposite role. Smooth muscle cell proliferation has also been demonstrated to be promoted by 
expression of alternatively spliced ID3 gene (Forrest et al. 2004).  
 
These studies have used targeted approaches for understanding transcript diversity. In 
contrast, the Affymetrix Human Exon 1.0 ST Array provides a global view of both gene and exon 
expression profiles. In the field of stroke, to date this platform has only been utilised in humans 
to study angiographic vasospasm in patients with aneurysmal subarachnoid haemorrhage (Ko 
et al. 2011). Investigation of global gene expression and splicing processes using the Affymetrix 
Human Exon 1.0 ST Array could reveal novel mechanisms underlying carotid plaque 
progression and biomarkers for predicting risk of ischaemic stroke. 
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Table 1.2: Summary of microarray transcriptomics investigations of carotid artery disease. 
Study Disease State Platform Used  Summary of Findings 
 
Di Taranto et al 2012 
 
Carotid Stenosing Plaque 
vs Non-Stenosing Plaque 
Region vs Healthy Control 
 
TaqMan low-density 
array human 
inflammation panel 
 
Differential expression of 44 genes between 
diseased and non-diseased tissue, mostly involved 
in the eicosanoid synthesis pathway. 
Wang et al 2012 Carotid Stenosing Plaque 
vs Healthy Control 
Affymetrix HG 
U133A 2.0 Array 
UpreguIation of IGFBP-1 in carotid plaques 
compared with normal arteries, and 
downregulation of IGF-1, IGF-2 and IGFBP-3 to 
IGFBP-6. No signiﬁcant difference of the gene 
expression level of IGFBP-1 between symptomatic 
and asymptomatic plaques. 
Korol et al 2011 Unstable Carotid Plaque vs 
Healthy Control 
Affymetrix HG 
U133A v2 Array 
Upegulation of collagen I, III and IV, lysyl oxidase 
and MMP-1, 9 and 12 in unstable plaque 
Martinet et al 2002 Carotid Stenosing Plaque 
vs Healthy Control 
ClonTech Human 
Apoptosis Array 
Differential expression of apoptosis-related and 
housekeeping genes, in particular death-associated 
protein (DAP) kinase 
Perisic et al 2013 Symptomatic vs 
Asymptomatic Carotid 
Plaque 
Affymetrix  
HGU133plus 2.0 
Array 
Differential expression of genes involved in immune 
response, cell proliferation, adhesion and apoptosis, 
lipid metabolism, glucose transport and proteases 
(e.g. PCSK6) 
Saksi et al 2011 Symptomatic vs 
Asymptomatic Carotid 
Plaque 
Affymetrix HG 
U133A Array 
Differential expression of genes involved in 
inflammatory responses, intracellular lipid and 
carbohydrate metabolism and transport, lysosomal 
activity, and reorganization of the extracellular 
matrix. 
Agardh et al 2011 Symptomatic vs 
Asymptomatic Carotid 
Plaque 
Affymetrix HG 
U133A Array 
Upregulation of FABP4/aP2 in unstable plaques, 
correlated with differential expression of CD36, 
CD68, CD163, CD52 and adipophilin 
Dahl et al 2007 Symptomatic vs 
Asymptomatic Carotid 
Plaque 
Affymetrix HG 
U133A Array 
Differential expression of 136 genes, including 
visfatin 
Vemuganti et al 2006 Symptomatic vs 
Asymptomatic Carotid 
Plaque 
Affymetrix HG 
U133A Array 
Upregulation in symptomatic plaques of genes 
involved in ionic homeostasis, signal transduction 
and lipid metabolism, as well as angiogenesis 
promoters, transcription factors, and RNA splicing 
and processing factors 
Woodside et al 2003 Paired Stenosing vs Non-
Stenosising Carotid Plaque 
Atlas Human 
Apoptosis cDNA 
Expression Arrays 
Differential expression of genes involved in 
signalling pathways that alter cellular apoptotic 
patterns 
Ijas et al 2007 Paired Symptomatic vs 
Asymptomatic Carotid 
Plaque 
Affymetrix 
GeneChip U95A v2 
Array 
Differential expression of genes particularly 
involved in the homeostasis of iron and heme, 
especially HO-1 and CD163 
Papaspyridonos et al 
2006 
Paired Symptomatic vs 
Asymptomatic Carotid 
Plaque 
Affymetrix HG 
U133A Array 
Differential expression of genes known to be 
associated with the recruitment of cells to sites of 
injury or inflammation, lipid metabolism and 
activation of MMPs and cathepsins 
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1.10 Genomics 
While genetics examines specific genes, genomics is the study of all the genetic information in a 
genome to determine biological markers that predispose an individual to a disease phenotype. 
The diploid human genome contains ~6 billion nucleotide bases, of which ~0.5% can differ 
between any two individuals (Lanktree et al. 2009). These differences include single nucleotide 
polymorphisms (SNPs), whereby a given base (A, T, G or C) differs between two alleles.  
 
With the ease and affordability of genotyping, as well as the cataloguing of common alleles and 
population variation by the International HapMap Consortium and the 1000 Genomes project, 
genome-wide association studies (GWAS) have become a popular strategy for investigating the 
association of SNPs to a disease phenotype. These studies contrast with candidate gene-based 
association approaches in that no a priori knowledge of possible causative mechanisms is 
required, as with most -omics study designs therefore allowing novel associations can be 
detected. The GWAS approach proposes a ‘common disease, common variant’ hypothesis, 
whereby common diseases are likely influenced by genetic variation that is also common within 
a general population. Hence compared to linkage analysis and candidate gene-based association 
analysis, GWAS provides a useful strategy for polygenic traits such as ischaemic stroke, with the 
implication that a number of common alleles confer small genetic effects (i.e. have low 
penetrance).  
 
Biomarkers identified through GWAS could prove useful for patient risk stratification or 
prognostic categorisation following medical therapy. Most importantly though, these genomic 
markers can provide distinctive mechanistic information about disease pathogenesis and 
therefore deliver new targets for drug development (Kingsmore et al. 2007). Previous GWAS 
have successfully identified the role of complement factor H in age-related macular 
degeneration (Klein et al. 2005), and a number of genes associated with pancreatic islet beta cell 
function and insulin biosynthesis in type 2 diabetes (Sladek et al. 2007) that can act as 
therapeutic targets. More recently, novel genetic loci associated with established tau and 
phosphorylated tau protein biomarkers for Alzheimer’s Disease demonstrate the ability of 
GWAS to detect new genetic variants that could drive the dysregulation of known molecular 
pathways involved in disease progression (Cruchaga et al. 2013). Despite their small effects, 
alleles identified through GWAS could have a substantial impact on human health due to their 
high incidence within a population. Thus identification of SNPs associated with ischaemic stroke 
could improve risk profiling, although multiple markers of small effect, rather than a single SNP, 
would likely be required. 
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1.10.1 Methods for GWAS Analysis 
The GWAS strategy is built upon knowledge that the relatively brief history of most human 
populations has impeded the number of generations required to create recombination events 
(or mutations) between closely linked markers, thus 80% of the human genome is comprised of 
~10 kilobase regions, termed haplotype blocks, that do not show recombination and are in 
linkage disequilibrium (LD) (International HapMap Consortium 2005). 
 
The fundamental requirement of a genotyping array used for GWAS is the ability to interrogate 
the genetic loci associated with a trait, so that allele frequency differences between ‘disease’ and 
‘control’ populations can be measured. Direct locus interrogation involves the genotyping of 
SNPs directly responsible for the observed phenotype. More commonly, interrogation is 
indirect: genotyped SNPs are not necessarily causal, but in close proximity to functional 
mutations, and are therefore associated with a trait due to LD – the non-random association of 
alleles at two or more genomic loci.  
 
A number of arrays are available for GWAS, which can be compared by their global coverage and 
platform design. Global coverage is defined as the fraction of common SNPs (minor allele 
frequency (MAF) ≥0.05) across the genome that are tagged by, or in LD with, the SNPs on the 
array (typically at a threshold of r2 ≥0.8). Analysis of data from the HapMap project estimates 
that >80% of commonly occurring SNPs in a CEU population (individuals of northern and 
western European descent) can be captured using a subset of 500,000 to 1 million SNPs across 
the genome (Li et al. 2008). Assay designs vary across platforms, for example Illumina arrays 
employ a tag SNP approach, whereby SNPs on the platform are chosen based upon LD patterns 
from the HapMap data set, and have been shown to demonstrate unparalleled and coverage for 
efficient association discovery (Delano et al.2010). The Illumina Human 1M BeadChip consists 
of 900,000 tag SNPs from the HapMap dataset as well as 100,000 non-HapMap SNPs, allowing 
coverage of 93% of common SNPs in the CEU population. The Illumina 610 Quad chip and the 
Illumina HumanHap550k chip consist of 550,000 SNPs (with the 610 Quad chip containing an 
extra ~60,000 copy number variants), and provide 87% coverage (Spencer et al. 2009). In 
contrast to the Illumina design, other arrays, such as the Affymetrix SNP Array 6.0, use an 
unbiased selection of SNPs from various sources (recombination hotspots, mitochondria etc.) 
and therefore do not employ a tag SNP strategy.  
 
As with all –omics-based approaches, GWAS faces the challenge of ‘multiple testing’. When 
multiple statistical tests are conducted for a single hypothesis (i.e. over 500,000 SNPs are tested 
for association with a trait), it is likely that a proportion display association by chance alone, 
hence stringent adjustment is required to limit the number of type I errors (false positive 
associations). The Wellcome Trust Case Control Consortium proposed both frequentist and 
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Bayesian approaches to multiple testing adjustment (Wellcome Trust Case Control Consortium 
2007). Current GWAS have settled on a frequentist-based threshold of p<5 × 10-8 for assigning 
‘genome-wide’ significance in populations of European ancestry, based upon a significance level 
(α) of 0.05, adjusted for an estimated 1 million independent SNPs in the genome (n) by the 
Bonferroni method, as described in the equation below (Johnson et al. 2010):  
p (Study-wide Type I error) = 1 –(1-α)n 
The Bonferonni correction method is often used due to its simplilcity, but it is conservative and 
inappropriately assumes independence of SNPs on a SNP array. Therefore, others have 
proposed using weaker significance levels in order to account for underlying SNP LD (Ziegler et 
al. 2008). Monte-Carlo, permutation methods and False Discovery Rate (FDR) have also been 
advocated (Bush & Moore 2012).  
 
 
1.10.2 GWAS for Ischaemic Stroke Biomarker Discovery 
Early stroke studies attempted to replicate associations detected by GWAS of other 
cardiovascular diseases such as atrial fibrillation and coronary artery disease. The first GWAS of 
ischaemic stroke analysed 278 cases and 275 neurologically normal controls, finding no genetic 
loci reaching genome-wide significance after adjustment for conventional risk factors (Matarin 
et al. 2007). Nonetheless, replication of 3 of the 25 top associated SNPs in a Han Chinese 
population (Ding et al. 2010) provided encouragement for the utility of the GWAS strategy for 
examining genetic variants in ischaemic stroke. Genotyping of 1,661 Icelandic ischaemic stroke 
patients and 10,815 control subjects in another meta-analysis found that SNP rs2200733, in the 
gene PITX2, was uniquely associated with cardioembolic stroke subtype. This gene has also 
previously been found to be associated with atrial fibrillation, thus providing evidence for the 
function of distinct genetic variants in the risk of different stroke subtypes (Gretarsdottir et al. 
2008).  
 
Initial GWAS investigation of ischaemic stroke was based on small cohort sizes. Due to the large 
number of SNPs studied in GWAS, and the small associations of each SNP with the phenotype 
studied (typically OR 1.1-1.3), large sample sizes are required for statistically meaningful 
associations to be derived. GWAS cohorts examining the same trait can be grouped in a meta-
analysis to increase the power of detecting significant and reproducible results (Thompson et al. 
2011). Genotype imputation is usually performed before meta-analysis to facilitate the 
combination of studies. This involves using reference data from the HapMap project or 1000 
Genomes project to infer missing genotypes and untyped SNPs based upon genomic LD 
structure (Marchini & Howie 2010). Recent GWAS have developed a meta-analysis approach, 
either for primary analysis or in the replication phase of the study (International Stroke 
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Genetics Consortium [ISGC] & Wellcome Trust Case-Control Consortium [WTCCC2] 2010; 
Meschia et al. 2011; ISGC & WTCCC2 2012; Holliday et al. 2012a; Traylor et al. 2012).  
 
A GWAS of four large cohorts (Caucasian and black) from the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) Consortium found an association of a locus on 
12p13 (NINJ2) with ischaemic stroke (Ikram et al. 2009), but this failed to be replicated in a 
larger case-control study of 9000 ischaemic stroke individuals (ISGC & WTCCC2 2010). A 
subsequent GWAS meta-analysis of 3 cohorts, comprising 1464 ischemic stroke cases and 1932 
controls also failed to identify any SNPs reaching genome-wide significance of p=5x10-8. 
However, all SNPs reaching suggestive significance of p=1x10-5 were incorporated into a 
multivariate risk profile model and revealed that genetic loading of alleles was related to an 
earlier age of ischaemic stroke onset (Meschia et al. 2011).  
 
Although these studies have been largely disappointing for identifying novel genetic 
associations in ischaemic stroke, recent GWAS studies have proved more fruitful. The 2012 
WTCCC2 GWAS investigated ischaemic stroke and its 3 major subtypes (cardioembolic, lacunar 
and large artery) in 3548 cases and 5972 controls of European ancestry, and replicated 
suggestive findings in a further 5859 cases and 6281 controls. Previously reported associations 
of PITX2 and ZFHX3 for cardioembolic stroke and 9p21 locus for large artery stroke were 
replicated, and a novel association of HDAC9 with large artery stroke was also discovered. This 
association was additionally replicated in 735 cases with large artery stroke. A recent 
experimental study has shown the HDAC9, a protein that regulates chromatin structure and 
gene transcription by histone deacetylation, is expressed in endothelium and smooth muscles of 
carotid arteries, supporting its role in carotid disease and ischaemic stroke (Markus et al. 2013). 
 
A GWAS of subclinical carotid atherosclerosis (common cIMT, internal cIMT and carotid 
plaque), the only one of its kind, has recently been performed on 31,211 individuals from 9 
study cohorts from the CHARGE Consortium, with  replication of initial findings in an additional 
11,273 individuals from seven more studies (Bis et al. 2011). Three genomic loci were identified 
for association with common cIMT (ZHX2, APOC-1, PINX1) and two regions (PIK3CG, EDNRA) 
were associated with the presence of carotid plaque, indicating that genes related to cellular 
signalling, lipid metabolism and blood pressure regulation are involved in the risk of carotid 
disease. 
 
The largest GWAS for ischaemic stroke published to date has combined 15 studies comprising 
12,389 ischaemic stroke cases and 62,004 controls, and conducted a follow-up study of 16 
cross-sectional and two population-based studies with 13,347 cases and 29,083 controls 
(Traylor et al. 2012). The four previous reported loci, PITX2, ZFHX3, 9p21and HDAC9, were 
CHAPTER ONE: INTRODUCTION 
61 
replicated, with PITX2 and ZFHX3 being associated with cardioembolic stroke and 9p21and 
HDAC9 being associated with large artery stroke. A further 12 novel loci were identified but 
could not be replicated in the follow-up study. Another GWAS of ischaemic strokes in an 
Australian population of European ancestry confirmed that genetic factors explain a substantial 
proportion of the ischaemic stroke phenotype, with the highest genetic load observed for large 
artery stroke as compared to other stroke subtypes. A novel association of the 6p21.1 locus with 
large artery stroke was also observed (Holliday et al. 2012).  
 
Table 1.3 summarises GWAS investigations of ischaemic stroke and carotid disease in European 
cohorts, with details of associations reaching high significance. The studies establish the value of 
GWAS for determining novel genetic mechanisms involved in ischaemic stroke risk. 
Importantly, they indicate that stroke subtypes have different underlying pathophysiological 
mechanisms and could therefore require distinct treatment profiles. Given that genetic variants 
commonly have association ORs of ~1.2, it has been calculated that up to 300 variants could 
explain the combined risk of complex polygenic disorders such as ischaemic stroke (Kraft & 
Hunter 2009; Hirschhorn 2009). Therefore further studies are required in order to investigate 
the novel genetic variants and biological pathways conferring risk of ischaemic stroke subtypes. 
 
 
  
CHAPTER ONE: INTRODUCTION 
62 
 
Table 1.3: Summary of GWAS of ischaemic stroke and carotid artery stenosis. SNPs reaching genome wide 
significance of <10-6 are listed, along with their respective associated genes. ISGS, International Stroke Genetics 
Consortium; NS, none significant; WTCCC2, Wellcome Trust Case–Control Consortium 2. 
 
 
 
  
Study Trait SNP Region Reported Gene(s) 
Traylor et al 2012 Ischaemic Stroke rs2107595 7p21.1 HDAC9 
  rs6843082 4q25 PITX2 
  rs879324 16q22.3 ZFHX3 
  rs13407662 2p16.2 Intergenic 
  rs16851055 3q23 SPSB4 
  rs2238151 12q24.12 ALDH2 
Holliday et al 2012 Ischaemic Stroke rs556621 6p21.1 CDC5L, SUPT3H 
ISGC & WTCCC2 2012 Ischaemic Stroke rs11984041 7p21.1 HDAC9 
Meschia et al 2011 Ischaemic Stroke NS NS NS 
ISGC & WTCCC2 2010 Ischaemic Stroke NS NS NS 
Ikram et al 2009 Ischaemic Stroke rs12425791 12p13.33 NINJ2 
Gretarsdottir et al 2008 Ischaemic Stroke rs2200733 4q25 PITX2 -RPL36AP23 
Matarin et al 2007 Ischaemic Stroke rs7506045 18p11.21 IMPA2 
  rs9536591 13q14.3 Intergenic 
  rs10486776 7p21.2 Intergenic 
  rs783396 6q21 AIM1 
Bis et al 2011 Carotid intima media 
thickening and carotid plaque 
rs17398575 7q22.3 PIK3CG 
 rs1878406 4q31.22 EDNRA 
 rs445925 19q13.32 APOC-1 
 rs11781551 8q24.13 ZHX2 
 rs6601530 8p23.1 PINX1 
 rs4712972 6p22.2 SLC17A4 
 rs6511720 19p13.2 LDLR 
 rs17045031 3p14.1 LRIG1 
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1.10.3 Functional Enrichment Analysis 
Adjusting for multiple testing in GWAS by using a stringent significance threshold reduces the 
number of type I errors at the expense of type II errors (false negatives). Thus many true 
associations may be concealed within the p=10-7 to p=0.05 region, and the huge amount of 
genotypic information obtained from GWAS may not be optimally used. Furthermore, it is often 
unclear how associated loci exert an effect at both a gene and pathway level, which is essential 
for understanding disease pathogenesis.  
 
Functional enrichment analysis provides a method for multiple SNP-disease testing that may 
provide better grasp of disease mechanisms, using prior biological knowledge of gene function 
and interaction to leverage deeper mining of genotypic data (Wang et al. 2007; Elbers et al. 
2009). This approach is likely to be more powerful than single SNP analysis when applied to 
small studies, as well as being more robust to the effects of genetic heterogeneity between 
individuals, ethnic backgrounds, genotyping platforms and study design (Holmans et al. 2009). 
Functional enrichment and pathway analysis can also add power to GWAS meta-analyses based 
upon only p-values across studies (Cantor et al. 2010). 
 
Three main strategies exist for functional enrichment analysis: 1) the ‘hypothesis-driven’ 
approach 2) the ‘hypothesis-generating’ approach and 3) the ‘hypothesis-free’ approach. Using 
the ‘hypothesis-driven’ approach, specific pathways are examined based upon presumed 
biological processes involved in the disease being studied. The ‘hypothesis-generating’ 
approach involves taking a subset of significant SNPs from a GWAS and examining the 
enrichment of these SNPs in functional categories, classified, for example, by Gene Ontology 
(GO). The ‘hypothesis-free’ approach takes SNPs that may only have reached nominal 
significance (e.g. p<10-4), or all SNPs tested, and investigates pathway associations with no a 
priori speculation.  
 
Over-representation analysis can be used in ‘hypothesis-generating’ and ‘hypothesis-free’ 
approaches to identify biologically-related genes and group them into functional pathways. 
These methods are commonly based upon a hypergeometric distribution, with the assumption 
that if a biological process is abnormal in a given study, the co-functioning genes are more likely 
to be selected as a relevant group by high-throughput screening than by chance alone. A number 
of knowledge databases have been developed to aid this process, for example Ingenuity 
Pathway Analysis (Ingenuity®Systems, www.ingenuity.com), gene ontology (GO) (Ashburner et 
al. 2000) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa & Goto 2000) and 
protein protein interaction databases such as STRING (Jensen et al. 2009) and InWeb (Lage et al. 
2007). The over-representation method has been widely used in gene expression studies to 
investigate the molecular pathways underlying atherosclerosis (Sluimer et al. 2007; Diez et al. 
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2010), and it has recently shown to be a promising approach to GWAS analysis as well (Wang et 
al. 2007; Morris et al. 2012). 
 
One of the biggest limitations of over-representation analysis is that it requires an arbitrary 
level of significance to be set (e.g. by FDR or Bonferroni correction) on the data obtained from 
high-throughput screening. It also only uses gene numbers while ignoring the strength of 
association between the gene and phenotype being studied. In contrast, functional class scoring 
methods use all the genes obtained from a high-throughput experiment and compute 
enrichment scores for each pathway by considering the genes’ association statistics (e.g. p-
value, fold difference). As above, these pathways are generated based upon functional 
knowledge databases. Gene Set Enrichment Analysis (GSEA) is a popular functional class scoring 
approach that calculates pathway enrichment scores by increasing a running-sum statistic when 
a gene is in a gene set and decreasing it when it is not, with the size of the increase or decrease 
determined by the level of association between the gene and phenotype (Aravind Subramanian 
et al. 2005). Gene set enrichment approaches have previously been employed in gene 
expression analyses of carotid atherosclerosis (Sluimer et al. 2007; Cagnin et al. 2009) and more 
recently to interrogate data from GWAS of complex diseases such as type 2 diabetes (Voight et 
al. 2010) and coronary heart disease (de las Fuentes et al. 2012). 
 
 
1.10.4 Expression Quantitative Trait Locus and Quantitative Trait Transcript Analysis 
GWAS aims to identify loci in the genome associated with a phenotypic trait, with the 
assumption that a functional genetic variant underlies phenotypic variation across a population. 
Continuous traits, such as degree of carotid stenosis, are phenotypes that vary in degree and can 
be attributed to polygenic effects. Consequently, a quantitative trait locus (QTL) is a genetic 
variant (e.g. SNP) that underlies a continuous trait. Gene expression data can be used as an 
intermediate between genotype and a continuous phenotype by performing expression 
quantitative trait locus (eQTL) analysis to provide a better understanding of the genetic 
regulation underlying gene expression (Veyrieras et al. 2008; Nicolae et al. 2010). Two types of 
eQTLs exist: cis-eQTLs describe loci in ‘local’ proximity to the transcript they are mapped to, 
with proximities ranging from 100kb (Cookson et al. 2009) to 10MB (Hubner et al. 2005); in 
contrast trans-eQTLs describe loci that are in a distant region, or different chromosome, to the 
transcript they are mapped to. Some transcripts can be regulated by both cis- and trans- eQTLs 
(Petretto et al. 2010).  
 
Similarly, the relationship between gene expression and phenotypic variation can be examined 
by quantitative trait transcript (QTT) analysis (Passador-Gurgel et al. 2007). In this method, 
genome-wide gene expression data, or a subset of cis-eQTL genes, are used to investigate the 
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correlation between gene expression level and degree of phenotypic variation, with significant 
correlations inferring a functional relationship between the gene and the phenotype (Morrissey 
et al. 2011).  
 
Although GWAS of ischaemic stroke and its intermediate phenotypes (e.g. carotid disease in LAA 
stroke) have advocated the examination of distinct stroke subtypes and identified new genetic 
associations of disease, at present the findings do not hold any direct implications for ischaemic 
stroke risk stratification and the pathways underlying ischaemic stroke subtypes are unclear. 
Functional enrichment analysis could be used to better understand the biological context of 
genetic variants identified through GWAS and deduce molecular networks, rather than single 
genes, causing ischaemic stroke. Further eQTL and QTT analysis can establish the role of SNPs 
and genes identified through enrichment analysis at the functional level, hence helping to 
establish a causal link between the SNP, expression of its related gene, and its importance 
within a pathogenic molecular pathway. This integrative genomics approach can identify novel 
genetic biomarkers and mechanisms involved in carotid plaque pathogenesis and risk of 
ischaemic stroke. To date, this approach has not been attempted in the field of ischaemic stroke 
research. 
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1.11 Hypothesis and Aims 
 
The rising global burden of ischaemic stroke necessitates effective disease management. 
However, current diagnostic, prognostic and risk stratification tools have a number of 
limitations. Molecular biomarkers can be effective indicators of disease mechanisms and 
progression, and proteomic, transcriptomic and genomic approaches represent unbiased, 
system-wide strategies for biomarker discovery in polygenic, complex disorders such as 
ischaemic stroke.  
 
The hypothesis underlying this thesis is that -omics approaches can be employed to identify 
novel candidate biomarkers that could aid diagnosis and disease monitoring for ischaemic 
stroke. The subsequent chapters aim to evaluate the current status of biomarkers for ischaemic 
stroke and develop workflows for novel biomarker discovery, as follows: 
 
Chapter Two: To undertake a comprehensive systematic review and meta-analysis of literature 
to identify current blood-based biomarkers associated with ischaemic stroke, and assess the 
implications of these biomarkers in clinical practice. 
 
Chapter Three: To use proteomic profiling to identify novel blood-based protein biomarkers 
for the diagnosis of acute ischaemic stroke. 
 
Chapter Four: To use transcriptomic and genomic profiling to characterise the molecular 
mechanisms underlying carotid stenosis and plaque instability, and identify tissue-based 
biomarkers that could aid risk stratification of ischaemic stroke.  
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2.1 Introduction 
 
An accurate diagnosis of ischaemic stroke and its likely prognosis holds many important 
implications, for example, whether to admit a patient to a hyperacute stroke unit or medical 
ward, administer medications to reduce the risk of future vascular events, or to consider 
appropriate avenues for rehabilitation. Prompt diagnosis is required for the administration of 
intra-venous recombinant tissue plasminogen activator (rt-PA) thrombolytic therapy within the 
first few hours of ischaemic stroke onset. Furthermore, up to 8% of high risk patients suffer a 
recurrent stroke within the first 2 days (Johnston et al. 2007), hence rapid initiation of 
secondary preventative treatments is key. However, the diagnosis of ischaemic stroke and 
prediction of outcome is difficult to make. The probability of a stroke diagnosis and its likely 
prognosis is usually determined by an assessment of clinical symptoms, brain imaging and past 
history, but the accuracy of this evaluation is largely dependent upon the expertise of an 
experienced clinician.  
 
Point of care testing for ischaemic stroke holds many advantages, including speed and ease of 
use even by those with little training. As well as improving clinical efficiency, it could reduce 
costs by shortening hospital stay and decreasing the requirement for other diagnostic tools. 
Circulating molecules in the bloodstream can provide a means to monitor physiological 
processes following acute ischaemic stroke, and these blood-based biomarkers are routinely 
used in the management of many disorders. For example, raised cardiac troponin levels can 
differentiate myocardial infarction from angina or other causes of chest pain (Brott et al. 1989), 
and the incorporation of brain natriuretic peptide into the GRACIE score increases prediction of 
outcome after myocardial infarction (Lorgis et al. 2009). Blood-based biomarker tests could 
increase diagnostic certainty by helping to distinguish cerebral ischaemia from haemorrhagic 
stroke and common stroke mimics, while also identifying patients at high risk of developing 
future vascular complications. Prognostic biomarkers will be valuable in stratifying a patient 
population by potential outcomes, as well identifying patients most likely to benefit from early 
therapeutic intervention.  
 
While many protein and metabolic blood biomarkers have been implicated in the diagnosis or 
prognosis of ischaemic stroke, the successful development of blood-based tests through 
biomarker identification has proved to be a challenge. Studies investigating potential 
biomarkers have yielded inconsistent results and hence the significance of many proposed 
biomarkers remains unclear.  
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Aims of the Study 
In an attempt to better understand the relevance of currently proposed biomarkers for stroke 
before undertaking research for novel biomarker discovery, this study aimed to: 
 Perform a comprehensive systematic review of published literature reporting blood-
based biomarkers for the diagnosis and prognosis of ischaemic stroke. 
 Assess the statistical association, if any, between reported biomarkers and the diagnosis 
or prognosis of ischaemic stroke. 
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2.2 Methods 
 
2.2.1 Literature-Based Meta-Analysis of Diagnostic and Prognostic Biomarkers for Stroke 
 
2.2.1.1 Data Sources and Extraction  
Electronic databases MEDLINE, EMBASE and Google Scholar were searched up to January 1st 
2013 for all studies detailing the use of blood biomarkers for stroke in humans.  Search retrieval 
was maximised by using 14 terms for ischaemic stroke (ischaemic, ischemic, cerebral, 
intracranial, parenchymal, intraventricular, infratentorial, supratentorial, cerebrovascular, 
infarction, stroke, thrombus, occlusion and embolus), 4 for thrombolysis (thrombolysis, 
thrombolytic therapy, plasminogen activator and alteplase), 3 for generic biomarkers 
(biological, biochemical marker and biomarker), and 780 specific biomarker terms with 
‘and/or’ used as a Boolean operator (Appendix 1). References from all relevant papers were 
hand searched for additional studies, and the MEDLINE ‘Related Articles’ option was used to 
identify further articles. The search was restricted to the English language, but both 
unpublished and published articles were included, providing the full text was available. While 
the introduction of unpublished literature has raised concerns, it is widely acknowledged that if 
this ‘grey’ literature undergoes strict quality control (as performed here, with three 
independent reviewers), it can improve the reliability of a meta-analysis by mitigating 
publication bias (Bossuyt & Leeflang 2008). 
 
Inclusion criteria were set following recommendations from the Cochrane Handbook for 
Systematic Reviews of Diagnostic Test Accuracy (Bossuyt & Leeflang 2008). For the evaluation 
of diagnostic biomarkers, studies were required to have reported candidates that discriminated 
between ischaemic stroke and non-stroke subjects (healthy, stroke mimics or other 
neurological diseases), or between ischaemic and haemorrhagic stroke, with blood being drawn 
within 24 hours of stroke onset. Where more than one cohort was examined, data for each 
population were extracted separately. Studies reporting the prognostic value of biomarkers 
were eligible for inclusion if blood had been drawn within 24 hours of stroke onset, and 
outcome was measured using death, disability or handicap scales. No minimal sample size was 
set for study inclusion, but only papers reporting continuous measures of candidate biomarker 
activity or concentration (mean/median and standard deviation/range) were chosen for meta-
analysis. Papers reporting only the risk of subsequent stroke or risk of stroke in a non-stroke 
population were not included. Papers examining subarachnoid haemorrhage were excluded.  
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2.2.1.2 Statistical Analysis  
For each candidate biomarker for which data were available for more than two studies, a meta-
analysis was performed. Where values were reported as medians and ranges, the mean and 
standard deviation were estimated using a variety of models dependent upon sample size, as 
described by Hozo et al. (2005). Data were analysed using the Review Manager v5.0 software. 
Standardised Mean Differences (SMDs) were calculated for each candidate biomarker using the 
DerSimonian-Laird random-effects model (DerSimonian & Laird 1986), as well as 95% 
confidence intervals (CI) to measure the strength of association. SMD was calculated as follows: 
 
 
 
Heterogeneity was tested with the chi-square (2) test and assessed using I2 (p<0.05) to 
describe the percentage of variability in point estimates that was due to heterogeneity rather 
than sampling error (Deeks & Altman 2001). The possibility of publication bias was not 
formally assessed as it has been noted that test power is usually too low to distinguish 
chance from real asymmetry when considering fewer than ten studies (Sterne et al. 
2011). 
 
 
2.2.2 Literature-Based Meta-Analysis of Admission Glucose Level as a Prognostic 
Biomarker for Post-Thrombolytic SICH  
 
2.2.2.1 Data Sources and Extraction  
Electronic databases MEDLINE, EMBASE and Google Scholar were searched up to January 1st 
2013 for all studies examining blood glucose levels in thrombolysed acute ischaemic stroke 
patients who developed SICH post-treatment. Papers were identified using the following key 
words: ‘symptomatic’, ‘intracerebral’, ‘haemorrhage’, ‘stroke’ and ‘thrombolytic’. Studies were 
eligible for inclusion if blood glucose levels were measured within 24 hours of stroke onset, and 
primary outcome measures included SICH (of any classification) and an assessment of 
functional outcome (mRS). The search was limited to those patients treated only with 
intravenous rt-PA alteplase. Reference lists of all relevant papers were hand-searched for 
additional studies and the MEDLINE ‘Related Articles’ option was used to identify further 
articles. The search was not restricted by language, and both unpublished and published articles 
were included, providing the full text was available. No minimum sample size was set for study 
inclusion.  
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2.2.2.2 Statistical Methods  
The association of glucose levels with the presence of post-thrombolysis SICH was analysed 
against the absence of SICH. In instances when glucose level was reported in mg/dL, the units 
were converted to mmol/L for consistency.  
 
Studies reporting the odds ratio (OR) associated with developing SICH at specific incremental 
changes of glucose were pooled for analysis. For each of these studies, ORs and CIs were 
standardised to 1mmol/L increase of glucose, using the following formula (Allison 1999):  
 
OR per 1mmol/L increase in glucose = OR per θ mmol/L ^ (1/ θ)  [A] 
 
For studies reporting continuous data (means and standard deviations for their SICH and non-
SICH populations) SMDs were calculated. This firstly involved re-expressing the difference in 
mean glucose between SICH and non-SICH groups as a multiple of the pooled standard deviation 
(Spooled), which is a weighted average of the standard deviations (SDs) from the SICH (t) and non-
SICH (c) group in each data set:  
where n =  number of subjects 
 
SMD was then calculated as: 
SMD = mean difference/Spooled 
 
The SMD was converted into a logOR by multiplying by 1.81 (
 
√ 
 ) (Chinn 2000) and then 
converted to an OR. The calculation of OR for each continuous data set and thus be summarised 
as follows: 
OR = exp [1.81*mean diff/Spooled] 
 
Multiplying the SMD by standard deviation (in this case Spooled) gives the amount of glucose 
which changes outcome from non-SICH to SICH (Higgins & Green 2011). Having calculated the 
OR associated with SICH, and already knowing the level of glucose increase responsible for this 
outcome, an OR per 1mmol/L increase in glucose was calculated, again using formula [A] above. 
This subsequently allowed studies reporting ORs and studies reporting continuous data to be 
pooled together in one meta-analysis. Funnel plot and two-tailed Egger regression test were 
used to assess publication bias using Comprehensive Meta-Analysis v2.0 software (Egger et al. 
1997).  
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2.2.3 Individual Patient Data Meta-Analysis of Admission Glucose Level as a Prognostic 
Biomarker for Post-Thrombolytic SICH  
 
2.2.3.1 Study Inclusion and Data Acquisition 
Studies were identified through literature search, as detailed in Section 2.2.2 above. Inclusion 
was restricted to studies with a sample size of more than 50 patients to ensure that the 
logistical effort of obtaining and organising the data was commensurate with the contribution of 
the data to the analysis (Riley et al. 2010). In an attempt to limit heterogeneity due to study 
design, randomised trials were excluded and only observational studies were considered. 
 
Authors and principal investigators of eligible studies were invited to provide individual patient 
data (IPD). Primary data of interest included patient admission glucose level and 
presence/absence of SICH following thrombolysis, with a clear explanation of how SICH was 
defined. When possible, the following patient information was also obtained: age, sex, presence 
of diabetes and hypertension, onset to treatment time (OTT), baseline NIHSS score and 
functional outcome (mRS).  
 
2.2.3.2 Statistical Analysis  
The primary analysis used the IPD to estimate the absolute risk of SICH in relation to admission 
glucose level. The largest study cohort (SITS-ISTR, >30,000 patients, (Mazya et al. 2012) was 
firstly used to examine the relationship between glucose levels and SICH and enable key 
modelling decisions to be made. Preliminary analysis was performed on continuous variables to 
assess the normality of their distribution. All available baseline variables (age, sex, onset to time 
of treatment, admission NIHSS, hypertension, diabetes, smoking, atrial fibrillation, 
hyperlipidaemmia, previous stroke) were analysed and differences between continuous and 
categorical variables in the SICH and non-SICH groups was assessed using the Mann-Whitney U 
test and the Pearson χ² method respectively. Variables showing an association with all three 
definitions of SICH (NINDS, ECASS and SITS-MOST) at p<0.05 in univariate analysis and 
available across all datasets were included as potential predictors into multivariate logistic 
regression models. 
 
It is essential to maintain the clustering of patients within studies when performing individual 
patient data meta-analyses (Abo-Zaid et al. 2013), therefore a two-step analysis approach was 
taken. Individual datasets were first subjected to logistic regression analysis to calculate a 
regression coefficient (log odds ratio) and 95% confidence interval (95% CI). Weighted average 
log odds ratios were then calculated using a weight of 1/SE2 for each study, and these were 
combined in a meta-analysis to produce a pooled odds ratio (OR) and 95% CI. To test 
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robustness, both random effects and fixed effects models were used. Meta-analyses were 
performed separately for each classification of SICH (NINDS, ECASS and SITS-MOST). 
Heterogeneity was examined using the I2 statistic to describe the percentage of variability in 
point estimates due to heterogeneity rather than sampling variability (Deeks & Altman 2001). 
Publication bias was not formally assessed as there were fewer than ten studies in the meta-
analysis (Sterne et al. 2011).  
 
The pooled ORs calculated from the meta-analyses related to the risk of SICH associated with 
each 1mmol/L increase in admission glucose level. The absolute risk of SICH associated with 
each increment of 1mmol/L in admission glucose level was calculated as: 
 
A x (B(C)) 
 
where ‘A’ is the known % risk of SICH within the pooled population, ‘B’ is the estimated OR per 
unit increase of log10glucose and ‘C’ represents the difference, in log10 units, between the log10 
target value and anchor (mean) glucose value of the pooled population. For rare events, with 
risks less than 10%, the relative risk (RR) and OR are very closely similar, therefore the step 
required to converted OR to RR could be omitted (Professor Doug Altman, personal 
communication). All analyses were performed using PASW Statistics v18 and Stata v11. 
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2.3 Results 
 
2.3.1 Literature-Based Meta-Analysis of Diagnostic and Prognostic Biomarkers for Stroke 
The primary search identified 3974 papers reporting candidate diagnostic and prognostic 
biomarkers for ischaemic stroke and candidate prognostic biomarker for thrombolysis. Of these, 
703 studies met criteria for inclusion into the qualitative analysis. Following screening of full 
text articles, 65 studies for diagnostic biomarkers for ischaemic stroke, 40 studies for prognostic 
biomarkers for ischaemic stroke and 39 studies for biomarkers of prognosis following 
thrombolysis were incorporated into meta-analyses (Figure 2.1).  
 
 
 
 
 
Figure 2.1 PRISMA flow diagram for systematic review and meta-analysis of diagnostic and prognostic 
biomarkers of ischaemic stroke. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram illustrates the search strategy and number of studies included in the systematic review 
(qualitative analysis) and meta-analysis (quantitative analysis). AIS, acute ischaemic stroke; rt-PA, recombinant 
tissue plasminogen activator. 
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A total of 137 different candidate biomarkers were identified. A review of the papers reporting 
diagnostic and prognostic biomarkers for ischaemic stroke revealed that most candidates were 
only investigated in a single study and had not been validated in large patient populations.  
 
Candidate biomarkers implicated for ischaemic stroke could be classified into functional 
pathways including lipid metabolism (cholesterol, triglyceride, apolipoproteins), coagulation 
(fibrinogen, D-dimer, PAI-1) and inflammation (CRP, TNF-α, interleukins), metabolites 
(creatinine, glutamate, glucose), brain derived molecules (B-type neurotrophic growth factor, 
S100B, neurone specific enolase, GFAP) and proteins indicating endothelial processes (MMP-9, 
ICAM-1, P-Selectin). A summary of candidate biomarkers with significant association, as 
identified through meta-analysis, is illustrated in Figure 2.2. 
 
 
 
 
 
Figure 2.2 Candidate diagnostic and prognostic biomarkers of significant association with ischaemic stroke 
upon meta-analysis. Candidates were found to be either blood or tissue derived, and could be broadly separated 
into six main categories: lipid metabolism (total cholesterol, triglyceride, HDL cholesterol), coagulation (fibrinogen, 
D-dimer, PAI-1), inflammation (CRP, TNF-α, IL-6, IL-10), metabolites (creatinine, glucose, glutamate), brain-derived 
proteins involved in cell cycle progression (S100B) and proteins involved in endothelial cell adhesion and 
extracellular matrix integrity (MMP-9, ICAM-1, P-selectin). Proteins involved in cell adhesion and extracellular matrix 
integrity could derive from endothelial cells of the blood brain barrier, or the endothelium of unstable plaque regions 
causing the ischaemic stroke. CRP, C-reactive protein; HDL, high-density lipoprotein; ICAM-1, intercellular adhesion 
molecule-1; IL, interleukin; MMP-9, matrix metalloproteinase-9, PAI-1, plasminogen activator inhibitor-1; TNF-α, 
tumour necrosis factor-α.  
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2.3.1.1 Diagnostic Biomarkers of Ischaemic Stroke  
Meta-analysis effect size was calculated as pooled standardised mean difference (SMD) between 
mean biomarker levels in study populations. Table 2.1 describes the SMDs associated with each 
candidate diagnostic biomarker for which meta-analysis could be performed.  
 
Ten candidate biomarkers were found to be of statistical significance for differentiating 
between acute ischaemic stroke (AIS) and healthy controls after meta-analysis: triglyceride, 
HDL cholesterol, fibrinogen, CRP, IL-6, IL-10, TNF-α, glucose, ICAM-1 and P-Selectin. In 
particular proteins involved in lipid metabolism were associated with AIS at high significance 
upon meta-analysis, with triglycerides being higher and HDL cholesterol levels being lower in 
AIS patients as compared to healthy controls (triglyceride: SMD=0.80, 95% CI 0.41, 1.18, 
p=0.0001; HDL cholesterol: SMD=-0.65, 95% CI -0.89, -0.40, p=0.0001). However, the high level 
of heterogeneity (p<0.0001) between studies examining these candidate biomarkers lends 
uncertainty to the quality of the results. Inflammatory acute phase proteins TNF-α (SMD=0.39, 
95% CI 0.18, 0.60, p=0.0002), CRP (SMD=0.78, 95% CI 0.11, 1.44, p=0.02) and fibrinogen 
(SMD=1.08, 95% CI 0.35, 1.82, p=0.004) were also found to be elevated in acute ischaemic 
stroke patients as compared to healthy controls. A forest plot of significant associations is 
provided in Figure 2.3. 
 
Meta-analysis of two studies (Rainer et al. 2007; Glickman et al. 2011) consisting of 142 
subjects, found that higher levels of S100B were present in AIS patients as compared to stroke 
mimics (SMD=0.60, 95% CI 0.26, 0.94, p=0.0005; Figure 2.4). Furthermore, meta-analysis of 
another two studies (Kavalci et al. 2011; Montaner et al. 2012) consisting of 266 patients found 
that lower MMP-9 levels could distinguish AIS from ICH (SMD=-0.93, 95% CI -0.30, -1.55, 
p=0.004; Figure 2.5).  
 
 
  
Table 2.1: Candidate diagnostic biomarkers of ischaemic stroke identified through literature review. Results from RevMan meta-analysis for candidate biomarkers reported 
in two studies or more are detailed, and biomarkers of significance are highlighted in blue. BNP, brain natriuretic peptide; CI, confidence interval; CRP, c-reactive protein; GFAP, glial 
fibrillary acidic protein; HDL, high density lipoprotein; H-FABP, heart-type fatty acid binding protein; ICAM, intracellular adhesion molecule; IL, interleukin; IMA, ischaemia modified 
albumin; LDL, low density lipoprotein; MMP, matrix metalloproteinase; NT-BNP, N-terminal brain natriuretic peptide; PAI, plasminogen activator inhibitor; SMD, standardised mean 
differences; TNF, tumour necrosis factor. References in the table are numbered and listed separately at the end of the References section of the thesis. 
 Biomarker 
Number of 
Studies  
(References) 
Number of 
Subjects 
SMD 95% CI p-value 
Inter-study Heterogeneity 
(I2;  p-value) 
AIS vs Healthy Control        
 ICAM-1 3(1–3) 420 1.72 0.12, 3.32 0.04 I2 = 97%; p- value < 0.00001 
 Glucose 2(4,5) 1395 0.71 0.35, 1.07 0.0001 I2 = 84%; p- value = 0.01 
 Total Cholesterol 9 (4–12) 2881 0.39 -0.03, 0.81 0.07 I2 = 94%; p- value < 0.00001 
 Triglyceride 6 (4–8,10) 1713 0.80 -0.41, 1.18 0.0001 I2 = 88%; p- value < 0.00001 
 HDL Cholesterol 6 (4–6,9–11) 2628 -0.65 -0.89, -0.40 0.00001 I2 = 79%; p- value = 0.0003 
 LDL Cholesterol 5 (4,6,7,10,11) 627 0.93 -0.05, 1.91 0.06 I2 = 96%; p- value < 0.00001 
 Creatinine 4 (4,8,11,13) 558 0.21 -0.09, 0.52 0.18 I2 = 59%; p- value = 0.06 
 TNF-a 2 (1,4) 396 0.39 0.18, 0.60 0.0002 I2 = 0%; p- value = 0.66 
 CRP 9 (4,5,10,14–19) 3765 0.78 0.11, 1.44 0.02 I2 = 98%; p- value < 0.00001 
 IL-6 4 (1,9,18,20) 1134 1.21 0.04, 2.38 0.04 I2 = 96%; p- value < 0.00001 
 Neopterin 2 (21,22) 168 0.92 -1.90, 3.75 0.52 I2 = 98%; p- value < 0.00001 
 IMA 2 (23,24) 132 4.10 -3.48, 11.68 0.29 I2 = 99%; p- value < 0.00001 
 Fibrinogen 4 (6,14–16) 1089 1.08 0.35, 1.82 0.004 I2 = 97%; p- value < 0.00001 
 P-Selectin 2 (7,25) 179 3.16 -1.04, 7.35 0.02 I2 = 99%; p- value < 0.00001 
 IL-10 2 (18,21) 64 -1.07 -1.67, -0.48 0.004 I2 = 17%; p- value = 0.27 
 H-FABP 2 (24,26) 74 0.65 -1.62, 2.91 0.58 I2 = 94%; p- value < 0.0001 
 CD40L 2 (8,27) 131 -3.98 -11.87, 3.91 0.32 I2 = 99%; p- value < 0.00001 
 Nitric Oxide 2 (5,28) 1186 -3.51 -14.75, 7.73 0.54 I2 = 99%; p- value < 0.00001 
 Homocysteine 3 (10,29,30) 759 4.05 0.05, 8.06 0.06 I2 = 99%; p- value < 0.00001 
AIS vs Neurological Disorders        
 CRP 2 (31,32) 389 10.87 -6.47, 28.49 0.23 I2 =100%; p- value < 0.00001 
AIS vs Stroke Mimic        
 S100B 2 (33,34) 142 0.60 0.26, 0.94 0.0005 I2 = 0%; p- value = 0.63 
AIS vs ICH        
 GFAP 3 ((35–37) 352 1.17 -0.09, 2.44 0.07 I2 = 94%; p- value < 0.00001 
 NT-BNP 2 (38,39) 133 -0.28 -0.66, 0.10 0.15 I2 = 0%; p- value = 0.83 
 BNP 2 (40,41) 266 -0.60 -1.77, 0.57 0.31 I2 = 94%; p- value < 0.0001 
 D-Dimer 2 (40,41) 266 -0.16 -1.46, 1.13 0.80 I2 = 95%; p- value < 0.00001 
 MMP-9 2 (40,41) 266 -0.93 -0.30, -1.55 0.004 I2 = 77%; p- value = 0.04 
 S100B 4 (33,37,40,41) 516 1.02 -0.24, 2.28 0.11 I2 = 96%; p- value < 0.00001 
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Figure 2.3: Forest plot of candidate diagnostic biomarkers able to significantly differentiate between acute 
ischaemic stroke patients and he althy controls. CI, confidence interval; CRP, C-reactive protein; HDL, high-
density cholesterol; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; TNF-α, tumour necrosis factor-α. 
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Figure 2.4: Forest plot comparing S100B levels in acute ischaemic stroke patients and stroke mimics. High 
S100B levels show a significant association with acute ischaemic stroke. CI, confidence interval. 
 
 
 
 
 
 
Figure 2.5: Forest plot comparing MMP-9 levels in acute ischaemic stroke and haemorrhagic stroke patients. 
Lower MMP-9 levels show a significant association with acute ischaemic stroke. CI, confidence interval; MMP-9, 
matrix metalloproteinase-9. 
 
 
2.3.1.2 Prognostic Biomarkers of Ischaemic Stroke  
Table 2.2 describes the SMDs associated with each candidate prognostic biomarker for which 
meta-analysis could be performed. Studies reported a number of post-AIS outcome measures, of 
which four were examined in more than one study cohort and amenable to meta-analysis: 
haemorrhagic transformation (HT) vs. no haemorrhagic transformation, in-hospital survival vs. 
death and good vs. bad outcome at 3 months (as measured modified Rankin Score or Barthel 
Score). 
 
Prognostic biomarkers of significant association with ischaemic stroke were identified in two 
outcomes. Creatinine (SMD=-0.33, 95% CI -0.66,-0.01, p=0.04), D-dimer (SMD=-4.34, 95% CI -
8,49, -0.18, p=0.04), fibrinogen (SMD=-5.51, 95% CI -9.06,-1.97, p=0.002) and glucose levels 
(SMD=-0.72, 95% CI -1.22,-0.22, p=0.005) were all higher in patients who died in hospital as 
compared to those who survived (Figure 2.6). High admission glucose levels were also found to 
be associated with poor functional outcome and death (mRS 3-6) at 3 months after stroke onset 
(SMD=-0.72, 95% CI -1.44, 0.01, p=0.04). Additionally, high fibrinogen levels were associated 
with poor outcome at 3 months (SMD=-0.59, 95% CI -1.10, -0.08, p=0.02) following iterative 
analysis and exclusion of one study (Welsh et al. 2009) that accounted for high heterogeneity.
  
 
  
 
  
 
Table 2.2: Candidate prognostic biomarkers of ischaemic stroke identified through literature review. Results from RevMan meta-analysis for candidate biomarkers reported 
in two studies or more are detailed, and biomarkers of significance are highlighted in blue. CI, confidence interval; CRP, c-reactive protein; HbA1c, haemoglobin A1C; HT, 
haemorrhagic transformation; ICAM, intracellular adhesion molecule; IL, interleukin; mRS, modified rankin scale; SMD, standardised mean differences; TNF, tumour necrosis factor. 
References in the table are numbered and listed separately at the end of the References section of the thesis. 
 
 
 Biomarker 
Number of 
Studies  
(References) 
Number of 
Subjects SMD 95% CI p-value 
Inter-study Heterogeneity  
(I2;  p-value) 
HT vs no HT        
 Glucose 3 (42–44) 551 0.59 -0.06, 1.25 0.08 I2 = 90%; p- value < 0.0001 
 Fibrinogen 3 (42–44) 551 0.04 -0.43, 0.50 0.88 I2 = 82% ; p- value = 0.004 
Good Outcome (mRS 0-2) vs. 
Poor Outcome (mRS 3-6)        
 Glucose 5 (45–49) 2061 -0.72 -1.44, 0.01 0.04 I2 = 98%; p- value < 0.00001 
 Fibrinogen 5 (45,47–50) 2187 -0.14 -0.91, 0.62 0.71 I2 = 98%; p- value < 0.00001 
 Glutamate 3 (46,49,51) 616 -1.59 -3.50,0.32 0.10 I2 = 99%; p- value < 0.00001 
 IL-6 4 (48,50–52) 1146 -0.21 -2.96, 2.54 0.88 I2 = 99%; p- value < 0.00001 
 TNF-a 3 (50–52) 396 1.00 -0.06, 2.05 0.06 I2 = 94%; p- value < 0.00001 
 CRP 3 (46,48,50) 984 1.67 -1.46, 4.80 0.30 I2 = 99%; p- value < 0.00001 
 D-Dimer 2 (46,50) 234 0.37 -2.37, 3.11 0.79 I2 = 99%; p- value < 0.00001 
Good Outcome (Barthel >85) vs. 
Poor Outcome (Barthel <85)        
 ICAM-1 2 (1,3) 184 -0.29 -1.21, 0.62 0.53 I2 = 87%; p- value = 0.005 
Survival Inhospital vs. 
Death In-hospital        
 Glucose 3 (57–59) 1401 -0.72 -1.22, -0.22 0.005 I2 = 75%; p- value = 0.02 
 Total Cholesterol 2 (58,60) 566 0.33 -0.01, 0.67 0.06 I2 = 0% ; p- value = 0.68 
 CRP 2 (32,60) 431 -7.89 -16.90, 1.11 0.09 I2 = 99% ; p- value < 0.00001 
 Fibrinogen 2 (32,60) 431 -5.51 -9.06, -1.97 0.002 I2 = 97% ; p- value < 0.00001 
 D-Dimer 3 (32,58,60) 766 -4.34 -8.49, -0.18 0.04 I2 = 99%; p- value < 0.00001 
 HbA1c 2 (58,61) 352 0.74 -1.23, 2.70 0.46 I2 = 87% ; p- value = 0.005 
 Albumin 3 (32,58,61) 751 0.29 -1.00, 1.58 0.66 I2 = 88% ; p- value = 0.0003 
 Creatinine 2 (58,59) 441 -0.33 -0.66, -0.01 0.04 I2 = 0% ; p- value = 0.78 
 Sodium 2 (58,59) 441 -0.12 -0.69, 0.44 0.67 I2 = 67% ; p- value = 0.08 
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Figure 2.6: Forest plot of candidate biomarkers significantly associated with in-hospital death after 
ischaemic stroke. CI, confidence interval. 
 
 
 
2.3.1.3 Prognostic Biomarkers for Thrombolysis  
Thirty-nine papers reporting candidate prognostic biomarkers for intravenous rt-PA 
thrombolysis were identified for meta-analysis. These papers reported a number of prognostic 
outcomes, including survival vs. death, poor vs good outcome, efficiency of recanalisation and 
occurrence of haemorrhagic transformation and/or symptomatic intracerebral haemorrhage 
(SICH). Table 2.3 describes the SMDs associated with each candidate prognostic biomarker for 
which meta-analysis could be performed. 
 
Of these, only one outcome, risk of SICH, was found to have candidate biomarkers of statistical 
significance upon meta-analysis. Meta-analysis of two studies found that lower levels of 
admission PAI-1 are associated with a higher risk of a patient developing SICH post-
thrombolysis (SMD -0.54, 95% CI -1.09, 0.01, p=0.04). Admission glucose levels were also found 
to predict post-thrombolytic SICH. Results of this separate systematic review and meta-analysis 
are detailed in Section 2.3.2. 
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2.3.1.4 Clinical Relevance of Statistically Signiﬁcant Biomarkers 
Statistical association between a candidate biomarker and an outcome does not necessarily 
imply that the biomarker can discriminate between two population groups adequately (Pepe 
2004), and moderately large effect sizes calculated by meta-analysis may still represent a 
substantial overlap in the distributions between study populations (Cook 2007). Similarly, in 
this current study, a difference in means between two populations does not eliminate the 
possibility of considerable overlap between the two distributions and high rates of false 
positives and false negatives at set thresholds. This concept was examined by plotting 
distribution curves from studies included in our meta-analysis of CRP levels in ischaemic stroke 
and healthy controls. Figure 2.7 demonstrates that CRP lacks the sensitivity and specificity 
required for effective discrimination between the two study populations, casting doubt upon its 
value as a clinically valuable biomarker.  
 
 
  
 
 
Table 2.3: Candidate biomarkers predicting prognosis after thrombolysis for ischaemic stroke, as identified through literature review. Results from RevMan meta-analysis 
for candidate biomarkers reported in two studies or more are detailed, and biomarkers of significance are highlighted in blue. APC, activated protein C; CI, confidence interval; CRP, 
c-reactive protein; mRS, modified rankin scale; PAI, plasminogen activator inhibitor; PH, parenchymal haemorrhage; SICH, symptomatic intracerebral haemorrhage; SMD, 
standardised mean differences; TAFI, thrombin-activatable fibrinolysis inhibitor. References in the table are numbered and listed separately at the end of the References section of 
the thesis. 
 
 
 
 
 Biomarker 
Number of 
Studies  
(References) 
Number of 
Subjects 
SMD 95% CI p-value 
Inter-study Heterogeneity  
(I2;  p-value) 
Good Outcome (mRS 0-2) vs. 
Poor Outcome (mRS 3-6) 
       
 Glucose 2 (62,63) 541 -0.98 -3.59, 1.62 0.46 I2 = 99%; p- value < 0.00001 
PH vs no PH        
 APC 2 (64,65) 234 0.56 -0.64, 1.76 0.36 I2 = 88%; p- value = 0.004 
SICH vs No SICH        
 TAFI 2 (66,67) 191 0.21 -1.22, 1.65 0.77 I2 = 85%; p- value = 0.01 
 PAI-1 2 (66,67) 191 -0.54 -1.09, 0.01 0.04 I2 = 0%; p- value = 0.34 
Survival vs Death        
 CRP 2 (68,69) 254 -0.64 -2.26, 0.97 0.44 I2 = 94%; p- value < 0.0001 
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Figure 2.7: Assessing candidate biomarkers by examining distribution profiles. A) Biomarker discrimination 
limits are dependent upon the separation of distributions between two populations, affecting the numbers of true 
positives (TP), true negatives (TN), false positives (FP) and false negatives (FN). Moving an arbitrary discrimination 
threshold can alter the sensitivity and specificity of a biomarker test by changing the ratio of TPs and TNs. The 
discrimination threshold of a biomarker is usually reported to maximise the combination of sensitivity and 
specificity, as illustrated; however, the optimal discrimination threshold for a biomarker can vary depending on the 
relative importance of missing a TP versus that of misclassifying FPs. B) C-reactive protein (CRP) distribution profiles 
were created for ischaemic stroke and healthy control populations from data used in the meta-analysis. Despite the 
significant association between CRP and ischaemic stroke derived from meta-analysis, the distribution profiles 
indicate that an arbitrary discrimination threshold results in a high rate of FP and FNs, suggesting that CRP has 
questionable value as a diagnostic biomarker for acute ischaemic stroke. 
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2.3.2 Literature-Based Meta-Analysis of Admission Glucose Level as a Prognostic 
Biomarker for Post-Thrombolytic SICH  
The findings of the systematic review demonstrated that admission glucose level could be a 
promising candidate biomarker for predicting prognosis following ischaemic stroke. It also has 
the advantage of being a simple, routinely measured blood-based clinical variable. Therefore the 
association between hyperglycaemia and post-thrombolytic SICH was investigated in more 
detail.  
 
A separate literature search was conducted to obtain all studies reporting the association of 
admission glucose levels with SICH after intravenous rt-PA thrombolysis. Upon screening 204 
studies, 66 studies reporting the presence of haemorrhagic transformation rather than SICH or 
examining prognosis after drugs other than intravenous rt-PA (Alteplase) were excluded. After 
reading the full texts of 138 papers, 116 were further excluded due to repeat data sets, or no 
quantitative assessment of the relationship between glucose levels and association with SICH. 
Thirteen observational studies and five clinical trials, encompassing 40,790 subjects, were 
identified for quantitative analysis (Figure 2.8).  
 
 
 
Figure 2.8 PRISMA flow diagram for systematic review and meta-analysis of glucose as a prognostic 
biomarker for post-thrombolytic SICH. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram illustrates the search strategy and number of studies included in the systematic review 
(qualitative analysis) and meta-analysis (quantitative analysis). AIS, acute ischaemic stroke, SICH, symptomatic 
intracerebral haemorrhage, rt-PA, recombinant tissue plasminogen activator.  
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Due to methodological differences between clinical trials and observational study protocols, it is 
not always appropriate to combine these two different study designs in a single meta-analysis 
(Professor Doug Altman, personal communication). For this reason, observational studies and 
clinical trials were analysed separately. 
 
The mean admission glucose level in the 733 patients who developed SICH in the observational 
studies was calculated to be 8.7mmol/L where information was available, in contrast to a mean 
admission glucose level of 7.5mmol/L in the 30,611 patients who did not develop SICH. Eight 
observational studies reported continuous data, providing values of admission glucose levels 
(mean and standard deviation) for SICH and non-SICH populations (Table 2.4). Six 
observational studies reported the odds ratio (OR) of SICH per incremental increase in 
admission glucose level, with increments ranging from 1.0 – 5.6 mmol/L.  
 
 
 
 
Table 2.4: Characteristics of studies included in the literature based meta-analysis of the association of 
glucose with post-thrombolytic symptomatic intracerebral haemorrhage. NR, not reported; OR, odds ratio, SD, 
standard deviation. 
 
 Study Data Reporting 
SICH non-SICH % 
SICH 
 
Mean SD n Mean SD n 
O
b
se
rv
a
ti
o
n
a
l 
S
tu
d
ie
s 
Lansberg et al 2007 Continuous 9.8 5.4 7 7.3 2.8 67 9.5 
Katzan et al 2000 Continuous 11.0 4.7 11 8.4 3.4 59 15.7 
Tanne et al 2002 Continuous 8.8 3.5 72 8.3 2.9 86 6.0 
Alvarez-Sabin et al 2004 Continuous 9.5 1.7 8 8.6 3.8 130 5.8 
Cocho et al 2006 Continuous 9.6 4.8 8 7.6 3.7 106 7.0 
Strbian et al 2012 Continuous 7.2 0.8 68 6.6 0.4 906 7.0 
Mazya et al 2012 Continuous 7.1 0.5 546 6.6 0.4 29018 1.8 
Uyttenboogaart et al 2008 
OR per increment 
and Continuous 
6.9 2.3 13 6.4 1.9 239 5.2 
Meurer et al 2010 OR per increment NR NR 18 NR NR 250 6.6 
Paciaroni et al 2009 OR per increment NR NR 2 NR NR 63 3.2 
Naganuma et al 2011 OR per increment NR NR 25 NR NR 553 4.3 
Hill et al 2005 OR per increment NR NR 52 NR NR 1083 4.6 
Demchuk et al 1999 OR per increment NR NR 13 NR NR 125 9.0 
          
C
li
n
ic
a
l 
T
ri
a
ls
 
NINDS  
(Bruno et al 2002) 
OR per increment 10.4 6.3 40 8.2 4.0 584 6.4 
ATLANTIS I & II  
(Bruno et al 2002) 
OR per increment NR NR NR NR NR NR 5.2 
SAINT I & II  
(Cucchiara et al 2009) 
OR per increment 7.5 2.9 54 7.3 2.7 911 5.6 
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2.3.2.1 Meta-Analysis of Observational Studies  
Meta-Analysis of Observational Studies Reporting Continuous Data 
Meta-analysis of the eight observational studies reporting means and standard deviations (SD) 
in SICH and non-SICH populations resulted in a pooled SMD of 0.87 (95% CI 2.61- 8.97; 
p<0.0001) using a random effects model. This indicates that a 2.3mmol/L (SMD x mean SD of 
2.7) change in admission glucose levels can make the difference between a patient being safe or 
being at risk of developing SICH post-thrombolysis.  
 
The OR of the association of glucose with SICH was calculated from the obtained SMDs for each 
of these studies. The resulting ORs and 95% CIs were then standardised to calculate the OR for 
SICH per 1mmol/L glucose (Table 2.5). Meta-analysis of these ORs using a random effects model 
resulted in a pooled OR of 2.41 (95% CI 1.23-3.59; p<0.0001) for the association of post-
thrombolysis SICH with admission blood glucose level per 1mmol/L. 
 
It was observed that the two largest datasets in the analysis (Mazya et al. 2012; Strbian et al. 
2012) produced very large SMDs and consequently inflated ORs, most probably due to the small 
SDs commonly observed in large datasets. Removal of these two studies from the analysis 
resulted in a pooled OR of SICH per 1mmol/L glucose of OR 1.60 (95% CI 1.34-1.86; p<0.0001). 
 
Meta-Analysis of Observational Studies Reporting Incremental Data 
For the six observational studies reporting the OR of SICH for an incremental increase in 
admission glucose levels, data was standardised to calculate the OR for SICH per 1mmol/L of 
glucose (Table 2.5). Meta-analysis of these ORs resulted in a pooled OR 1.08 (95% CI 1.01-1.15; 
p<0.0001). 
 
Pooled Meta-Analysis of Observational Studies 
Studies reporting continuous data and studies reporting incremental data were combined in a 
single meta-analysis, using ORs calculated per mmol/L glucose from all studies, For one study 
(Uyttenboogaart et al. 2008a) reporting both continuous and incremental data, only the OR 
per1mmol/L calculated from incremental data was used in the meta-analysis. This resulted in a 
pooled OR 1.23 (95% CI 1.08-1.38; p<0.0001) (Table 2.5). However, Egger’s regression test 
revealed a significant degree of publication bias (intercept value 2.65, standard error 0.64, two-
tailed p-value 0.002). This was supported by outliers (Mazya et al. 2012; Strbian et al. 2012) 
found in the funnel plot of each study’s odds ratio and standard error (Figure 2.9). Removal of 
these outliers still resulted in significant publication bias (intercept value 1.84, standard error 
0.26, two-tailed p-value<0.0001).  
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2.3.2.2 Meta-Analysis of Clinical Trials  
The three studies reporting data from five clinical trials (NINDS, ATLANTIS I and II, SAINT I and 
II) all reported the association of admission glucose levels with risk of SICH as OR per 
incremental increase in glucose levels. As with the observational studies, data was standardised 
to calculate the OR for SICH per 1mmol/L of glucose. Meta-analysis of these ORs resulted in a 
pooled OR of 1.01 (95% CI 0.87-1.14; p<0.0001) (Table 2.5). 
 
2.3.2.3 Comment on the Evaluation of Biomarkers Using Literature Based Meta-Analysis 
The benefits of analysing continuous rather than dichotomised/non-continuous data have been 
well described (Streiner 2002; Suissa & Blais 1995; Heritier & Ronchetti 2004; Royston et al. 
2006). Continuous outcome measures usually provide greater analytical power that should be 
retained if possible (Chinn 2000; Streiner 2002). However, the use of SMDs to understand the 
relationship between glucose and risk of SICH is not ideal, as demonstrated by large SMDs 
calculated for the two largest studies (Mazya et al. 2012; Strbian et al. 2012). While meta-
analysis of studies reporting ORs per increment of glucose may have led to a more accurate 
assessment of risk of SICH associated with admission glucose levels, the ORs reported by the 
respective studies are based upon either univariate analysis (Naganuma et al. 2011; Paciaroni et 
al. 2009; Cucchiara et al. 2009) or multivariate models incorporating different confounding 
variables (Uyttenboogaart et al. 2008a; Meurer et al. 2010; Hill et al. 2005; Demchuk et al. 
1999). Therefore the ORs reported in these studies are not strictly comparable. 
 
Meta-analysis of all published observational studies yielded OR 1.23 for the association of 
admission glucose levels with risk of post-thrombolytic SICH. However, the conversion of SMD 
to OR assumes that data in both the SICH and non-SICH study populations are normally 
distributed. In studies reporting glucose as a continuous variable, the standard deviations of 
glucose levels were higher in the SICH patients than non-SICH patients and large compared to 
the means, indicating that the data are not normally distributed (Altman & Bland 1996).  
 
Additionally, analysis of data from a study by Uyttenboogaart et al. (2008) found that the OR of 
SICH per mmol/L glucose calculated from SMD was substantially larger than that reported in 
the published paper (OR 2.37 compared to OR 1.41). This discrepancy may be due to the fact 
that the relationship between glucose and OR may not be linear. This possibility, as well 
investigation of normal distribution and the effects of univariate or multivariate analysis cannot 
be examined using the published information available, but is essential for understanding the 
true prognostic value of glucose as a candidate biomarker for SICH following thrombolysis. 
  
Table 2.5 Analysis of studies included in literature based meta-analysis of the association of glucose with post-thrombolytic symptomatic intracerebral haemorrhage. For 
studies reporting continuous data, standardised mean differences were calculated and then used to estimate odds ratios per 1mmol/L glucose. Studies reporting the association of 
symptomatic intracerebral haemorrhage (SICH) with incremental change sin admission glucose were standardised to an association (odds ratio) per 1mmol/L increase in admission 
glucose. Separate meta-analyses of observational studies and clinical trials were performed, using a random effects model to pool odds ratios per 1mmol/L glucose calculated for 
each study. CI, confidence interval. 
 
  
Standardised Mean Difference 
(SMD; 95% CI) 
Odds Ratio per 1mmol/L Glucose 
(OR; 95% CI; p-value) 
O
b
se
rv
a
ti
o
n
a
l 
 S
tu
d
ie
s 
Lansberg et al 2007 0.86 1.56; 95% CI: 1.14-2.14 
Katzan et al 2000 0.79 1.56; 95% CI: 1.00-2.44 
Tanne et al 2002 0.56 1.76; 95% CI: 1.04-2.97 
Alvarez-Sabin et al 2004 0.23 1.92; 95% CI: 0.26-14.07 
Cocho et al 2006 0.74 1.54; 95% CI: 1.05-2.26 
Strbian et al 2012 1.53 27.05; 95% CI: 15.62-46.86 
Mazya et al 2012 1.38 61.70; 95% CI: 47.77-79.70 
Uyttenboogaart et al 2008 (from continuous data) 0.26 2.37; 95% CI: 0.38-14.91 
Uyttenboogaart et al 2008 (from incremental data) - 1.41; 95% CI: 0.96-1.92 
Meurer et al 2010 - 1.03;  95% CI: 0.86-1.23 
Paciaroni et al 2009 - 1.01;  95% CI: 1.00-1.01 
Naganuma et al 2012  - 1.11;  95% CI: 0.96-1.26 
Hill et al 2005 - 1.10;  95% CI: 1.04-1.18 
Demchuk et al 1999 - 1.16;  95% CI: 1.01-1.32 
Pooled Odds Ratio 
 
1.23; 95% CI: 1.08-1.38; p<0.0001 
C
li
n
ic
a
l 
T
ri
a
ls
 
NINDS (Bruno et al 2002) - 1.11;  95% CI: 1.02-1.20 
ATLANTIS I & II (Bruno et al 2002) - 0.84;  95% CI: 0.69-1.02 
SAINT I & II (Cucchiara et al 2009) - 1.13;  95% CI: 1.05-1.20 
Pooled Odds Ratio 
 
1.01; 95% CI: 0.87-1.14; p<0.0001 
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Figure 2.9 Examination of publication bias in all observational studies included in literature based meta-
analysis of the association of glucose with post-thrombolytic symptomatic intracerebral haemorrhage. The 
funnel plot of odds ratio against standard error for each study revealed two outlying studies (Mazya et al. 2012; 
Strbian et al. 2012) and two-tailed Egger’s Regression test found evidence of significant publication bias (p=0.002). 
Iterative analysis and removal of the two outlying studies still resulted in significant publication bias (p<0.0001). 
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2.3.3 Individual Patient Data Meta-Analysis of Admission Glucose Level as a Prognostic 
Biomarker for Post-Thrombolytic SICH  
In light of the issues identified in performing a literature-based meta-analysis detailed in 
Section 2.3.2.3, it was concluded that an accurate investigation of the role of admission glucose 
levels in predicting post-thrombolytic SICH could only be performed by analysis of individual 
patient data (IPD). 
 
Given the relatively low incidence of SICH within a thrombolysed patient population, reliable 
evaluation of the relationship between glucose levels and SICH requires accumulation of data 
from as many studies as possible. Therefore authors of 15 observational studies identified 
through systematic review and qualitative analysis were contacted for IPD, with the aim of 
quantifying the absolute risk of post-thrombolytic SICH associated with admission glucose 
levels.  
 
Data was gained from 8 observational studies (53%), representing 83% of the potential patient 
data available (33,370 patients out of the possible 40,336 reported from literature). The 
characteristics of these 8 studies are detailed in Table 2.6. Mean admission glucose level was 
6.59mmol/L (SD=0.34mmol/L), mean onset time to treatment 186 minutes (SD=73 minutes), 
and mean baseline NIHSS score 13 (SD=2.4) for studies from which information was available.  
 
  
Table 2.6 Characteristics and patient demographics of studies contributing individual patient data for analysis of the association of admission glucose levels with risk of 
post-thrombolytic symptomatic intracerebral haemorrhage (SICH). Values are medians and interquartile ranges (IQR), unless specified otherwise. ECASS, European Cooperative 
Acute Stroke Study; NINDS, National Institute of Neurological Disorders and Stroke; OTT, onset to treatment time; SITS-ISTR, Safe Implementation of Thrombolysis in Stroke 
International Stroke Thrombolysis Register; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study. 
 
 
Alvarez-Sabin 
et al 2004 
Hill  
et al 2005 
Lansberg  
et al 2007 
Meurer  
et al 2010 
Paciaroni 
et al 2009 
Mazya  
et al 2012 
Tanne  
et al 2002 
Uyttenboogaart  
et al 2008 
Study Description  
Spanish 
prospective 
cohort study 
CASES 
Canadian 
prospective 
cohort study 
DEFUSE multi-
centre 
prospective 
open-label study 
US multi-
centre 
prospective 
cohort study 
Italian multi-
centre  
prospective 
cohort study 
SITS-ISTR multi-
national, prospective 
thrombolysis register 
Multi-national 
prospective 
cohort study 
Dutch prospective 
cohort study 
Total Number of Subjects 406 1049 74 268 65 30088 784 636 
Age 67.9 (10) 73 (63-80) 75 (64-82) 68 (60-76) 76 (62-88) 70 (60-77) 67 (58-72) 71 (58-79) 
Women (%) 58 (34.3) 512 (45.1) 32 (43.2) 123 (45.9) 29 (44.6) 12647 (42.0) 624 (52.0) 290 (45.6) 
OTT (mins) 
141  
(108-176) 
155  
(130-175) 
315  
(287-343) - - 
145  
(116-170) - 
174  
(139–210) 
NIHSS on admission 17 (9-25) 14(9-19) 12 (8-16) - - 12 (7-17) - 11 (7-16) 
Glucose, mmol/L  
6.56  
(5.39-8.00) 
6.60  
(5.70-8.10) 
6.69  
(5.65-7.96) 
6.47  
(5.51-7.99) 
6.11  
(5.28-7.25) 
7.20  
(5.70-7.90) 
6.78  
(5.72-8.22) 
6.20  
(5.40-7.40) 
Diabetes Mellitus (%) 34 (20.2) 180 (15.9) 20 (27.0) 59 (22.0) 14 (20.7) 5172 (17.2) 240 (20.1) 29 (12.4) 
SICH n (%)   
      
  
NINDS definition 
     
2242 (8.2) 126 (16.1) 36 (5.7) 
ECASS definition 20 (4.9) 49 (4.7) 5 (6.8) 23 (8.4) 
 
1563 (5.6) 
  
SITS-MOST definition 
  
5 (6.8) 
 
2 (3.07) 543 (1.9) 
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2.3.3.1 Absolute Risk of SICH Associated with Admission Glucose Level 
Studies measured SICH by three different classifications: 1) SICH per the National Institute of 
Neurological Disorders and Stroke (NINDS) classification: any deterioration in NIHSS score or 
death within 7 days combined with intracerebral haemorrhage of any type, on any post-
treatment imaging after the start of thrombolysis. 2) SICH per the European Cooperative Acute 
Stroke Study (ECASS) classification: any type of intracerebral haemorrhage on any post-
treatment imaging after the start of thrombolysis and increase of ≥4 NIHSS points from 
baseline, or from the lowest value within 7 days, or leading to death. 3) SICH per the SITS-MOST 
classification: a local or remote type 2 parenchymal haemorrhage on imaging 22-36 hours after 
treatment combined with a neurological deterioration of ≥4 NIHSS points from baseline or from 
the lowest NIHSS score between baseline and 24 hours or leading to death within 24 hours. 
Meta-analyses were performed separately for each classification of SICH (NINDS, ECASS and 
SITS-MOST).  
 
The incidence of SICH differed considerably depending on the classification of SICH, therefore 
each classification was considered separately in subsequent analyses. Three studies reported a 
NINDS classification of SICH (Mazya et al. 2012; Tanne et al. 2002; Uyttenboogaart et al. 2008) 
with a mean SICH rate of 10.0%, five reported an ECASS classification (Alvarez-Sabin et al. 2004; 
Hill et al. 2005; Lansberg et al. 2007; Meurer et al. 2010; Mazya et al. 2012) with a mean SICH 
rate of 6.1% and three reported a SITS-MOST classification (Lansberg et al. 2007; Paciaroni et al. 
2009; Mazya et al. 2012) with a mean SICH rate of 3.9%.  
 
Examination of glucose levels within each dataset found minimal evidence of a non-linear 
relationship between glucose levels and risk of SICH up to glucose levels of 30mmol/L. 
However, glucose levels in every dataset demonstrated a highly skewed distribution, therefore 
it was considered appropriate to log transform admission glucose values and use log10glucose in 
all subsequent regression analyses. Univariate logistic regression analysis performed 
independently on data from each study found a statistically significant association between 
admission glucose levels and risk of SICH in all but two studies (Paciaroni et al. 2009; 
Uyttenboogaart et al. 2008), with regression coefficients ranging from OR 2.03 (95%CI 1.43-
2.63, p<0.0001) (Mazya et al. 2012; SICH per SITS-MOST classification) to OR 6.17 (95%CI 0.98-
11.36, p=0.020) (Lansberg et al. 2007; SICH per SITS-MOST and ECASS classification) in those 
studies yielding a statistically significant association (Table 2.7). The small sample size and 
scarcity of SICH events in two studies (Paciaroni et al. 2009, n=65; Lansberg et al. 2007, n=74) 
was considered to result in a poor estimation of regression coefficients, therefore these studies 
were excluded from meta-analysis. 
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Table 2.7 Analysis of studies contributing individual patient data. Regression coefficients were calculated for 
each study in a univariate logistic model to assess the association between admission glucose levels and risk of 
symptomatic intracerebral haemorrhage (SICH). Glucose levels were log10 transformed before prior to regression 
analysis. CI, confidence interval; ECASS, European Cooperative Acute Stroke Study; NINDS, National Institute of 
Neurological Disorders and Stroke; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study. 
 
 
All Patients 
Mean Admission Glucose 
mmol/L (SD) Odds 
Ratio 
95% CI p-value 
 
SICH/ 
Total Population (%) 
SICH No SICH 
Alvarez-Sabin et al 2004       
ECASS  19 / 406 (4.68%) 7.96 (4.32) 7.00 (3.53) 3.01 0.19-5.83 0.037 
Hill et al 2005       
ECASS  43 / 1098 (4.47%) 8.67 (4.15) 7.40 (2.86) 2.32 0.52-4.12 0.012 
Lansberg et al 2007       
ECASS  5 / 74 (6.76%) 11.35 (5.70) 7.28 (2.77) 6.17 0.98-11.36 0.020 
SITS-MOST 5 / 74 (6.76%) 11.35 (5.70) 7.28 (2.77) 6.17 0.98-11.36 0.020 
Meurer et al 2010       
ECASS  23 / 268 (8.58%) 8.37 (3.34) 7.16 (2.78) 2.76 0.03-5.50 0.048 
Paciaroni et al 2009       
SITS-MOST 2 / 65 (3.08%) 5.78 (1.10) 6.50 (2.32) -0.99 -8.48-6.5 0.796 
Mazya et al 2012       
SITS-MOST 543 / 29440 (1.84%) 7.94 (3.11) 7.17 (2.50) 2.03 1.43-2.63 <0.0001 
ECASS  1563 / 29429 (7.60%) 8.08 (3.11) 7.14 (2.47) 2.56 2.21-2.92 <0.0001 
NINDS 2242 / 29497 (16.07%) 8.03 (3.07) 7.12 (2.45) 2.55 2.25-2.85 <0.0001 
Tanne et al 2002       
NINDS 126 / 658 (16.07%) 8.52 (3.13) 7.54 (3.23) 2.45 1.25-3.65 <0.0001 
Uyttenboogaart et al 2008       
NINDS 36 / 636 (5.66%) 7.51 (2.73) 6.56 (1.90) 1.45 -0.16-3.06 0.077 
 
 
 
Pooling of ORs obtained from individual regression analysis in meta-analyses gave the following 
results: OR 2.51 (95%CI 2.22-2.80, p<0.001) for SICH per NINDS classification, OR 2.56 (95%CI 
2.22-2.90, p<0.001) for SICH per ECASS classification. Only one study (Mazya et al. 2012) 
reported SICH per SITS-MOST classification after exclusion of two studies (Paciaroni et al. 2009; 
Lansberg et al. 2007), giving OR 2.03 (95% CI 1.43-2.63, p<0.001) (Figure 2.10). Calculation of 
absolute risk of SICH associated with each mmol/L of glucose found that at the current 
thrombolysis glucose threshold of 22 mmol/L, the absolute risk of a patient developing SICH is 
11.9% per NINDS classification, 8.2% per ECASS classification and 2.7% per SITS-MOST 
classification (Figure 2.11).  
 
  
 
 
 
 
 
 
Figure 2.10: Meta-analysis of studies contributing individual patient data. A two-step approach meta-analysis was performed using weighted log odds ratios calculated from 
individual patient data of each study cohort. Meta-analyses were performed separately for each definition of symptomatic intracerebral haemorrhage (NINDS, ECASS, SITS-MOST) 
using a fixed effects model. ECASS, European Cooperative Acute Stroke Study; I-squared (I2), measure of heterogeneity; NINDS, National Institute of Neurological Disorders and 
Stroke; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study. 
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Figure 2.11 Estimated absolute risk of post-thrombolytic SICH associated with admission glucose levels. Using 
the odds ratios obtained from two-step meta-analysis, absolute risk of symptomatic intracerebral haemorrhage 
(SICH) associated with each 1mmol/L increment of admission glucose level was calculated for the three definitions of 
SICH. For example, at the current thrombolysis glucose threshold of 22mmol/L, an individual would be expected to 
have an 11.9% absolute risk of SICH per NINDS definition, 8.2% per ECASS definition and 2.7% per SITS-MOST 
definition. ECASS, European Cooperative Acute Stroke Study; NINDS, National Institute of Neurological Disorders and 
Stroke; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study. 
 
  
-MOST 
CHAPTER TWO: BIOMARKERS FOR ISCHAEMIC STROKE – SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS 
99 
Exploratory multivariable analysis on the largest study cohort (Mazya et al. 2012; >30,000 
patients) found that risk of SICH was associated with four variables in addition to admission 
glucose level: age, baseline NIHSS score, hypertension and stroke onset to time of treatment 
(OTT). Multivariate logistic regression analysis still yielded a significant association between 
admission glucose level and SICH: OR 2.55 (95%CI 2.25-2.85, p<0.001) for SICH per NINDS 
classification, OR 2.20 (95%CI 1.81-2.58, p<0.001) for SICH per ECASS classification and OR 
1.78 (95%CI 1.15-2.41, p<0.001) for SICH per SITS-MOST classification. Furthermore, the 
analysis did not substantially alter the absolute risk of SICH, with absolute risk of SICH 
associated at an admission glucose level of 22mmol/L calculated as 11.2% per NINDS 
classification, 7.8% per ECASS classification and 2.4% per SITS-MOST classification. Significant 
interaction effects (p<0.05) were not observed between any of the five variables. 
 
2.3.3.2 Association of SICH with Poor Functional Outcome 
While patients with SICH have been shown to have an increased risk of poor and fatal outcome 
post-thrombolysis (Strbian et al. 2011), not all SICH events may be detrimental. The 
relationship between SICH and poor functional outcome and survival was assessed in the 
largest study cohort (Mazya et al. 2012; >30,000 patients). Incidence of mortality and 
dependence (mRS 3-6) within 3 months follow-up was significantly greater in the SICH 
population than in the non-SICH population, regardless of the classification of SICH used 
(p<0.0001). SICH per SITS-MOST classification was the strongest predictor of mortality (OR 
3.17, 95% CI 2.95-3.38, p<0.001, compared to NINDS classification: OR 2.46, 95% CI 2.37-2.56, 
p<0.001, ECASS classification: OR 3.09, 95% CI 2.96-3.12, p<0.001). SICH per ECASS 
classification was found to be the strongest predictor of dependence at 3 months (OR 3.70, 95% 
CI 3.41-3.99, p<0.001, compared to NINDS classification: OR 2.91, 95% CI 2.74-3.08, p<0.001, 
SITS-MOST classification: OR 3.33, 95%CI 2.90-3.75, p<0.001) (Table 2.8). Nonetheless, 
differences between SICH classifications were marginal, as indicated by overlapping confidence 
intervals. 
 
 
 
  
 
 
 
Table 2.8 Investigation of functional outcome in patients with SICH. Three-month outcomes in patients with and without symptomatic intracerebral haemorrhage (SICH) were 
assessed in the largest study cohort (Mazya et al. 2012; >30,000 patients). Dependence was defined as modified rankin score (mRS) of 3-6 and independence was defined as mRS 0-2. 
Events and non-events (alive vs dead, independence vs dependence) were examined for statistical significance of using Pearson’s Chi-square (2) test. Odds ratios (ORs) of the 
association between each definition of SICH and functional outcome were calculated using a random effects model. CI, confidence interval. 
 
 
SICH NINDS SICH ECASS SICH SITS-MOST 
 
No. of Patients /  
Total Population (%) 
 
  
No. of Patients /  
Total Population (%) 
 
  
No. of Patients /  
Total Population (%) 
 
  
 
SICH No SICH p value 
OR (95% 
CI); 
p value 
SICH No SICH 
p 
value 
OR (95% CI); 
p value 
SICH No SICH 
p 
value 
OR (95% CI); 
p value 
M
o
rt
a
li
ty
 w
it
h
in
 
3
m
o
n
th
s 
1179 / 2024 
(58.3%) 
2451 / 23076 
(10.6%) 
<0.0001 
2.46 
(2.37-2.56); 
<0.001 
1059 / 1457 
(72.7%) 
2556 / 23593 
(10.8%) 
<0.0001 
3.09 
(2.96-3.21); 
<0.001 
394 / 505 
(78.0%) 
3180 / 24474 
(13.0%) 
<0.0001 
3.17 
(2.95-3.38); 
<0.001 
D
e
p
e
n
d
e
n
ce
 a
t 
 
3
 m
o
n
th
s 
1864 / 2010 
(92.7%) 
9352 / 22739 
(41.1%) 
<0.0001 
2.91  
(2.74-3.08); 
<0.001 
1400 / 1448 
(96.7%) 
9770 / 23252 
(42.0%) 
<0.0001 
3.70  
(3.41-3.99); 
<0.001 
483 / 505 
(95.4%) 
10633 / 24124 
(44.1%) 
<0.0001 
3.33  
(2.90-3.75); 
<0.001 
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2.4 Discussion 
 
While numerous molecules have been suggested as diagnostic and prognostic biomarkers of 
ischaemic stroke, their clinical relevance is unclear. To assess the utility of blood-based 
biomarkers in improving the diagnosis and prognosis of ischaemic stroke in the acute phase 
(within 24 hours of onset), a systematic literature review was conducted.  
 
Systematic literature review identified 137 blood-based candidate biomarkers implicated for 
diagnosis or prognosis of ischaemic stroke. Subsequent meta-analysis found that few withstood 
statistical scrutiny, with only 12 diagnostic biomarkers (ICAM-1, glucose, HDL cholesterol, 
triglyceride, TNF-α, CRP, IL-6, fibrinogen, P-selectin, IL-10, S100B and MMP-9) and 5 prognostic 
biomarkers (glucose, fibrinogen, D-Dimer, creatinine and PAI-1) being significantly associated 
with acute ischaemic stroke. These findings demonstrate the value of performing meta-analysis 
in order to discount potential candidate biomarkers that have inflated associations in single, 
under-powered studies. It also highlights the importance of designing well-powered studies for 
biomarker discovery, which contain multiple independent levels of replication and validation, in 
order to reduce false positive associations. In line with this, Ioannidis & Panagiotou (2011) 
recently commented upon the risk of individual studies exaggerating biomarker associations 
and the caution needed in interpreting the reported results. 
 
Diagnostic and Prognostic Biomarkers of Ischaemic Stroke 
Ten candidate biomarkers were identified that could significantly differentiate between 
ischaemic stroke and healthy controls. The majority of these candidates fell into three main 
categories: endothelial cell adhesion (ICAM-1, P-selectin), lipid metabolism (triglyceride, HDL 
cholesterol) and immune response (TNF-α, CRP, IL-6, IL-10). Upregulation of ICAM-1 and P-
selectin has been widely reported in experimental models of cerebral ischaemia (Nishiwaki et 
al. 2003; Love & Barber 2001), being responsible for neutrophil adhesion and an indication of 
compromised vessel integrity (Zhang et al. 1999). Dyslipidaemia is a well-known risk factor for 
CVD and high triglyceride and low HDL cholesterol levels have been reported during acute 
ischaemic stroke, although this association likely represents an intricate biological interaction 
that may not be most suitably represented by the results of previous multivariate analyses 
(Miller et al. 2011; Kisialiou et al. 2012).  
 
A number of studies have also established a key role for inflammatory responses in 
atherosclerosis, cardiovascular disease and in the acute phase pathophysiology of ischaemic 
stroke (Ross 1999; Pearson et al. 2003; Tamam et al. 2005). Initial inflammation during acute 
CHAPTER TWO: BIOMARKERS FOR STROKE – SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS 
102 
ischaemic stroke stimulates the production of acute phase proteins involved in the innate 
immune response, including TNF-α, fibrinogen and CRP. Consistent with this knowledge, acute 
phase proteins were found to be significantly higher in patients with ischaemic stroke as 
compared to healthy controls in this meta-analysis. In particular, CRP has gained popularity in 
recent years and has been proposed to be useful as a risk stratifying, diagnostic and prognostic 
biomarker for ischaemic stroke (Di Napoli 2001). However, in the current study, deeper 
examination of CRP levels in ischaemic stroke and healthy control populations demonstrated 
considerable overlap in distribution profiles, indicating that despite CRP being a recognised 
pathophysiological player in ischaemic stroke, a biomarker test based upon CRP is unlikely to 
provide the sensitivity or specificity required for a clinically valuable diagnostic tool (Greenland 
& O’Malley 2005). 
 
The candidate biomarkers above can differentiate between ischaemic stroke patients and 
healthy controls. However, the clinical relevance of such biomarkers is questionable. An ideal 
biomarker test should be able to distinguish between ischaemic strokes patients and individuals 
with suspected stroke and stroke-like symptoms (stroke mimics), to replicate a realistic clinical 
environment. One candidate biomarker, MMP-9, was found to be able to significantly 
differentiate between ischaemic and haemorrhagic stroke. Differentiating between ischaemic 
and haemorrhagic stroke is a critical step in planning immediate stroke management. Both 
types require specific protocols of action, for example, rt-PA treatment is beneficial to ischaemic 
stroke patients but can be potentially lethal to haemorrhagic stroke patients. While CT imaging 
can distinguish between ischaemic and haemorrhagic stroke types with high sensitivity, a 
blood-based biomarker test for stroke could allow patients to be triaged even before entering 
the hospital e.g. inside an ambulance. MMP-9 plays an important role in cell adhesion and extra-
cellular matrix breakdown, thus mediating the integrity of microvasculature and the blood-
brain barrier, explaining why MMP-9 levels were found to be much higher in haemorrhagic 
stroke as compared to ischaemic stroke patients (Kavalci et al. 2011). 
 
A diagnostic biomarker test with the ability to distinguish between ischaemic stroke and stroke 
mimics would also be clinically useful for effective stroke management. Systematic review of the 
literature revealed few studies examining biomarker differences between ischaemic stroke 
patients and stroke mimics (Glickman et al. 2011; Ahn et al. 2011; Foerch et al. 2012; Doehner 
et al. 2012; Airas et al. 2008; Rainer et al. 2007). Only one biomarker, S100B, was reported in 
more than one study and amenable to meta-analysis. S100B is an astrocyte-derived protein 
known to be elevated during ischaemic stroke and cerebral damage. Disruption of the blood-
brain barrier during stroke causes the release of brain-derived molecules into the bloodstream 
(Aoki et al. 2002; Kastrup et al. 2008; Jin et al. 2010). Thus blood-based, brain-derived 
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biomarkers have the potential to be accurate measures of cerebral damage following stroke. 
However, S100B is a common brain-derived protein which is up-regulated in a number of 
traumatic situations, therefore its specificity and sensitivity in a clinical setting is debatable. 
 
Candidate biomarkers identified as being significantly associated with poor prognosis following 
ischaemic stroke could be classified as metabolites (glutamate, glucose, creatinine) and proteins 
involved in coagulation and fibrinolysis (fibrinogen, D-dimer, PAI-1). The amino acid glutamate 
is the most abundant neurotransmitter in the brain, and it is likely that high levels are an 
indication of the extent of neuronal damage and therefore prognosis following stroke (Jin et al. 
2010). Elevated creatinine levels have also been associated with ischaemic stroke, implicated as 
an indication of subtle renal damage consequent to raised blood pressure and thus a risk factor 
for cerebrovascular disease (Wannamethee et al. 1997).  
 
The benefits of thrombolytic therapy for AIS have been well documented, significantly reducing 
the proportion of patients dead or dependent six months after stroke (Wardlaw 2009). 
Nevertheless haemorrhagic transformation is a common complication, and while SICH occurs in 
an estimated 6% of treated stroke patients, it has a fatality rate of 50-80% (Hacke et al. 2004).  
Studies have shown that poor outcome and risk of intracranial haemorrhage following tPA 
administration increases outside the optimum 3-hour treatment window, determined in part by 
disruption of the blood-brain barrier (Aoki et al. 2002; Kastrup et al. 2008; Jin et al. 2010). 
However, clinicians may overestimate the risk of ICH when considering rt-PA treatment and an 
excessive fear of haemorrhagic transformation complications remains a key reason for 
clinicians to withhold thrombolytic therapy (Derex & Nighoghossian 2008). Therefore a 
prognostic biomarker would be helpful for predicting poor outcome following thrombolysis and 
aiding patient selection and stratification, allowing safe administration thrombolytic therapy as 
quickly as possible.  
 
PAI-1 was found to be significantly associated with risk of SICH post-thromobolysis. PAI-1 is a 
protein involved in the coagulation/fibrinolysis cascade, and is a major inhibitor of tissue 
plasminogen activator, the molecule found in licensed thrombolytic therapy. Thus the decrease 
in PAI-1 in patients developing SICH can be explained by the fact that lower PAI-1 levels 
enhance a fibrinolytic state, predisposing to intracranial bleeds (Ribo et al. 2004).  
 
In addition to PAI-1, elevated admission glucose levels were shown to be associated with post-
thrombolytic SICH as well as poor outcome (mRS 3-6) and in-hospital death following ischaemic 
stroke. It is well established that conditions such as stroke and myocardial infarction can lead to 
an increase in glucose levels, with hyperglycaemia occurring in up to 60% of stroke patients 
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without known diabetes (Kiers et al. 1992; Van Kooten et al. 1993). There is also ample 
evidence to suggest that high glucose levels are detrimental in cerebral ischaemia, as 
summarised in a meta-analysis by Capes et al. (2001). Hyperglycaemia has been shown to 
aggravate microvascular lesions, leading to a cascade of events including cellular acidosis, 
increased free radical production and the initiation of cell death. With the up-regulation of 
matrix metalloproteinases (MMPs) during thrombolytic therapy, ischaemic damage to the 
vessel basal lamina may increase, damaging the integrity of vessel walls and causing 
haemorrhage (Montaner et al. 2003). 
 
Admission Glucose Level as a Prognostic Biomarker of Post-Thrombolytic SICH 
The possible use of glucose in a blood-based biomarker to predict risk of SICH has the 
advantage of glucose being a simple, routinely measured clinical variable, thus removing the 
need for a test based upon biomarkers that could potentially require longer and more complex 
laboratory analysis.  
 
High blood glucose levels can be particularly detrimental after thrombolysis, with 
hyperglycaemic patients being less likely to recanalise (Ribo et al. 2005) and more likely to have 
SICH and poor outcome, even after recanalisation (Demchuk et al. 1999; Alvarez-Sabin et al. 
2003; Dharmasaroja et al. 2012). To explore the prognostic value of admission glucose values in 
predicting post-thrombolytic SICH, separate literature-based systematic review and meta-
analyses were performed. Meta-analyses of observational studies and clinical trials suggested a 
small yet significant association of glucose levels with SICH. However, these findings were 
subject to a number of limitations, as discussed in Section 2.3.2.3, and could not provide 
accurate quantification of the relationship between admission glucose levels and absolute risk 
of SICH. Therefore an individual patient data (IPD) analysis, consisting of 32,000 subjects and 
the largest of its kind to date, was conducted to address these issues.  
 
Current international glucose guidelines for thrombolysis, set at 22mmol/L, are based upon 
exclusion criteria from the NINDS trial (n=624) in 1995. However, these guidelines have no 
scientific foundation, and post-hoc analysis of the NINDS trial found that admission blood 
glucose level is associated with poor outcome and SICH post thrombolysis (Ingall et al. 2004). A 
number of recent studies have also supported this finding: Putaala et al. (2011) recently 
reported that hyperglycaemia (≥8.0 mmol/l) up to 48 hours after intravenous rt-PA is strongly 
associated with poor outcome, SICH and death; Demchuk et al. (1999) reported that glucose 
levels >11mmol/L are associated with a 25% increased risk of SICH and Alvarez-Sabin et al.  
(2004) that a value of >7.7mmol/L may counterbalance the beneficial effect of thrombolysis.  
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A survey by the American College of Emergency Physicians (Brown et al. 2005) found that its 
members would only tolerate a risk of 3.4% SICH before thrombolysing (as compared to the 
6.4% risk reported in the NINDS trial). The results of this current IPD study found that at the 
current thrombolysis guideline admission glucose threshold of 22mmol/L, the absolute risk of a 
patient developing SICH was 11.9% using the NINDS classification, 8.2% with the ECASS 
classification and 2.7% with the SITS-MOST classification. Furthermore, using the SITS-MOST 
classification of SICH, the role of admission glucose in predicting SICH is slight (2.7% risk of 
SICH at 22mmol/L, 3.0% risk at 30mmol/L). Thus, contrary to previous studies, the findings 
lend evidence to suggest that the current glucose guideline threshold could be extended beyond 
22mmol/L. 
 
Many patients who experience SICH may already be destined for a poor outcome and may not 
have had their outcome altered as a result of the haemorrhage (Saver 2007). The Helsinki 
Stroke Thrombolysis Registry Group recently reported that despite SICH having a small 
contribution to stroke prognosis, patients with SICH had increased risk of death and poor 
outcome, with the ECASS (rather than NINDS or SITS-MOST) classification of SICH providing the 
largest contribution to worst outcome (Strbian et al. 2011). Similarly, the current study found a 
larger incidence of poor prognosis at 3 months in SICH patients than non-SICH patients, with 
SICH per SITS-MOST classification being the strongest predictor of mortality and SICH per 
ECASS classification being the strongest predictor of dependence (mRS 3-6).  
 
When interpreting these results, it is also important to remember that hyperglycaemia is not the 
only factor contributing to poor prognosis following thrombolysis. A number of multivariate 
scores have been developed for predicting SICH post-thrombolysis (HAT score, 3 variables (Lou 
et al. 2008); SEDAN score, 5 variables (Strbian et al. 2012); SITS score, 9 variables (Mazya et al. 
2012); Multicenter Recombinant Tissue-Type Plasminogen Activator Stroke Survey Group 
score, 4 variables (Cucchiara et al. 2008)). However, these scores are often limited by the 
consideration of variables in a dichotomised fashion. The results from this current IPD meta-
analysis benefit from analysing glucose as a continuous variable, having accounted for skewness 
in the distribution via log10 transformation, thus providing greater analytical power (Chinn 
2000; Streiner 2002). Investigation of confounding variables in the largest IPD study (Mazya et 
al. 2012) identified four factors (age, baseline NIHSS score, hypertension and stroke onset to 
time of treatment) aside from admission glucose levels that were associated with SICH. All of 
these factors have previously been identified in previous risk scores; nonetheless, adjustment of 
the model to include these factors did not substantially alter the absolute risk of SICH associated 
with an admission glucose level. The predictive capacity of the multivariate scores above has 
been moderate at best (Mazya et al. 2013), and this current study supports previous findings 
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that a mere association between risk factors and SICH does not assure their ability to predict 
risk of SICH in individual patients (Whiteley et al. 2012). Thus despite being associated with 
SICH outcome, it seems admission glucose level is of modest value for predicting the absolute 
risk of SICH after thrombolysis. 
 
Limitations of the Study 
As with any meta-analysis, there are a number of limitations worth consideration. It is difficult 
to avoid publication bias when conducting a meta-analysis. This was accounted for in part by 
manually searching abstracts and letters and performing Egger regression asymmetry tests. 
However, it has been noted that when considering fewer than ten studies, test power is usually 
too low to distinguish chance from real asymmetry (Sterne et al. 2011), therefore the lack of 
statistical significance for publication bias found in this study must be interpreted with caution.  
 
The scarcity of statistically significant biomarkers may in part be due to the fact that data could 
not be extracted from a number of studies, and many candidate biomarkers were only reported 
by a single study, therefore a meta-analysis could not be performed. However, biomarkers 
reported by more than one paper were either not significant upon analysis, or the studies were 
too statistically heterogeneous to be able to draw any firm conclusions. This underscores the 
need for studies examining candidate biomarkers to adhere to strict protocols and data 
reporting, for example by following the REMARK guidelines (McShane et al. 2005).  
 
Heterogeneity in study design and data presentation inhibited the inclusion of many studies 
into quantitative analysis. Papers that reported ORs without detailing the mean/ median and 
variability were excluded, as were papers reporting only ORs associated with a threshold value 
for a candidate biomarker. Meta-analyses were therefore conducted collectively to maintain 
high statistical power, rather than splitting studies based upon their sample of measurement 
(plasma/serum/whole blood); iterative analysis found that inclusion/exclusion of certain 
sample types did not make signiﬁcant differences to the results achieved. It is likely that the 
timing of a blood sample affects the concentrations of the biomarkers measured but this could 
not be explored owing to the paucity of data. Despite the presence of heterogeneity, a number of 
measures have been taken to limit its impact e.g. the use of the random-effects model and 
subgroup analysis. 
 
Examination of the relationship between admission glucose levels and SICH using IPD has 
overcome many of the challenges of heterogeneity associated with literature based meta-
analyses. The relative advantages of analysing IPD over published data are summarised in Table 
2.9. Importantly, the differing results obtained with literature based meta-analysis and IPD 
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meta-analysis demonstrate that the deductions of any meta-analysis must be considered within 
the context of its inherent limitations. 
 
 
Table 2.9: The relative merits of individual patient data meta-analysis over published literature-based meta-
analysis. 
 
Published Data Individual Patient Data (IPD) 
Data quality unclear and limiting Ensure data quality and standardise between studies 
Sub-group analysis not always possible Accurate sub-group analysis can be performed 
Multivariate analysis not always possible Option of performing multivariate analysis 
Outcome data not always available Flexible analysis of outcomes 
Analysis options limited Ensure appropriateness of analysis 
 
 
Conclusions from the IPD analysis are based upon data obtained from observational studies and 
not RCTs, which could be considered a limitation. However, several sources have queried the 
value of RCTs over other study designs (Sanson-Fisher et al. 2007; Rothwell 2005) or 
commented upon the similarities between data obtained from RCTs and observational studies 
(Golder et al. 2011). The sizeably larger subject population in the collection of observational 
studies as compared to clinical trials investigating stroke thrombolysis adds statistical power to 
the analysis conducted in this IPD meta-analysis. Thus the use of data from observational 
studies in our meta-analysis has allowed robust examination of the relationship between 
admission glucose levels and the risk of SICH, to reach conclusions that are likely to be more 
applicable to an uncontrolled clinical environment.  
 
Concluding Remarks 
This study has found that despite a plethora of candidate biomarkers being investigated for the 
diagnosis or prognosis of ischaemic stroke, most of these markers are evaluated in too few 
studies to infer any true clinical relevance. While meta-analysis found candidate biomarkers of 
statistical signiﬁcance likely to be indicative of the pathophysiology of stroke, these may have 
only marginal translational value (as demonstrated upon examination of CRP and glucose) and 
prospective studies will be required to further evaluate whether they stand up to scrutiny. Thus 
it can be concluded that at present, no diagnostic or prognostic biomarkers for acute ischaemic 
stroke can be recommended for routine clinical practice. This supports the pursuit of novel 
biomarkers for ischaemic stroke using non-bias, non-targeted approaches that are not 
constrained by the current understanding of stroke pathophysiology. 
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Systematic review of the literature also highlighted many limitations of study design that are 
likely to explain why many reported impressive biomarker associations could not be replicated 
upon meta-analysis. Effective assessment of a candidate biomarker requires a well-powered 
study with multiple levels of replication and validation. The study must also be performed in 
clinically relevant disease and control populations. These findings helped to inform and develop 
the design of biomarker discovery studies conducted in Chapter 3 and Chapter 4 of this thesis. 
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3.1 Introduction 
 
In Chapter 2, systematic literature review revealed a number of studies advocating biomarkers 
for ischaemic stroke, the vast majority of which were examined through targeted, candidate-
based investigations. The data obtained from these reports provides evidence for the possibility 
that molecules released into the bloodstream within the acute phase of stroke could form the 
basis for sensitive diagnostic tests. Nonetheless, the findings also highlighted the current 
absence of clinically valuable biomarkers.  
 
The challenges of AIS diagnosis have been previously discussed in Chapter 1, with CT imaging 
being insensitive to acute lesions and MRI imaging being expensive and unavailable in many 
hospitals. Thus the search for novel diagnostic biomarkers for acute ischaemic stroke has 
received growing attention (Whiteley et al. 2008).  
 
With blood being readily accessible for clinical evaluation, analysis of human plasma is a 
promising approach to biomarker discovery. Studying the proteome through high-throughput 
plasma proteomic pattern analysis can directly inform on energy changes and molecular 
mechanisms underpinning acute insults. Therefore proteins are useful not only for 
understanding the pathogenesis of complex diseases such as AIS, but also have the potential to 
be used as accurate diagnostic biomarkers.  
 
Early investigations have established SELDI-TOF MS protein profiling as a valuable platform for 
biomarker discovery in ovarian and breast cancer, with studies reporting biomarkers with over 
90% sensitivity and specificity (Petricoin et al. 2002; Li et al. 2002). In vascular disease, SELDI-
TOF MS has been used to study acute coronary syndrome (Florian-Kujawski et al. 2004) and 
carotid atherosclerosis (Degraba et al. 2011). Studies  have also employed SELDI-TOF MS for the 
detection of diagnostic biomarkers for ischaemic and haemorrhagic stroke (Allard et al. 2004; 
Zhang et al. 2008; Staals et al. 2008), providing further evidence for the utility of this 
experimental approach (Table 1.3, Chapter 1). 
 
Aims of the Study 
The aim of the following study was to make progress towards developing a blood-based 
diagnostic test for AIS by: 
 Comparing plasma protein profiles from patients with AIS against non-AIS individuals. 
 Assessing the merits of both single marker and multi-marker models. 
 Identifying candidate markers with discriminating potential.  
CHAPTER THREE: PROTEOMICS FOR DIAGNOSTIC BIOMARKER DISCOVERY 
112 
3.2 Methods 
 
3.2.1 Materials 
Proteinchip CM10 arrays, all-in-one peptide standard and all-in-one protein-standard were 
obtained from Bio-Rad Laboratories Inc. (Hercules, CA, USA).  Sinapinic acid (SPA) and alpha-
cyano hydroxy cinnamic acid (CHCA) (>99% purity for MALDI-MS) were obtained from 
Fluka/Sigma-Aldrich Company Ltd. (Dorset, UK). High-performance liquid chromatography 
(HPLC) grade acetonitrile (ACN) was obtained from VWR International Ltd. (Lutterworth, UK). 
Trifluoroacetic acid (TFA) was from Rathburn Chemicals Ltd. (Walkersburn, Scotland).   
 
 
3.2.2 Patient Selection and Sample Acquisition 
 
3.2.2.1 Pilot Study 
For the pilot study, blood samples were collected after written consent from recruited patients, 
under guidelines approved by the Hammersmith and Queen Charlotte’s and Chelsea Hospitals 
Research Ethics Committee. Thirteen patients diagnosed with AIS were recruited for the study, 
having had their lesions confirmed by MRI on recruitment and 10 days later. Blood was 
collected from these patients within 24 hours of symptom onset and then again in a follow-up 
session 2–4 months after the initial stroke. These follow-up samples served as controls for the 
study, with the assumption that the patients were healthy and no longer had any acute stroke 
symptoms. Furthermore, two patients diagnosed with TIA and two stroke mimics were included 
as comparative subjects in the study.  
 
Blood samples were collected in ethylene di-amino tetra-acetic acid (EDTA) tubes and 
centrifuged at 1300g for 10 minutes, within 30 minutes of collection. The plasma samples 
obtained from centrifugation were aliquoted into 200μl volumes and immediately frozen 
at -80oC until required. All samples were collected and processed under a stringent protocol, 
developed through consideration of Human Proteome Organisation (HUPO) Plasma Proteome 
Project recommendations (Rai et al. 2005). This included drawing blood from the median 
cubital vein only, and leaving sufficient time between sterilisation and blood withdrawal to 
allow complete evaporation of the sterilising alcohol. Blood was drawn until one whole EDTA 
tube was filled, and then the tube was inverted ten times to ensure effective mixing of the blood 
with the anticoagulant EDTA. 
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3.2.2.2 Replication: Discovery Phase Study 
For the discovery phase study, samples collected under similar conditions as detailed above 
were obtained from the University of Edinburgh under a Materials Transfer Agreement. This 
cohort consisted of acute plasma samples from 404 subjects: 235 patients with CT or MRI-
confirmed AIS, 15 with haemorrhagic stroke (13 ICH, 2 Subarachnoid Haemorrhage), 72 with 
TIA and 82 stroke mimics.  
 
The cohort was divided into three sets to allow independent replication of experimental 
conditions and candidate markers:  
Training Set: 20 AIS + 20 Non AIS (10 TIA, 10 Stroke Mimics)  
Test Set: 32 AIS + 32 Non AIS (16 TIA, 16 Stroke Mimics) 
Validation Set: 300 subjects (183 AIS, 46 TIA, 13 ICH, 2 SAH, 56 Stroke Mimics) 
 
 
3.2.3 SELDI-TOF MS Proteomic Profiling 
 
3.2.3.1 Principles of SELDI-TOF MS 
SELDI-TOF MS is a variation of MALDI-TOF MS, coupling selective protein binding using 
ProteinChip technology with quantitative mass detection. Two major types of ProteinChip 
surfaces exist: chemical (e.g. anionic, cationic, hydrophilic, hydrophobic, immobilised metal 
affinity metal) and biological (e.g. antibody, receptor, DNA, enzyme). This spectrum of different 
arrays allows a broad range of the proteome to be analysed: the variety of ProteinChip surface 
chemistries selectively capture specific proteins from complex biological samples while 
simultaneously removing detergents and salts. Hence information about a protein’s chemical 
properties can be determined, as proteins bind to the array surface through specific chemical 
interactions.  
 
The MS element of the SELDI-TOF MS technique is based upon the principles of matrix-assisted 
laser desorption/ionisation (MALDI)-TOF technology. In SELDI-TOF MS, some peptides and 
proteins are selectively adsorbed onto chemically modified surfaces while others are washed 
away. An energy-absorbing matrix solution crystallises with the sample, responsible for 
converting laser energy to thermal energy to facilitate the desorption/ionisation process. 
 
The mass spectrum is recorded by the ProteinChip Reader, a laser desorption ionisation time-
of-flight MS instrument. When the matrix on the surface of the ProteinChip absorbs energy at 
the wavelength of the pulsed ultraviolet nitrogen laser of the ProteinChip Reader, proteins 
within the sample/matrix mixture desorb and are ionised in the gas phase. These ions are 
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accelerated down a flight tube through an electric potential and a detector at the end of the tube 
measures the time of flight.  The mass-to-charge ratio of each ion can be determined from the 
length of the tube, the kinetic energy given to ions by the electric field, and the time taken to 
travel the length of the tube (Figure 3.1). 
 
The analyser used for SELDI is specially designed to achieve high-sensitivity quantification. The 
ion source and detector are adapted for efficient ion transmission and detection over a wide 
mass range, with the system being generally more favourable for proteins and peptides with 
molecular weight lower than 20kDa (Wiesner 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Illustration of SELDI-TOF MS technology. Upon application of a plasma sample onto a ProteinChip 
array, a subset of plasma proteins is retained on the chip surface, dependent on the interacting  physico-chemical 
properties. These proteins are co-crystallised with a matrix solution. Inside the mass spectrometer, a laser induces 
desorption & ionisation of protein ions, which are accelerated down a flight tube through an electric potential based 
upon their mass to charge (m/z) ratio (normally z=1). The detector converts the arrival time of the protein ions into a 
spectral profile depicting the quantity of detected protein ions versus its m/z ratio.  
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3.2.3.2 Sample Pre-Processing 
Experiment design and protocol were created according to recommendations from Bio-Rad 
Laboratories Inc. (2008). Samples were applied to a weak cation exchange (CM10) chip. Thawed 
plasma samples were denatured by the addition of a solution of 9M urea, 2% CHAPS, 5mM DTT, 
and were incubated for 1 hour on a vortex mixer. This was followed by a 1:10 or 1:20 plasma 
dilution in binding buffers of pH3, pH4, pH6 (0.1M sodium acetate plus 1M acetic acid to adjust 
to final pH) or pH8 (0.1M trizma base, plus 1M acetic acid to adjust to final pH). The interactive 
relationship between the CM10 chip, binding buffer and plasma proteins are illustrated in 
Figure 3.2. 
 
3.2.3.3 Target Chip Preparation and Sample Incubation 
CM10 chips were assembled in a bioprocessor consisting of a plastic cassette and aluminium 
frame, which together allow isolation of each individual spot on the chip for application of 
different samples and buffers. The interactive spots of the chips were equilibrated twice with 
200μl of binding buffer within the bioprocessor assembly (Ciphergen Biosystems Inc., 
Freemont, USA) for 5 minutes, followed by incubation of 150μl of the diluted plasma samples 
for one hour with orbital shaking at 1050rpm (Heidolph Titramax 100 shaker). Solutions in the 
wells were discarded and the chips were washed three times with binding buffer for 5 minutes 
per wash, followed by one brief wash with deionised water to remove excess salts. Each 
washing step was performed with orbital shaking. The chips were then removed from the 
bioprocessor and allowed to air dry. Saturated solutions of SPA and CHCA energy absorbing 
matrix were prepared according to the recommendations of the manufacturer (in solution of 
50% ACN and 0.5% TFA). The matrix was added twice to each spot (either SPA: 0.5μl x 2 or 
CHCA: 0.8μl x 2) and the spots were allowed to air dry. 
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Figure 3.2: The dynamic interaction between the CM10 ProteinChip array surface, experimental buffers and 
plasma proteins. The CM10 ProteinChip array incorporates carboxylate chemistry (negative charge), thus operating 
as a weak cationic exchanger whose selectivity can be varied depending on buffer pH. The net charge of a protein can 
be manipulated by buffer pH and depends upon the side chain (‘R’), which is unique to each amino acid, as well as the 
amino (H2N) and carboxyl (COOH) groups of each amino acid. The positively charged amino groups of lysine and 
arginine amino acids and the negatively charged carboxyl groups of aspartic acid and glutamic acid amino acids 
primarily determine the electrochemical character of a protein. A) When the buffer pH matches a protein’s isolectric 
point (pI), the protein’s amino acids have an overall neutral charge. Most plasma proteins have a pI in the range of 
pH5-7. B) Decreasing the buffer pH (more acidic) neutralises acidic amino acids and imparts an overall net positive 
charge on plasma proteins due to amino groups and basic amino acids, such as lysine and arginine carrying a positive 
charge. Therefore a greater number of proteins bind to the CM10 surface. C) Conversely, increasing pH (more basic) 
neutralises basic amino acids and imparts an overall net negative charge on amino groups and acidic amino acids such 
as aspartic acid and glutamic acid within the proteins, resulting in less binding. Protein binding specificity can also be 
modified by varying the ionic strength of the buffer; increasing ionic strength increases competition between protein 
ions and buffer ions, causing weakly bound proteins to be eluted from the CM10 surface. Low stringency buffers (e.g. 
sodium acetate, trizma base) were used throughout to maximise protein yield. 
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3.2.3.4 Data Acquisition 
The CM10 chips were analysed using a Protein Biology System IIc Reader (Ciphergen 
Biosystems Inc., Freemont, USA) which was calibrated for mass accuracy using ‘All in One’ 
peptide and protein standards. During the discovery phase study, a pooled ‘quality control’ 
sample from the pilot study was included on eight spots during each experiment to ensure 
reproducibility. 
 
The TOF-MS spectra were generated by averaging 117 pulsed UV laser shots with an intensity of 
200-210 units when SPA was used and 160-180 units when CHCA was used. Two warming 
shots were fired at a laser intensity of 5 units greater than acquisition and the data from these 
shots was discarded. Peak detection was performed using Biomarker Wizard software 3.1 
software (Ciphergen Biosystems Inc., Freemont, USA). All peaks from m/z 2000 to 30,000Da 
with a signal to noise ratio above 5 at first pass and 2 at second pass were auto-detected and the 
peaks were aligned within 0.3% of mass error. Molecular masses below 2000Da were not 
analysed due to masking of peptide signals by peaks from the matrix. All peaks detected were 
required to be present in at least 5% of the spectra, in an attempt to avoid inclusion of peaks 
with poor discriminatory power. Automatic baseline correction was used and data filtering was 
set as default at 0.2 times expected peak width. 
 
3.2.3.5 SELDI-TOF MS Protocol Optimisation  
The SELDI-TOF MS protocol was optimised in a number of ways to ensure high quality data 
acquisition and processing. Plasma samples were diluted 1:100 and 1:200 in buffer to ascertain 
which dilution gave a better protein profile, without saturating the detector. Matrix application 
was standardised by using different volumes (but same concentration) of matrix solution to 
ensure the solution covered the entirety of each spot, and drying times between matrix 
applications were also controlled. The data acquisition protocol was optimised on the Ciphergen 
software by adjusting the following parameters: detector sensitivity, mass range, focus mass, 
matrix attenuation, warming shot energy and data shot energy. The number of peaks detected, 
dependent on settings used, ranged from 37 to 106. 
 
In order to investigate data quality, the total ion current (TIC) from m/z 2000 to 20,000 was 
measured and compared between spectra of different samples. This normalisation process 
calculates an average TIC from all spectra over a mass range appropriate to the matrix used (2–
10kDa for CHCA and 10– 50kDa for SPA) and adjusts the intensity scales for all the spectra to 
this average.  
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3.2.4 Data Interpretation and Analysis 
Protein ions detected by the Biomarker Wizard software (and distinguished as ‘peaks’) were 
exported into Microsoft Excel as intensity values. Means and the intra-assay coefficient of 
variation (CV) values for each peak were calculated from replicates, and differences between 
mean peak intensities were compared between sample groups. Mann-Whitney test (unpaired) 
or Wilcoxon Signed Rank test (paired), were used to examine statistical significance. Proteins 
showing significant differences between analysis groups (p<0.05) were selected for further 
analysis.  
 
Data were subjected to unsupervised analysis by Principal Component Analysis (PCA), and 
visualised with scatter plots and volcano plots using GraphPad Prism v4 and Statistica v6.1 
(Statsoft Ltd) software.  
 
The relative merits of a single marker and multi-marker diagnostic test for cerebral ischaemia 
were assessed. Discriminant function analysis, utilising a forward step-wise regression model, 
was performed to determine variables that were able to discriminate between the clinical 
groups. With this type of model, at each step all variables are assessed to evaluate which one 
contributed most to the discrimination between groups; this variable is incorporated into the 
model and the process starts again, in a forward step-wise manner until a robust model of the 
most discriminating factors is built. The process is guided by F to enter and F to remove values, 
with the F value of a variable (the ratio of the intergroup variance over the average intragroup 
variance) determining whether or not that variable has the ability to discriminate between the 
groups. All protein ions as well as continuous phenotypic variables (age, admission NIHSS, time 
of blood sampling) were used as variables, with an F to enter value set at 4 and F to remove set 
at 3.9. 
 
Protein ions identified through discriminant function analysis (DFA) were used to build a 
multiple regression model. Iterative reverse step-wise analysis was performed to generate 
classification matrices. Receiver Operating Characteristic (ROC) curves were generated from the 
regression model predicted values to calculate sensitivity and specificity and further assess the 
value of these ions independently or combined in a multi-marker model. The DeLong, Delong 
and Clarke-Pearson method (DeLong et al. 1988) was used for calculating the statistical 
difference between ROC curve areas. Standardised Mean Difference (SMD) and odds ratio (OR) 
were calculated using Comprehensive Meta-Analysis v2.0 software, as detailed in Chapter 2. 
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3.2.5 Identification and Quantification of Candidate Biomarker 
 
3.2.5.1 Immunodepletion of m/z6640 
Immunodepletion of the candidate biomarker was performed using two anti-human 
apolipoproteinC-1 (ApoC-1) antibodies, one mouse monoclonal (Abnova, Taipei City, Taiwan) 
and one rabbit polyclonal (Abcam, Cambridge, UK). A pooled plasma sample (previously used as 
a quality control sample) was incubated with anti-ApoC-1 antibody in 1:200 dilution in pH4 
buffer, with or without the addition of 9M urea, 2% CHAPS, on rotation for one hour. An 
antibody concentration curve was performed, from 0.18μg/ml to 18μg/ml. Control incubations 
using anti-ApoC-1 antibody only, plasma only, and affinity-purified rabbit IgG control (courtesy 
of Dr Robert Edwards) were used to confirm specificity. All samples were applied to CM10 
ProteinChips then processed by SELDI-TOF MS and analysed as detailed above. 
 
3.2.5.2 ApolipoproteinC-1 ELISA 
A total of 40 plasma samples were chosen from both Training and Test Sets to cover the range 
of intensities of m/z6640 detected by SELDI-TOF MS. Duplicate samples were measured by 
enzyme-linked immunosorbent assay (ELISA) kit (AssayPro, St Charles, MO, USA) as per 
manufacturer’s instructions. The assay employs a quantitative sandwich enzyme immunoassay 
technique, with immobilised polyclonal anti-ApoC-1 antibody on a 96-well microplate. Plasma 
samples were diluted 1:100 in the provided diluent, then 50μl of samples and standards were 
added to each well of the microplate and incubated at room temperature for 2 hours. Following 
five washes with 200μl of wash buffer, 50μl of biotinylated polyclonal ApoC-1 antibody was 
added to each well and incubated for 2 hours. The plate was washed again, as above, then 50μl 
of streptavidin-peroxidase conjugate was added to each well and incubated for 30 minutes. 
Following another washing step, 50μl of chromogen substrate was added to each well and 
incubated for 30 minutes, after which 50μl of stop solution was added. Colour intensity was 
measured at 450nm on a microplate reader within 10 minutes. 
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3.3 Results 
 
3.3.1 Pilot Study 
SELDI-TOF MS employs a variety of ProteinChip arrays and conditions to allow biomarker 
discovery. A pilot study was performed to optimise a number of variables for biomarker 
elucidation. The study consisted of 13 AIS patients (11 of which had paired acute and follow-up 
blood samples) as well as acute blood samples taken from 2 TIA patients and 2 stroke mimics 
(Table 3.1).  
 
3.3.1.1 Evaluation of Data Quality 
Establishing good reproducibility is critical before determining whether blood protein profiles 
differ in various clinical states. It is expected that the median intra-assay CV should be between 
10-20% (Bio-Rad Laboratories Inc. 2008). Preliminary experiments demonstrated a very high 
CV (>50%), therefore adjustments were made to the protocol to improve data quality. Extrinsic 
variables including instrument performance, buffer composition, sample preparation and 
acquisition settings were altered. However, the greatest improvement in CV was made by 
increasing plasma sample dilution from 1:100 to 1:200 to minimise detector saturation, and 
refining matrix preparation. A sample dilution of 1:200 combined with freshly made, saturated 
matrix, applied with careful pipetting to each interactive spot, decreased CV to a mean of 18%, 
similar to previously reported values (Schaub et al. 2004). Intra-assay CV values, pre- and post- 
optimisation of the experimental protocol, are shown for 6 protein ions of interest in Table 3.2. 
 
3.3.1.2 Investigating Matrix and pH Binding Conditions for Biomarker Discovery 
Three ProteinChip arrays are recommended for analysis of plasma proteins (Bio-Rad 
Laboratories Inc. 2008): the CM10 cation exchange, H50 reverse-phase and the IMAC30 
immobilised metal affinity chips. Previous work within the lab with plasma samples has found 
that CM10 chips produce the greatest number of detectable protein ions and also yield the 
highest number of significant differences between study groups (Dr Waheedah Abdul-Salam, 
personal communication). Therefore the CM10 chip was chosen for investigation. 
 
The CM10 ProteinChip array provides flexibility for biomarker discovery by allowing different 
subsets of proteins to bind to its surface by using a variety of pH buffers. In a preliminary study 
of 11 paired AIS samples (acute and follow-up) a range of pHs were used, from less stringent 
(pH3, pH4) to more stringent (pH6, pH8). Two different matrices were also used: CHCA (better 
for measuring proteins <20kDa) and SPA (for proteins >20kDa). Figure 3.3 depicts 
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representative spectra obtained from AIS plasma samples, using CM10 chips and SPA matrix at 
various pH binding conditions. 
 
The majority of proteins detected lay in the 2-20kDa molecular weight range. Nonetheless, it 
was found that SPA matrix yielded more detectable protein ions than CHCA, as well as more 
significantly different (p<0.05) ions (Figure 3.4A). The proportion of significantly differentially 
expressed ions was greater using SPA rather than CHCA matrix, implying that more of these ions 
detected with SPA were true positive associations rather than being false positives (type 1 error 
rate of 5%, at a threshold of p<0.05). Therefore this matrix was chosen for subsequent 
investigation. 
 
 
  
 
Table 3.1: Pilot study patient characteristics. Demographic and clinical information relating to the 13 AIS patients (from which paired acute and follow-up plasma samples were 
taken from 11 subjects), as well as 2 patients with TIA and 2 stroke mimics. Values are median and interquartile ranges (IQR), or range when n=2.   
 
 
 
 
Total Ischaemic 
Population (n=15) 
Large AIS 
 (>10 cm3 lesion 
volume)  
(n=4) 
Moderate AIS  
(>3 cm3 lesion 
volume)  
(n=3) 
Mild AIS  
(<3 cm3 lesion 
volume)  
(n=6) 
TIA  
(no lesion on MRI)  
(n=2) 
Stroke Mimics  
(no lesion on MRI)  
(n=2) 
Age 
70.00 
(62.00-81.00) 
63.00 
(54.50-78.25) 
82.00 
(70.00-91.50) 
63.00 
(47.50-74.50) 
73.00 
(65-81) 
74.50 
(70.00-79.00) 
Gender 5F, 10M 1F, 3M 2F, 1M 2F, 4M 0F, 2M 0F, 2M 
Admission NIHSS 
4.00 
(2.50-6.00) 
4.00 
(2.50-10.00) 
8.00 
(4.00-12.00) 
3.50 
(1.75-4.00) 
2.00 
(1-3) 
3.50 
(2-5) 
Time of Acute Blood Sampling 
(hours) 
14.00 
(7.50-22.00) 
13.00 
(4.38-20.50) 
17.00 
(13.00-21.00) 
7.75 
(4.38-21.00) 
6.50 
(2.00-11.00) 
20.50 
(18.00-23.00) 
Lesion Volume (cm3) 
3.30  
(0.75-13.40) 
15.50 
(12.65-16.70) 
3.80 
(3.30-5.60) 
0.75 
(0.43-1.15) 
n/a n/a 
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Figure 3.3: Representative SELDI-TOF MS spectra from the pilot study using CM10 ProteinChip arrays with 
SPA matrix. The pilot study consisted of 13 AIS subjects (11 from which paired acute and follow-up plasma samples 
were taken, the other two from which only acute plasma samples were available), 2 TIA subjects and 2 stroke mimics. 
The spectra show profiles of one acute AIS patient plasma sample, analysed on CM10 ProteinChip arrays with 0.1 M 
sodium acetate and 0.1% triton X-100 as the binding buffer at pH’s 3, 4, 6 and 8. Some protein ions appeared under 
many conditions, whereas others were unique to a single pH. Protein ions considered of interest (see Table 3.2) are 
labelled.  
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Figure 3.4: The effect of matrix choice and pH on plasma protein profiles in the pilot study. A) Total number of 
protein ions detected using SPA and CHCA matrix at various pHs (light blue bars) and number of significantly 
different ions (Wilcoxon Signed Rank test, p<0.05) between paired acute and follow-up plasma samples from 11 AIS 
patients (dark blue bars). B) A number of protein ions were significantly differentially expressed between acute and 
follow-up paired AIS samples and between AIS and TIA (n=15) and stroke mimics (n=2) using SPA matrix and 
different pH binding conditions, as calculated by Mann-Whitney or Wilcoxon Signed Rank test . In all but pH8, the 
proportion (%) of significantly different protein ions found, from the total number of peaks detected, is greater than 
5%, indicating that the pH3, pH4 and pH6 binding conditions yield more significantly different protein ions than 
would be expected by chance alone 
 
 
pH3 SPA pH4 SPA pH6 SPA pH8 SPA 
Total Number of Peaks Detected: 
 
46 73 53 59 
Number of Peaks Significantly Different (% of Total Number of Peaks Detected): 
Acute AIS 
(n=11) 
vs 
Follow-Up AIS 
(n=11) 
 
 
9 (19.6%) 
 
m/z 3901, 4163, 4316, 
4643, 6498, 6850, 7765, 
7927, 9243 
18 (24.7%) 
 
m/z 3093, 3224, 3331, 
3901, 3925, 4142, 4163, 
4196, 4286, 4803, 5397, 
6440, 6498, 6640, 6694, 
6765, 6850, 8706 
5 (9.4%) 
 
m/z 3136, 3579, 3888, 
7967, 8143 
2 (3.4%) 
 
m/z 3369, 22665 
AIS+TIA (n=15) 
vs 
Stroke Mimics 
(n=2) 
 
7 (15.2%) 
 
m/z 5199, 5237, 6640, 
9243, 9510, 15873, 
18305 
8 (11.0%) 
 
m/z 2719, 3013, 4142, 
15135, 15910, 16104 
11 (20.8%) 
 
m/z 3208, 3312, 3416, 
3579, 3888, 6833, 
11662, 12552, 12836, 
15872, 16047 
4 (6.8%) 
 
m/z 7019, 7765, 10467, 
14852 
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3.3.1.3 Preliminary Diagnostic Biomarkers 
Using SPA matrix, each pH binding condition produced different sets of protein ions that varied 
significantly in ion intensity between the various study groups (Mann-Whitney or Wilcoxon 
Signed Rank test, p<0.05), as shown in Figure 3.4B. 
 
Of the 63 significantly differentially expressed protein ions detected with SPA matrix at various 
pHs, six (9.5%) were considered as potential putative biomarkers for AIS (Table 3.2), based 
upon degree of statistical significance, fold difference and visual inspection of the ability of the 
protein ions to distinguish between study groups. Box and whisker plots for these nine protein 
ions are presented in Appendix 2. Two protein ions (m/z 4163, 3888) could differentiate 
between acute and follow-up AIS samples and four protein ions (m/z 6640, 3208, 3416, 7019) 
between AIS and TIA against stroke mimics. Thus the pilot study confirmed the hypothesis that 
SELDI-TOF MS is able to detect a protein profile that is significantly affected during acute 
ischaemic cerebral event. 
 
Table 3.2: Preliminary diagnostic biomarkers identified from the pilot study. Six protein ions from the pilot 
study were selected as ‘putative markers’ from the pilot study. Protein ions were captured using binding conditions 
of pH3, pH4, pH6 and pH8, on CM10 ProteinArray chips with SPA matrix. The putative markers were selected based 
upon visual inspection of their ability to distinguish between study groups, as well as degree of significance 
(Wilcoxon Signed Rank test p-value) and fold difference between study groups. Intra-assay coefficient of variation 
(CV) values for each peak are shown pre- (in brackets) and post- optimisation of the experimental protocol. 
Associated box and whisker plots for the nine protein ions are presented in Appendix 2. 
 
 
CM10 
Binding 
Condition 
Protein 
Ion 
m/z 
Relative Intensity of Peaks  
(mean ± sd) 
Fold 
Difference 
p-value 
Intra-
Assay CV 
% 
 
Acute (n=11) 
vs 
Follow-Up 
(n=11) 
AIS 
pH4 4163 
Acute = 4.9 ± 1.8 
Follow-Up = 2.2 ± 1.7 2.23 0.001 15.8 (63.2) 
 
pH6 
 
3888 
 
Acute = 42.6 ± 20.4 
Follow-Up = 11.2 ± 8.4 
 
3.80 
 
0.027 
 
9.6 (62.80) 
AIS + TIA 
(n=15) 
vs 
Stroke 
Mimics 
(n=2) 
pH4 6640 AIS+TIA = 45.9 ± 10.3 
Stroke Mimics = 32.8 ± 10.6 
1.40 n/a 12.6 (47.9) 
pH6 3208 AIS+TIA = 21.9 ± 6.0 
Stroke Mimics = 11.6 ± 2.9 
1.89 n/a 14.1 (39.1) 
pH6 3416 AIS+TIA = 8.1 ± 2.4 
Stroke Mimics = 3.4 ± 0.1 
2.38 n/a 14.8 (68.4) 
pH8 7019 AIS+TIA = 0.8 ± 0.5 
Stroke Mimics = 2.3 ± 0.3 
0.35 n/a 17.3 (56.3) 
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3.3.2 Discovery Phase Study 
Preliminary results from the pilot study provided justification for the feasibility of SELDI-TOF 
MS in elucidating diagnostic biomarkers for AIS. Therefore a second patient cohort was 
obtained for a well-powered discovery study utilising the same experimental approach, 
following a study design that has proven successful in the past (Abdul-Salam et al. 2010). 
 
Samples were obtained from the University of Edinburgh (with consent from Professor Peter 
Sandercock and Dr. William Whiteley) and consisted of 404 well-characterised patients:  235 
patients with CT or MRI-confirmed AIS, 15 with haemorrhagic stroke (13 ICH, 2 Subarachnoid 
Haemorrhage), 72 with TIA and 82 stroke mimics. 
 
Power calculations were performed based upon the intensities of the nine protein ions from the 
pilot study deemed to be putative biomarkers.  An average sample size of 10 from each arm (AIS 
and TIA vs non-stroke) delivered a 95% power at p<0.01, and a sample size of 7 from each arm 
delivered a 95% power at p<0.05 to detect a 2-fold difference in means. 
 
With consideration of the power calculations above, the discovery cohort was randomised by a 
third party into three independent ‘Training’, ‘Test’ and ‘Replication’ sets, as suggested by Burke 
(2005), to ascertain the validity of any potential biomarkers. This approach serves to minimise 
variations arising from sample processing and possible changes in instrument performance, 
thus ensuring the robust confirmation of findings. 
 
The Training Set consisted of 40 patients (20 AIS, 20 Non-AIS [10 TIA, 10 Stroke Mimic]), the 
Test Set of 64 patients (32 AIS, 32 Non-AIS [16 TIA, 16 Stroke Mimic]) and the Validation Set of 
the remaining 300 patient samples. A ‘quality control’ sample obtained from the pilot study was 
run alongside Training and Test samples to ascertain suitable replication of data. Patient 
characteristics for the Training Set cohort are given in Table 3.3. 
 
 
  
 
 
Table 3.3: Discovery Study Training Set patient characteristics. Demographic and clinical information relating to 20 AIS and 20 Non-AIS (10 TIA, 10 Stroke Mimics) patient 
plasma samples comprising the Training Set. Values are median and IQR. 
 
 Total Population 
(n=40) 
AIS (n=20) TIA Positive 
(NIHSS<5) (n=10) 
AIS and TIA Positive 
combined (n=30) 
Stroke Mimics 
(NIHSS<5) (n=10) 
AIS&TIA vs Stroke 
Mimics 
(p-value) 
Age 75.00 
(59.50-84.75) 
81.50 
(72.75-85.00) 
71.00 
(60.50-76.50) 
78.00 
(69.00-85.00) 
57.00 
(46.75-76.75) 
0.021 
Gender 24F, 16M 14F, 6M 7F, 3M 21F, 9M 3F, 7M 0.025 
Confirmation of 
 Stroke 
20 CT, 17 MRI 12 CT, 8 MRI 8 CT, 2 MRI 20 CT, 10 MRI 3 CT, 7 MRI 0.087 
OCSP 
Classification 
4 LACS 
9 PACS 
3 POCS 
10 TACS, 
4 Uncertain 
10 Non-Stroke 
2 LACS 
7 PACS 
10 TACS 
1 Uncertain 
1 PACS 
2 POCS 
7 Uncertain 
2 LACS 
8 PACS 
2 POCS 
10 TACS 
8 Uncertain 
10 Non-Stroke 0.065 
Time of Blood 
Sampling (hours) 
6.62 
(3.08-17.17) 
3.79 
(2.50-16.38) 
6.38 
(5.13-8.25) 
5.63 
(2.92-14.19) 
14.67 
(6.17-25.50) 
0.039 
Previous MI/Angina 6Y, 34N 5Y, 15N 0Y, 10N 5Y, 25N 1Y, 9N 0.609 
Previous Stroke/TIA 10Y, 30N 5Y, 15N 4Y, 6N 9Y, 21N 1Y, 9N 0.206 
Admission NIHSS 5.50 
(1.00-16.75) 
16.50 
(13.25-21.00) 
0.50 
(0.00-1.00) 
13.50 
(1.00-18.25) 
1.00 
(0.5-3.00) 
0.018 
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3.3.2.1 Training Set: Establishing Optimum Experimental Conditions 
Experimental conditions were re-established and optimised in the Training sample set. 
Following the findings from the pilot study, CM10 Protein Chips were used along with SPA 
matrix and binding buffers of pH3, pH4, pH6 and pH8.  
 
Preliminary Data Analysis 
As in the pilot study, the number of protein ions detected and number of significantly different 
ions (p<0.05) between various study groups was examined, alongside visual inspection of the 
distribution of protein ion intensities. Of all the experimental conditions, pH4 provided the 
greatest number of significantly differentially expressed protein ions between ischaemic (AIS 
and TIA) and non-ischaemic (stroke mimic) subtypes (Table 3.4). 
 
 
Visualisation of Data 
In order to gain a better understanding of the value of SELDI-TOF MS for biomarker discovery 
for AIS, complete data sets obtained from each pH condition were examined by unsupervised 
analysis using Principal Components Analysis (PCA). 
 
Dimensionality reduction decreases the number of redundant peaks or noise that might 
otherwise confuse the final analysis. PCA has become a standard tool in large dataset analysis to 
study causes of variation, and can be used to infer continuous axes of variation (eigenvectors) 
that reduce the data to a small number of dimensions, whilst describing as much of the 
variability between individuals as possible. PCA analysis of protein ions obtained from all pH 
conditions showed that patient diagnosis (AIS/TIA/Stroke Mimic) was a key factor for 
classification, and in particular demonstrated clustering of ischaemic events (AIS and TIA) 
versus non-ischaemic events (stroke mimics). Other demographic variables (e.g. age, gender, 
evidence of infection) did not exhibit this separation. This result indicated that differential ion 
expression can be used for patient diagnostic classification, unconfounded by demographic 
variables (Figure 3.5, Appendix 3). 
 
  
CHAPTER THREE: PROTEOMICS FOR DIAGNOSTIC BIOMARKER DISCOVERY 
129 
Table 3.4: Differentially expressed protein ions in the Discovery Study Training Set. Peaks found to be 
differentially expressed between study groups at various pH binding conditions with SPA matrix (Mann-Whitney test, 
p<0.05). 
 
 
pH3 pH4 pH6 pH8 
Total Number of Peaks Detected:    
              55 66 61 68 
Number of Peaks Significantly Different: 
   
 
AIS(n=20) vs 
TIA(n=10) and 
Stroke Mimics 
(n=10) 
29 (52.7%) 
m/z 2648, 2670, 2698, 
2971, 3228, 3328, 3432, 
3700, 4301, 5866, 6448, 
6646, 6853, 7044, 7083, 
7777, 7856, 7984, 8158, 
8479, 8584, 9210, 9306, 
9419, 9598, 11566, 
11710, 15950, 16113 
37 (56.1%) 
m/z 3228, 3333, 3382, 
3432, 3452, 3550, 4366, 
4482, 4639, 4822, 5866, 
6451, 6652, 6855, 6963, 
7043, 7082, 7228, 7581, 
7784, 7853, 7970, 8156, 
8589, 8720, 8905, 9601, 
9748, 10023, 11557, 
11702, 11962, 12143, 
13795, 15157, 15341, 
15916 
20 (32.8%) 
m/z 3697, 3898, 
3917, 4030, 5052, 
5116, 5933, 6442, 
6486, 6643, 6684, 
6846, 7039, 7580, 
7679, 10844, 13778, 
15145, 15331, 23482 
38 (55.9%) 
m/z 2892, 3080, 3458, 
3522, 3547, 3663, 3860, 
3880, 3931, 3991, 4173, 
4271, 4303, 4600, 4700, 
4900, 4934, 5066, 5578, 
5791, 6285, 6438, 6634, 
7034, 7546, 7837, 8466, 
9921, 11618, 12105, 
13161, 13545, 14304, 
15138, 15354, 16976, 
27084, 28119 
 
AIS (n=20) +TIA 
(n=10) vs 
Stroke Mimics 
(n=10) 
31 (56.4%) 
m/z 2648, 2670, 2698, 
2971, 3164, 3228, 3328, 
3381, 3432, 3453, 3700, 
4610, 4973, 5281, 6448, 
6646, 6853, 7044, 7083, 
7777, 7856, 7984, 8158, 
9139, 9210, 9306, 9419, 
9598, 11566, 11710, 
15950 
52 (78.8%) 
m/z 2642, 2687, 2710, 
2857, 2971, 3165, 3228, 
3333, 3382, 3432, 3452, 
3550, 4366, 4609, 4639, 
4797, 4977, 5177, 5291, 
5866, 6451, 6652, 6855, 
6963, 7043, 7082, 7228, 
7581, 7784, 7853, 7970, 
8156, 8589, 8720, 8905, 
9210, 9314, 9394, 9601, 
9748, 10023, 11557, 
11702, 11962, 12143, 
13795, 15157, 15341, 
15916, 18592, 18774, 
28170 
24 (39.3%) 
m/z 3697, 3898, 
3917, 4030, 4903, 
5052, 5933, 6075, 
6486, 6643, 6684, 
6846, 7039, 7580, 
7679, 7847, 10036, 
10844, 11649, 
12879, 13778, 
15145, 23482, 28157 
46 (67.6%) 
m/z 2729, 2822, 2861, 
2892, 3080, 3131, 3152, 
3458, 3522, 3663, 3698, 
3860, 3880, 3931, 3991, 
4027, 4099, 4173, 4271, 
4303, 4372, 4424, 4900, 
4934, 5066, 5145, 5791, 
6040, 6096, 6285, 6438, 
6634, 7034, 7837, 7882, 
8167, 9448, 9921, 12105, 
12901, 14304, 15138, 
15354, 16976, 27084, 
28119 
 
TIA (n=10) vs 
Stroke Mimics 
(n=10) 
13 (23.6%) 
m/z 2971, 3164, 3228, 
3328, 3381, 3432, 3453, 
3700, 6448, 6646, 6853, 
7044, 7083 
9 (13.6%) 
m/z 2642, 2687, 2710, 
2857, 3228, 3333, 3432, 
3701, 6652 
5 (8.2%) 
m/z 3697, 6684, 
7039, 12879, 28157 
 
11 (16.2%) 
m/z 2822, 2861, 2892, 
3860, 3931, 3991, 4099, 
4173, 4424, 8167, 12901 
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Figure 3.5: Unsupervised analysis of Training Set data by principal component analysis (PCA). Unsupervised 
analysis of all protein ions obtained at pH4 binding conditions from the Training Set data (comprising 20 AIS patients, 
10 TIA patients and 10 stroke mimics) demonstrated a natural ability of the collective protein ions to separate 
patients by their diagnostic classification. PCA analysis of protein ions at pH3, pH6 and pH8 binding conditions found 
similar grouping of AIS, TIA and stroke mimic populations. The same analysis performed on a number of 
demographic variables (admission NIHSS, time of blood sampling,, history of MI, stroke or TIA and gender) did not 
demonstrate this ability for classification (Appendix 3), indicating that differential protein ion expression can be 
useful for patient diagnostic classification, independent of other confounding variables.  
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For all pH conditions, a volcano plot was generated to visualise protein ions along two key 
parameters: fold difference of ion intensity between ischaemic and non-ischaemic samples, and 
the corresponding Mann-Whitney p-value for each ion. A volcano plot generated from all 
Training Set results (Figure 3.6A) demonstrated that pH4 and pH8 were the only two binding 
buffer conditions that yielded protein ions exhibiting a fold difference >2 between ischaemic 
(AIS and TIA) versus non-ischaemic (stroke mimic) groups, and a Mann-Whitney p-
value<0.0001. The substantial skew observed in the volcano plot also indicated that the 
majority of protein ions detected by SELDI-TOF MS are up-regulated during acute cerebral 
ischaemia. 
 
To explore the relationships between the eleven protein ions found to have high fold difference 
and low p-value by the volcano plot (pH4: m/z 3333, 3432, 6640, 6855, 7043, 7228, 8720; pH8: 
m/z 3860, 4173, 6440, 6640) the protein ion intensities were examined for co-linearity through 
the creation of correlation matrices (Figure 3.6B). The seven protein ions captured at pH4 
showed substantial correlation with each other (r2=0.46-0.92). Conversely, of the four protein 
ions captured at pH8, only m/z 6440 and m/z 6640 exhibited a lower degree a correlation 
(r2=0.34-0.79). This implies that the ions captured at pH8 represent three distinct proteins 
whose expression alters independently in response to acute ischaemic insult. This lack of 
relationship between proteins is essential when building an effective multi-marker model: each 
protein ion behaves differently and therefore cumulatively adds to the sensitivity and specificity 
of the model. Nonetheless, the high degree of correlation between many of the ions captured at 
pH4, and the high intensity of m/z 6640 (also captured at pH8), indicated the potential to find 
one very valuable biomarker for the differentiation between ischaemic  (AIS and TIA) and non-
ischaemic (stroke mimic) events. Therefore, the pH4 binding buffer was chosen for further 
investigation. 
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pH8 m/z 3860 m/z 4173 m/z 6440 m/z 6640 
m/z 3860 1.00 0.61 0.34 0.47 
m/z 4173 
 
1.00 0.35 0.40 
m/z 6440 
  
1.00 0.79 
m/z 6640 
   
1.00 
 
 
Figure 3.6: Evaluating pH binding conditions in the Discovery Study Training Set to identify potential 
diagnostic biomarkers. A) A volcano plot of fold difference (log2) against Student’s t-test p-value (-log10) was 
generated from all protein ions detected in the Training Set. This displayed eleven protein ions with high fold 
difference (>2) and significance (p-value<0.0001) between ischaemic (AIS and TIA) and non-ischaemic (stroke 
mimic) patient groups. B) Correlation matrices revealed high correlation between ions detected at pH4, in contrast to 
those detected at pH8. This indicates that the proteins detected at pH8 have an independent relationship to the 
presence of ischaemic and could constitute a multi-marker diagnostic test by cumulatively increasing the sensitivity 
and specificity of the test.  
pH4 m/z 3331 m/z 3432 m/z 6640 m/z 6855 m/z 7043 m/z 7228 m/z 8720 
m/z 3331 1.00 0.88 0.89 0.92 0.65 0.46 0.72 
m/z 3432 
 
1.00 0.75 0.76 0.49 0.38 0.69 
m/z 6640 
  
1.00 0.92 0.74 0.62 0.76 
m/z 6855 
   
1.00 0.74 0.59 0.74 
m/z 7043 
    
1.00 0.67 0.59 
m/z 7228 
     
1.00 0.47 
m/z 8720 
      
1.00 
 
Fold Difference log2 
A 
B 
  
Mean Relative 
Ion Intensity ±SD 
  
AIS + TIA Stroke Mimic 
p
H
4
 
m/z 3331 9.07 ± 5.27 2.62±1.75 
m/z 3432 2.44 ± 1.61 0.46 ± 0.59 
m/z 6640 47.09 ± 20.91 16.64 ± 12.06 
m/z 6855 12.40 ± 7.98 3.58 ± 2.70 
m/z 7043 3.65 ± 2.02 1.25 ± 0.81 
m/z 7228 1.55 ± 1.10 0.46 ± 0.28 
m/z 8720 3.14 ± 1.81 1.12 ± 0.73 
p
H
8
 
m/z 3699 2.29 ± 1.03 3.10 ± 1.21 
m/z 3860 13.47 ± 5.98 5.79 ± 1.98 
m/z 4173 13.60 ± 5.26 6.65 ± 2.89 
m/z 6440 5.20 ± 2.94 2.46 ± 1.40 
m/z 6640 7.46 ± 4.57 3.15 ± 1.42 
 
Fold Difference log2 
p
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e
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As no single protein ion was able to completely differentiate between ischaemic and non-
ischaemic patients based upon ion intensity, a multi-marker approach was considered to select 
a minimum number of protein ions that allowed maximum discrimination between the two 
groups. Forward stepwise discriminant function analysis was performed on all 66 protein ions 
identified from the pH4 binding condition in the Training Set, resulting in the selection of 2 
protein ions (m/z 3699 and 6640) that in combination gave high measures of sensitivity and 
specificity. Multiple regression analysis on these 2 protein ions again confirmed their high 
discriminatory power.  
 
A receiver operating characteristic (ROC) curve combining the 2 protein ions selected by 
discriminant function analysis gave a very high area under the curve (AUC) based upon multiple 
regression predictive values (AUC=0.97), and an overall test accuracy (proportion of individuals 
correctly classified) of 90.5% (Figure 3.7). Furthermore, scatterplots of the 2 individual proteins 
demonstrate relatively good discrimination between ischaemic versus non-ischaemic groups, 
with m/z 6440 being upregulated in the presence of ischaemia and m/z 3699 being 
downregulated (Figure 3.8A). This result demonstrates the ability of discriminant function 
analysis and multiple regression analysis to select protein ions that are poorly correlated with 
one another and that could collectively contribute to a multi-marker test. 
 
3.3.2.2 Test Set: Replication of Training Set Findings  
With consideration of the findings from the Training Set, SELDI-TOF MS was performed on the 
32 AIS, 16 TIA and 16 stroke mimic samples comprising the Test Set (Table 3.5), using CM10 
Protein Chips with SPA matrix and pH4 binding buffer. A total of 101 protein ions were 
detected, of which 30 showed significant (p<0.05) differential expression between ischaemic 
(AIS and TIA) versus non-ischaemic (stroke mimic) populations. 
 
The performance of putative biomarkers identified from forward stepwise discriminant 
function analysis of the Training Set was examined in the Test Set (Figure 3.8B). Logistic 
regression analysis found that previous history of stroke/TIA and admission NIHSS were 
associated with m/z 6640 relative ion intensity (Table 3.6). However, these associations were 
not as strong as that demonstrated by diagnostic classification (previous history of stroke/TIA: 
OR 1.10, 95% CI 0.24-4.18, p=0.033; admission NIHSS: OR 0.89, 95% CI -0.35-3.18, p=0.007; 
Diagnosis: OR 12.91, 95% CI 4.22-39.49 p<0.0001). 
 
The sensitivity of m/z6640 was lower in the Test Set than in the Training Set, with a value of 
83% (as compared to 94%), and specificity increased to 94%. Addition of m/z3699 resulted in a 
sensitivity of 85% and specificity of 95%, with an AUC of 0.93 (95% CI 0.87-0.98; p<0.0001).  
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Figure 3.7: Examination of putative biomarkers identified through discriminant function analysis (DFA) of 
Training Set data. DFA performed on all 66 protein ions detected from the pH4 binding condition with Training Set 
plasma samples yielded 2 protein ions (m/z 3699 and m/z 6640) that could differentiate between ischaemic (AIS and 
TIA; n=30) and non-ischaemic (stroke mimics; n=10) acute cerebral events. These two protein ions demonstrated 
little inter-correlation, implicating their utility in a multi-marker diagnostic test (A). Predicted values from multiple 
regression analysis were used to generate Receiver Operator Characteristic (ROC) curves. Use of only m/z 6440 in 
the model (sensitivity=94%; specificity=80%) gave an area under the curve (AUC) of 0.93 (95% confidence interval 
0.82-1.03; p<0.0001), while use of only m/z 3699 in the model (sensitivity=67%; specificity=78%) gave an area 
under the curve (AUC) of 0.70 (95% confidence interval 0.50-0.90; p=0.065). Incorporation of both ions 
(sensitivity=93%; specificity=90%) into the model resulted in an AUC value of 0.97 (95% confidence interval 0.93-
1.02; p<0.0001). Comparison of AUCs derived from m/z 6640 and m/z 3699 alone or in combination demonstrated a 
statistically significant improvement in prediction using a dual-marker model (m/z 6640 alone vs m/z 3699 alone: 
p=0.012; m/z 6640 + m/z 3699 vs m/z 3699 alone: p=0.007; m/z 6640 + m/z 3699 vs m/z 6640 alone: p=0.023) (B).  
 
 
 
 
 
 
 m/z 3699 m/z 6640 
m/z 3699 1.00 0.03 
m/z 6640 0.03 1.00 
 
 
B A 
  
 
 
Table 3.5: Discovery Study Test Set patient characteristics. Demographic and clinical information relating to 32 AIS and 32 Non-AIS (16 TIA, 16 stroke mimics) patient plasma samples 
comprising the Test Set. Values are median and IQR.
 
Total 
Population 
(n=64) 
AIS and TIA 
Positive 
combined 
(n=48) 
AIS 
(n=32) 
TIA Positive 
(NIHSS<5) 
(n=11) 
TIA Positive 
(NIHSS≥5) 
(n=5) 
TIA Positive 
Total 
(n=16) 
Stroke 
Mimics 
(NIHSS<5) 
(n=8) 
Stroke 
Mimics 
(NIHSS≥5) 
(n=8) 
Stroke 
Mimics Total 
(n=16) 
AIS&TIA 
vs Stroke 
Mimics 
(p-value) 
Age 69.50 
(56.25-79.00) 
69.50 
(57.00-79.00) 
75.50 
(66.25-81.00) 
55.00 
(43.00-71.00) 
57.00 
(35.50-74.50) 
56.00 
(41.50-70.75) 
73.00 
(46.25-79.75) 
72.00 
(59.00-82.75) 
72.00 
(51.50-79.75) 
0.774 
Gender 33F, 31M 26F, 22M 16F, 16M 6F, 5M 4F, 1M 10F, 6M  4F, 4M 7F, 9M 0.47 
Confirmation of 
Stroke 
34 CT, 26 MRI 25 CT, 19 MRI 19 CT, 13MRI 2 CT, 5 MRI 4 CT, 1 MRI 6 CT, 6 MRI 3 CT, 5 MRI 6 CT, 2 MRI 9 CT, 7 MRI 0.491 
OCSP 
Classification 
10 LACS, 
20 PACS, 
4 POCS, 
12 TACS, 
2 Uncertain, 
16 Non-Stroke 
5 LACS, 
19 PACS, 
2 POCS, 
12 TACS, 
10 Uncertain 
3 LACS, 
16 PACS, 
1 POCS, 
12 TACS 
2 LACS, 
2 PACS, 
1 POCS, 
6 Uncertain 
1 PACS, 
4 Uncertain 
2 LACS, 
3 PACS, 
1 POCS, 
10 Uncertain 
3 LACS, 
1 PACS, 
1 POCS, 
3 Non-Stroke 
2 LACS, 
1 POCS, 
1 Uncertain, 
4 Non-Stroke 
5 LACS, 
1 PACS, 
2 POCS, 
1 Uncertain, 
7 Non-Stroke 
0.003 
Time of Blood 
Sampling 
(hours) 
4.42 
(2.44-8.06) 
3.84 
(2.25-6.94) 
3.34 
(2.25-7.19) 
4.00 
(2.00-7.50) 
5.00 
(2.25-6.63) 
4.25 
(2.13-7.06) 
4.46 
(2.38-12.88) 
11.63 
(5.00-20.63) 
7.75 
(3.11-15.63) 
0.053 
Previous 
MI/Angina 
23Y, 41N 16Y, 32N 12Y, 20N 3Y, 8N 1Y, 4N 4Y, 12N 4Y, 4N 3Y, 5N 7Y, 9N 0.452 
Previous 
Stroke/TIA 
18Y, 46N 13Y, 35N 7Y, 25N 2Y, 9N 4Y, 1N 6Y, 10N 3Y, 5N 2Y, 6N 5Y, 11N 0.748 
Admission 
NIHSS 
6.00 
(3.00-10.00) 
7.50 
(5.00-12.50) 
10.00 
(7.00-15.50) 
1.00 
(0.00-2.00) 
6.00 
(5.00-8.50) 
2.00 
(1.00-5.00) 
1.00 
(1.00-2.75) 
5.50 
(5.00-7.00) 
4.50 
(1.00-5.75) 
0.002 
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Figure 3.8: Individual scatter plots of m/z 3699 and m/z 6640. The 2 protein ions selected by forward stepwise 
discriminant function analysis of the Training Set data at pH4 (m/z 3699, m/z 6640) demonstrated good 
discrimination between ischaemic (AIS and TIA) and non-ischaemic (stroke mimic) groups. Scatter plots of ion 
intensity from both Training Set (A) and Test Set (B) samples illustrate their ability to discriminate between the 
patient groups with high sensitivity and specificity. Mean intensities of each classification group are presented, with 
data points representing the average intensity of duplicates from each patient sample. In both Training and Test sets, 
m/z3699 is significantly downregulated during ischaemia, while m/z 6640 is significantly upregulated (Mann-
Whitney test p-value) (C). 
 
 Training Set Test Set 
 m/z 3699 m/z 6640 m/z 3699 m/z 6640 
Ischaemic Events 
Mean Relative Ion Intensity % (sd) 
2.29 (1.03) 47.09 (20.91) 2.01 (1.19) 
70.62 
(16.52) 
Non-Ischaemic Events 
Mean Relative Ion Intensity % (sd) 
3.10 (1.21) 16.64 (12.06) 2.97 (0.87) 49.94 (6.16) 
Fold Difference 
(Ischaemic/Non-Ischaemic) 
0.86 1.73 0.68 1.41 
p-value 0.006 <0.0001 0.0006 <0.0001 
 
 
A 
B 
C 
 
  Sensitivity = 67% 
  Specificity = 78% 
Sensitivity = 94% 
Specificity = 80% 
m/z 6640 m/z  3699 
 
 
 
  Sensitivity = 75% 
  Specificity = 81% 
Sensitivity = 83% 
Specificity = 94% 
m/z 6640 m/z  3699 
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Table 3.6: Logistic regression analysis of Test Set demographic variables. A number of demographic variables 
available for the Test Set patients (32 AIS and 32 non-AIS) were tested for their association with relative ion intensity 
of m/z 6640. Diagnostic classification (ischaemic vs non-ischaemic) proved to have the strongest association with 
m/z 6640 levels. 
 
Odds Ratio 95% CI p-value 
Diagnosis (Ischaemic vs Non-Ischaemic) 12.91 4.22-39.49 <0.0001 
Gender 0.43 0.12-1.57 0.201 
Time of Blood Sampling -3.33 -8.87-2.40 0.252 
Previous History of MI 0.83 -2.58 0.078 
Previous History of Stroke/TIA 1.10 0.24-4.18 0.033 
Admission NIHSS 0.89 -0.35-3.18 0.007 
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3.3.2.3 Selection of a Candidate Biomarker 
Both m/z 3699 and m/z 6640 were identified as being significantly differentially expressed in 
both Training and Test sets (Figures 3.6, 3.7). In particular, m/z 6640 had been detected in both 
the pilot study (pH3, 4 and 8) and Training set (pH4 and 8) and exhibited potential to 
discriminate between TIA and stroke mimic groups. Furthermore, m/z 6640 was detected at a 
higher intensity (AIS and TIA mean = 70.6, sd = 16.5, stroke mimic mean = 49.9, sd = 6.1) than 
m/z 3369 (AIS and TIA mean = 2.0, sd = 1.2, stroke mimic mean = 3.0, sd = 0.8), indicating a 
more robust fold difference and allowing greater ease in purification of the protein. For these 
reasons, m/z 6640 was chosen as the best candidate to take forward for identification. 
 
As mentioned in Chapter 2, a significant difference in mean biomarker levels between study 
groups must be considered within the context of the degree of overlap between the two 
populations. The normal distributions for ischaemic and non-ischaemic populations based upon 
relative ion intensities of m/z 6640 from the Test Set demonstrated reasonably good separation 
(Figure 3.9). Furthermore, calculation of Standardised Mean Difference (SMD) between the two 
study groups resulted in SMD 1.41 (95% CI 0.79 – 2.03; p<0.0001), relating to an estimated 
odds ratio (OR) of 12.91 (95% CI 4.22 – 39.49; p<0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Distribution proﬁle of m/z 6640 from Test Set ischaemic and non-ischaemic populations. Normal 
distribution profiles of m/z 6640 relative ion intensities taken from Test Set ischaemic and non-ischaemic 
populations demonstrate reasonable separation, implying good discriminatory power with few false positive and 
false negative results.  
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3.3.3 Identification of Candidate Marker m/z 6640 
A number of studies have reported the identity of m/z 6640 as apolipoproteinC-1 (ApoC-1), 
using both MALDI-TOF (Chang et al. 2013) and SELDI-TOF (Allard et al. 2004; Takano et al. 
2008; Xue et al. 2010) techniques. Hence it was considered that this was the most likely identity 
of the candidate marker. 
 
3.3.3.1 Immunodepletion of m/z 6640 
In order to test the above hypothesis, SELDI-TOF MS immunodepletion was attempted with one 
monoclonal and one polyclonal anti-human ApoC-1 antibody. A subgroup of 24 samples (8 AIS, 
8 TIA, 8 stroke mimics) were randomly selected to comprise a pooled plasma sample for this 
immunodepletion pull-down experiment. SELDI-TOF MS processing was performed according 
to the protocol performed in the Test Set discovery study, using CM10 ProteinChip arrays and 
pH4 binding buffer. 
 
Incubation of the pooled plasma samples directly with a rabbit polyclonal anti-ApoC-1 antibody 
demonstrated a depletion of m/z 6640 (full-length, single charged ApoC-1 ion), as well as m/z 
6440, the single-charged ApoC-1 fragment ion without the N-terminal threonine-proline 
residues (Chang et al. 2013). However this effect was not specific to these two ions. Incubation 
of the plasma sample with IgG control antibody showed that this lack of specificity was not due 
to antibody isotype (Figure 3.10). Therefore this antibody was not deemed to be appropriate for 
confirmation of m/z 6640 identity. Subsequent incubation of the pooled plasma sample with a 
mouse monoclonal anti-ApoC-1 antibody failed to demonstrate any pull-down effect, even at 
high antibody concentrations (18μg/ml). With both antibodies, the findings above were 
unchanged by the removal of Urea/CHAPS from the binding buffer, which was theorised to be 
interfering with the binding of antibody to the ApoC-1 protein (Figure 3.10).  
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Figure 3.10: Immunodepletion of m/z 6640, theorised to be apolipoproteinC-1 (ApoC-1). A pooled plasma 
sample was diluted in pH4 buffer and incubated with either a rabbit polyclonal or mouse monoclonal anti-human 
ApoC-1 antibody, applied to CM10 ProteinChips and then processed by SELDI-TOF MS. The full ApoC-1 m/z 6640 ion, 
as well as its fragment without the N-terminal Threonine-Proline (m/z 6440) are highlighted in blue. Control 
incubations were performed using anti-ApoC-1 antibody only, plasma only, and affinity-purified IgG control antibody. 
Rabbit polyclonal ApoC-1 antibody depletion (6μg/ml) was not specific to m/z6640, while the monoclonal antibody 
(18μg/ml) failed to demonstrate any depletion of the m/z 6640 peak. Similar results were observed with or without 
the addition of 9M urea, 2% CHAPS to the plasma sample. No interaction was observed between plasma and IgG 
control antibody, and no peaks were observed when only ApoC-1 antibody was added to CM10 ProteinChips. All 
spectra represent samples profiled at pH4 with CM10 chips, according to the original protocol. 
  
 
 
 
 
 
 
R
e
la
ti
ve
 Io
n
 In
te
n
si
ty
 (
%
) 
Plasma 
only 
Plasma + 
ApoC-1 
polyclonal 
antibody 
 
Plasma +  
IgG control  
 
 
Plasma + 
ApoC-1 
monoclonal 
antibody 
 
ApoC-1 
polyclonal 
antibody 
only 
 
CHAPTER THREE: PROTEOMICS FOR DIAGNOSTIC BIOMARKER DISCOVERY 
143 
3.3.3.2 Measurement and Quantification of m/z 6640 by ELISA 
Despite immunodepletion of m/z 6640 failing to confirm the protein ion’s identity as ApoC-1, an 
ApoC-1 ELISA was performed to further test this hypothesis.  
 
Plasma samples from 40 patients from the Training and Test Sets were chosen at random, 
covering the range of m/z6640 ion intensities observed via SELDI-TOF MS (30-90%). An ELISA 
performed on these samples allowed quantification of ApoC-1 protein levels in µg/ml. One 
plasma sample was also spiked with a range of concentrations (0 - 16µg/ml) of authentic ApoC-
1 protein (obtained from the ELISA kit) and then analysed on a CM10 ProteinArray chip at pH4 
with SELDI-TOF MS. The intensity of m/z6640 increased linearly with increasing concentrations 
of ApoC-1 and the association between relative ion intensity and concentration of ApoC-1 
demonstrated good correlation (r2=0.91). This relationship was used to estimate ApoC-1 levels 
in a subgroup of 24 samples which were run on ELISA and also on SELDI-TOF MS. ApoC-1 levels 
determined by ELISA corresponded well with m/z 6640 relative ion intensities obtained from 
SELDI-TOF MS (r2=0.80; Figure 3.11A). 
 
The high correlation between SELDI-TOF MS relative ion intensities and ApoC-1 levels 
measured by ELISA provided strong evidence to suggest that the identity of m/z 6640 was 
indeed ApoC-1. To further confirm this identification, SELDI-TOF MS was performed on a 
preparation of authentic ApoC-1 protein, obtained from the ELISA kit. This yielded two peaks at 
m/z 6440 and m/z 6640 with similar shapes to the ions observed in plasma, as expected. 
Additionally, spiking of a plasma sample containing detectable levels of m/z 6440 with 
authentic ApoC-1 protein increased the intensity of these two ions without altering the intensity 
of other protein ions in the profile (Figure 3.11B).  
 
ApoC-1 levels, determined by ELISA in the total 40 plasma samples (AIS=10; TIA=10; stroke 
mimic=15) were significantly higher in the ischaemic group than the non-ischaemic group 
(ischaemic=1.42µg/ml, non-ischaemic=0.90µg/ml; p=0.001; Student’s t-test on log-transformed 
data). An ROC curve constructed from these levels gave an AUC of 0.84 (95% CI 0.71-0.97), with 
sensitivity of 83% and specificity of 70% at a cut-off level of 1.85µg/ml. This again confirmed 
the potential of ApoC-1 to be a valuable diagnostic biomarker for distinguishing ischaemic 
cerebral events from stroke mimics (Figure 3.12). 
  
CHAPTER THREE: PROTEOMICS FOR DIAGNOSTIC BIOMARKER DISCOVERY 
144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Measurement and quantification of m/z 6640 by ELISA. (A) Authentic human ApoC-1 was added to 
a plasma sample at various concentrations and the intensity of the m/z 6640 ion determined by SELDI-TOF MS. This 
relationship was used to correlate the ApoC-1 concentration in 24 plasma samples run on ELISA as well SELDI-TOF 
MS. ApoC-1 relative ion intensities determined by SELDI-TOF MS corresponded well to ApoC-1 levels determined by 
ELISA (r2=0.80), regardless of the sample classification grouping. (B) Confirmation of the identity of m/z 6640. The 
intensity of m/z 6640 is shown in samples containing (i) plasma only (15μl) (ii) a mixture of ApoC-1 (4μg/ml) and 
plasma (15μl) and (iii) authentic human ApoC-1 only. All samples were applied to CM10 ProteinChip arrays in pH4 
binding buffer and analysed under the conditions described earlier. The intensity of m/z 6440 and m/z 6640 
increased when plasma was spiked with authentic human ApoC-1, without altering the intensity of other protein ions 
in the spectrum. Analysis of authentic human ApoC-1 only with SELDI-TOF MS produced major peaks at m/z 6440 
and m/z 6640 that matched the size and shape of these ions in plasma. 
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Figure 3.12: Distribution proﬁle of ApoC-1 in ischaemic and non-ischaemic populations. Normal distribution 
profiles of ApoC-1 relative ion intensities taken from ischaemic and non-ischaemic patient samples (AIS=10; TIA=10; 
stroke mimic=15) on which ApoC-1 ELISA was performed. The distribution profiles demonstrate reasonable 
separation, implying good discriminatory power, relating to an AUC of 0.84 (95% CI 0.71-0.97), with sensitivity of 
83% and specificity of 70% at a cut-off level of 1.85µg/ml. 
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3.4 Discussion 
 
The rapid development of ischaemic stroke pathophysiology means that prompt diagnosis is 
critical for preventing large-scale brain damage and early intervention is crucial, with 
approximately 2 million neurons lost per minute after stroke onset (Saver 2006). A blood-based 
diagnostic test that is able to detect acute cerebral ischaemia could substantially improve 
patient management. The aim of this study was to utilise a whole proteome approach to identify 
plasma proteins with diagnostic value for acute ischaemic stroke. Using SELDI-TOF MS, two 
candidate biomarkers were obtained for the differentiation of acute cerebral ischaemia from 
stroke mimics. One of these plasmatic markers was identified as apolipoproteinC-1 (ApoC-1) 
and was found to be up-regulated during acute cerebral ischaemia. The other marker, m/z 3699, 
exhibited down-regulation during acute cerebral ischaemia.  
 
The difficulties in diagnosing TIA and the importance of accurate diagnosis in order to provide 
adequate patient management and prevent subsequent ischaemic events, has been previously 
described in Chapter 1. The differentiation between TIAs and stroke mimics poses a particular 
challenge as both appear negative upon CT imaging. While recruiting patients from the Charing 
Cross Hospital Hyper Acute Stroke Unit it was noted that almost a third of patients admitted to 
the ward transpired to be stroke mimics, consistent with findings from an observational study 
that reported a diagnosis of stroke mimics in 31% of patients, of whom 40% were labelled as 
labelled "possible stroke or TIA" (Hand et al. 2006). Therefore, even though a recent cohort 
study has demonstrated the relative safety of (incorrectly) treating these patients with 
thrombolysis (Zinkstok et al. 2013), the ability to triage stroke mimics effectively would greatly 
improve time and resource management for clinicians.  
 
With this in mind, studies have attempted to investigate biomarkers differentiating between 
ischaemic events and stroke mimics using a candidate protein approach (detailed in Chapter 2), 
and have postulated a role for 11 candidate biomarkers including NMDA receptor peptide NR2 
(Dambinova et al. 2012), NSE, S100B (Gonzalez-Garcia et al. 2012), plasma DNA (Rainer et al. 
2007), GFAP (Foerch et al. 2012), CRP, D-Dimer (Glickman et al. 2011) IMA (Ahn et al. 2011), 
PTA (Doehner et al. 2012) and VAP-1 (Airas et al. 2008). However, thus far none of these 
markers seem to have shown sufficient value within a clinical setting. 
 
ApoC-1 as Diagnostic Biomarker for AIS 
The combination of selective protein binding with quantitative mass detection makes SELDI-
TOF MS a simple and attractive method for comparative protein analysis. Nonetheless, proteins 
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are not subjected to digestion or tandem mass spectrometry; therefore candidate protein ions 
discovered through SELDI-TOS MS require downstream processing for identification.  
 
It has been argued that proteomic patterns should be based upon proteins of known identity 
(Diamandis 2002). However this current study, like others (Petricoin et al. 2002), maintains 
that the diagnostic utility of markers identified through proteomics can be independent of 
protein identity.  
 
Identification of m/z 6640 was unsuccessful by antibody immunodepletion. Direct 
immunodepletion requires precise titration of plasma in order to allow a network of 
interactions to form between the antibody and antigen; the inability to find the exact 
antibody:antigen ratio required may explain the failure of this method. Immobilisation of the 
anti-ApoC-1 antibody, through protein-A agarose beads (Takano et al. 2008) or RS100 
ProteinChip array (Xue et al. 2010) may have been a more reliable technique for 
immunoprecipitation. ELISA provided convincing evidence of the identity of m/z 6640 being 
ApoC-1. Nonetheless, conclusive verification of this would be provided by tryptic digestion of 
plasma run on 2D SDS PAGE, with subsequent processing by liquid chromatography and tandem 
MS (LC-MS/MS).   
 
The finding that ApoC-1 levels increase during acute ischaemic events is supported by its key 
role in lipid metabolism. ApoC-1 is a secreted plasma protein produced by the liver and 
comprises ~10% of circulating very low density lipoprotein (VLDL) and ~2% of high density 
lipoprotein (HDL), being up-regulated when monocytes differentiate into macrophages. In 
humans the protein has a high basic pI due to its high content of lysine, and the acidic form, 
present in bonobos, chimpanzees and orang-utans, has become a pseudogene (Jong et al. 1999).  
 
ApoC-1 is synthesised with a 26-residue signal peptide that is cleaved in the rough endoplasmic 
reticulum. Subsequently, residues 7 to 24 and 35 to 53 of the protein are important for 
lipoprotein binding (Rozek et al. 1995). MALDI-TOF MS has ascertained that two isoforms of the 
protein can be detected in plasma (Jin & Manabe 2005): full ApoC-1 (m/z 6640) and truncated 
ApoC-1 lacking N-terminal threonine and proline (m/z 6440); both these isoforms were 
detected in this current study (Figures 3.4 and 3.6).  
 
Upregulation of ApoC-1 displaces ApoE from the VLDL complex, decreasing their clearance from 
plasma (Kolmakova et al. 2004). ApoC-1 inhibits phospholipase A2 activity and cholesterylester 
transfer protein, a plasma protein that facilitates the homoexchange of cholesteryl esters from 
HDL to triglycerides on VLDL and LDL. ApoC-I also regulates plasma triglycerides levels through 
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inhibition of triglyceride-rich lipoprotein uptake via hepatic receptors, particularly the LDL 
receptor-related protein (Cohn et al. 2003). Thus ApoC-1 presence on VLDL and HDL may 
prolong triglyceride residence time within the circulation (Jong et al. 1999), enabling the 
conversion of triglyceride-rich lipoproteins to LDL and exacerbating a hypertriglyceridemic 
state that could have a pro-atherogenic effect (Madden 2012; Cohn et al. 2003). 
 
The findings of this current study provide validation of previous studies that have reported an 
upregulation of ApoC-1 in AIS, with ApoC-1 being implicated as a diagnostic biomarker to 
distinguish between AIS and ICH using proteomics techniques such as SELDI-TOF MS (Allard et 
al. 2004) and Selective Reaction Monitoring on a triple quadrupole mass spectrometer (Lopez et 
al. 2012). ApoC-1 has been shown to be uniquely elevated in post-prandial VLDL and 
chylomicron particles in men with early asymptomatic atherosclerosis (Bjorkegren et al. 2002), 
and ApoC-1 enriched HDL activation of the neutral sphingomyelinase-ceramide signalling 
pathway leads to apoptosis in aortic smooth muscle cells, possibly promoting plaque rupture 
(Kolmakova et al. 2004). Global gene expression analysis also uncovered an ApoC-1-centric 
network associated with atherosclerotic carotid artery disease (Diez et al. 2010), reinforcing 
findings that ApoC-1 content of VLDL particles is associated with plaque size in patients with 
carotid atherosclerosis (Noto et al. 2008). The location of ApoC-1 is of significance, with 
systemic ApoC-1 increasing development of atherosclerosis, but local macrophage production of 
ApoC-1 in the arterial wall having little effect on plasma lipid levels or atherosclerotic lesion 
area in mice (Westerterp et al. 2007). Based upon its role in promoting carotid artery disease 
and plaque rupture (a process that is not as likely to be present in stroke mimics), these studies 
provide strong biological evidence that ApoC-1 is a plausible diagnostic biomarker for AIS and 
TIA. 
 
A Multi-Marker Diagnostic Test for Acute Cerebral Ischaemia  
Given the complexity of AIS pathophysiology, it is very likely that a multi-marker test would 
provide superior sensitivity and specificity to a single marker. Proteomic approaches can 
interrogate hundreds of proteins simultaneously and are therefore ideal for assessing diseases 
such as stroke, in which complex protein cascades are induced in response to injury. A number 
of studies have attempted this multi-marker approach (Dambinova et al. 2002; Reynolds et al. 
2003; Lynch et al. 2004; Laskowitz et al. 2005; Montaner  et al. 2005; Tuttolomondo et al. 2009), 
with a panel of four markers (S100B, von Willebrand Factor, MMP9, VCAM-1) demonstrating 
90% sensitivity and specificity to distinguish AIS from controls (Lynch et al. 2004), and a similar 
panel of five markers (S100B, von Willebrand Factor, MMP9, MCP-1, BNGF) demonstrating 92% 
sensitivity and 93% specificity to distinguish AIS from healthy controls (Reynolds et al. 2003).  
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However, the relevance of these markers is doubtful as the clinical problem is not the difficulty 
in differentiating AIS from healthy controls, but rather to be able to diagnose ischaemic events 
from non-ischaemic events. The "Triage® Stroke Panel", comprising many of the markers above, 
failed to demonstrate any significant difference between AIS and stroke mimic populations in a 
recent prospective study (Knauer et al. 2012). Although the identification and validation of m/z 
3699 was not possible in the current study, its ability to improve the specificity of a test based 
upon m/z 6640 alone warrants further investigation into its incorporation into a multi-marker 
test to distinguish between ischaemic and non-ischaemic cerebral insults.  
 
Clinical Utility of Candidate Biomarkers 
In order to examine their relative contribution to ischaemic stroke diagnosis, the utility of the 
candidate biomarkers must be assessed within the context that they will be used. Existing 
clinical variables have shown to be unhelpful for the classification of stroke mimics (Tobin et al. 
2009). In Chapter 2, meta-analysis of published data identified only one protein, S100B, as being 
significantly able to differentiate between AIS and stroke mimics. The current study found that 
ApoC-1 has 83% sensitivity and 70% specificity at a cut-off of 1.85μg/ml, indicating that ApoC-1 
may be a more valuable biomarker than S100B, which was recently reported as having 54% 
sensitivity and 84% specificity for discriminating AIS from stroke mimics (Park et al. 2013). 
 
A recent meta-analysis reported sensitivity and specificity values of 39% and 100% respectively 
for CT imaging, and 99% and 92% respectively for MRI imaging (Brazzelli et al. 2009). Being a 
retrospective study, the value of using the proposed single/multi-marker biomarker test in 
conjunction to CT or MRI could not be investigated; prospective analysis of this will shed light 
on the actual value of the test, over and above standard clinical practice. The finding that ApoC-1 
alone has 83% sensitivity and 70% specificity to detect acute cerebral ischaemia implies that a 
diagnostic test based upon this protein has the potential to identify double the number of true 
positives than currently identified by CT, and could be a valuable diagnostic tool when used in 
conjunction with CT imaging. The value of being able to distinguish between TIAs and stroke 
mimics in particular has been discussed in Chapter 1, and the substantial improvement of 
sensitivity provided by an ApoC-1 test over CT imaging hold promise for its value as a diagnostic 
biomarker. Both this single marker test and a test based upon ApoC-1 in combination with m/z 
3699 do not provide the diagnostic utility of MRI imaging. However, given the limited 
availability of MRI within an acute clinical setting (particularly in developing countries), the 
tests could have substantial value either pre- hospital admission (e.g. while a patient is in an 
ambulance) or for triaging before CT imaging. 
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Choice of Proteomic Platform 
The presence of a large number of proteins in blood plasma and the ease of sample collection 
within a clinical setting makes human plasma an excellent material for discovering diagnostic 
biomarkers. However, the complexity and large concentration ranges of proteins within plasma 
samples present major challenges for their analysis. A handful of highly abundant proteins, such 
as albumin, represent over 90% of the plasma proteome and can mask the detection of low-
abundance proteins that are likely to be more valuable as clinical biomarkers (Anderson & 
Anderson 2002). Indeed, a mere 21 proteins represent 99% of the plasma proteome, hence the 
challenge is to probe the remaining 1% for disease-specific markers (Righetti et al. 2005). 
Furthermore, the complete measured dynamic range of proteins spans more than 10 logs of 
molar abundance (Hortin & Sviridov 2010). Nonetheless, the HUPO PPP Specimens Committee 
recommends that plasma is preferable to serum because it contains less peptides of degradation 
and therefore presents less variability (Omenn et al. 2005; De Bock et al. 2010). 
 
There are a number of advantages of using SELDI as a proteomic technique (reviewed in Bons et 
al. 2006). The unique chromatographic properties of the ProteinChip arrays preclude the 
necessity for pre-fractionation steps, which are usually performed on plasma samples in order 
to simplify the proteome and maximise protein separation and resolution. Another advantage of 
the surface enhanced process is that components such as detergents, lipids and salts that 
commonly cause problems with other analytical tools are washed away in the SELDI process 
(Wiesner 2004).  
 
Importantly, unlike the relatively time-consuming process of purification, processing and 
analysis required for LC/MS, SELDI-TOF MS allows hundreds of samples to be screened in a 
short time period, providing an opportunity to compare patient-patient variability and a rapid 
screening for potential biomarkers. As a soft ionisation technique SELDI-TOF MS reduces the 
frequency of protein fractionation, which aids in distinguishing between mature proteins and 
fragments produced from larger precursor proteins. This is more difficult to ascertain with 
LC/MS-MS, which is susceptible to higher levels of fractionation.  
 
The analyser used for SELDI-TOF MS is designed to achieve high-sensitivity quantification, and 
the ion source and detector are adapted for efficient ion transmission and detection over a wide 
mass range. Although the system is generally more favourable for proteins and peptides with 
molecular weight lower than 20kDa, it is able to analyse proteins over a wide molecular weight 
range (0-200kDa) and the entire isoelectric point (pI) range, giving it an advantage over other 
proteomic techniques such as 2D electrophoresis (limited to protein separation >10kDa, pI 3-
10; Wiesner 2004). 
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Choice of Study Design 
A commonly recommended study design for large-scale proteomics and SELDI-TOF MS 
experiments is to collect a large number of samples and randomly assign them to Training and 
Test sets (Burke 2005; Petricoin et al. 2002). This design is especially important for avoiding 
overfitting if considering a multi- rather than single biomarker model (Baker et al. 2002). 
Furthermore, it is suggested that candidate markers be further replicated in an independent 
Validation set (Baker et al. 2002). The scarcity of published literature using this study design 
suggests that previously reported biomarkers for AIS identified via high-throughput approaches 
may not have been reproduced and confirmed in subsequent studies. 
 
Given the challenges of collecting blood samples within the acute phase (<24hours) from stroke 
patients who are able to consent, in this study an initial 13 AIS subjects were recruited for 
investigation in a pilot study. This allowed optimisation of conditions favouring biomarker 
discovery, and more importantly, justified the use of SELDI-TOF MS for detecting a protein 
profile that is deranged during acute ischaemic insult. Despite the small number of patients, the 
effect of inter-subject variability was minimised by comparison of 11 paired plasma samples, 
taken from the same individual at acute and follow-up time intervals. Thus there is greater 
likelihood that differences observed between these groups represent genuine biological changes 
in peptide expression than if independent healthy subjects had been chosen as control samples. 
 
The findings of the pilot study allowed attainment of over 400 blood samples from collaborators 
at Edinburgh University. These samples were divided into well-powered Training (40 subjects), 
Test (64 subjects) and Validation (300 subjects) sets. The Training set was used to optimise 
experimental conditions and found two ions (m/z 3699 and m/z 6640) that could be 
incorporated into a multi-marker diagnostic test for distinguishing acute ischaemic events from 
stroke mimics. Results from the Test set further confirmed the performance of these two ions, 
although m/z 6640 was deemed to be the best candidate for further investigation. 
 
Limitations 
SELDI-TOF MS investigations have been criticised due to a general lack of standardised 
methodology, rendering results difficult to reproduce (Alaoui-Jamali & Xu 2006). 
Reproducibility and CVs are affected by factors including accuracy of matrix application, plasma 
concentration and settings used on the SELDI-TOF MS instrument for data collection. These 
issues were optimised in the pilot study, and variability due to blood collection and plasma 
processing were minimised by following HUPO PPP Specimen Collection and Handling 
Committee recommendations (Rai et al. 2005).  
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Appropriate characterisation of patients, especially individuals with TIA, was difficult during 
the acute phase of ischaemia in which blood samples were collected. Similarly, diagnosis of 
stroke mimics was also challenging. Ironically, this again highlights the potential utility of a test 
that could correctly differentiate between TIA and stroke mimics.  
 
A number of other variables may impact the findings of this study; statistically significant 
differences between age, gender, OCSP classification, admission NIHSS and time of blood sample 
collection between ischaemic and non-ischaemic populations are likely to confound the results. 
In particular, the time course of ApoC-1 and m/z 3699 over the acute phase of cerebral 
ischaemia needs investigation in order to optimise the threshold values of the biomarkers for 
diagnosis and determine how soon after AIS/TIA onset the test could be used.  
 
Concluding Remarks 
This study has demonstrated the ability of SELDI-TOF MS to detect differential protein profiles 
between ischaemic (AIS, TIA) and non-ischaemic (stroke mimic) cerebral events and its value in 
preliminary diagnostic biomarker discovery. One protein in particular, ApoC-1, has been shown 
to have promising potential for being a novel diagnostic biomarker for acute cerebral ischaemia. 
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4.1 Introduction 
 
It is predicted that by 2030, the global number of people suffering from first-ever stroke will be 
23 million in the absence of population-wide intervention (Strong et al. 2007). In the UK, stroke 
incidence and mortality have decreased over the past decade. However, there is still a pressing 
need for better risk stratification and improvements in risk factor reduction in high-risk 
individuals (Lee et al. 2011). 
 
Carotid atherosclerosis is associated with ~20% of ischaemic strokes and extracranial carotid 
atherosclerosis is the most common cause of large artery atherosclerotic (LAA) strokes in 
Caucasian populations (Mohammad et al. 2010). While carotid plaques causing substantial 
stenosis may lead to reduced blood flow and ischaemic stroke, the Asymptomatic Carotid 
Atherosclerotic Study (ACAS) and the North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) demonstrated that the size of a plaque alone does not determine stroke 
symptomology, with stroke rates differing significantly between asymptomatic and 
symptomatic individuals with the same level of stenosis (Gasecki et al. 1995; Baker et al. 2000).   
 
The composition of atherosclerotic plaques is considered to be an important determinant of 
arterial thrombus development and embolic complications. Biological attributes such as 
inflammation, matrix degradation, intra-plaque haemorrhage and intra-plaque angiogenesis 
have been acknowledged as key determinants of plaque stability and future stroke. However, 
while it is known that atherosclerosis is a complex disease involving multiple genes, pathways 
and cell types (Lusis 2000), the specific genetic mechanisms underlying plaque development 
and progression remain unclear. Thus, there exists a translational need for molecular and 
cellular characterisation of plaque stability for efficient stroke risk stratification. Such 
elucidation is essential for understanding the pathways responsible for disease progression and 
in offering biomarkers for identification of atherosclerotic burden and instability, in addition to 
putative therapeutic drug targets. Identification of high-risk individuals could improve their 
clinical management and select candidates who would benefit most from stroke-prevention 
therapies. Furthermore, an integrated model combining traditional risk factors with common 
genetic variants could more effectively discriminate patients likely to suffer from recurrent 
ischaemic events.  
 
The proportion of ischemic stroke in a population that can be attributed to a particular risk 
factor is called the population attributable risk and has been estimated as 60% in total, 
indicating a 40% gap that may in part be accounted for by genetic variants (Whisnant 1997). A 
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number of studies have demonstrated that ischaemic stroke and carotid disease share similar 
environmental and genetic risk factors (Humphries & Morgan 2004). The role of the 9p21 locus 
has previously been implicated in carotid disease (Congrains et al. 2012) and atherosclerotic 
stroke (Gschwendtner et al. 2009). This finding has been replicated in stroke GWAS, which have 
also identified two other loci (HDAC9, 6p21.1) associated with the LAA ischaemic stroke subtype 
(Holliday et al. 2012; ISGC & WTCC2 2012). Meta-analysis of GWAS from the Cohorts for Heart 
and Aging Research in Genomic Epidemiology (CHARGE) Consortium recently identified 
multiple SNPs associated with carotid intima-media thickening and plaque, mapping to genes 
related to cellular signalling, lipid metabolism, blood pressure and homeostasis (Bis et al. 2011).  
 
These results demonstrate the ability of GWAS to identify genetic variants that could provide 
new insights into the mechanisms underlying carotid atherosclerosis and LAA ischaemic stroke. 
However, while GWAS offers unbiased ways to examine the association of more than a million 
SNPs associated with disease, the list of significant SNPs obtained often fails to provide 
mechanistic insights into the underlying biology of the disease being studied, and the challenge 
remains in extracting functionally and biologically relevant information from GWAS results. 
 
Functional enrichment analysis approaches have been used to overcome this challenge. 
Hypergeometric testing and GSEA have been successfully employed to investigate molecular 
pathways underlying cardiovascular and metabolic diseases using data derived from gene 
expression studies (Sluimer et al. 2007; Diez et al. 2010; Cagnin et al. 2009) and GWAS (Morris 
et al. 2012; Voight et al. 2010; de las Fuentes et al. 2012). Both approaches have the advantage 
of reducing the complexity of data obtained from GWAS and gene expression studies from 
thousands of genes to a handful of pathways. Furthermore, the characterisation of functional 
molecular pathways that differ between two study populations often holds more information 
than simple gene lists alone (Khatri et al. 2012). However, these analyses may be susceptible to 
false positive results and thus require replication and scrutiny in independent cohorts.  
 
One method of replication is to use an integrative genomics approach to correlate the findings 
from GWAS with gene expression data to elucidate novel molecular mechanisms underlying 
complex diseases such as carotid atherosclerosis and stroke. Subsequent identification of robust 
disease-causing pathways can provide new biomarkers for targeted diagnostic and therapeutic 
intervention. This approach also allows investigation of eQTLs and QTTs or differential gene 
expression as detailed in Chapter 1, underpinned by the hypothesis that mutations or 
polymorphisms (non-disease causing genetic variation) near or in genes can have an effect on 
the expression of a disease-causative gene and are also associated with the disease itself (Ware 
et al. 2013). Given that 15% of disease-causing point mutations regulate splicing in humans 
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(Pagani & Baralle 2004), integrative genomics can also be used to investigate the genetic 
mechanisms underlying alternative splicing, a key process in disease risk and progression but 
one that is often overlooked. For example, 9p21, implicated in ischaemic stroke and carotid 
disease as mentioned above, has been found to have a complex pattern of variable splicing and 
gene expression change in a study investigating the effects of the haplotype block in expression 
microarray datasets (Folkersen et al. 2009).  
 
Aims of the Study 
Understanding global expression, splicing and genetic regulation of mRNA is of key importance 
in the field of human carotid atherosclerosis, however to date, no study of this kind has been 
performed. The aim of this study was to identify novel biomarkers that could aid in the risk-
stratification of ischaemic stroke by: 
 Using the Affymetrix Human Exon 1.0 ST Array to characterise gene expression and 
alternative splicing profiles underlying carotid stenosis and plaque instability. 
 Utilising functional enrichment analysis approaches to identify gene sets associated with 
symptomatic carotid stenosis in both the gene expression study and a GWAS meta-
analysis of carotid disease in ischaemic stroke patients. 
 Employing an integrative genomics approach to correlate results from the whole 
transcriptome study with the GWAS meta-analysis to elucidate genetic mechanisms 
underlying symptomatic carotid stenosis. 
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4.2 Methods 
 
An overview of the study workflow and methodologies used in this chapter is given in Figure 
4.1. 
 
4.2.1 Gene Expression Profiling Study 
 
4.2.1.1 Sample Selection 
Specimens from the Charing Cross Hospital carotid endarterectomy tissue bank (maintained by 
Professor Alun Davies, Imperial College London) were chosen from eighteen highly 
characterised individuals with asymptomatic or symptomatic carotid disease. Patients 
characterised as ‘symptomatic’ exhibited focal neurological symptoms pertaining to the 
ipsilateral cerebral hemisphere or amaurosis fugax, as confirmed by CT or MRI. This diagnosis 
was further supported by individual discussion of patients in a clinical MDT meeting of vascular 
surgeons and neurologists, considering contributing factors such as previous history of vascular 
events or vascular risk factors.  
 
Each flash-frozen carotid endarterectomy specimen was dissected on dry ice into two distinct 
areas relating to stenosing plaque (>20% stenosis) or non-stenosing tissue (<20% stenosis) by 
an experienced vascular surgeon (Mr Joseph Shalhoub, Imperial College NHS Trust). Multiple 
sections were taken where possible. Percentage stenosis, defined by North American 
Symptomatic Carotid Endarterectomy Trial (NASCET) criteria, was calculated from the internal 
carotid artery peak systolic velocity/common carotid artery end diastolic velocity ratio, as 
measured by Doppler ultrasound prior to surgery.  
 
Plaque segments were classified as follows: stenosing areas from symptomatic plaques were 
considered to be unstable (ruptured), whilst stenosing areas from asymptomatic plaques were 
considered stable (Figure 4.1). This classification was also based upon plaque histology by 
macroscopic examination, with stable segments covered by a smooth luminal surface indicative 
of an intact fibrous cap, while unstable plaques commonly displayed an ulcerated surface 
alongside evidence of thrombosis or haemorrhage. Patient characteristics and tissue section 
classifications are detailed in Table 4.1 and Figure 4.2. 
  
CHAPTER FOUR: INTEGRATIVE GENOMICS FOR RISK BIOMARKER DISCOVERY  
158 
 
 
 
Figure 4.1: Study design and methodology flowchart. A) The gene expression study and GWAS were conducted in 
different cohorts and analysed separately. B) Functional enrichment analysis was conducted using two methods, 
hypergeometric testing and gene set enrichement analysis (GSEA). C) Assessment of gene ontology (GO) terms 
yielded two molecular processes that were found to be significantly enriched in both the gene expression study and 
GWAS. Two genes (LTBP4 and TRIOBP) within these GO terms, common to both the gene expression study and GWAS, 
were selected as candidate biomarkers and investigated in more detail to understand whether their expression and 
splicing profiles were under the control of SNPs. D) Protein-protein interaction (PPI) analysis was performed using 
significantly differentially expressed genes from the gene expression study, to further examine the role of LTBP4 as a 
key node in the PPI disease network and a biomarker able to predict symptomatic carotid plaque progression. 
 
  
 
 
Table 4.1: Gene expression study total patient population characteristics. Demographic, clinical and histological information relating to 10 patients from whom SP and NST 
carotid endarterectomy tissue samples were taken for gene expression analysis. AIS, acute ischaemic stroke; IHD, ischaemic heart disease; NST, non-stenosing tissue; PAD, 
peripheral artery disease; SP, stenosing plaque, TIA, transient ischaemic attack. 
Patient ID 
Tissue 
Type 
Symptoms 
Carotid 
Stenosis 
(%) 
Gender Age IHD PAD Hypertension 
Diabetes 
Mellitus 
Smoking 
History 
Statin 
Use 
Antiplatelet 
Use 
V0012 2 SP + 1 NST TIA 90-95 F 76 x x  x   
V0162 3 SP + 2 NST - 90-95 M 75     x  
V1139 2 SP + 1 NST TIA 45-65 M 72    x x  
V1236 1 SP + 1 NST - 85 M 85 x   x   
V1241 2 SP - 85-95 M 50 x x x x   
V1299 2 SP + 1 NST TIA 90-95 M 79 x x  x x  x 
V1355 2 SP TIA 95 M 63 x x     
V1376 1 SP + 1 NST AIS + AmFu 90 M 60  x x    
V1377 2 NST AIS 30 M 73 x x     
V1388 1 NST - 80 F 66 x x  x x  x 
V1420 1 SP + 1 NST AIS 55-65 M 51 x x  x  x x 
V1465 1 SP + 1 NST - 75-80 M 67 x x   x x 
V1468 1 SP + 1 NST AIS 30 M 55 x x x x x x 
V1470 2 SP + 1 NST - 95 M 78 x x x x x x x 
V1471 1 SP + 1 NST - 80 M 56  x  x x  
V1477 2 SP + 1 NST AmFu 60-75 M 54 x x  x x  
V1478 1 SP + 1 NST - 90 M 73 x x  x x  
V1486 3 SP - 80 M 67 x  x x   
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Figure 4.2: Carotid endarterectomy specimen dissection into stenosising plaque or non-stenosing tissue 
areas. Where possible more than one section was taken from each area, resulting in a total of 44 tissue samples (27 
stenosing plaque, 17 non-stenosing tissue) taken from 18 patients. Of these 18 patients, 9 were asymptomatic 
(yielding 14 stenosing plaque and 8 non-stenosing plaque sections) and 9 were symptomatic (yielding 13 stenosing 
plaque and 9 non-stenosing plaque sections). Patient characteristics are further detaileid in Table 4.1. 
 
 
 
4.2.1.2 RNA Isolation 
Total RNA was isolated from carotid endarterectomy tissue samples (50-100mg) using the 
miRNeasy 96-well kit (Qiagen, UK), and a minimum of one extraction was performed from each 
tissue sample. Samples were homogenised using the TissueLyser system with 1ml of QIAzol 
lysis reagent for 4-5 minutes. Following incubation at room temperature for 10 minutes, 200μl 
of chloroform was added to each sample and the tubes were mixed vigorously for 15 seconds. 
Tubes were again incubated at room temperature for 10 minutes and then centrifuged at 12,000 
x g at 4oC for 15 minutes. The aqueous phase (upper layer containing RNA) was transferred to 
new collection tubes and RNA was precipitated by adding 800μl of 100% ethanol (1.5 volume of 
the aqueous phase). The samples were transferred into RNeasy Mini spin columns and these 
were centrifuged at 8000 x g for 1 minute to allow the RNA in the solution to bind to the spin 
column membrane. The supernatant was discarded and samples were washed to remove salt 
traces and impurities by adding 700μl of washing buffer and centrifuging for 15 seconds at 
8000 x g. This was repeated 3 times, with the final centrifugation lasting for 2 minutes. Total 
RNA was eluted from the spin column by the addition of 60μl of RNase-free water, and each 
sample was divided into 20 μl aliquots. 
 
4.2.1.3 Expression proﬁling using Affymetrix GeneChip® Human Exon 1.0 ST Arrays  
Expression proﬁling on the Affymetrix GeneChip® Human Exon 1.0 ST Arrays (Affymetrix, High 
Wycombe, UK) was outsourced to AROS Applied Biotechnology AS company laboratories 
(http:// www.arosab.com). Total RNA (200ng) was used for generation of cRNA and 
subsequent cDNA preparation with the Ambion WT Expression Kit, then cDNA was biotin 
labelled with the Affymetrix Gene-Chip Whole Transcript Sense Target Labelling Assay, as per 
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manufacturer’s instructions. Following this in vitro transcription reaction, unincorporated 
nucleotides were removed using RNeasy columns (Qiagen). Fragmented cDNA was heated to 
95OC for 5 minutes and then 45OC for 5 minutes, then loaded onto the Affymetrix Human Exon 
1.0 ST array cartridge (all samples on one cartridge, to eliminate batch effect errors). The 
cartridge was then incubated at 45OC for 16 hours, with constant rotation (60rpm), then washed 
10 times with 6x SSPE-T (sodium chloride + sodium phosphate + EDTA + 0.01%Tween-20) 
buffer at 25OC, followed by 4 washes of 0.5x SSPE-T at 50OC.  
 
For detection, the biotinylated cDNA was stained with a streptavidin-phycoerythrin conjugate 
(ﬁnal concentration 2mg/ml; Affymetrix) in 6x SSPE-T for 30 minutes at 25OC then 10 washes in 
6x SSPE-T at 25OC. An antibody amplification was performed with biotinylated anti-streptavidin 
goat antibody (final concentration 3mg/ml; Affymetrix), using goat IgG as a blocking reagent 
(final concentration 0.1mg/ml; Affymetrix). This was followed by another staining step with the 
streptavidin-phycoerthrin conjugate (ﬁnal concentration 2mg/ml; Affymetrix) in 6x SSPE-T for 
30 minutes at 25OC then 10 washes in 6x SSPE-T at 25OC. The hybridised Affymetrix Human 
Exon 1.0 ST arrays were scanned at 560nm using a confocal laser scanning microscope 
(GeneChip Scanner 3000 7G) and visually inspected for hybridisation artefacts. 
 
4.2.1.4 Quality Control 
Following RNA extraction, the NanoDrop ND-1000 Spectrophotometer V3.3.0 was used to 
assess the concentration and purity of each RNA sample. The concentration of each sample was 
noted (ng/μl), and samples with 260 nm/280 nm and 260 nm/230 nm ratios of absorbance 
<1.8 were removed.  RNA samples were also applied to an RNA 6000 Nano-LabChip and 
analysed using the Agilent 2100 Bioanalyzer (Agilent Technologies UK Ltd). RNA Integrity 
Number (RIN) values were calculated by the 2100 Expert Software (Agilent Technologies UK 
Ltd) and each RNA electropherogram was inspected to further asses RNA quality. Samples with 
RIN <3.0 were removed. 
 
Following exon array processing, quality control (QC) parameters were examined using the 
Affymetrix Expression Console software version 1.2 (www.affymetrix.com), as recommended by 
Affymetrix guidelines (Affymetrix White Paper: Quality Assessment of Exon and Gene Arrays). 
Labelling, hybridisation, scanning and background signals were evaluated by probe set 
summarisation using Robust Multichip Analysis (RMA) (Irizarry, Bolstad, et al. 2003; Irizarry, 
Hobbs, et al. 2003; Bolstad et al. 2003).  
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4.2.1.5 Exon Array Data Analysis 
Normalisation, filtering and statistical analyses were performed using Partek Genomics Suite 
v6.6 (Partek Inc., St. Louis, USA). Arrays were pre-processed using RMA quantile normalisation 
with GC background correction and probesets summarised with median polish were log2 
transformed. Probesets containing SNPs that could affect array hybridisation were identified 
using the SNPinProbe1.0 database (Duan et al 2008) and PiP Finder Tool (Ramasamy et al 
2013) and were excluded from downstream analysis. Exons were summarised to genes using 
the 90% winsorised mean of the corresponding probe sets, based upon the meta probeset 
provided by Affymetrix. Filtering was performed so that only the ‘core’ meta probeset was 
considered (21,980 gene and 232,448 exon probesets, consisting of RefSeq and full-length 
GenBank mRNAs) and Affymetrix probe sets were re-mapped onto the human RefSeq build 19 
(GRCh37), as detailed in the NetAffx annotation file (HuEx-1_0-st-v2 Probeset Annotations, 
Release 31).  
 
Differences in gene-level expression and splicing were investigated with ANOVA models to 
examine significant associations between tissue type (stenosing plaque vs. non-stenosing 
tissue) or patient diagnosis (asymptomatic vs. symptomatic) with age and gender included as 
covariates. Paired analysis was performed using repeated measures ANOVA, with covariates as 
above. Significance p-values for the ANOVA models were calculated using log2-transformed 
data, and expression fold differences calculated by least squares (LS) means. 
 
A range of fold change (1.2-2.5) and significance thresholds (p<0.01-0.1), with and without FDR 
correction, were tested on the gene expression and exon level data. Optimal thresholds were 
deemed to be those that captured the top ~5% of the total data, representing a set of 
genes/exons that displayed relatively high fold difference and high significance, as previously 
recommended (Dalman et al. 2012; Yang et al. 2002). 
 
 
4.2.2 Genome-Wide Association Study (GWAS) 
 
4.2.2.1 Patient Selection 
A discovery meta-analysis of two GWAS comprising individuals from the BRAINS and 
ISGS/SWISS cohorts was performed to investigate the genetics of carotid artery disease in 
ischaemic stroke. All study subjects were of self-reported European ancestry and were classified 
into mutually exclusive etiologic subtypes according to the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) (Adams et al. 1993). All subjects were collected prospectively under 
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protocols approved by the review boards at participating institutions, and all participants gave 
their written informed consent. Details of the cohorts are given below. 
 
Bio-Repository of DNA in Stroke (BRAINS) cohort 
The BRAINS study is an on-going case control study consisting of a UK European cohort (15 UK 
recruitment centres) and a South Asian cohort (UK South Asians as well as recruitment centres 
in India and Sri Lanka) (Yadav et al. 2011). Patients are eligible for inclusion if aged over 18 
years, with a diagnosis of ischaemic or haemorrhagic stroke confirmed by CT or MRI imaging. 
Known monogenic causes of stroke are excluded. Upon patient consent, blood samples are 
obtained for DNA extraction, analysis and storage. A total of 344 genotyped ischaemic stroke 
patients from BRAINS were included in this study. 
 
Ischemic Stroke Genetics Study (ISGS) cohort 
The ISGS is an on-going, case control study of first-ever ischaemic stroke patients recruited from 
five centres in the US, designed to investigate candidate genes from the thrombosis and 
haemostasis cascade (Meschia et al. 2003). Ischaemic stroke patients are eligible if over 18 
years of age and having symptoms within 30 days of enrolment, as diagnosed by a study 
neurologist and confirmed by CT or MRI brain imaging. The study excludes cases of post-
operative or post-procedural stroke (e.g. carotid stenting, cerebral angiography), stroke related 
to recent subarachnoid haemorrhage or mechanical heart valve, patients with known inherited 
stroke syndromes (e.g. CADASIL, homocysteinaemia) and patients with biopsy-proven central 
nervous system vasculitis or stroke occurring in the setting of active bacterial endocarditis. 
Once eligibility is confirmed, blood samples are obtained for DNA extraction, analysis, and 
storage. A total of 272 genotyped ischaemic stroke patients from ISGS were included in this 
study. 
 
Siblings with Ischemic Stroke Study (SWISS) cohort 
SWISS is a family study recruiting probands from 49 centres across the US and Canada, designed 
to identify genetic risk factors through a genome-wide linkage screen in sibling pairs 
concordant and discordant for ischemic stroke (Meschia et al. 2006). Probands are adult men 
and women invited to participate in SWISS if they have a diagnosis of at least one ischaemic 
stroke confirmed by a study neurologist and CT or MRI imaging, and report having at least one 
living full sibling with a history of ischaemic stroke. Upon verification of concordance by 
medical record review, blood samples are obtained from proband, concordant sibling, and, if 
applicable, discordant sibling, for DNA extraction, analysis, and storage. Patients who are 
already enrolled in SWISS are not eligible for participation in ISGS. A total of 37 genotyped 
ischaemic stroke patients from SWISS were included in this study. 
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4.2.2.2 Evaluation of Carotid Stenosis 
Each study cohort evaluated the degree of carotid artery stenosis using high-ultrasound B-mode 
ultrasonography of the common carotid arterty (CCA), external carotid artery (ECA) and 
internal carotid artery (ICA). An average stenosis value (%) was calculated from CCA, ECA and 
ICA stenosis measurements for each patient (as available) and used as the carotid stenosis 
phenotype. This was based upon the findings of a population-based cohort study, which 
reported that carotid plaques increase the risk of stroke and cerebral infarction irrespective of 
their location and with no clear difference in the risk estimates between ipsilateral or 
contralateral ischaemic strokes (Hollander et al. 2002). Patients with carotid stenosis ≥20% 
were deemed ‘cases’, while those with stenosis <20% were deemed controls. This threshold was 
chosen in concordance with a previous GWAS study of carotid artery disease (Bis et al. 2011), 
and allowed a relatively equal distribution of the study population between ‘cases’ and 
‘controls’. 
 
4.2.2.3 Genotyping and Quality Control 
Samples from the BRAINS cohort were genotyped on the Illumina HumanHap 610-quad 
Beadchip by Dr Sunaina Yadav (Imperial College London) and Miss Kerra Pearce (University 
College London), according to the manufacturer’s protocol. Intensity data was initially examined 
using the genotyping module in Illumina Genome Studio software. Sample-dependent and 
sample-independent control probes were checked to investigate possible processing errors. 
Data for successfully genotyped samples was extracted and SNPs were clustered using the 
GENCALL algorithm within GENCALL Genome studio V2010.1 Genotyping module software, 
with plots manually checked for incorrect clustering. Samples from the ISGS/SWISS cohort were 
genotyped on Illumina HumanHap550K chips and Illumina Bead Studio software was used for 
the initial sample processing. 
 
Quality control analysis was used performed in PLINK. Sample quality control was performed to 
remove individuals from BRAINS and ISGS/SWISS GWAS cohorts based upon the following 
filters: genotyping call rate ≤ 95%, non-European ancestry, outlying autosomal heterozygosity 
and cryptic relatedness (pi-hat ≥ 0.2). SNP quality control was also performed to remove SNPs 
with minor allele frequency less than 1% (MAF ≤ 0.01), if the SNP had more than 5% missing 
data (call frequency ≤ 95%) or if the Hardy-Weinberg p-value was ≥ 10-6. 
 
4.2.2.4 GWAS Imputation, Association Analysis and Meta-Analysis 
GWAS analysis was performed by Dr Doug Speed (University College London), Dr Sunaina 
Yadav (Imperial College London) and Dr Ioana Cotlarciuc (Imperial College London). 
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Imputation Imputation was performed across the whole genome to allow combination of GWAS 
cohorts. Imputation aims to predict genotypes at SNPs not directly genotyped in a GWAS by 
assuming linkage disequilibrium (LD) with experimental SNPs. The experimental SNPs, in 
conjunction with predicted in silico SNPs, expand the number of SNPs that can be tested for 
association and hence increase the power of a study (Clark & Li 2007; Marchini & Howie 2010). 
Imputation was performed using IMPUTE version2 software and the 1000 Genomes 06_2010 
imputation build. Annotation of the ISGS/SWISS cohort SNPs was based upon the human 
genome sequence hg18 build, and therefore updated to the hg19 build using the UCSC Genome 
Browser Liftover tool, for consistency with the BRAINS cohort prior to imputation. Imputed 
SNPs with correlation of r2 <0.5 with genotyped SNPs and MAF ≤ 0.01 were excluded. 
 
Association Analysis: Logistic regression analysis was performed independently for each cohort 
using PLINK software (Purcell et al. 2007) to investigate the association of 5,094,295 genotyped 
and imputed SNPs with the presence (≥20%) or absence (<20%) of carotid stenosis in 
ischaemic stroke patients. An additive model was used, with age and gender used as covariates.  
 
Meta-analysis: Results of the association analyses from each cohort were meta-analysed using 
PLINK software with a fixed effects inverse-variance model, weighted by standard error, to 
produce a final p-value for each SNP tested. Inter-study heterogeneity was assessed with an I2 
heterogeneity index and a p-value for Cochran’s Q statistic. 
 
4.2.2.5 SNP to Gene Annotation 
Nicolae et al. (2010) have shown that SNPs associated with complex traits are significantly more 
likely to be eQTLs than MAF-matched SNPs from high-throughput GWAS platforms. However, 
the definition of a cis-eQTL is open to interpretation. Here, cis-eQTLs were defined within a 
20kb wingspan, consistent with a gene expression study that showed that the majority of eQTLs 
lie within 20kb either side of a gene (Veyrieras et al. 2008). 
 
To ensure consistent SNP-to-gene annotation between different analytical tools, independent 
software, LDAK (www.ldak.org) was used. The complete GWAS meta-analysis SNP list was 
coded into LDAK by Dr Doug Speed (University College London).  Genes were downloaded from 
UCSC Genome Browser using the latest annotations (hg19), and SNPs were annotated to genes 
within a 20kb wingspan either side of gene transcription start and stop sites. As longer genes 
tend to contain more SNPs by chance alone, Bonferroni correction was applied to account for 
the fact that these longer genes would have smaller p-values. Genes passing a significance 
threshold of p<0.01 after Bonferroni correction were selected as the gene list for further 
investigation.   
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4.2.3 Functional Enrichment Analysis 
 
While the Bonferonni method was used for multiple testing adjustment during SNP to gene 
annotation (Section 4.2.2.5) and protein-protein interaction analysis (Section 4.2.4), FDR 
correction was applied during functional enrichment analysis. FDR methods aim to reduce the 
probability of even one false discovery and are therefore less stringent than family-wise error 
rate procedures such as the Bonferroni method, which aims to reduce the expected proportion 
of false discoveries. Consequently, FDR methods lead to increased rates of type 1 errors but 
have greater power. 
 
A number of FDR-based procedures have been proposed, including the Benjamini-Hochberg 
method (which relies on p-values being uniformly distributed under the null hypothesis; 
Benjamini & Hochberg 1995); the Benjamini–Hochberg–Yekutieli method (recommended when 
test statistics have positive regression dependency on each of the test statistics corresponding 
to the true null hypotheses; Benjamini & Yekutieli 2001); an empirical bayes method (Efron & 
Tibshirani 2002) and a q-value analog of the p-value method (Storey 2002). The Benjamini-
Hochberg is the most widely used FDR-method as it is simple and robust under most 
circumstances (Kim & van de Wiel 2008). Therefore this method was chosen for multiple testing 
adjustment throughout the functional enrichment analysis. 
 
4.2.3.1 Hypergeometric Testing 
Singular Enrichment Analysis (SEA) for gene expression and GWAS data was performed with 
DAVID Bioinformatics Resources v6.7 (Huang da et al. 2009a; Huang da et al. 2009b). For SEA a 
subgroup of significantly different genes between two study populations, as selected using a 
user-defined significance threshold, are uploaded to DAVID. For each pathway or gene set 
(based upon databases including GO and KEGG), input genes that are part of the pathway or 
gene set are counted, and the process repeated for an appropriate background list of genes (e.g. 
all the genes in the genome or all the genes captured on a microarray). Every pathway is then 
tested for over-representation in the list of input genes.  
 
Over-representation analysis in DAVID assumes a Gaussian hypergeometric probability 
distribution, which describes the number of successes in a series of n draws without 
replacement, from a finite population, N. A test against this distribution determines the 
probability that the number of successes observed could be achieved by chance alone, and thus 
determines the possibility that a certain GO term or KEGG pathway is over-represented in the 
inputted gene list, with respect to the background population. In the DAVID annotation system, 
the hypergeometric distribution is tested by a one-tailed Fisher’s Exact test or a modified 
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variant, the Expression Analysis Systematic Explorer (EASE) score, to measure the gene-
enrichment in annotation terms. When genes within two independent groups can fall into one of 
two mutually exclusive categories, Fisher’s Exact test determines whether the proportions of 
those falling into each category differs by group, taking into account the effects of a finite 
population that are ignored by other statistical methods such as Chi-square (Hosack et al. 2003). 
The EASE score is a conservative adjustment to the Fisher’s exact probability that weights 
significance in favour of terms containing more genes, and relies on jack-knifing the probability 
distribution so as to penalise categories supported by only a few genes. Thus the EASE score 
prioritises GO terms containing larger number of genes (Hosack et al. 2003). 
 
In this study, DAVID was utilised for over-representation analysis of both gene expression and 
GWAS data. For analysis of gene expression data, genes passing nominal p<0.05 significance and 
fold difference >2 were uploaded to DAVID and compared to a background population 
comprising all genes captured on the Affymetrix Human Exon 1.0 ST array. For analysis of 
GWAS data, SNPs were first annotated to genes using LDAK at 20kb wingspan (as described in 
Section 4.2.2.5), uploaded to DAVID and compared to a background population comprising all 
genes in the genome. 
 
4.2.3.2 Gene Set Enrichment Analysis (GSEA) 
GSEA of Gene Expression in Partek 
GSEA analysis of gene expression data was performed within Partek Genomics Suite v6.6 
(Partek Inc., St. Louis, USA). Given pre-defined gene sets (e.g. GO annotations), GSEA determines 
whether the members of these defined gene sets are distributed randomly throughout an 
experimental list of genes, or primarily found at the top or bottom of the ranked list (i.e. 
substantially up- or down-regulated). As signal-to-noise ratio is larger for a set of genes, GSEA is 
statistically sensitive to small but consistent changes within a gene set, which may be 
biologically important (Clark & Ma’ayan 2011). Genes are first ranked according to their degree 
of differential expression between two study groups, then grouped into biological categories as 
determined by a reference database (e.g. GO). An enrichment score (ES) is calculated to reflect 
the degree to which these pre-defined gene sets are overrepresented and corresponds to a 
weighted Kolmogorov-Smirnov-like statistic. The ES is calculated by walking down the entire 
gene list and increasing a running sum statistic when a gene in the gene set is encountered and 
decreasing it when the gene is not in the gene set. The increment of increase or decrease is 
based upon the degree of correlation between the gene and the phenotype. The statistical 
significance of the ES is estimated by phenotype label permutation (preserving gene-gene 
correlations and the complex nature of gene expression data). The ES of the permutated data is 
calculated and the p-value of the experimental ES is calculated relative to this null distribution. 
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Correction of multiple hypothesis testing is performed by normalising the ES for each gene set 
to account for the size of the set and then applying an FDR correction (Subramanian et al. 2005).  
GSEA of gene expression data was performed on Partek using 1000 permutations and GO as a 
reference database. 
 
GSEA of GWAS in ICSNPathway 
GSEA analysis of GWAS data was performed using ICSNPathway (Zhang et al. 2011). 
ICSNPathway is a web-based tool that uses GWAS data to discover candidate causal SNPs and 
associated causal pathways. Unlike many platforms that either annotate SNPs to genes to infer 
causal SNPs or identify causal pathways by pathway analysis, ICSNPathway integrates LD 
analysis, functional SNP annotation and pathway analysis into one tool.  
 
Firstly, SNPs in LD with the most significant SNPs obtained from GWAS are collated from the 
Hapmap CEU hg19 build to capture all possible candidate causal SNPs. Candidate causal SNPs 
are selected based upon a functional SNP that alter protein structure, gene expression or the 
role of a protein within a molecular pathway. These functional SNPs are defined by the Ensembl 
Variant Effect Predictor, and include deleterious and non-deleterious non-synonymous SNPs, 
SNPs leading to gain or loss of stop codon, SNPs resulting in frame shift, and SNPs 
in transcription factor binding sites, essential splice sites (the first two bp and last two bp of an 
intron) or regulatory regions.  
 
ICSNPathway performs pathway analysis on the full list of GWAS-obtained SNPs based upon the 
improved gene set enrichment analysis (i-GSEA) method (Zhang et al. 2010). The Ensembl 61 
database is used to map each SNP to a gene, with the maximum –log10(p-value) of the SNPs 
mapped to gene (t) used to represent the gene. All genes are ranked according to their t values 
and enrichment scores are calculated per pathway by Kolmogorov-Smirnov like running-sum 
statistic. These enrichment scores are converted to significant proportion based enrichment 
scores (SPESs) by multiplying by m1/m2, where m1 is the proportion of significant genes 
(defined as genes mapped with at least one of the 5% most significant SNPs of GWAS) for a 
pathway, and m2 is the proportion of significant genes for all the genes in the GWAS. Unlike 
traditional GSEA that conducts phenotype label permutation, i-GSEA implements SNP label 
permutation and normalisation to generate a distribution of SPES and to correct for gene 
variation (the bias caused by different genes having different numbers of mapped SNPs) and 
pathway variation (the bias caused by different pathways comprising different numbers of 
genes). Based upon SPES distributions generated by permutation, a nominal p-value is 
calculated and FDR correction performed for multiple testing. By implementing SNP label 
permutation instead of phenotype label permutation, and by focussing on pathways with high 
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proportions of significant genes (SPES) rather than relying on the total significance attributed to 
a few or many significant genes (ES), it has been shown that i-GSEA has better sensitivity than 
traditional GSEA for identifying pathways that represent combined effects of possibly modest 
SNPs (Zhang et al. 2010). 
 
Here, significant SNPs were defined as those with p<10-5, the parameter for searching for LD 
neighbourhood was restricted to r2>0.8 at a distance of 200kb, and SNPs were annotated to 
genes within a 20kb wingspan. GO annotations were explored for pathway/gene set analysis, 
with the minimum number of genes in each pathway being set to 3 and FDR cut-off for pathway 
analysis set at p<0.05. 
 
 
4.2.4 Protein-Protein Interaction Analysis 
The Disease Association Protein-Protein Link Evaluator (DAPPLE; Broad Institute) was used to 
assess significant physical connectivity among proteins encoded for by genes in loci associated 
to symptomatic carotid stenosis (Rossin et al. 2011). The hypothesis underlying DAPPLE is that 
causal genetic variation affects a group of biological mechanism that are detectable by protein-
protein interactions. Protein-protein interactions are defined by the InWeb database, which 
combines information from a number of sources including MINT, BIND, IntAct and KEGG and 
scores interactions based upon the scale of the experiment in which the interaction was 
reported and the number of publications in which the interaction had been cited (Lage et al. 
2007).  
 
‘High confidence’ InWeb protein-protein interactions are used to test whether direct and 
indirect networks built from seed regions are more connected than by chance alone,  which is 
defined by the connectivity expected if connectivity were purely a function of the binding 
degree of participating proteins. The HapMap CEU hg18 build (www.hapmap.org) is used by 
DAPPLE for hotspot and LD information, with the wingspan of a SNP defined as the region 
containing SNPs with r2>0.5 to the associated SNP, and this region being further extended to the 
nearest recombination hotspot. The hg18 gene list is downloaded from UCSC using Ensemble 
transcripts, and splice isoforms are collapsed to define the maximum gene footprint from 
transcription start site to transcription stop site, including flanking regulatory DNA.  
 
DAPPLE builds direct networks from direct interactions between associated proteins according 
to the InWeb database, as well as indirect networks by considering connections between 
proteins associated via a protein elsewhere in the genome. Within-degree node-label 
permutation, comprising a permutation step and a switching step, is used to generate random 
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protein networks, then an empirical distribution is constructed for each network and used to 
evaluate the significance of disease networks. Individual proteins within a network are scored 
using the same permutation method and a subset of candidate proteins per locus is suggested to 
be harbouring causal variants, with these candidate proteins scores being Bonferroni corrected 
to adjust for the number of possible candidates within each locus.  
 
For analysis of gene expression data obtained from the transcriptomics study, genes passing a 
nominal significance of p<0.05 and fold difference >2 were input to DAPPLE. Common 
interactor binding degree cut-off was set at 2, running 1000 permutations and iteration such 
that if any gene achieves a Bonferroni corrected score of p<0.05, that gene was prioritised and 
the analysis restarted.   
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4.3 Results 
 
4.3.1 Analysis of Gene Expression Data 
 
4.3.1.1 Sample Selection and Patient Characteristics 
Eighteen patients undergoing carotid endarterectomy were selected for the study, of which 9 
were symptomatic and 9 asymptomatic. From these 18 endarterectomy specimens, RNA was 
extracted from 44 samples (27 samples from stenosing plaque and 17 samples from non-
stenosing tissue).  Of these, 25 samples failed the threshold of RNA integrity required using 
Nanodrop 260/280nm ratio (accept >1.8) and Agilent Bioanalyser RNA Integrity Number (RIN; 
accept >3.0), hence only 19 were analysed for global gene expression using the Affymetrix 
Human Exon 1.0 ST array. Two of these 19 samples failed chip hybridisation control, hence 17 
samples were available for analysis, relating to 8 stenosing plaque and 9 non-stenosing tissue 
samples, taken from 10 patients (7 symptomatic, 3 asymptomatic) (Figure 4.2). Mean age of the 
population was 67 years (sd = 11.6 years) and mean % carotid stenosis was 72% (sd = 24.2%). 
The majority of patients were male (80%) and were on statin (70%) and antiplatelet medication 
(70%). Patient characteristics are detailed in Table 4.2. Power calculations performed on Partek 
Genomics Suite software found that a sample size of 10 (5 in each analysis arm) delivered 80% 
power at p<0.05 to detect a 2-fold difference in means.  
 
4.3.1.2 Quality Control Analysis 
Following RMA normalisation, quality control (QC) parameters were used to investigate 
reproducibility and consistency of signals across arrays, and to identify any outlier arrays that 
differed substantially from the majority of the cohort. The following metrics were used to 
examine sample and hybridisation quality: 
 
Area Under the Curve (AUC): The AUC value is taken from a ROC curve, generated by evaluating 
how well the probe set signals separate the positive controls from the negative controls with the 
assumption that the negative controls are a measure of false positives and the positive controls 
are a measure of true positives. This provides a measurement for overall data quality, with an 
AUC of 1 representing perfect separation and an AUC value of 0.5 representing no difference 
between positive and negative controls. The mean score from 17 arrays in this study was 0.82. 
 
Probeset Summarisation Values: The mean signal of all probesets should be consistent between 
arrays. The mean Probeset Mean in this study cohort was 5.67 (SD=0.14). The mean absolute 
relative log expression compares probeset signals against the median signal, with higher values 
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indicating that the signal is different from the others. The mean of the absolute deviation of the 
residuals from the median (X_mad_residual_mean) produces a measure of how well or poorly all 
of the probes on a given chip fit the RMA normalisation model, with the difference between the 
actual value and the predicted value termed the residual. All these metrics provide measures of 
the overall quality of data that will be used for downstream analysis. 
 
Hybridisation and Labelling Controls: Bacterial spikes are the set of probesets which hybridise to 
the pre-labelled bacterial spike controls (as BioB, BioC, BioD and Cre). This category is useful in 
identifying problems with the hybridization and/or chip. PolyA spikes are the set of 
polyadenylated RNA spikes (Lys, Phe, Thr, and Dap), and can be used to identify problems with 
the target preparation phase.  
 
Arrays were considered outliers if the metric value was >10% above or below the mean value 
for the whole cohort. None of the arrays failed on more than two metrics, therefore all arrays 
were considered in the downstream analysis (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Table 4.2: Gene expression study patient characteristics. Demographic, clinical and histological information relating to 10 patients from whom SP and NST carotid endarterectomy 
tissue samples were used for gene expression analysis using Affymetrix Human Exon 1.0 ST array. AIS, acute ischaemic stroke; IHD, ischaemic heart disease; NST, non-stenosing tissue; 
PAD, peripheral artery disease; SP, stenosing plaque, TIA, transient ischaemic attack. 
 
Patient ID 
Tissue 
Type 
Symptoms 
Carotid 
Stenosis 
(%) 
Plaque 
Histology 
Gender Age IHD PAD Hypertension 
Diabetes 
Mellitus 
Smoking 
History 
Statin 
Use 
Antiplatelet 
Use 
V0012 SP + NST TIA 90-95 Smooth F 76 x x  x    
V1236 SP + NST - 85 Smooth M 85 x   x    
V1299 SP + NST TIA 90-95 Irregular M 79 x x  x x  x 
V1376 SP + NST AIS + AmFu 90 Smooth M 60  x x     
V1377 NST AIS 30 Irregular M 73 x x      
V1388 NST - 80 Smooth F 66 x x  x x  x 
V1420 SP AIS 55-65 Irregular M 51 x x  x  x x 
V1465 SP + NST - 75-80 Smooth M 67 x x   x x  
V1468 SP + NST AIS 30 Smooth M 55 x x x x x x  
V1477 SP + NST AmFu 60-75 Irregular M 54 x x  x x   
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Figure 4.3: Plotted QC metrics to assess array data quality. A: Box plot of the relative log expression signal for all 
probesets analysed. Deviations from a median value of 0 (e.g. A653_1457, corresponding to patient V1377 NST sample) 
could indicate skew in the raw intensities for the array that cannot be corrected by RMA normalisation. B: Mean absolute 
deviation of residuals (red), mean absolute relative log expression (blue) and the area under the receiver operator curve 
for signal discrimination of the positive and negative controls (AUC; green) suggest that array A653_1457 may be an 
outlier. C: PolyA spikes can identify potential problems with the target preparation phase of the experiment. Here, the 
rank order of the polyA spikes is as expected (lys [pink] <phe [red] <thr [blue] <dap [green]). D: Bacterial spikes can 
identify potential problems with the hybridisation and array chip. The rank order of the bacterial spikes is as expected 
(BioB [red] < BioC [pink] < BioD [green] < Cre [blue]). Array chip A653_1467 (corresponding to patient V1420 SP sample) 
shows a compromised signal value with both PolyA and Bacterial Spikes, suggesting hybridisation or target preparation 
errors. Nonetheless, neither array A653_1457 nor A653_1467 failed (>10% deviation from mean) on more than two 
metrics, and therefore were not excluded from downstream analysis. 
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4.3.1.3 Unsupervised Analysis 
PCA based on global gene expression demonstrated distinct classification based upon tissue 
type (non-stenosing tissue (NST) or stenosing plaque (SP)), which was a stronger determining 
factor of gene expression than any other demographic variable. Furthermore, little 
differentiation was observed between NST samples from symptomatic and asymptomatic 
individuals, while SP samples from asymptomatic and symptomatic individuals clustered 
separately. One outlier (corresponding to patient V1377 NST sample) was identified and 
removed from further analysis (Figure 4.4). 
 
 
 
 
 
Figure 4.4: Unsupervised analysis of gene expression data by PCA. PCA of the gene expression profiling study 
(comprising 9 NST and 8 SP carotid endarterectomy tissue samples from 7 symptomatic and 3 asymptomatic 
individuals) demonstrated a natural ability of global gene expression to separate individuals by tissue type (NST or 
SP). Furthermore, asymptomatic and symptomatic SP samples were seen to cluster separately. The same analysis 
performed all other demographic variables did not demonstrate this ability for classification, indicating that global 
gene expression is useful for tissue and patient classification, independent of other confounding variables. One outlier 
was identified, corresponding to patient V1377 NST sample. This sample had also been found to be of questionable 
quality during quality control procedures, and was therefore excluded from downstream analysis. NST, non-
stenosing tissue; SP, stenosing plaque. 
 
  
CHAPTER FOUR: INTEGRATIVE GENOMICS FOR RISK BIOMARKER DISCOVERY  
176 
4.3.1.4 Supervised Inter-Plaque and Intra-Plaque Analysis 
Gene expression analysis was performed based upon the Genbank RNA transcript ‘core’ gene set 
of 21,980 genes. Examination of demographic variables found that age, gender and statin use 
accounted for substantial sources of variation (F-ratios of 2.06, 2.01 and 2.46 respectively; F-
ratio of tissue type of 3.78). Therefore these were included as covariates in the ANOVA model. 
 
Differential expression of 2,988 genes (13.5%) was found between all NST (n=9) and SP (n=8) 
tissue samples (p<0.05). None of these genes were found to reach significance of p<0.05 after 
FDR correction. However, 564 genes were differentially expressed at a fold difference >2 (341 
up-regulated in SP and 223 down-regulated). Alternative splicing was evident in 17,060 genes 
(uncorrected p<0.05), of which 3121 were found to be alternatively spliced at FDR p<0.05. A 
total of 1620 genes were found to be differentially expressed but not alternatively spliced and 
911 showed alternative splicing without being differentially expressed (the ‘cassette exon’ use 
case). 
 
Expression and alternative splicing profiles were also compared between NST and SP tissue 
segments of asymptomatic and symptomatic patients, with SP segments of symptomatic 
patients deemed vulnerable and unstable (as confirmed by clinical experts and histological 
examination), and SP segments of asymptomatic patients deemed stable. Four analyses were 
performed: 
Asymptomatic NST (n=3) vs Asymptomatic SP (n=2) 
Symptomatic NST (n=5) vs Symptomatic SP (n=6) 
Asymptomatic NST (n=3) vs Symptomatic NST (n=5) 
Asymptomatic SP (n=2) vs Symptomatic SP (n=6) 
 
The results of these analyses are summarised in Figure 4.5. It was found that tissue type (NST or 
SP) was a stronger determinant of differential gene expression and alternative splicing than 
whether a patient was symptomatic or asymptomatic. Nonetheless, the number of differentially 
expressed genes was more than double between symptomatic NST and SP as compared to 
asymptomatic NST and SP (2778 genes as compared to 1329 genes, at uncorrected p<0.05, fold 
difference >2). Furthermore, the degree of alternative splicing observed between symptomatic 
NST and SP samples (2373 genes, FDR p-value<0.05) was substantially higher than in any other 
analysis. 
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Figure 4.5: Venn diagrams depicting gene expression and alternative splicing profiles in various phenotypes. 
Independent analyses were performed to explore the effects of tissue type (NST or SP) and symptomatic status on 
global gene expression, using ANOVA models adjusted for age and gender. Little overlap was noted between genes 
from the four analyses, indicating the presence of unique pathological processes. Tissue type (NST or SP) was a 
greater determinant of gene expression and alternative splicing differences than symptomatic status. Interestingly, 
analysis of differences between symptomatic SP and NST yielded the greatest level of differential gene expression and 
a marked increase in alternative splicing, suggesting that alternative splicing of genes, rather than gene expression 
itself, could play a key role in a symptomatic plaque phenotype. For gene expression analysis, genes passing a 
nominal significance threshold of p<0.05, and fold difference >2 are shown. For alternative splicing analysis, genes 
passing an FDR corrected significance of p<0.05 are shown. Asymptomatic NST: n=3, asymptomatic SP: n=2, 
symptomatic NST: n=5, symptomatic SP: n=6. NST, non-stenosing tissue; SP, stenosing plaque. 
 
 
4.3.1.5 Paired Symptomatic NST vs SP Analysis 
For comparison with GWAS data, gene expression profiles of paired NST and SP CEA samples 
from 5 symptomatic individuals (V0012, V1299, V1376, V1468, V1477) were explored. Probes 
were first interrogated with SNPinProbe1.0 database and Pip Finder tool to remove 17,552 
probesets (6.3%) containing known SNPs that could affect probe binding affinity to the 
microarray, leaving 261,033 probesets for analysis.  Differential gene expression and alternative 
splicing between paired NST and SP were analysed using repeated measures ANOVA, with age, 
gender and statin use incorporated into the model as covariates.  
 
Differential expression of 2,723 genes (12.4%) was found between paired symptomatic NST and 
SP tissue samples (p<0.05). None of these genes were found to reach significance of p<0.05 after 
FDR correction. However, 368 genes were differentially expressed at a fold difference >2 (162 
up-regulated in SP and 206 down-regulated). Furthermore, alternative splicing was evident in 
4,573 genes (uncorrected p<0.05), of which 2,761 were found to be alternatively spliced at FDR 
p<0.05. A total of 55 genes were found to be differentially expressed but not alternatively 
spliced and 1714 showed alternative splicing without being differentially expressed. These 
findings verified earlier indications that alternative splicing of genes, rather than gene 
expression itself, could play a key role in plaque progression and a symptomatic plaque 
phenotype.  
 
Gene Expression 
 
 
Alternative Splicing 
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4.3.2 Analysis of GWAS Data 
 
4.3.2.1 Patient Characteristics 
A discovery meta-analysis of two GWAS was performed to investigate the genetics of carotid 
artery stenosis in ischaemic stroke patients. GWAS meta-analysis comprised 653 patients from 
the BRAINS (n=344) and ISGS/SWISS cohorts (n=309). Patient demographics are given in Table 
4.3. Patients with carotid artery stenosis ≥20% were deemed ‘cases’ (n=369), and patients with 
carotid artery stenosis <20% were deemed ‘controls’ (n=284).  
 
4.3.2.2 Quality Control Analysis 
SNP imputation was performed to allow meta-analysis of BRAINS and ISGS/SWISS genotyped 
data, using IMPUTE2 version2 software and the 1000 Genomes 06_2010 imputation build as a 
reference haplotype. Logistic regression analysis was performed on the resulting 5,094,295 
SNPs independently for both cohorts, with a cross-sectional study design to model the genetic 
effects on risk for the dichotomous outcome of presence (≥20%) or absence (<20%) of carotid 
stenosis in an ischaemic stroke population. An additive model was employed to relate genotype 
dose to carotid stenosis, using age and gender as covariates. Meta-analysis of the association 
results from each cohort was performed using a fixed-effects inverse variance weighted model.  
 
Probability value quantile-quantile (Q-Q) plots were derived before and after meta-analysis for 
visual inspection of the quality of GWAS data (Figure 4.6). A Q-Q plot allows interrogation of 
possible confounding factors (e.g. unrecognised population structure, microarray platforms, 
genotyping artefacts) affecting GWAS results, by plotting the expected null χ² distribution of 
association test statistics (x-axis) against the observed values (y-axis). Deviation from the 
central line implies a consistent difference across the genome that may be due to a confounding 
factor that warrants closer inspection. General concordance between observed and expected 
values, with sharp deviation from the central line at high p-values suggests a small number of 
true associations that are more significant than expected under the null hypothesis. A Q-Q plot 
of the genome-wide distribution of meta-analysis association results demonstrated substantial 
departure from the null hypothesis of no association. Furthermore, a genomic inflation factor 
(GIF; λ) value of 0.97 was obtained, indicating low population stratification and therefore no 
necessity to adjust the logistic regression model for other confounding variables or principal 
components. 
  
 
 
 
Table 4.3: GWAS cohort patient characteristics. Demographic and clinical information relating to the 653 ischaemic stroke patients comprising the GWAS meta-analysis. 
Patients with carotid artery stenosis ≥20% were deemed ‘cases’ (n=369), and patients with carotid artery stenosis <20% were deemed ‘controls’ (n=284). BRAINS, Bio-
Repository of DNA in Stroke; ISGS, Ischaemic Stroke Genetics Study; SWISS, Siblings With Ischemic Stroke Study. 
 
 
 
BRAINS (n=344) ISGS (n=272) SWISS (n=37) 
Mean Age (± sd) 71.4 (14.0) 66.0 (14.4) 69.0 (9.9) 
Gender 151F, 193M 164F, 109M 20F, 17M 
Carotid Stenosis (≥ /< 20%) 
   
≥20% n (%) 165 (48.0%) 204 (66.0%) 
< 20% n (%) 179 (52.0%) 105 (34.0%) 
Ischaemic Stroke Subytpe (TOAST) 
  
Cardioembolic n  79 27 19 
Small Vessel Disease n  30 15 19 
Large Vessel Disease n  42 34 24 
Hypertension (%) 71% 64% 73% 
Smoking (%) 21% 68% 11% 
Diabetes (%) 14% 21% 24% 
Hypercholesterolaemia (%) 44% 48% 59% 
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Figure 4.6: Quantile-Quantile (Q-Q) plots of GWAS association results obtained from A) BRAINS cohort B) 
ISGS/SWISS cohort and C) BRAINS and ISGS/SWISS meta-analysis. Observed association significance is plotted 
against the expected association significance for each SNP, with strong deviation away from the central line indicating 
substantial departure from the null hypothesis of no association. Genomic inflation factors (GIF; λ) of ~1.00 were 
obtained for all three analyses, indicating low population stratification and therefore no necessity to adjust the 
logistic regression model for other confounding variables or principal components.  
 
 
 
4.3.2.3 Genetic Loci Associated with Carotid Stenosis in the Presence of Ischaemic Stroke 
No single SNP (either genotyped or imputed) demonstrated a genome-wide significant 
association with carotid stenosis (≥20%) in the presence of ischaemic stroke, with genome-
wide significance being defined as p<5x10-8 relating to a Bonferroni correction of p<0.05 for 
approximately 1 million independent tests conducted. Nevertheless, 462 SNPs approached 
suggestive significance of p<1x10-5, and a total of 4039 SNPs reached significance of p<1x10-3.  
 
Candidate genomic regions of interest were observed on chromosomes 4, 11 and 20, as 
illustrated in the Manhattan plot in Figure 4.7 These regions corresponded to SNPs residing in 
or near to the RasGEF domain family member 1B (RASGEF1B) gene, olfactory receptor family 9 
subfamily G member 1 (OR9G1) gene and kinesin family member 16B (KIF16B) gene. 
 
A cluster of 77 SNPs with p<1x10-5 were found around the RASGEF1B locus (4q21.21), a guanine 
nucleotide exchange factor with specificity for Ras family proteins. In particular, 13 SNPs with 
p<1x10-6 were identified spanning a 20kb region, in high LD (r2>0.95) with each other and the 
sentinel SNP rs592145. The SNPs lie 315kb (rs28528190) to 335kb (rs500213) downstream of 
RASGEF1B and were all found to show the same direction of association, with effect sizes 
ranging from OR 0.509 (95% CI 0.45-0.80, rs592145) to OR 0.524 (95% CI 0.49-0.81, 
rs611140), as detailed in Table 4.4. Effect sizes in the same direction were almost a necessity of 
significance in this case, with only two studies in the meta-anaysis. All SNPs exhibited moderate 
heterogeneity in the meta-analysis (I2=51-61%). 
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Seven SNPs with p<1x10-6 were identified near the olfactory receptor loci on chromosome 11, a 
family of G-protein-coupled olfactory receptors. The SNPs demonstrated high LD with each 
other and the sentinel SNP rs584144 (r2>0.95), and spanned a 14kb region downstream of the 
OR9G1 locus (11q11). The SNPs lie 27kb (rs548921) to 42kb (rs513873) downstream of the 
OR9G1 gene and demonstrated the same direction of association with OR 0.55, although the 
SNPs exhibited moderate heterogeneity in the meta-analysis (I2 ~72%) (Table 4.4). A previous 
GWAS identified an association between OR9G1 and hemostatic factors and hematological 
phenotypes in the Framingham Heart study (Yang et al. 2007). However, investigation of LD 
between the reported SNP (rs1397048) and the sentinel SNP in this study (rs584144) 
demonstrated minimal correlation (r2>0.059). 
 
A cluster of five SNPs with p<1x10-6 was also identified inside an intron of the KIF16B gene 
(20p11.23), a kinesin-like microtubule dependent motor protein involved in intracellular 
trafficking. The SNPs spanned a 1.2kb region and demonstrated high LD with each other and the 
sentinel SNP rs12151916 (r2>0.88) and exhibited the same direction of association, with effect 
sizes ranging from OR 1.85 (95% CI 1.42-2.37, rs12151916) to OR 1.83 (95% CI 1.38-2.26, 
rs603444) and low evidence of heterogeneity in the meta-analysis (I2<25%) (Table 4.4). 
 
 
 
 
Figure 4.7: Manhattan plot of genome-wide association signals from meta-analysis of GWAS of BRAINS and 
ISGS/SWISS ischaemic stroke cohorts. Chromosomes are laid down end-to-end along the x-axis and physical 
position of each association test plotted against the −log10 of the significance p-value. No SNPs passed the genome-
wide significance level of p=5×10−8, however the yellow line represents suggestive significance at genome-wide 
significance level of p=1×10−5. Three genetic loci in or near RASGEF1B, OR9G1 and KIF16B genes at significance 
p<1×10−5 were identified on chromosome 4, 11 and 20 respectively.  
  
Table 4.4: GWAS association results of carotid stenosis ≥20% in ischaemic stroke patients, after meta-analysis of BRAINS and ISGS/SWISS cohorts. Clusters of SNPs with 
p<1x10-6 were identified in three genetic loci corresponding to RASGEF1B, OR9G1 and KIF16B genes. Sentinal SNPs are identified in bold, with odds ratios (OR) describing increase or 
decrease per copy of the risk allele (A1) as compared to the non-risk allele (A2). I2, I2 measure of heterogeneity; KIF16B, kinesin family member 16B; LD, linkage disequilibrium; OR, 
odds ratio; OR9G1, olfactory receptor family 9 subfamily G member 1; Q, Cochran’s  Q measure of heterogeneity; RASGEF1B, RasGEF domain family member 1B; SNP, single 
nucleotide polymorphism. 
 
 
 
 
 
 
 
 
Gene SNP Chromosome Position A1/A2 OR (95% CI) p-value Q I2 (%) 
LD with sentinel SNP,  
r2 (D') 
RASGEF1B rs592145 4 82726387 G/A 0.509 (0.45-0.80) 3.72 x 10-6 0.14 54.9 1.00 (1.00) 
 
rs669481 4 82727177 T/A 0.513 (0.40-0.73) 4.42  x 10-6 0.15 51.6 0.95 (1.00) 
 
rs656129 4 82727881 G/A 0.513 (0.40-0.73) 4.44 x 10-6 0.15 51.4 0.95 (1.00) 
 
rs653923 4 82728376 T/G 0.513 (0.40-0.73) 4.44 x 10-6 0.15 51.4 0.95 (1.00) 
 
rs509133 4 82724731 T/G 0.516 (0.41-0.73) 5.30 x 10-6 0.14 54.3 0.95 (1.00) 
 
rs593528 4 82726035 T/A 0.516 (0.41-0.73) 5.32 x 10-6 0.14 54.2 0.95 (1.00) 
 
rs669908 4 82727097 G/A 0.516 (0.41-0.73) 5.32 x 10-6 0.14 54.2 0.95 (1.00) 
 
rs555028 4 82727198 C/T 0.516 (0.41-0.73) 5.35 x 10-6 0.14 54.1 0.95 (1.00) 
 
rs500213 4 82728569 C/T 0.516 (0.41-0.73) 5.37 x 10-6 0.14 53.9 0.95 (1.00) 
 
rs538307 4 82723874 G/A 0.523 (0.44-0.79) 7.83 x 10-6 0.12 59.2 0.95 (1.00) 
 
rs510654 4 82708507 A/G 0.523 (0.45-0.78) 8.91 x 10-6 0.11 60.2 0.95 (1.00) 
 
rs28528190 4 82707806 G/A 0.522 (0.43-0.76) 9.14 x 10-6 0.11 61.3 0.95 (1.00) 
 
rs611140 4 82708464 T/C 0.525 (0.49-0.81) 9.81 x 10-6 0.11 61.2 0.95 (1.00) 
OR9G1 rs584144 11 56503728 C/T 0.552 (1.74-2.25) 7.18 x 10-6 0.06 72.8 1.00 (1.00) 
 
rs645359 11 56508191 C/T 0.553 (1.76-2.21) 7.43E x 10-6 0.06 72.5 1.00 (1.00) 
 
rs504021 11 56496947 G/A 0.553 (1.75-2.27) 7.51 x 10-6 0.06 72.5 1.00 (1.00) 
 
rs483798 11 56497255 C/T 0.553 (1.76-2.26) 7.51 x 10-6 0.06 72.5 1.00 (1.00) 
 
rs548921 11 56496107 G/A 0.554 (1.79-2.28) 8.44 x 10-6 0.06 72.0 1.00 (1.00) 
 
rs679888 11 56496757 G/A 0.555 (1.81-2.29) 9.34 x 10-6 0.06 71.2 0.96 (1.00) 
 
rs513873 11 56510623 A/G 0.557 (1.84-2.31) 9.81 x 10-6 0.05 73.8 1.00 (1.00) 
KIF16B rs12151916 20 16270957 C/G 1.8491 (1.42-2.37) 7.87 x 10-6 0.25 25.0 1.00 (1.00) 
 
rs6034443 20 16271601 C/T 1.8294 (1.38-2.26) 9.75 x 10-6 0.28 12.9 0.88 (0.96) 
 
rs6043872 20 16272136 G/C 1.8294 (1.38-2.26) 9.75 x 10-6 0.28 12.9 0.88 (0.96) 
 
rs6034445 20 16272189 A/G 1.8294 (1.39-2.28) 9.75 x 10-6 0.28 12.9 0.88 (0.96) 
 
rs6043869 20 16271690 C/T 1.8367 (1.42-2.34) 9.89 x 10-6 0.27 18.9 0.88 (0.96) 
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4.3.2.4 SNP Annotation and Cis-eQTL Mapping 
SNPs obtained from GWAS meta-analysis following imputation and meta-analysis were 
annotated to genes within a 20kb wingspan using LDAK software. 
 
A total of 21,911 genes were identified by LDAK, of which 207 achieved a Bonferroni adjusted 
significance threshold of p<0.05. Bonferroni correction was applied to account for the fact that 
longer genes are likely to contain more SNPs. The SNP and CNV Annotation Database (SCAN; 
Gamazon et al. 2010) was used to identify eQTL annotations. Annotation confirmation of SNPs 
reaching a suggestive genome-wide significance of p<1x10-5 by SCAN analysis identified 20 loci 
with SNPs inside genes that achieved Bonferroni adjusted p<0.05 in LDAK: CSF1R, ENTPD6, 
FAM5B, FMOD, GRB14, KIF16B, LTBP4, MAP4K5, MEGF11, MPND, MRGPRD, MYO3B, OR9G4, 
OSBPL3, PTGDR, SAV1, SIGLEC15, SLC25A24, SLC6A13, UGT3A1. A further 28 genes were found 
within a 20kb region of annotated SNPs and annotated as expression genes associated with 
eQTLs.  
 
 
4.3.2.5 Comparison of GWAS Results with Previously Reported Associations  
A comparative search was performed with previously reported GWAS hits using the gene list 
obtained from LDAK. Six annotated genes from SNPs reaching significance p<1x10-5 from GWAS 
meta-analysis were reported in GWAS of CVD and metabolic disorders, of which 2 had SNPs 
within the gene (GRB14, MYO3B) and 3 were flanking genes within a 20kb region of the SNP 
(AGR2, KIF13B, SLC14A2). These genes had been previously reported in disorders including type 
2 diabetes, obesity-related traits and response to statin therapy. None of the SNPs identified 
through the search were found to be the same as those from the current GWAS analysis (Table 
4.5).  
 
  
 
 
 
Table 4.5: Comparison of GWAS results with previously reported associations. Genes found significant in the experimental GWAS of carotid stenosis through LDAK annotations 
were searched in the literature for reported associations from GWAS of CVD and metabolic disorders. Two genes (GRB14 and MYO3B), with SNPs within genes, were found to be 
previously reported in GWAS of type 2 diabetes, blood pressure and obesity-related traits.  Further three flanking genes (AGR2, KIF13B and SLC14A2) within 20kb of the sentinel SNP 
were found to be associated in previous GWAS of type 2 diabetes, response to statin therapy and metabolic levels. However, none of the SNPs within these genes were common 
between the experimental GWAS and literature, often demonstrated different directions of association, and exhibited weak linkage disequilibrium with the experimental SNP (r2<0.4). 
NR, not reported. 
 
Gene Region Experimental Literature 
  
SNP 
Risk 
Allele 
p-value 
OR  
(95% CI) 
Citation Disorder SNP 
Risk 
Allele 
p-value 
OR  
(95% CI) 
GRB14 2q24.3 rs11895467 T 6.21 x 10-5 
0.6195  
(0.42-0.68) 
Kooner et al 2011 Type 2 diabetes rs3923113 A 1 x 10-8 
1.09  
(1.06-1.13) 
      
Kato et al 2011  Blood pressure rs16849225 C 4 x 10-11 
0.75  
(0.53-0.97)  
 
MYO3B 2q31.1 rs2883655 T 3.92 x 10-5 
1.6767  
(1.32-2.13) 
Comuzzie et al 2012 
Obesity-related 
traits 
rs7561268 C 2 x 10-6 0.03 (NR)  
AGR2 7p21 rs17136605 C 9.14 x 10-5 
3.2913  
(2.58-4.18) 
Pasquale et al 2013 Type 2 diabetes rs1525739 ? 6 x 10-6 0.44 (NR)  
KIF13B 8p12 rs491687 C 7.63 x 10-5 
1.6722  
(1.31-2.12) 
Barber et al 2010 
Response to 
statin therapy 
rs10091038 A 3 x 10-8 NR 
SLC14A2 18q12.3 rs12965695 T 9.57 x 10-5 
2.2873  
(1.80-2.92) 
Kim et al 2011 Metabolite levels rs7232775 C 8 x 10-14 
0.0148  
[0.011-0.019]  
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4.3.3 Functional Enrichment Analysis 
Gene enrichment analysis of Gene Ontology (GO) terms and Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) pathways were performed to identify genes of pathophysiological importance 
to symptomatic plaque progression. 
 
 
4.3.3.1 Hypergeometric Testing 
GWAS 
A total of 451 genes passing a Bonferroni-adjusted significance threshold of p<0.01 after LDAK 
annotation were inputted to DAVID for hypergeometric over-representation testing.  
 
Of the databases searched in DAVID (GO, KEGG, Panther, OMIM, DB Disease), no functional 
annotation terms reached FDR corrected significance of p<0.05. A total of 125 GO terms were 
identified, of which 99 were biological processes (BP), 7 were cellular components (CC) and 19 
were molecular functions (MF). Eleven of these passed a suggestive uncorrected significance 
threshold of p<0.01: 6 BP terms (GO:0045621, GO:0045591, GO:0045582, GO:0045589, 
GO:0045619, GO:0006644); 1 CC term (GO:0005576) and 4 MF terms (GO:0003723, 
GO:0003836, GO:0051059, GO:0008374). The majority of terms were linked to immune 
response and regulation of T cell and lymphocyte differentiation in particular (Table 4.6). 
 
Of only two disease terms identified, one DB Disease class, ‘Cardiovascular’ reached uncorrected 
p=0.005, and one OMIM disease term, ‘C4 Deficiency’ reached uncorrected p=0.031 (consistent 
with the chromosome region 6p21.3, previously implicated in GWAS of metabolic disorders; 
Comuzzie et al. 2012; Fox et al. 2012). This result lends evidence to support the reliability of the 
analysis, despite no terms reaching FDR significance of p<0.05. 
 
Gene Expression Study 
From paired analysis of differential gene expression in NST vs SP samples, a total of 368 genes 
passing FDR correction of p<0.05 were inputted to DAVID. Of the 308 GO terms identified, 117 
reached a suggestive uncorrected significance threshold of p<0.01, and 22 passed FDR 
corrected significance threshold of p<0.05 (11 BP terms, 8 CC terms and 3 MF terms). These 
terms could be broadly separated into four functional categories: immune response 
(GO:0006955, GO:0009611, GO:0006954), adhesion (GO:0007155, GO:0022610, GO:0031589), 
cytoskeletal organisation (GO:0040012, GO:0030334, GO:0007010, GO:0016010, GO:0008092) 
and extracellular matrix organisation (GO:0007160, GO:0044421, GO:0005576, GO:0031012, 
GO:0005615, GO:0005578, GO:0001558,) (Table 4.5). 
  
Table 4.6: Functional Enrichment analysis by hypergeometric testing of gene expression and GWAS data.  Hypergeometric testing was performed using DAVID 
software (Huang da et al. 2009a; Huang da et al. 2009b) to explore the enrichment of Gene Ontology (GO) terms in gene expression and GWAS data. Enriched GO terms 
are shown for those passing significance of FDR p<0.01 in gene expression data, and those passing a nominal significance of p<0.01 in GWAS data (as no GO terms 
passed FDR corrected p-value). Enriched GO terms were those involved in immune response, protein binding, cytoskeleton organisation and extracellular matrix 
organisation. One term, GO:0005576~extracellular region, was significant in both gene expression and GWAS data, and contained three common genes: LTBP4, FMOD 
and ILR7. The LTBP4 and FMOD genes were also present in a number of other GO terms, highlighted in blue. 
 
GWAS Gene Expression Study 
GO Term p-value* FDR p-value GO Term p-value* FDR p-value 
GO:0045621~positive regulation of lymphocyte differentiation 4.7E-04 5.3 x 10-1 GO:0006955~immune response 4.8 x 10-8 8.3 x 10-5 
GO:0003723~RNA binding 4.9E-04 2.0 x 10-1 GO:0007155~cell adhesion 6.4 x 10-8 1.1 x 10-4 
GO:0003836~beta-galactoside alpha-2,3-sialyltransferase activity 1.1E-03 2.2 x 10-1 GO:0022610~biological adhesion 6.6 x 10-8 1.1 x 10-4 
GO:0005576~extracellular region 1.2E-03 2.7 x 10-1 GO:0009611~response to wounding 1.5 x 10-7 2.6 x 10-4 
GO:0051059~NF-kappaB binding 2.0E-03 2.7 x 10-1 GO:0007160~cell-matrix adhesion 2.0 x 10-6 3.4 x 10-3 
GO:0045591~positive regulation of regulatory T cell differentiation 2.1E-03 8.1 x 10-1 GO:0006954~inflammatory response 3.6 x 10-6 6.3 x 10-3 
GO:0045582~positive regulation of T cell differentiation 2.9E-03 7.9 x 10-1 GO:0031589~cell-substrate adhesion 5.1 x 10-6 8.8 x 10-3 
GO:0045589~regulation of regulatory T cell differentiation 3.4E-03 7.4 x 10-1 GO:0040012~regulation of locomotion 9.2 x 10-6 1.6 x 10-2 
GO:0008374~O-acyltransferase activity 6.1E-03 5.1 x 10-1 GO:0030334~regulation of cell migration 9.5 x 10-6 1.6 x 10-2 
GO:0045619~regulation of lymphocyte differentiation 6.6E-03 8.8 x 10-1 GO:0001558~regulation of cell growth 1.4 x 10-5 2.4 x 10-2 
GO:0006644~phospholipid metabolic process 1.0E-02 9.3 x 10-1 GO:0007010~cytoskeleton organization 2.8 x 10-5 4.9 x 10-2 
   
GO:0044421~extracellular region part 1.3 x 10-12 1.8 x 10-9 
   
GO:0005576~extracellular region 2.5 x 10-9 3.3 x 10-6 
   
GO:0044459~plasma membrane part 4.3 x 10-7 5.7 x 10-4 
   
GO:0031012~extracellular matrix 5.0 x 10-7 6.7 x 10-4 
   
GO:0005615~extracellular space 1.7 x 10-6 2.3 x 10-3 
   
GO:0005578~proteinaceous extracellular matrix 6.5 x 10-6 8.6 x 10-3 
   
GO:0005886~plasma membrane 9.9 x 10-6 1.3 x 10-2 
   
GO:0016010~dystrophin-associated glycoprotein complex 2.1 x 10-5 2.8 x 10-2 
   
GO:0005515~protein binding 3.9 x 10-8 5.7 x 10-5 
   
GO:0008092~cytoskeletal protein binding 1.8 x 10-5 2.6 x 10-2 
   
GO:0003779~actin binding 2.0 x 10-5 2.9 x 10-2 
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Comparison of Hypergeometric Testing between GWAS and Gene Expression Profiling 
Of the GO functional annotation terms obtained from over-representation analysis of GWAS and 
gene expression profiling data, only one term, GO:0005576~extracellular region, reached 
adequate significance and was common to both datasets. Investigation of genes annotated to 
this term revealed 3 genes that were common to both GWAS and gene expression profiling data: 
LTBP4, FMOD and IL7R. 
 
All three of these genes were also found in the GO:0005515~protein binding term, which was 
enriched in the gene expression profiling dataset.  LTBP4 and FMOD were annotated to three 
other GO terms involved with extracellular matrix organisation (GO:0044421~extracellular 
region part, GO:0031012~extracellular matrix, GO:0005578~proteinaceous extracellular 
matrix), and LTBP4 to an additional term GO:0001558~regulation of cell growth.  
 
 
4.3.3.2 Gene Set Enrichment Analysis (GSEA) 
Over-representation analysis by hypergeometric tools uses a threshold to define genes of 
interest that warrant further investigation. In contrast, GSEA uses the list rank information from 
all genes examined in a gene expression study or GWAS without the use of a threshold, hence 
making use of all the data obtained from an experiment (Subramanian et al. 2005).  
 
GSEA analysis of GWAS data in ICSNPathway found enrichment of five GO terms with FDR-
corrected significance of p<0.05, involved with extra-cellular matrix collagen binding 
(GO:0005518), cytoskeletal myosin binding (GO:0017022), epithelial differentiation and 
morphogenesis (GO:0030855, GO:0002009) and RNA processing (GO:0006396). ICSNPathway 
analysis hypothesised that 4 SNPs (rs2296871, rs543573, rs1183768, rs1185193) in the SETX 
locus contributed to changes in RNA processing, 2 SNPs (rs892089, rs892090) in the GP6 locus 
contributed to changes in collagen binding, 1 SNP (rs61929765) in the KRT3 locus contributed 
to changes in epithelial differentiation and morphogenesis, and 1 SNP (rs1074407) in the 
TRIOBP locus contributed to changes in myosin binding. 
 
GSEA analysis of gene expression data in Partek uncovered 2 GO terms with FDR corrected 
significance of p<0.05, involving regulation of GTPase activity (GO:0043087) and cell cortex 
(GO:0005938). A further 143 GO terms were found to be enriched at FDR corrected p<0.25, a 
discovery level of significance suggested by Subramanian et al. (2005). All four genes of interest 
from ICSNPathway GWAS analysis (SETX, GP6, KRT3 and TRIOBP) were found in GO terms with 
significance of FDR p<0.25 within the gene expression functional enrichment analysis. The most 
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significant GO term was found to be GO:0017022 myosin binding, containing 15 genes including 
TRIOBP (p=0.025).  
 
 
4.3.3.3 Selection of Candidate Biomarkers 
Functional enrichment analysis with both hypergeometric testing and GSEA highlighted two key 
processes, cytoskeleton organisation and extracellular matrix remodelling, involved in carotid 
plaque progression and rupture in ischaemic stroke patients. Hypergeometric testing suggested 
an important role for LTBP4 in extracellular matrix organisation. LTBP4, found at 19q13.2, also 
contained two SNPs at suggestive genome-wide significance (rs2303729, p=7.91x10-5; 
rs10403833, p=9.71x10-5). GSEA analysis highlighted a role for the non-synonymous SNP 
rs1074407, within TRIOBP, in cytoskeletal organisation. These findings indicated that LTBP4 
and TRIOBP warranted further investigation. 
 
 
4.3.4 Alternative Splicing of TRIOBP 
A total of 181 SNPs within a 20kb wingspan were annotated to the TRIOBP locus using LDAK 
software, resulting in the gene achieving a Bonferroni adjusted value of p=0.025. 11 SNPs 
achieved genome-wide significance of p<1 x 10-3, of which 3 SNPs were found to be genotyped 
(rather than imputed) and within the TRIOBP gene. The sentinel SNP rs1074407 was found to 
have an association of OR 0.62 (95% CI 0.40-0.72, p=1.38x10-4) with symptomatic carotid 
stenosis ≥20%. The two other genotyped SNPs demonstrated very strong correlation with the 
sentinel SNP (r2>0.90) and comparable strengths of association (rs4820297: OR 0.63, 95% CI 
0.42-0.75, p=2.45x10-4; rs12628603: OR 0.65, 95% CI 0.48-0.79, p=6.55x10-4).  
 
Investigation of rs1074407 in Ensembl found that the SNP is located in the 3’ UTR region of a 
TRIOBP exon, 759bps downstream of the splice region TMP_ESP_22_38155424 (NHLBI Exome 
Sequencing Project, release 6500). Furthermore, two SNPs in high LD with rs1074407 (r2>0.90), 
spanning a 39kb region, were also found to be a 3’ UTR variant (rs1129448) and an intronic 
variant predicted to be within an enhancer region (rs13054052). These SNPs were imputed 
during GWAS analysis, and found to have significant associations with carotid stenosis 
(rs1129448: OR 0.62, p=1.45x10-4; rs13054052: OR 0.64, p=5.29x10-4; Table 4.7).  
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 Table 4.7: SNPs in the TRIOBP gene. The sentinel SNP rs1074407 and two other genotyped SNPs in high LD with 
the sentinel SNP were found to have a strong association with symptomatic carotid stenosis ≥20%. The sentinel SNP 
was found to be located within a 3’ UTR region of TRIOBP exon, as were two other imputed SNPs in high LD with the 
sentinel SNP. A1, risk allele; D’, D-prime measure of linkage disequilibrium; I2, I2 measure of heterogeneity; LD, 
linkage disequilibrium; OR, odds ratio; Q, Cochran’s Q measure of heterogeneity. 
 
To investigate the relationship between rs1074407 and symptomatic carotid stenosis, 
quantitative trait locus (QTL) analysis was performed in the BRAINS patient cohort. Degree of 
carotid stenosis was found to increase consecutively with allele count, with the TT genotype of 
rs1074407 associated with lower degree of stenosis than the AT or AA genotype (mean 
stenosis: TT=21%, AT=22%, AA=29%; ANOVA p-value: 0.005). This relationship was replicated 
in the two other genotyped SNPs (rs4820297 and rs12628603) in high LD with rs1074407 
(Figure 4.8A). 
 
Analysis of differential gene expression between TRIOBP in paired symptomatic stenosing 
plaque (SP) and non-stenosing tissue (NST) samples found no significant differential expression 
of TRIOBP (p=0.209, fold difference=1.20). The unique design of the Affymetrix Human Exon 
array, with probe sets targeting individual exons, also allowed investigation of regional 
differences in TRIOBP mRNA splicing (p= 0.0144). This demonstrated a relative reduction in the 
expression of exons 10 and 11 in symptomatic SP samples when compared with symptomatic 
NST samples, indicating lower expression of isoforms containing these exons specifically in 
symptomatic SP (Figure 4.8B). Furthermore, rs1074407 was found to reside in the 3’ UTR 
region of exon 8. This suggests that the rs1074407 T allele may be responsible for the 
alternative splicing of the TRIOBP mRNA, which in turn influences degree of carotid stenosis 
and plaque rupture in ischaemic stroke patients. Significant alternative splicing of TRIOBP was 
not apparent between asymptomatic SP and NST samples (p=0.357) or between asymptomatic 
NST and symptomatic NST samples (p=0.644). However, significant alternative splicing was 
observed between asymptomatic SP and symptomatic SP samples (p=0.0435), indicating that 
lower expression of isoforms containing exons 10 and 11 is specific to symptomatic SP and may 
be determined by rs1074407.  
Position SNP 
Genotyped/ 
Imputed 
A1/A2 p-value 
OR  
(95% CI) 
Q I2 
LD with 
sentinel SNP, r2 
(D') 
3815618
3 
rs1074407 Genotyped T/A 1.38 x 10-4 0.62 (0.40-0.72) 0.85 0 1.00 (1.00) 
38105981 rs4820297 Genotyped C/T 2.45 x 10-4 0.63 (0.42-0.75) 0.85 0 0.93 (1.00) 
38119213 rs12628603 Genotyped G/A 6.55 x 10-4 0.65 (0.48-0.79) 0.92 0 0.97 (1.00) 
38130385 rs13054052 Imputed A/C 5.29 x 10-4 0.64 (0.47-0.77) 0.64 0 0.91 (0.97) 
38170026 rs1129448 Imputed G/A 1.45 x 10-4 0.62 (0.42-0.74) 0.62 0 0.97 (0.98) 
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Figure 4.8: Exploring the alternative splicing profile of TRIOBP. A) The association between degree of carotid 
stenosis (%) and genotyped SNPs within the TRIOBP gene was investigated in the BRAINS GWAS cohort of 344 
individuals with ischaemic stroke to explore quantitative trait loci (QTL). Box and whisker plots are shown for the 
sentinel SNP rs1074407 and two other genotyped SNPs in high LD with the sentinel SNP (rs4820297 and 
rs12628603). The horizontal line indicates the median, the box covers the 25−75% percentiles and the maximum 
length of each whisker is 1.5 times the interquartile range. Mean values of % stenosis are given. These means were 
used in a non-parametric ANOVA test of variance explained; the pvalues are based on the variance explained by a 
linear regresson of stenosis on allele count, using two degrees of freedom (the intersect and the gradient, and mean 
effect of each allele). Individuals with the ‘risk’ allele T of the sentinel SNP rs1074407 demonstrate a significantly 
lower degree of carotid stenosis than those with the A allele. A similar relationship is observed with the tested ‘risk’ 
alleles of SNPs rs4820297 and rs12628603. B) TRIOBP exon structure and protein isoforms were explored in the 
gene expression study data using Partek Genomics Suite software. Three protein isoforms were annotated 
(NM_001039141, NM_007032, NM_138632), and sentinel SNP rs1074407 was found to lie within the 3’ UTR region of 
exon 8 of the gene, corresponding to Affymetrix exon array probe sets 3944969 and 394470. Least Square (LS) mean 
expression levels (log2scale) plotted for each probe set covering the whole TRIOBP transcript demonstrated an 
increased inclusion of exons 10 and 11 (Affymetrix exon array probe sets 3944973-3944982) in non-stenosing tissue 
regions, as compared with stenosing plaque regions (p= 0.0144). It is hypothesised that SNP rs1074407 may be 
responsible for this alternative splicing profile, resulting in a protein isoform which is responsible for the stenosing 
plaque phenotype. 
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4.3.5 Differential Gene Expression of LTBP4 
Annotation of 129 SNPs within a 20kb wingspan of the LTBP4 locus in LDAK software achieved 
a Bonferroni adjusted value of p=0.01. 35 SNPs achieved genome-wide significance of p<1 x 10-
3, of which 4 SNPs were found to be genotyped (rather than imputed) and within the LTBP4 
gene. The sentinel SNP rs2303729 (risk allele G) demonstrated an association of OR 1.64 (95% 
CI 1.29-2.08, p=7.91x10-5) with carotid stenosis ≥20%. The three other genotyped SNPs 
demonstrated moderate correlation with the sentinel SNP (r2=0.68-0.71) and similar strengths 
of association (rs1131620: OR 1.62, 95% CI 1.30-2.08, p=1.3x10-4; rs7259067: OR 1.62, 95% CI 
1.26-1.97, p=1.3x10-4; rs1051303: OR 1.62, 95% CI 1.26-1.97, p=1.3x10-4) (Table 4.8).  
 
Examination of rs2303729 using Ensembl found that the SNP is located on the forward DNA 
strand and encodes an exonic missense purine variant, resulting in a change in amino acid from 
valine to isoleucine (GTA to ATA, VAR_037119). ENCODE segmentation analysis of mammary 
epithelial cells (HMEC) and epidermal keratinocytes (NHEK) found that this variant lies in a 
predicted strong enhancer/cis-regulatory element. Furthermore SNP rs10410606, in high LD 
with rs2303729 (r2=0.92), was also found to lie in a predicted strong enhancer/cis-regulatory 
element. This was an imputed SNP in the GWAS, found to have an association with carotid 
stenosis of OR 1.63 (95% CI 1.29-2.12; p=1.09x10-4) (Table 4.7). Both SNPs were further 
investigated in is-rSNP, an in silico software tool that predicts the possibility of variant being a 
regulatory SNP affecting transcription factor binding (Macintyre et al. 2010). A number of 
transcription factors were identified at a Bonferroni adjusted significance of p<0.05, including 
potentially altered Smad4 and PLZF binding due to rs2303729 (p=0.250 and p=0.0013 
respectively) and altered SRY, SOX5 and HNF3A binding due to rs10410606 (p=2.5x10-4, 
p=0.0030 and p=0.0032 respectively). 
 
 
Table 4.8 SNPs in the LTBP4 gene. The sentinel SNP rs2303729 and three other genotyped SNPs in moderately high 
LD with the sentinel SNP were found to have a strong association with symptomatic carotid stenosis ≥20%. The 
sentinel SNP was found to lie  in a predicted strong enhancer/cis regulatory element, as was two another imputed 
SNPs in high LD with the sentinel SNP. A1, risk allele; D’, D-prime measure of linkage disequilibrium; I2, I2 measure of 
heterogeneity; LD, linkage disequilibrium; OR, odds ratio; Q, Cochran’s ; Q measure of heterogeneity. 
 
Position SNP 
Genotyped
/Imputed 
A1/A2 p-value 
OR 
(95% CI) 
Q I2 
LD with 
sentinel SNP, r2 
(D') 
41111069 rs2303729 Genotyped G/A 7.91 x 10-5 1.63 (1.29-2.08) 0.93 0 1.00 (1.00) 
41117869 rs1131620 Genotyped A/G 1.33 x 10-4 1.63 (1.30-2.08) 0.88 0 0.68 (0.88) 
41118056 rs1051303 Genotyped A/G 1.35 x 10-4 1.62 (1.26-1.97) 0.88 0 0.68 (0.88) 
41124931 rs7259067 Genotyped C/T 1.34 x 10-4 1.62 (1.26-1.97) 0.90 0 0.71 (0.92) 
41108975 rs10410606 Imputed A/C 1.09 x 10-4 1.63 (1.29-2.12) 0.99 0 0.92 (0.93) 
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QTL analysis was performed in the BRAINS GWAS patient cohort to investigate the relationship 
between rs2303729 and symptomatic carotid stenosis. Degree of stenosis was shown to 
increase significantly from the AA genotype to the GG genotype (mean stenosis: AA=20%, 
AG=23%, GG=29%; ANOVA p-value=0.009), providing evidence for an additive effect of the risk 
allele G. This relationship was replicated in the three other genotyped SNPs, rs1131620, 
rs7259067 and rs1051303 (Figure 4.9A). 
 
Analysis of differential gene expression between LTBP4 in paired symptomatic stenosing plaque 
(SP) and non-stenosing tissue (NST) samples found significantly lower expression of LTBP4 in 
SP (p= 0.033, fold difference=2.61; Figure 4.9B). No evidence of alternative splicing of LTBP4 
was observed (p=0.187, Figure 4.9C). Furthermore, no significant difference in LTBP4 gene 
expression was observed between asymptomatic SP and NST samples (p=0.319), or between 
asymptomatic and symptomatic NST samples (p=0.609), but was apparent between 
asymptomatic and symptomatic SP (p=0.046, fold difference=2.23), indicating that substantial 
down-regulation of LTBP4 is a specific phenomenon occurring within symptomatic plaques and 
may be a factor in causing plaque rupture. 
 
 
4.3.6 LTPB4 as a Biomarker for Symptomatic Carotid Stenosis 
The findings above indicate that SNP rs2303729 could represent an eQTL for LTBP4, with 
LTBP4 having potential to be a biomarker capable of identifying plaque progression and 
rupture. Nonetheless, it is important to note that this relationship has not been formerly tested 
here, as GWAS and gene expression data come from separate patient cohorts. 
 
The Disease Association Protein-Protein Link Evaluator (DAPPLE) software was next used to 
investigate protein-protein interaction networks in the paired analysis of gene expression 
differences between symptomatic stenosing plaque and non-stenosing tissue. The gene list   
input to DAPPLE was limited to the 368 genes exhibiting a fold difference of >2 at a significance 
threshold of p<0.05, using an iterative process with 1000 network permutations. 97 disease 
proteins found to participate in the direct network (Figure 4.10). LTBP4 was shown to be a key 
network node and interact directly with one other protein, CD209, found to be significantly up-
regulated in symptomatic stenosing plaque as compared to non-stenosing tissue in the paired 
gene expression study (p=0.0058, fold difference=2.57). Furthermore, LTBP4 was shown to 
interact indirectly with 39 other proteins, of which one, FMOD, was earlier annotated in LDAK 
(Bonferroni adjusted p=0.01), and found to be associated with 11 SNPs with a genome-wide 
significance of p<1x10-3. 
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Figure 4.9: Exploring the differential expression of LTBP4. A) The association between degree of carotid stenosis (%) and 
genotyped SNPs within the LTBP4 gene was investigated in the BRAINS GWAS cohort of 344 individuals with ischaemic stroke to 
explore quantitative trait loci (QTL). Box and whisker plots are shown for the sentinel SNP rs2303729 and three other genotyped 
SNPs in moderately high LD with the sentinel SNP (rs1131620, rs7259067 and rs1051303). The horizontal line indicates the 
median, the box covers the 25−75% percentiles and the maximum length of each whisker is 1.5 times the interquartile range. . Mean 
values of % stenosis are given. These means were used in a non-parametric ANOVA test of variance explained; the pvalues are based 
on the variance explained by a linear regresson of stenosis on allele count, using two degrees of freedom (the intersect and the 
gradient, and mean effect of each allele). Individuals with the risk allele G of the sentinel SNP rs2303729 demonstrate a significantly 
higher degree of carotid stenosis than those with the A allele. A similar relationship is observed with the tested risk alleles of SNPs 
rs1131620, rs7259067 and rs1051303. These plots provide a robust assessment of the associations observed. B) LTBP4 gene 
expression levels were next examined in symptomatic patients from the gene expression study (n=5). In differential gene expression 
analysis, least Square (LS) mean expression levels of LTBP4 were found to be significantly higher in non-stenosing tissue samples as 
compared to paired stenosing plaque regions (p=0.0334, fold difference=2.61). C) LTBP4 exon structure and protein isoforms were 
explored in the gene expression study data using Partek Genomics Suite software. Three protein isoforms were annotated 
(NM_003573, NM_001042544, NM_001042545), and sentinel SNP rs2303729 was found to lie within the predicted strong 
enhancer/cis regulatory element region of the gene, corresponding to Affymetrix exon array probe sets 3833639 and 383640. It is 
hypothesised that SNP rs2303729 may be an expression quantitative train locus (eQTL) responsible for the differential expression 
of LTBP4 associated with the stenosing carotid plaque phenotype and plaque rupture.  
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FMOD was found to be significantly associated with carotid disease in ischaemic stroke through 
GWAS analysis (top SNP rs2364940, OR: 1.814, p=1.33x10-4) and was involved in many GO 
terms identified through functional enrichment analysis through hypergeometric testing (Table 
4.5). The gene was also found to be significantly down-regulated in symptomatic stenosing 
plaque as compared to non-stenosing tissue in the paired gene expression study (p=0.0039, fold 
difference=-2.63).  
 
To establish the effects of LTBP4 down-regulation on the molecular network, the LS mean gene 
expression profiles of LTBP4, CD209 and FMOD were investigated for correlation. LTBP4 and 
FMOD demonstrated good correlation (r2=0.80), and FMOD and CD209 also demonstrated 
relatively high correlation (r2=0.70). The correlation between LTBP4 and CD209 levels was 
found to be r2=0.41; however removal of one outlying data point substantially improved 
correlation to r2=0.72. The scatterplots of these relationships are illustrated in Figure 4.11. 
Given that both LTBP4 and FMOD were found to be genes of significance in both the gene 
expression and GWAS functional enrichment analyses, these findings show that common genetic 
associations implicate regions encoding proteins that physically interact to determine complex 
disease processes (Rossin et al. 2011). In particular, it provides evidence for the importance of 
LTBP4 within a molecular network influencing carotid plaque progression and rupture in 
ischaemic stroke patients. 
 
Sensitivity and specificity ROC analysis between LTBP4 gene expression in paired symptomatic 
stenosing plaque and non-stenosing tissue regions yielded an AUC of 0.92, with a sensitivity of 
100% and specificity of 80% at a LS mean cutoff of 7.04 (Figure 4.12). 
 
 
 
  
 
 
Figure 4.10: Protein-Protein Interaction analysis of LTBP4. The 368 genes exhibiting differential expression in the gene expression study of symptomatic non-stenosing tissue versus stenosing plaque, 
with a fold difference of >2 at a significance threshold of p<0.05, were included as an input to DAPPLE to create a protein-protein interaction network. Associated proteins are represented as nodes connected 
by an edge if there is in vitro evidence for a high-confidence interaction. The large coloured circles represent proteins found to be differentially expressed in the gene expression study, and small circles in 
grey represent the connected proteins (not known found to be differentially expressed). Each interaction defined in the DAPPLE network is depicted by a line (edge) between nodes. LTBP4 was found to be a 
key node, directly connected to CD209 and indirectly connected to FMOD.  
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Figure 4.11: Correlations in expression levels between genes involved in the LTBP4 network. The relationship 
between LTBP4 and interacting proteins was explored using gene expression study data, with the assumption that 
differential expression of LTBP4 in symptomatic stenosing plaque should similarly affect the expression profiles of 
interacting genes FMOD and CD209. All three genes demonstrated good correlation (removal of one data point 
substantially improved correlation of LTBP4 and CD209 from r2=0.41 to r2=0.72), indicating that LTBP4 could have a 
key functional role in symptomatic plaque pathology and could be a promising biomarker of symptomatic plaque 
instability.  
 
 
 
 
 
Figure 4.12: Examination of LTBP4 as a biomarker for predicting carotid plaque rupture. Least square (LS) 
mean gene expression profiles for LTBP4 were examined in paired stenosing plaque and non-stenosing tissue regions 
of 5 symptomatic patients. ROC analysis between LTBP4 expression in these paired samples yielded an AUC of 0.92, 
with a sensitivity of 100% and specificity of 80% at a LS mean threshold of 7.04, indictating the potential value of 
LTBP4 as a biomarker for predicting carotid plaque rupture. 
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4.4 Discussion 
 
The degree of carotid stenosis and characteristics such as thin fibrous cap and immune cell 
infiltration are associated with symptomatic carotid plaques. However, these features are poor 
predictors of thromboembolism and it is still unclear why some carotid stenosis progress to 
occlusion without causing symptoms and others manifest themselves with sudden cerebral 
infarction. Here, gene expression profiling was undertaken on stenosing and non-stenosing 
tissue regions of individuals with asymptomatic or symptomatic carotid disease. Results from 
this gene expression analysis were combined with a GWAS of ischaemic stroke patients with 
varying degrees of carotid artery stenosis in an integrative genomics approach. The study 
provides evidence that genetic variation impacts pathological processes underlying 
symptomatic carotid stenosis and upholds the value of utilising an integrative genomics 
approach for exploring genetic contributions to carotid disease. 
 
The approach used in this study has been undertaken by other research groups to understand 
the molecular mechanisms of human cardiovascular disease. Coupling multi-tissue expression 
gene expression profiles with GWAS data from the CARDIoGRAM study, Huan et al. (2013) 
discovered a number of co-expression modules involved in B-cell activation, immune response, 
and ion transport in coronary artery disease, and identified FMOD as a causal differential 
module upon network analysis. Application of network approaches to gene expression data of 
carotid endarterectomies from the Biobank of Karolinska Endarterectomies (BiKE) biobank also 
implicated a key role for ApoC-1 in the pathogenesis of carotid disease (Diez et al. 2010). 
Nonetheless, the current study is the first of its kind to utilise a pathway-based, integrative 
genomics approach to understanding the biology underlying symptomatic carotid disease. 
 
Gene Set Enrichment in Symptomatic Stenosing Plaques 
High-throughput technologies produce extensive lists of ‘genes of interest’, however the 
biological implications of these genes is often difficult to deduce. Pathway and gene set analysis 
allows identification of biological processes that are likely to be most influential to a disease 
process. A plethora of these analysis tools have been developed, and as yet there is still no 
unified method or ‘gold standard’ (Huang da et al. 2009a). Three major layers are consistent 
between all these bioinformatics tools: the reference annotation database, algorithm and 
statistical analysis, and the presentation; the characteristics of each of these layers account for 
different outputs from each tool (Huang da et al. 2009a). Huang da et al. (2009b) propose that a 
‘good’ gene list should contain a reasonable number of genes, of which most pass a set statistical 
threshold and explain expected biological processes, with enriched processes being present 
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more likely than by chance alone and being reproducible between analytical tools and in 
subsequent wet lab experiments. In this study, hypergeometric testing and GSEA were used for 
examination of gene expression and GWAS data, under the hypothesis that robust biological 
processes are likely to withstand analytical differences between tools and be common to both. 
The current functional enrichment analysis demonstrated intrinsic differences between non-
stenosing tissue and unstable plaques in a number of biological processes, in particular 
extracellular matrix organisation and myosin binding. Further investigation of genes involved in 
these pathways uncovered two genes, LTBP4 and TRIOBP respectively, which were strongly 
associated with symptomatic carotid stenosis in GWAS meta-analysis and demonstrated 
alternative splicing (TRIOBP) or differential gene expression (LTBP4) in microarray analysis of 
symptomatic stenosing plaques. 
 
Further examination of the GO:0017022 myosin binding term, containing the TRIOBP gene and 
shown to be enriched through GSEA analysis, found it to be a child term of the cytoskeletal 
protein binding (GO:0008092) and protein binding (GO:0005515) terms. The protein binding 
term was also found to be enriched in hypergeometric testing of gene expression data, and 
contained the LTBP4 and FMOD genes. This finding demonstrates the ability of hypergeometric 
testing and GSEA analysis to identify similar enriched gene sets, and in particular establishes the 
role of LTBP4 and TRIOBP in related pathological mechanisms within symptomatic stenosing 
plaques. The cytoskeleton connects to the extracellular matrix via focal adhesions - dynamic 
protein complexes through which both mechanical and regulatory signals are transmitted. 
Actomyosin contractility stimulates focal adhesion development (Wolfenson et al. 2011), 
leading to vascular smooth muscle cell proliferation, differentiation and migration and affecting 
focal adhesions between smooth muscle cells in the fibrous cap, thus affecting cap integrity and 
plaque stability (Nikol et al. 1997; O’Sullivan et al. 2011). 
 
Interestingly, exploration of the top hits from GWAS analysis, the RASGEF1B and KIF16B genes, 
found them to be in  a common GO cellular component term (GO:0005769 early endosome) and 
both involved in signal transduction (GO:0007165). Additionally, KIF16B plays a key role in 
microtubule-assisted movement, providing further evidence for the role of the cytoskeleton in 
plaque progression. 
 
The molecular mechanisms identified through hypergeometric testing and GSEA have 
previously been implicated in ischaemic stroke carotid disease, hence it could be argued that 
this study provides little novel insight into the molecular mechanisms underlying plaque 
progression and rupture. However, one of the biggest strengths of the integrative genomics 
approach is that it helps to infer casual associations. Hence, the fact that genes in the significant 
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pathways show evidence of genetic association and appear to be alternatively spliced or 
differentially expressed makes them highly plausible causal biomarkers for disease.  
 
TRIOBP Alternative Splicing in Symptomatic Stenosing Plaque 
GSEA analysis of GWAS data hypothesised that SNP rs1074407 in TRIOBP, part of the 
GO:0017022~myosin binding gene set, was associated with carotid stenosis in ischaemic stroke 
patients. TRIOBP encodes the TRIO And F-Actin Binding Protein, which stabilises F-actin to 
regulate actin cytoskeleton organisation. It also interacts with trio protein, which promotes the 
exchange of GDP by GTP via Rho GTPases to coordinate cell-matrix and cytoskeletal 
rearrangements necessary for cell migration and cell growth (Seipel et al. 2001).  
 
The role of the cytoskeleton in the complex regulation of vascular endothelial repair has been 
well documented. Upon damage and loss of endothelial integrity, cytoskeletal systems are 
activated to regulate cell migration and proliferation through re-organisation of F-actin 
distribution for endothelial repair (Lee & Gotlieb 2003). The loss of structural and functional 
integrity of the endothelial monolayer, although unlikely to be the cause of initial 
atherosclerotic lesions, is observed on the surface of lesions leading to ulceration and fissure 
formation that could promote thrombosis and rupture of the atheroma through the fibrous cap 
(Virmani et al. 2001).  
 
A major finding in this study was that alternative splicing of mRNAs might be more important 
than gene expression in determining plaque rupture. This is consistent with a genome-wide 
screen by Heinzen et al. (2008), who discovered a number of SNPs associated with tissue-
specific splicing events. Alternative splicing has been shown to be more frequent than 
commonly suggested, with every human multi-exon protein-coding gene containing an average 
of 6.3 alternatively spliced transcripts (Frankish et al. 2012). The ENCODE project reported that 
while most alternative isoforms do not seem to have a role as functional proteins, they may hold 
implications for the control of gene regulation and expression. The collaborators suggested that 
potentially deleterious splice variants lie dormant within the gene and become highly expressed 
only as a result of a disease event (Tress et al. 2007).  
 
Studies have previously reported that alternative isoforms of TRIOBP can affect the durability 
and rigidity of F-actin bundling, and could be a cause of hereditary human deafness (Kitajiri et 
al. 2010). There is also accumulating evidence that polymorphisms in the 3’ UTR can alter 
miRNA binding sites and RNA secondary structure (Yu et al. 2007; Sasaki et al. 2013), 
suggesting that the TRIOBP rs1074407 polymorphism could lead to changes in exon expression. 
Without data based upon RT-PCR and RNA sequencing, it is difficult to ascertain the identity of 
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the TRIOBP transcripts related to the alternative splicing profile observed. However, the finding 
that consecutive probesets within exons 10 and 11 of TRIOBP were found to be down-regulated 
in symptomatic stenosing plaque indicates that these exons are likely to be part of the transcript 
that is regulated in relation to the rs1074407 genotype (Folkersen et al. 2009).  
 
The finding that TRIOBP is uniquely alternatively spliced in unstable symptomatic plaques 
could allow for the development of specific therapies targeting this splice variant without 
affecting the function of normal TRIOBP in other tissue regions. However at this stage a number 
questions remain unanswered, including the identity of the specific isoform, it’s functional role 
within the plaque and whether the isoform plays a role in normal cytoskeletal function or is a 
specific biomarker of an unstable plaque state. It is known that 13 alternatively spliced 
transcript variants exist for TRIOBP, some that may be subject to nonsense-mediated decay. 
TRIOBP is widely expressed at both the RNA and protein levels, especially within vascular tissue 
(heart), blood and the placenta, with isoform 3 being uniquely expressed in foetal brain, retina 
and cochlea (NCBI GEO db). Further experimental investigation of the splice variant uncovered 
in this present study, and its tissue-specific gene and protein expression is required to assess its 
value as a therapeutic target for plaque instability. 
 
LTBP4 as a Biomarker for Plaque Rupture 
Functional enrichment analysis of GWAS and gene expression data by hypergeometric testing 
identified extracellular matrix remodelling as a key process involved in carotid plaque 
instability. This finding is in keeping with a number of previous studies that have implicated the 
role of extracellular matrix remodelling in fibrous cap thinning and plaque rupture (Heo et al. 
2011; Bobryshev et al. 2008). Changes in extracellular matrix organisation have also been 
reported in microarray studies examining symptomatic carotid plaques versus healthy control 
tissue (Korol et al. 2011), and symptomatic versus asymptomatic carotid plaques (Saksi et al. 
2011; Papaspyridonos et al. 2006). 
 
Two genes involved in extracellular matrix organisation, LTBP4 and FMOD, were found to be 
differentially expressed between symptomatic stenosing plaque and non-stenosing tissue 
regions, as well as being associated with carotid stenosis upon GWAS meta-analysis of 
ischaemic stroke patients. Gene expression studies have previously shown that modules of 
differentially expressed genes identified through GO form networks of interacting genes 
(Minguez & Dopazo 2011; Narayanan et al. 2010). Furthermore, a study of GWAS of complex 
diseases found that genes found harbouring disease-associated SNPs implicate regions encoding 
proteins that physically interact (Rossin et al. 2011). Through DAPPLE protein-protein 
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interaction analysis, LTBP4 was found to be a key network node likely to affect the gene 
expression levels of CD209 (directly) and FMOD (indirectly, via TGF-1).  
 
LTBP4 is a protein that specifically binds to transforming growth factor beta (TGF-1) as it is 
secreted and targeted to the extracellular matrix, thus serving as a molecular modulator for the 
disposition of TGF-1 and the assembly of other matrix proteins. Mutations in the LTBP4 gene 
have previously been found to effect TGF-1 signalling and extracellular matrix organisation 
(Urban et al. 2009). TGF-1 has been shown to have anti-inflammatory and atheroprotective 
functions; its production by lipid laden foam cells stimulates collagen production by smooth 
muscle cells, stabilising fibrous cap formation over the atheromatous plaque (Amento et al 
1991). A down-regulation of gene expression was also observed for FMOD, a protein found to 
regulate the extracellular matrix collagen structure and sequester TGF-1 into the extracellular 
matrix, thus affecting the development of atherosclerotic plaque tissue (Hildebrand et al. 1994; 
Shami et al. 2013). Thus the down-regulation of LTBP4 and FMOD in stenosing plaques, as 
observed in the current gene expression study, may cause a subsequent decrease in the 
expression of TGF-1 and decreased stability of the fibrous cap, leading to plaque rupture. 
LTBP4 has also been shown to directly interact with CD209, an expression marker found on 
dendritic cells that have been observed in human atherosclerotic carotid plaques and known to 
activate the T cell and B cell immune response (Zhang & Zhang 2010). A close relationship exists 
between the mean signal intensity of dendritic cells in plaques and the symptoms of patients 
with significant carotid plaques (Kawahara et al. 2007), and CD209+ dendritic cells have been 
found in rupture-prone unstable plaques (Soilleux et al. 2002). These findings suggest that 
LTBP4 could be a key player in plaque pathophysiology and rupture and a good target for 
therapeutic intervention. The functional network developed in silico can be tested by knocking 
down key network nodes such as LTBP4 in vitro using RNA interference (RNAi) and studying 
the effects of loss of gene function on downstream nodes. 
 
QTL mapping uncovered four LTBP4 genotyped SNPs in high LD (rs2303729, rs1131620, 
rs1051303 and rs7259067), which affected degree of carotid stenosis in a genotype-dependent 
manner. All these four SNPs were strongly associated with symptomatic carotid stenosis 
(genome-wide significance of p<1x10-4, OR1.6) and found to be located within the LTBP4 gene 
sequence or within a 20kb wingspan of the LTBP4 gene. The sentinel SNP rs2303729 was found 
to lie within an exon of LTBP4, in a predicted strong enhancer/cis-regulatory element. LTBP4 
was shown to be uniquely down-regulated in symptomatic stenosing plaque in the gene 
expression study. It is therefore hypothesised that this SNP could be responsible for the lower 
expression of LTBP4 observed in symptomatic stenosing plaques within the gene expression 
study.  
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QTL mapping and differential expression analysis suggest that LTBP4 is a gene whose 
expression may be under genetic control.  Genes whose expression is cis-regulated, significantly 
correlated with a quantitative trait and co-localised with a physiological QTL have been 
postulated to be strong candidate genes for complex diseases (Hubner et al. 2005; Morrissey et 
al. 2011), demonstrating a robust relationship between the gene and the phenotype and 
indicating that the gene itself is under regulation by a local SNP. Unfortunately in this study, 
analysis was based upon different patients from the GWAS and gene expression studies, as no 
patients were common to both cohorts; investigation of LTBP4 gene expression in genotyped 
individuals through robust eQTL anlysis will help to confirm the hypothesis that rs2303729 is 
responsible for differential LTBP4 expression and carotid plaque instability. 
 
The search for therapeutic options to prevent plaque destabilisation is limited by the lack of 
surrogate markers of disease progression (Peeters et al. 2009). The combination of standard 
clinical variables and molecular variables influenced by genetic mechanisms could provide an 
improved tool for ischaemic stroke risk stratification. Using a similar strategy, McGeachie et al. 
(2009) found that a predictive coronary artery calcification model based upon 13 SNPs and five 
clinical variables gave a predictive accuracy of 85%, a significant improvement (p<0.001) on a 
model using clinical variables alone.  
 
LTBP4 has previously been implicated in abdominal aortic aneurysm (Thompson et al. 2010) 
and proposed as a vascular tissue marker of peripheral vascular disease  (Buechler 2004). 
LTBP4 may prove to be a candidate biomarker for identifying vulnerable plaques prone to 
rupture. Its expression is measurable in blood plasma by a number of commercially available 
ELISA kits, hence providing an easy and non-invasive blood test for ischaemic stroke risk 
stratification. Nonetheless, it is important to consider that gene expression levels differ between 
various tissue types and biofluids (Hardy et al. 2009; Hernandez et al. 2012). Additionally, 
previous eQTL mapping has found that on average, more loci are associated with the level of a 
transcript than of its corresponding protein (Ghazalpour et al. 2011), and translation rate 
constants have been shown to be better predictors of protein levels than mRNA levels, which 
can explain only approximately 40% of protein level variation (Schwanhausser et al. 2011). 
These results demonstrate that accurate quantification of LTBP4 blood protein level is required 
before consideration as a non-invasive risk biomarker for ischaemic stroke. 
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Limitations of the Study 
Technical Challenges 
The Affymetrix Human Exon Array 1.0 ST allows interrogation of over a million exons; however 
it suffers from inherent problems common to all microarrays, such as probe hybridisation 
behaviour and probe annotation. These issues were minimised in the present study by 
removing from analysis probes that were predicted to be affected by SNPs, and developing a 
stringent analysis workflow based on only the ‘core’ annotated probesets.  
 
The findings of this study are dependent upon factors such as pathway annotations, deﬁnition of 
gene boundaries, and assignment of a p value to a gene which has multiple SNPs, which could 
substantially alter analysis results and make them unstable (Jia et al. 2011). In an attempt to 
overcome this, two methods of functional enrichment analysis were undertaken to evaluate the 
reliability of the results, and preliminary findings were explored further in both the gene 
expression study and GWAS in order to replicate the conclusions. 
 
In the field of ischaemic stroke and carotid artery disease, GWAS has had limited success in 
identifying SNPs that have been able to withstand replication in independent cohorts. Genetic 
associations are most amenable to discovery in highly heritable traits, where a relatively small 
number of genes exert a relatively large physiological effect. Therefore it is possible that the 
‘common disease, common variant’ GWAS hypothesis may need to be revised, and future study 
designs need to be able to address the effects of both common and rare variants (Gibson 2011). 
Exome sequencing could provide a promising tool for exploring rare variants of high penetrance 
in complex disease such as ischaemic stroke (Cole et al. 2012). 
 
Definition of Carotid Stenosis 
Integrative genomics requires a sound understanding of the trait under study, and an 
appreciation of whether this trait is continuous (e.g. blood pressure) or categorical (e.g. 
hypertensive vs normotensive). In reality the relationship between the definition of a complex 
disease and its physiology is not straightforward (Ware et al. 2013). While categorisation of a 
continuous trait may lead to false associations during genomic analysis, it can also be theorised 
that genetic affects contribute to a threshold-dependent phenotype that overlies a continuous 
trait. In this GWAS study, the unavailability of individual patient data hindered the analysis of 
carotid stenosis as a continuous variable, and plaque was defined as stenosis ≥20%. This is in 
keeping with a meta-analysis of GWAS from the CHARGE Consortium, in which atherosclerotic 
thickening of the carotid artery wall was defined in seven of the nine cohorts as  either the 
presence of plaque or the proxy measure of stenosis greater than 25% (Bis et al. 2011). The 
validity of choosing ≥20% stenosis as a measure of clinically relevant carotid artery disease is 
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further supported by the gene expression study, in which two out of seven individuals had 
symptom-causing plaques of <50% stenosis.  
 
Study Design 
This study is limited by small sample size, however power calculations in the gene expression 
study determined that an average sample size of 10 (5 in each analysis arm) delivered 80% 
power at p<0.05 to detect a 2-fold difference in means, providing reliability to the results 
obtained. The non-stenosing tissue region adjacent to the stenosing plaque was used as a 
control because of the difﬁculty in obtaining healthy carotid artery samples, and benefits from 
eliminating inter-patient heterogeneity - a strategy used in previous studies (Zawadzki et al. 
2009; Di Taranto et al. 2012). 
 
The difficulties in conducting a well-powered GWAS of ischaemic stroke have been previously 
noted (Meschia 2010); the very small sample size utilised in this GWAS casts doubt upon the 
associations observed between genetic variants and the presence of carotid stenosis in 
ischaemic stroke patients, and is likely to result in inflated effect sizes. Nonetheless, the effect 
size observed for LTBP4 in this GWAS (OR1.64) is similar to effect sizes obtained for other genes 
found to be associated with large-vessel ischaemic stroke (e.g. HDAC9: OR1.42, p=1.87x10-11; 
LPA: OR1.27, p=6.72x10-4; 9p21.3: OR1.17, p=2.93x10-5; Meschia & Tournier-Lasserve 2013). 
The limitations of small population cohorts in both the gene expression study and GWAS meta-
analysis have been reduced by applying a pathway-based approach to biomarker discovery, 
rather than relying on single SNP or gene associations. Thus, despite small sample sizes, the 
combination of both GWAS and gene expression datasets helped to reduce false positive 
associations and the pathways identified through functional enrichment analysis are plausible 
based upon current biological knowledge. 
 
Heterogeneity of Carotid Stenosis and Ischaemic Stroke 
Basic histological examination of plaques used for gene expression profiling found that 
symptomatic plaques often exhibited greater irregular surface morphology and ulceration, as 
compared to asymptomatic plaques. However, variations in plaque histology arising from 
different ischaemic events (TIA or ischaemic stroke), as previously reported (Redgrave et al. 
2006), could not be delineated due to small sample size. Temporal symptomatic plaque 
remodelling also needs to be assessed before developing targeted therapies or a biomarker-
based test for risk prediction (Peeters et al. 2009). Consideration of subject age and gender as 
covariates in both gene expression and GWAS analysis aimed to improve the reliability of 
results obtained.  
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Studies have shown that different carotid artery sites may be influenced by different etiological 
pathways, with IMT of the common carotid artery linked to total atherosclerotic burden and 
IMT of the internal carotid artery being attributed to local turbulent haemodynamic flow 
(Crouse et al. 1996). Possible genetic mechanisms underlying these differences have also been 
demonstrated in a recent GWAS of common and internal artery IMT (Melton et al. 2013). Due to 
small sample size and limited availability of phenotypic information from GWAS cohorts, the 
effects of carotid artery stenosis site could not be explored.  
 
The METASTROKE GWAS study also demonstrated that pathophysiological mechanisms seem to 
vary between ischaemic stroke subtypes and advocated the need to study these subtypes 
independently. However, the authors also acknowledged that differing interpretations of TOAST 
subtypes in the 15 genotyped cohorts may have led to heterogeneity in classification (Traylor et 
al. 2012). This highlights the difficulty in collecting a ‘clean’ ischaemic stroke dataset. Large-
vessel disease represented the majority of ischaemic stroke cases in this present GWAS and it is 
therefore postulated that the genetic associations found can be ascribed to this subtype, even 
though other subtypes were included in the analysis in order to maintain sample size. 
Nonetheless, these associations require robust validation in an independent homogenous (LAA 
only) cohort, in which the presence of carotid artery disease can be directly attributed with 
ipsilateral cerebral ischaemia. Replication of the pathways involved in extracellular matrix 
organisation and cytoskeleton binding in independent ischaemic stroke and carotid disease 
GWAS datasets will also help to validate the association of the LTBP4 and TRIOBP with carotid 
plaque rupture and LAA stroke, similar to the strategy used by Anderson et al. (2013) to 
establish the association between common genetic variants within the oxidative 
phosphorylation genes and stroke. 
 
Concluding Remarks 
This study provides evidence for the genetic regulation of carotid disease using an integrative 
genomics approach. Cytoskeletal organisation and extracellular matrix remodelling were found 
to be key processes determining the stability of the carotid plaque that could be modulated by 
underlying genetic mechanisms. In particular, LTBP4, was found to be a key node gene involved 
in extracellular matrix organisation. LTBP4 down-regulation in symptomatic stenosing plaque is 
hypothesised to be affected by SNP rs2303729, a polymorphism found within an exonic region 
of the gene and located within a predicted enhancer/cis-regulatory region. The gene also 
exhibited high sensitivity and specificity to differentiate between non-stenosing carotid tissue 
and unstable stenosing plaque. Thus LTBP4 could prove to be a candidate risk biomarker for 
ischaemic stroke by predicting plaque instability and rupture.  
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Final Discussion 
 
This thesis set out with the aim of addressing the hypothesis that novel candidate biomarkers for 
ischaemic stroke exist and are amenable to detection using –omic approaches. This final chapter 
summarises the work presented thus far, discusses the key findings and recommends future directions 
of biomarker discovery for ischaemic stroke. 
 
The introductory chapter of the thesis brought to light the limitations of current risk stratification and 
diagnostic and prognostic evaluation of ischaemic stroke, and discussed the potential of biomarkers to 
overcome these issues. Biomarkers are used routinely in the management of many disorders. The 
delineation of biomarkers from normal biology can cause them to be newly expressed or up- or down-
regulated, thus they have the potential to serve as diagnostic, prognostic and risk stratifying tools for 
disease. Blood-based biomarkers are ideal for rapid diagnostic tests for point of care testing, while 
tissue-based molecules can serve as mechanistic biomarkers that reflect the response of an organism 
to a local stimulus, rather than the systemic effect of a disease state. Recent advances in genomic, 
transcriptomic and proteomic technologies, coupled with developments in bioinformatics tools, herald 
an exciting era for biomarker discovery. While numerous studies have attempted to identify 
biomarkers for ischaemic stroke using these techniques, to date no biomarkers have demonstrated 
suitable clinical potential. The work in this thesis aimed to evaluate the current status of diagnostic 
and prognostic biomarkers for stroke and develop improved –omics workflows for novel biomarker 
discovery. 
 
With the aim of summarising the state of biomarker research in ischaemic stroke and identifying 
existing candidate biomarkers that could warrant further investigation, a comprehensive systematic 
review and meta-analysis were conducted of published literature reporting acute blood-based 
biomarkers for the diagnosis and prognosis of ischaemic stroke. Review of the entire scientific 
literature ensured that no potential biomarkers were ignored, and combination of individual studies 
by meta-analysis allowed quantification of the association between candidate biomarkers and the 
phenotype of interest, with statistical power improved through increased sample size analysis. The 
results of the literature review and meta-analyses were presented in Chapter 2. 
 
A total of 137 candidate biomarkers were identified for the diagnosis or prognosis of ischaemic stroke, 
with biomarkers being either proteins or metabolites broadly involved in lipid metabolism, 
coagulation and inflammatory processes. Ten candidate biomarkers were found to be significantly 
associated with acute ischaemic stroke as compared to healthy controls. Nonetheless further 
investigation of one of these biomarkers, CRP, revealed that significant association with a phenotype 
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does not necessarily indicate a good candidate biomarker, and CRP distributions in ischaemic stroke 
and healthy control populations demonstrated poor discriminatory potential of a CRP-based 
diagnostic test.  
 
Systematic literature review and meta-analysis also identified coagulation factors and metabolites as 
significant candidate prognostic biomarkers for ischaemic stroke. Admission glucose levels were 
found to be significantly associated with poor outcome after ischaemic stroke and incidence of post-
thrombolytic SICH. However, literature-based meta-analysis of the association of admission glucose 
levels with SICH was found to be limited by a number of technical challenges, casting doubt upon the 
conclusions drawn. In order to accurately quantify the risk of SICH associated with admission glucose 
levels, an individual patient data meta-analysis was conducted by obtaining patient information from 
eight cohorts, comprising the largest collection of data for analysis to date (>32,000 patients). 
Contrary to previously published studies, it was shown that hyperglycaemia has minimal association 
with risk of SICH and that international guidelines for thrombolysis (currently recommending an 
admission glucose level threshold of 22mmol/L) could be re-evaluated in light of these findings. The 
study also demonstrated the advantages of performing individual patient data meta-analysis over 
literature-based meta-analysis when attempting to establish associations between a biomarker and an 
outcome of interest. 
 
Work in Chapter 2 found 11 candidate biomarkers studied for their potential to differentiate between 
ischaemic stroke and stroke mimics; however, only one of these, S100B, was found to be significantly 
associated with ischaemic stroke and to date no biomarkers have successfully progressed to use 
within a clinical setting, With the aim of identifying novel candidate biomarkers for AIS, a whole 
proteome approach, using SELDI-TOF MS, was conducted, the results of which were presented in 
Chapter 3. A pilot study consisting of 13 AIS, 2 TIA and 2 stroke mimic patients established the ability 
of SELDI-TOF MS and the CM10 ProteinChip to detect a protein profile that is significantly affected 
during acute cerebral ischaemia. Protein ions detected using SPA matrix were largely limited to the 
low molecular weight range, although this could be considered an advantage to biomarker discovery 
as it is a range that is often neglected by other proteomic techniques. It was recognised that the 
reproducibility of relative protein ion changes was a critical factor for determining candidate 
biomarker utility, therefore the pilot study also allowed optimisation of the SELDI-TOF MS workflow.  
 
Having established the value of the SELDI-TOF MS approach to diagnostic biomarker discovery, a 
second patient cohort was obtained for a well-powered study that could overcome common 
limitations of study design, as identified in Chapter 2. The cohort of 404 subjects was randomised into 
Training, Test and Validation sets to allow robust interrogation of any putative biomarkers detected. 
Unsupervised PCA analysis of the Training set data (20 AIS, 10 TIA, 10 stroke mimics) demonstrated 
CHAPTER FIVE: FINAL DISCUSSION  
209 
distinct clustering of ischaemic events (AIS and TIA) and non-ischaemic events (stroke mimics) based 
upon protein ion profiles, that was not observed with other demographic variables. Subsequent DFA of 
protein ions detected using the pH4 binding condition revealed that the up-regulation of m/z 6640 
and down-regulation of m/z 3699 in AIS and TIA could represent a potential dual-marker diagnostic 
test for acute cerebral ischaemia. Examination of these candidate biomarkers in the Test set (32 AIS, 
16 TIA, 16 stroke mimics) demonstrated high sensitivity and specificity of a biomarker test based 
upon m/z 6640 alone or in conjunction with m/z 3699. As proteins detected through SELDI-TOF MS 
are not subject to digestion or tandem mass spectrometry, antibody immunodepletion and ELISA were 
attempted to determine the identity of m/z 6640. Immunodepletion techniques proved unsuccessful 
due to technical limitations; however ELISA coupled with SELDI-TOF MS revealed the identity of m/z 
6640 as ApoC-1. The work undertaken in Chapter 3 demonstrated the ability of SELDI-TOF MS to 
detect differential plasma protein profiles and highlighted the role of lipid dysregulation in AIS and 
TIA incidence, in particular identifying ApoC-1 as a novel candidate biomarker for the diagnosis of 
acute cerebral ischaemia. 
 
Carotid disease and ischaemic stroke share similar environmental and genetic risk factor profiles. 
Modifiable, non-modifiable and clinical risk factors contribute a 60% population attributable risk for 
ischaemic stroke, suggesting that the 40% gap in risk could be attributed to genetic variables. In an 
attempt to identify tissue-based risk biomarkers for large artery ischaemic stroke that could predict 
carotid plaque destabilisation and rupture, an integrative genomics study was undertaken to combine 
data from transcriptomic and genomic platforms. The results of this study were presented in Chapter 
4. 
 
Transcriptomic profiling was conducted using the Affymetrix Human Exon 1.0 ST array to identify 
gene expression differences between stenosing carotid plaque and non-stenosing carotid 
endarterectomy tissue regions taken from 7 symptomatic and 3 asymptomatic individuals. The exon 
array allows interrogation of both gene-level and exon-level RNA expression, thus allowing discovery 
of differentially expressed genes as well as characterisation of alternative gene splicing. PCA based 
upon global gene expression found distinct clustering of stenosing plaque and non-stenosing tissue, 
and further differentiation between symptomatic and asymptomatic stenosing plaque regions. 
Analysis of paired stenosing plaque and non-stenosing tissue regions from 5 symptomatic individuals 
is suggestive of alternative splicing of genes (as well as than gene expression) playing a role in plaque 
progression and a symptomatic plaque phenotype.  
 
Paired symptomatic patient gene expression data was coupled with the results of GWAS meta-analysis 
of two cohorts (n=653) investigating the genetics of symptomatic carotid artery disease (>20% 
stenosis). Despite small sample sizes, functional enrichment analysis of both gene expression and 
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GWAS data using hypergeometric testing and GSEA analysis implicated the significance of cytoskeletal 
organisation and extracellular matrix remodelling in carotid plaque destabilisation and rupture.  
 
Genes in these functional pathways common to both gene expression and GWAS were examined in an 
attempt to uncover differential gene expression or alternative splicing profiles that may be under the 
control of a genetic variant. The TRIOBP gene, involved in cytoskeletal organisation, was found to be 
significantly alternatively spliced in the gene expression dataset and also contain a number of SNPs 
significantly associated with symptomatic carotid stenosis upon GWAS meta-analysis. It was 
hypothesised that the sentinel SNP rs1074407, lying within a 3’UTR exonic region of TRIOBP, could be 
responsible for alternative splicing of the gene at exons 10 and 11.  
 
Furthermore, the LTBP4 gene, involved in extracellular matrix remodelling, was found to be 
significantly down-regulated in stenosing carotid plaques and significantly associated with 
symptomatic carotid stenosis upon GWAS meta-analysis. QTL mapping and differential expression 
analysis suggested that LTBP4 is a gene whose expression may be under genetic control.  Further 
suggestion of this hypothesis was obtained by the finding that LTBP4 was a key node in a protein-
protein interaction network obtained from genes/transcripts significant in both the GWAS and gene 
expression studies. Within this network, LTBP4 was highly correlated with the expression of genes 
that it was directly or indirectly connected to, and could differentiate between non-stenosing tissue 
and unstable carotid plaque with high sensitivity and specificity. Thus the work in Chapter 4 
established a methodology for biomarker discovery using an integrative genomics approach and 
identified novel candidate risk biomarkers for ischaemic stroke.  
 
 
5.1 A Journey through the Molecular Mechanisms Underlying Ischaemic Stroke 
The work detailed in this thesis has highlighted a number of key processes in the development of 
ischaemic stroke, from the involvement of cytoskeletal organisation and extracellular matrix 
remodelling in carotid plaque instability and rupture, to the role of dysregulated lipid metabolism for 
identifying cerebral ischaemic pathophysiology. While these findings are not in themselves unusual, 
they emphasise the significance of these mechanisms in the development of ischaemic stroke. More 
importantly, the work has identified new molecular targets associated with these mechanisms that can 
be further investigated for their potential as novel biomarkers for risk stratification or diagnosis of 
ischaemic stroke.  
 
Systematic review and meta-analysis of the literature demonstrated the possibility of proteins 
involved in lipid metabolism to be used as diagnostic biomarkers for ischaemic stroke, a finding that 
was replicated with the discovery of the ability of ApoC-1 to differentiate cerebral ischaemic events 
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from stroke mimics using a proteomics approach. Furthermore, a recent GWAS found a highly 
significant association of APOC-1 and LDLR with the presence of carotid intima media thickness and 
plaque (Bis et al. 2011), implicating the potential of proteins involved in lipid metabolism to predict 
risk of ischaemic stroke. Thus it is interesting to note that in this thesis, neither transcriptomic nor 
GWAS analysis identified a highly significant association of APOC-1 or indeed any lipid metabolism-
related gene with symptomatic carotid stenosis, even after data being subjected to functional 
enrichment analysis. 
 
While lipid metabolism plays a key role in carotid plaque development, the concept of atherosclerosis 
as a passive accumulation of lipid in the arterial wall is outdated, and has been replaced by an 
understanding of the role of lipids in activating a cascade of inflammatory processes (Adibhatla et al. 
2008). Lipoproteins are predominantly synthesised in the liver (rather than locally within an 
atherosclerotic plaque), and it seems that systemic hyperlipidaemia, rather than a local accumulation 
of lipids, is associated with progression of atherosclerosis. Hyperlipidaemia and an increase in 
systemic ApoC-1 result in an accumulation of atherogenic cholesterol-rich remnants in the circulation 
(Björkegren 2006). Using mouse models, Westerterp et al. (2007) demonstrated that systemic ApoC-1 
increased atherosclerosis, while ApoC-1 production by macrophage foam cells within the arterial wall 
did not affect progression of atherosclerosis in vivo.  
 
At the tissue level, lipid-associated proteins could drive the process of plaque destabilisation and 
rupture. At an early stage within the atherosclerotic lesion, infiltrating monocytes differentiate into 
CD68+ macrophage lipid-rich foam cells. These cells have a high expression of ApoC-1 and ApoE, and 
are thought to produce proteases that affect the degradation of the extracellular matrix of the fibrous 
cap and cause plaque instability. As atherosclerosis progresses, vascular smooth muscle cells become 
senescent and undergo apoptosis, a process also thought to be initiated through ApoC-1 and ApoE 
expressing foam cells. Histological examination has found a high correlation between the presence of 
foam cells and the loss of vascular smooth muscle cells near the lipid-rich core, within the shoulder 
area of the atherosclerotic plaque prone to rupture. Thus local ApoC-1 and ApoE are strongly 
associated with the expansion of the necrotic core and destabilisation of the plaque through 
extracellular matrix remodelling (Eo et al. 2011). The failure to find significant associations between 
lipid-related pathways and symptomatic carotid plaque in the gene expression study undertaken in 
Chapter 4 may be due to the high number of dead cells present within the stenosing plaque tissue, 
impeding the examination of high integrity RNA from this region. Furthermore, gene expression 
analysis was based upon whole tissue sections rather than specific cell types; it is therefore possible 
that cell-specific mechanisms responsible for plaque rupture (e.g. apolipoprotein up-regulation in 
foam cells) may have been overlooked. Although GWAS has previously implicated a role for APOC-1 in 
carotid disease (Bis et al. 2011), the slightly different study design undertaken in the GWAS performed 
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in Chapter 4 (studying symptomatic plaque rupture, rather than carotid IMT and plaque progression) 
may account for the lack of lipid-related pathways detected in the study. 
 
Taken together, the findings suggest that lipid metabolism represents a key process in carotid plaque 
destabilisation and ischaemic stroke incidence, both at the systemic and tissue level.  It can be 
hypothesised that the detection of ApoC-1 in Chapter 3 as a candidate diagnostic biomarker for 
cerebral ischaemia represents an underlying systemic hyperlipidaemic state that can differentiate TIA 
and ischaemic stroke patients from stroke mimics. While local lipid-related mechanisms within the 
atherosclerotic lesion could instigate plaque destabilisation and rupture, it is possible that at this late 
stage of atherosclerosis the role of lipid metabolism and apolipoprotein expression is overshadowed 
by the consequent processes of inflammation, cytoskeletal reorganisation and extracellular matrix 
remodelling, as demonstrated in Chapter 4.  
 
 
5.2 A Workflow for Biomarker Discovery From –Omics-Derived Data 
The statistical paradigms used to analyse –omics-derived data depend upon the nature of the data 
generated; for example, the quantitative measures of proteins or gene expression require different 
statistical treatment to allele calls arising from GWAS microarrays (Ghosh & Poisson 2009). 
Nonetheless, the work in this thesis has identified a number of common themes that need to be 
considered in order to facilitate biomarker discovery from –omics data. 
 
5.2.1 Analysis of –Omics-Derived Data 
Firstly, raw data requires pre-processing, application of stringent quality control measures and 
possible normalisation to limit experimental noise. Associations between genes or proteins and the 
phenotype of interest can be assessed using unsupervised or supervised methods. Unsupervised 
exploratory methods, such as PCA, utilise pattern discovery algorithms to understand the structure of 
a dataset, with elements being clustered independent of clinical status and then assessed for 
phenotypic trends. Semi-supervised clustering algorithms can identify gene expression or protein 
groups via functional enrichment analysis, in relationship to prior knowledge e.g. Gene Ontology, 
protein-protein interaction database. These methods can inform on co-expressed genes or co-
regulated proteins and also help infer proteomic regulation from genomic regulation (Alawieh et al. 
2012).  
 
To directly examine the association between genes or proteins and a phenotype, statistical models and 
hypothesis testing can be used e.g. via Student’s t-test, ANOVA, logistic regression. A number of 
precautions need to be taken during statistical analysis of –omics data. When each element is test 
independently, the issue of multiple comparison testing arises, namely that the number of elements is 
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so large that many spurious statistically significant associations can be expected to occur by chance 
alone. In order to account for this and reduce the number of false positive results, multiple comparison 
correction should be performed e.g. by FDR or Bonferroni correction.  
 
The success of initial biomarker discovery studies lies in the depth of analysis and efficient selection of 
the most promising candidates for investigation. In many biomarker discovery studies, samples are 
often collected out of convenience rather than through a stringent protocol due to limited sample 
availability, which may introduce bias and confounding patterns. While statistical analysis may reveal 
candidate biomarkers of interest, it is imperative that these findings are validated in independent 
cohorts to establish reproducibility. It is also recommended that statistical models adjust for known 
clinical confounding parameters e.g. using univariate ANOVA models, to facilitate the conclusion that 
the candidate biomarker can provide information over and above that which is known by standard 
clinical factors. In heterogeneous disorders such as ischaemic stroke, the inclusion of comprehensive 
clinical and imaging patient data is essential to complement –omics profiling to allow the dissection of 
complex disease mechanisms.  
 
5.2.2 Assessing the Significance of Candidate Biomarkers 
In this thesis, candidate biomarkers have been assessed using standardised mean biomarker 
differences between case and control populations, odds ratios, and sensitivity and specificity analysis. 
Each of these methods requires careful interpretation in order to understand the true value of the 
biomarker under investigation. 
 
Pepe et al. (2004) maintain that while most epidemiological studies use odds ratios to assess 
biomarker association to disease, odds ratios do not themselves characterise the discriminatory 
capacity of a biomarker. This could explain why, despite strong associations reported in the literature 
for many ischaemic stroke biomarkers, few were found to be significant upon meta-analysis in Chapter 
2. Even markers with strong association e.g. CRP and glucose, did not exhibit adequate classification 
potential upon closer examination. Similarly, Pepe et al. (2004) describe the relationship between 
odds ratio and the AUC and demonstrate that an odds ratio of 3 may have little impact on the ROC 
curve, suggesting that an odds ratio of 16 (corresponding to AUC ~0.84) may be needed to achieve 
reasonable classification between cases and controls. They stipulate that biomarkers proposed for 
diagnosis or predicting risk in individual subjects must be held to a much higher standard than mere 
association with disease, and recommend that biomarker sensitivity and specificity should be 
assessed.  
 
In Chapter 3 and Chapter 4, the diagnostic value of ApoC-1 and risk prediction value of LTBP4 were 
examined using ROC curves and AUC statistics. Both were found to demonstrate relatively high 
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sensitivity and specificity, indicating their clinical potential as biomarkers. Nonetheless, these analyses 
were based upon limited sample numbers and require robust validation. It is often also taken for 
granted that the sensitivity and specificity of a biomarker test are not subject to alteration. However, 
these properties are very much dependent upon the population in which they are utilised. For 
example, the sensitivity of a test is likely to be greater in severe rather than mild cases of a disease, 
while specificity is dependent upon characteristics of control cases such as age, gender or the 
prevalence of associated risk factors (Cook 2007). Similarly, positive and negative predictive values 
are reliant upon study design (Elwood 2002; Pearl 2002; Rockhill 2002). Hence the value of a 
biomarker test needs to be evaluated within the context in which it is used.  
 
 
5.3 Future Directions 
Morrow and de Lemos (2007) recommended three main criteria that novel biomarkers should meet: 
1) easy measurement by the clinician and 2) addition of valuable new information which 3) allows 
more effective disease management.  
 
The work detailed in this thesis has led to the identification of candidate biomarkers of ischaemic 
stroke. However, these findings represent only the first steps of a long journey into the development of 
clinically relevant biomarker tests. The Early Detection Research Network (Pepe et al. 2001) describes 
five phases of biomarker development, of which the first phase – exploratory research – has been 
pursued in this thesis. The next four phases, mirroring a clinical trials process, include developing an 
assay with clinically reproducible results (phase 2), optimising the time interval in which to screen for 
the biomarker (phase 3), examining biomarker characteristics (phase 4) and assessing whether the 
biomarker tangibly improves clinical practice (phase 5). These experimental phases must now be 
undertaken in order to validate the utility of the candidate biomarkers identified in the thesis. 
 
Identification, qualification, and application of biomarkers remains the holy grail of the current -omics 
paradigm. It may seem that with the emergence of unbiased, –omics approaches to experimental 
design, traditional hypothesis-driven, single molecule-based approaches will soon become outdated. 
On the contrary, the molecular mechanisms underlying candidate biomarkers identified 
through -omics approaches require robust validation using candidate-based techniques and can only 
be understood through hypothesis-based investigation. Thus the two designs should be viewed as 
complimentary tools for biomarker discovery. 
 
Although genomic, transcriptomic and proteomic techniques have been successfully employed in this 
thesis to identify novel candidate biomarkers for ischaemic stroke, the role of these gene, transcript 
and protein components on the organism as a whole remains unclear. Large population-based studies 
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have established that chronic diseases such as cerebrovascular disease occur in a context of 
interaction between multiple genes, environmental risk factors and epigenetic changes (Knox 2010). 
New awareness of the non-linear, complex dynamics of living systems has led to the evolution of 
systems biology, whereby genomic, transcriptomic and proteomic information can be combined to 
understand disease pathophysiology at the level of molecular pathways, regulatory networks, cells, 
tissues, organs and ultimately the whole organism. Thus –omics provide a bottom-up approach for the 
identification and global measurement of molecular components, while systems biology modelling 
provides a top-down approach to form integrative models of disease (Butcher et al. 2004). This holistic 
approach, integrating massive molecular, clinical and pathological data with novel statistical and 
bioinformatics approaches, could have a major impact on the management of ischaemic stroke and 
could pave the way for individualised therapy in the future (Dominiczak et al. 2010). 
 
A rudimentary attempt at systems biology was undertaken in Chapter 4 of this thesis. Nonetheless, a 
true systems biology approach requires a much higher level of computational sophistication. It must 
also be noted that at present, successful biomarker discovery from systems biology approaches 
requires resolution of conceptual as well as practical challenges. Findings from the international 
Encyclopedia of DNA Elements (ENCODE) project have overturned the classic definition of the gene 
and Francis Crick’s ‘central dogma’, as well as highlighting the necessity to appreciate the complexity 
of the genome in experimental study design (Gerstein et al. 2007; Pearson 2006). Protein-coding genes 
comprise less than 2% of the eukaryotic genome and ∼98% of transcriptional output represents non-
coding RNAs (Vemuganti 2010).  Furthermore, recent literature suggests that <40% of cellular protein 
levels can be predicted from mRNA measurements, supporting the conclusion that mRNA levels 
should not be used as surrogates for corresponding protein levels (Kendrick 2012). Given that 
proteins are viewed as the functional molecules primarily driving disease pathogenesis, this 
information queries the use of mRNA expression levels as biomarkers, and emphasises the limitations 
associated with the assumptions made when using an integrative genomics approach. While the 
integration of genetic and protein biomarkers is a promising strategy for stroke management (Piran et 
al. 2012), until the relationships between the genome, transcriptome and phenotype are better 
understood it can be argued that proteins represent the most reliable molecular elements for 
investigating disease association and biomarker discovery. 
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5.4 Final Remarks 
The work in this thesis has confirmed the hypothesis that novel candidate biomarkers for ischaemic 
stroke are amenable to detection, using innovative –omics approaches for biomarker discovery.  The 
studies have generated new hypotheses to test the value of these candidates as relevant risk 
prediction and diagnostic biomarkers for ischaemic stroke. In particular, the work contributes the 
following to the field of biomarker research for ischaemic stroke: 
 
 Highlights existing candidate diagnostic and prognostic biomarkers that demonstrate 
significant association with ischaemic stroke and require additional investigation to evaluate 
clinical utility. 
 Identifies common limitations of biomarker study design and provides guidelines for improved 
biomarker discovery using –omics approaches. 
 Demonstrates that admission glucose level is not a valuable prognostic biomarker for the 
prediction of symptomatic intracerebral haemorrhage following intravenous rt-PA 
thrombolysis for ischaemic stroke, and advocates the extension of the international glucose 
threshold for thrombolysis to beyond 22mmol/L, thus allowing a greater number of patients to 
be considered for treatment. 
 Ascertains the ability to detect novel blood-and tissue-based biomarkers of ischaemic stroke 
by utilising -omics-based approaches to biomarker discovery, and highlights the complexity 
underlying carotid atherosclerosis and ischaemic stroke pathophysiology at both the gene and 
protein level. 
 Reaffirms a key role for lipid metabolism in the development of ischaemic stroke and the 
function of cytoskeletal organisation and extracellular matrix remodelling in determining 
plaque instability. 
 Establishes the need for deeper investigation of alternative splicing mechanisms in driving 
carotid plaque progression and instability. 
 Identifies novel candidate biomarkers that can be employed in single- or multi-panel tests to 
distinguish acute cerebral ischaemia from stroke mimics or predict carotid plaque instability 
and rupture. 
 
In conclusion, this thesis provides the scientific community with new recommendations and 
methodologies for biomarker discovery for ischaemic stroke and identifies novel candidate 
biomarkers for diagnosis and risk stratification. Research is now warranted to further characterise 
these candidate biomarkers and assess their clinical potential. 
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Search Strategy for Systematic Literature Review (Chapter 2) 
 
Diagnostic and Prognostic Biomarkers for Ischaemic stroke 
Modified from Whiteley et al 2008. 
 
1. cerebrovascular disorders OR basal ganglia cerebrovascular disease OR brain ischemia [MeSH 
Term] OR carotid artery diseases OR carotid artery thrombosis OR carotid stenosis OR 
cerebrovascular accident OR brain infarction [MeSH Term] OR intracranial arterial diseases [MeSH 
Term] OR "intracranial embolism and thrombosis" [MeSH Term] 
  
2. (brain [Title/Abstract] OR cerebr* [Title/Abstract] OR cerebell* [Title/Abstract] OR vertebrobasil* 
[Title/Abstract] OR hemispher* [Title/Abstract] OR intracran* [Title/Abstract] OR intracerebral 
[Title/Abstract] OR infratentorial [Title/Abstract] OR intraventricular [Title/Abstract] OR 
supratentorial [Title/Abstract] OR parenchymal [Title/Abstract] OR middle cerebr* [Title/Abstract] 
OR mca* [Title/Abstract] OR anterior circulation [Title/Abstract]) AND (ischemi* [Title/Abstract] OR 
ischaemi* [Title/Abstract] OR infarct* [Title/Abstract] OR thrombo* [Title/Abstract] OR emboli* 
[Title/Abstract] OR occlus* [Title/Abstract] OR hypoxi* [Title/Abstract]) 
  
3. (ischemi* [Title/Abstract] OR ischaemi* [Title/Abstract]) AND (stroke* [Title/Abstract] OR 
apoplex* [Title/Abstract] OR cerebral vasc* [Title/Abstract] OR cerebrovasc* [Title/Abstract] OR cva 
[Title/Abstract] OR attack* [Title/Abstract]) 
  
4. 1 OR 2 OR 3 
  
5. "biological markers" [MeSH Term] 
  
6. biomarker* [Title/Abstract] 
  
7. (biochemical [Title/Abstract] OR clinical [Title/Abstract] OR immun* [Title/Abstract] OR laboratory 
[Title/Abstract] OR biological* [Title/Abstract] OR [Title/Abstract] serum [Title/Abstract] OR 
[Title/Abstract] surrogate [Title/Abstract] OR viral [Title/Abstract]) AND (marker* [Title/Abstract]) 
  
8. (blood [Title/Abstract] OR plasma [Title/Abstract]) AND (marker [Title/Abstract]) 
  
9. Fructose-Bisphosphate Aldolase OR activins OR inhibin-beta subunits OR Inhibins OR Adiponectin 
OR Antiplasmin OR Macroglobulins OR alpha 1-antichymotrypsin OR alpha 1-antitrypsin OR 
Orosomucoid OR Peptidyl-Dipeptidase A OR Fibroblast Growth Factor 2 OR angiotensins OR 
angiotensin i OR angiotensin ii OR angiotensin iii OR Antithrombin III OR apolipoproteins OR 
apolipoproteins a OR apolipoprotein a-i OR apolipoprotein a-ii OR apolipoproteins b OR apolipoprotein 
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b-48 OR apolipoprotein b-100 OR apolipoproteins c OR apolipoprotein c-i OR apolipoprotein c-ii OR 
apolipoproteins d OR apolipoproteins e OR apolipoprotein e2 OR apolipoprotein e3 OR apolipoprotein 
e4 OR beta 2-Glycoprotein I OR Natriuretic Peptide, Brain OR Brain-Derived Neurotrophic Factor OR 
caspases, effector OR caspase 3 OR caspase 6 OR caspase 7 OR caspase 14 OR Cathepsin B OR antigens, 
cd40 OR cd40 ligand OR Ceruloplasmin OR Chitinase OR Cholesterol Ester Transfer Proteins OR 
Chromogranin A OR Clusterin OR Fibronectins OR Chimerin Proteins OR Chimerin 1 OR complement 
system proteins OR anaphylatoxins OR complement activating enzymes OR complement c1 OR 
complement c2 OR complement c3 OR complement c4 OR complement c5 OR complement c6 OR 
complement c7 OR complement c8 OR complement c9 OR complement factor b OR complement 
inactivator proteins OR complement membrane attack complex OR properdin OR C-Reactive Protein 
OR Fibrin Fibrinogen Degradation Products OR phosphopyruvate hydratase OR crystallins OR cell 
adhesion molecules OR antigens, cd22 OR antigens, cd24 OR antigens, cd31 OR antigens, cd146 OR 
antigens, cd164 OR cadherins OR carcinoembryonic antigen OR cd4 immunoadhesins OR cell adhesion 
molecules, neuronal OR integrin alpha beta2 OR intercellular adhesion molecule-1 OR receptors, 
lymphocyte homing OR selectins OR vascular cell adhesion molecule-1 OR endothelins OR endothelin-
1 OR endothelin-2 OR endothelin-3 OR Erythropoietin OR E-Selectin OR Factor XI OR Factor IX OR 
Factor XII OR Factor V OR Factor VII OR Factor VIII OR Factor X OR Factor XIIa OR Interleukins [MeSH 
Term] OR Fibrinogen [MeSH Term] OR Antigens, CD95 OR Ferritins [MeSH Term] OR fibrinopeptide a 
OR fibrinopeptide b OR Fibronectins [MeSH Term] OR Follistatin-Related Proteins [MeSH Term] OR 
Follistatin [MeSH Term] OR Fatty Acids [MeSH Term], Nonesterified OR Glial Fibrillary Acidic Protein 
[MeSH Term]OR Glutathione Transferase [MeSH Term] OR Granulocyte-Macrophage Colony-
Stimulating Factor OR Selectins [MeSH Term] OR Platelet Glycoprotein GPIIb-IIIa Complex OR growth 
hormone OR human growth hormone OR Haptoglobins [MeSH Term] OR Hemopexin OR Heparin 
Cofactor II OR Intercellular Adhesion Molecule-1 [MeSH Term] OR Immunoglobulin G [MeSH Term] OR 
Laminin OR Leptin OR Macrophage Colony-Stimulating Factor OR Malondialdehyde OR matrix 
metalloproteinases [MeSH Term], secreted OR Monocyte Chemoattractant Proteins [MeSH Term] OR 
Myelin Basic Proteins OR Peroxidase OR S100 Proteins [MeSH Term] OR Neurotrophin 3 OR 9 Nitric 
Oxide OR Nucleoside-Diphosphate Kinase OR Aryldialkylphosphatase OR Phosphoglycerate Mutase OR 
Pregnancy-Associated Plasma Protein-A OR Plasminogen Activator Inhibitor 1 OR Plasminogen OR 
Plasminogen Activator Inhibitor 2 OR Platelet Activating Factor OR Antigens, CD31 OR Platelet-
Derived Growth Factor OR Platelet Factor 4 OR Protein C OR Protein S OR Prothrombin OR Resistin OR 
Plasminogen Inactivators OR Platelet Activation OR tau Proteins OR Thrombin OR Thrombomodulin 
OR Thromboplastin OR Tumour Necrosis Factor-Alpha OR Transforming Growth Factor beta OR 
Vascular Endothelial Growth Factor A OR Vitronectin OR von Willebrand Factor 
  
10. Aldolase A [Title/Abstract] OR aldolase b [Title/Abstract] OR aldolase c [Title/Abstract] OR 
fructose bisphosphate aldolase [Title/Abstract] OR activin* [Title/Abstract] OR inhibin* 
[Title/Abstract] OR adiponectin [Title/Abstract] OR adipocyte specific secretory protein 
[Title/Abstract] OR gelatin binding protein [Title/Abstract] OR adipocyte complement related protein 
[Title/Abstract] OR antiplasmin [Title/Abstract] OR Alpha-2-AP [Title/Abstract] OR Alpha-2-PI 
[Title/Abstract] OR plasmin inhibitor [Title/Abstract] OR pigment epithelium derived factor 
[Title/Abstract] OR plasmin inhibitor [Title/Abstract] OR macroglobulin* [Title/Abstract] OR alpha 2 
[Title/Abstract] OR antichymotrypsin [Title/Abstract] OR alpha 1-antichymotrypsin [Title/Abstract] 
OR alpha 1-antitrypsin [Title/Abstract] OR Seromucoid [Title/Abstract] OR sialomucin 
[Title/Abstract] OR alpha 1-acid glycoprotein [Title/Abstract] OR acid seromucoid [Title/Abstract] OR 
acid seromucoid [Title/Abstract] OR acid alpha 1-glycoprotein [Title/Abstract] OR alpha 1 -acid 
glycoprotein [Title/Abstract] OR alpha 1-acid glycoprotein [Title/Abstract] OR alpha 1-glycoprotein 
acid [Title/Abstract] OR angiotensin converting enzyme [Title/Abstract] OR cd143 [Title/Abstract] OR 
cd143 [Title/Abstract] OR kininase ii [Title/Abstract] OR angiotensin i-converting enzyme 
[Title/Abstract] OR carboxycathepsin [Title/Abstract] OR dipeptidyl peptidase [Title/Abstract] OR 
kininase a [Title/Abstract] OR ACE [Title/Abstract] OR kininase 2 [Title/Abstract] OR Dipeptidyl 
carboxypeptidase I [Title/Abstract] OR basic fibroblast growth factor [Title/Abstract] OR fibroblast 
growth factor [Title/Abstract] OR hbgf-2 [Title/Abstract] OR cartilage-derived growth factor 
[Title/Abstract] OR heparin-binding growth factor [Title/Abstract] OR fgf-2 [Title/Abstract] OR fgf2 
 251 
[Title/Abstract] OR fibroblast growth factor-2 [Title/Abstract] OR heparin-binding growth factor 
[Title/Abstract] OR prostate epithelial cell growth factor [Title/Abstract] OR prostatropin 
[Title/Abstract] OR Fibroblast Growth Factor 2 [Title/Abstract] OR heparin-binding growth factor 2 
[Title/Abstract] OR angiotensin* [Title/Abstract] OR antithrombin ii [Title/Abstract] OR heparin 
cofactor i [Title/Abstract] OR at iii [Title/Abstract] OR antithrombin iii [Title/Abstract] OR 
antithrombin iii-alpha [Title/Abstract] OR atenativ [Title/Abstract] OR antithrombin [Title/Abstract] 
OR factor xa inhibitor [Title/Abstract] OR heparin cofactor i [Title/Abstract] OR thrombate iii 
[Title/Abstract] OR antithrombin 3 [Title/Abstract] OR antithrombin-3 [Title/Abstract] OR 
antithrombin iii [Title/Abstract] OR apolipoprotein* [Title/Abstract] OR beta 2 glycoprotein* 
[Title/Abstract] OR beta 2-Glycoprotein I [Title/Abstract] OR brain natriuretic peptide [Title/Abstract] 
OR nesiritide [Title/Abstract] OR b-type natriuretic peptide [Title/Abstract] OR bnp [Title/Abstract] 
OR bnp-32 [Title/Abstract] OR brain natriuretic peptide-32 [Title/Abstract] OR natrecor 
[Title/Abstract] OR natriuretic factor [Title/Abstract] OR natriuretic peptide type-b [Title/Abstract] 
OR type-b natriuretic peptide [Title/Abstract] OR ventricular natriuretic peptide [Title/Abstract] OR 
Brain-Derived Neurotrophic Factor [Title/Abstract] OR casp3 [Title/Abstract] OR apopain 
[Title/Abstract] OR caspase-3 [Title/Abstract] OR procaspase-3 [Title/Abstract] OR procaspase-3 
[Title/Abstract] OR caspase 3 [Title/Abstract] OR cathepsin b-like activity [Title/Abstract] OR 
cathepsin b-like proteinase [Title/Abstract] OR cathepsin b1 [Title/Abstract] OR cathepsin b 
[Title/Abstract] OR amyloid precursor protein secretase [Title/Abstract] OR endoglin* 
[Title/Abstract] OR CD105 [Title/Abstract] OR cd40 [Title/Abstract] OR Bp50 [Title/Abstract] OR 
caeruloplasmin [Title/Abstract] OR caeruloplasmin [Title/Abstract] OR ferroxidase [Title/Abstract] 
OR ceruloplasmin ferroxidase [Title/Abstract] OR ceruloplasmin oxidase [Title/Abstract] OR 
ferroxidase i [Title/Abstract] OR alpha 2 -ceruloplasmin [Title/Abstract] OR endochitinase 
[Title/Abstract] OR chitinase* [Title/Abstract] OR chitotriosidase [Title/Abstract] OR cholesterol ester 
transport protein [Title/Abstract] OR cetp [Title/Abstract] OR cholesteryl ester exchange protein 
[Title/Abstract] OR cholesteryl ester transfer protein [Title/Abstract] OR parathyroid secretory 
protein [Title/Abstract] OR secretory protein i [Title/Abstract] OR Chromogranin A [Title/Abstract] 
OR pancreastatin [Title/Abstract] OR parastatin [Title/Abstract] OR Pituitary secretory protein I 
[Title/Abstract] OR vasostatin [Title/Abstract] OR apoj protein [Title/Abstract] OR apolipoprotein j 
[Title/Abstract] OR complement lysis inhibitor [Title/Abstract] OR complement-associated protein sp-
40,40 [Title/Abstract] OR mac393 antigen [Title/Abstract] OR sgp-2 protein [Title/Abstract] OR sp 
40,40 protein [Title/Abstract] OR sulfated glycoprotein 2 [Title/Abstract] OR sulfated glycoprotein-2 
[Title/Abstract] OR trpm-2 protein [Title/Abstract] OR xip8 protein [Title/Abstract] OR Complement 
cytolysis inhibitor [Title/Abstract] OR clusterin [Title/Abstract] OR cold-insoluble globulins 
[Title/Abstract] OR lets proteins [Title/Abstract] OR fibronectin [Title/Abstract] OR opsonic 
glycoprotein [Title/Abstract] OR opsonic alpha 2 sb glycoprotein [Title/Abstract] OR alpha 2-surface 
binding glycoprotein [Title/Abstract] OR c-fibronectin [Title/Abstract] OR c fibronectin 
[Title/Abstract] OR cellular fibronectin [Title/Abstract] OR -1 chimerin [Title/Abstract] OR -2 
chimerin [Title/Abstract] OR -chimerin [Title/Abstract] OR n-chimerin [Title/Abstract] OR chimaerin 
[Title/Abstract] OR -1 chimaerin [Title/Abstract] OR -2 chimaerin [Title/Abstract] OR -chimaerin 
[Title/Abstract] OR alpha1-chimaerin [Title/Abstract] OR n-chimaerin [Title/Abstract] OR chimerin 
[Title/Abstract] OR chimerin* [Title/Abstract] OR complement [Title/Abstract] OR c reactive protein 
[Title/Abstract] OR c-reactive protein [Title/Abstract] OR CRP [Title/Abstract] OR antithrombin vi 
[Title/Abstract] OR fibrin degradation products [Title/Abstract] OR fibrin fibrinogen split products 
[Title/Abstract] OR Fibrin Fibrinogen Degradation Products [Title/Abstract] OR D-dimer 
[Title/Abstract] OR D dimer [Title/Abstract] OR enolase [Title/Abstract] OR neuron-specific enolase 
[Title/Abstract] OR 2-phospho-d-glycerate hydrolase [Title/Abstract] OR nervous system-specific 
enolase [Title/Abstract] OR non-neuronal enolase [Title/Abstract] OR Phosphopyruvate Hydratase 
[Title/Abstract] OR Neuron specific enolase [Title/Abstract] OR Neurone specific enolase 
[Title/Abstract] OR Neurone-specific enolase [Title/Abstract] OR endothelial protein c receptor 
[Title/Abstract] OR endothelial cell protein c receptor [Title/Abstract] OR protein c receptor 
[Title/Abstract] OR CD201 [Title/Abstract] OR cd106 [Title/Abstract] OR cd106 antigen 
[Title/Abstract] OR vcam-1 [Title/Abstract] OR cd106 [Title/Abstract] OR incam-110 [Title/Abstract] 
OR inducible cell adhesion molecule 110 [Title/Abstract] OR vascular cell adhesion molecule 
[Title/Abstract] OR big endothelin [Title/Abstract] OR big endothelin-1 [Title/Abstract] OR et-1 
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endothelin-1 [Title/Abstract] OR endothelin type 1 [Title/Abstract] OR endothelin [Title/Abstract] OR 
preproendothelin [Title/Abstract] OR preproendothelin-1 [Title/Abstract] OR proendothelin 
[Title/Abstract] OR proendothelin-1 precursor [Title/Abstract] OR Erythropoietin [Title/Abstract] OR 
cd62e [Title/Abstract] OR cd62 [Title/Abstract] OR e selectin [Title/Abstract] OR elam-1 
[Title/Abstract] OR endothelial leukocyte adhesion molecule-1 [Title/Abstract] OR lecam-2 
[Title/Abstract] OR cd62e antigen [Title/Abstract] OR endothelial leukocyte adhesion molecule 1 
[Title/Abstract] OR e-selectin [Title/Abstract] OR selectin e [Title/Abstract] OR autoprothrombin ii 
[Title/Abstract] OR christmas factor [Title/Abstract] OR coagulation factor ix [Title/Abstract] OR ptc 
[Title/Abstract] OR plasma thromboplastin component [Title/Abstract] OR blood coagulation factor ix 
[Title/Abstract] OR factor ix complex [Title/Abstract] OR factor ix [Title/Abstract] OR coagulation 
factor xi [Title/Abstract] OR plasma thromboplastin antecedent [Title/Abstract] OR blood coagulation 
factor xi [Title/Abstract] OR coagulation factor xii [Title/Abstract] OR hageman factor [Title/Abstract] 
OR blood coagulation factor xii [Title/Abstract] OR coagulation factor v [Title/Abstract] OR 
proaccelerin [Title/Abstract] OR ac globulin [Title/Abstract] OR blood coagulation factor v 
[Title/Abstract] OR factor pi [Title/Abstract] OR factor v [Title/Abstract] OR factor ix [Title/Abstract] 
OR factor xii [Title/Abstract] OR factor xi [Title/Abstract] OR coagulation factor vii [Title/Abstract] OR 
proconvertin [Title/Abstract] OR stable factor [Title/Abstract] OR blood coagulation factor vii 
[Title/Abstract] OR factor vii [title/abstract] or antihemophilic factor [title/abstract] or coagulation 
factor viii [title/abstract] or factor viii clotting antigen [title/abstract] or factor viii coagulant antigen 
[title/abstract] or factor viii procoagulant activity [title/abstract] or thromboplastinogen 
[title/abstract] or blood coagulation factor viii [title/abstract] or f viii-c [title/abstract] or factor viii-
heavy chain [title/abstract] or factor viiic [title/abstract] or hemofil [title/abstract] or hemofil m 
[title/abstract] or hemophil [title/abstract] or humate-p [title/abstract] or monoclate [title/abstract] 
or factor viii [title/abstract] or autoprothrombin iii [title/abstract] or coagulation factor x 
[title/abstract] or stuart factor [title/abstract] or stuart-prower factor [title/abstract] or blood 
coagulation factor x [title/abstract] or stuart prower factor [title/abstract] or factor vii activating 
protease [title/abstract] or coagulation factor xiia [title/abstract] or factor xii [title/abstract] or 
activated factor xii [title/abstract] or blood coagulation factor xii [title/abstract] or hageman-factor 
fragments [title/abstract] or prekallikrein activator [title/abstract] or factor xiia [title/abstract] or 
interleukin [title/abstract] or fibrinogen [title/abstract] or coagulation factor i [title/abstract] or 
factor i [title/abstract] or blood coagulation factor [title/abstract] or -fibrinogen [title/abstract] or 
apo-1 antigen [title/abstract] or apoptosis antigen 1 [title/abstract] or cd95 antigens [title/abstract] 
or fas [title/abstract] or tumor necrosis factor receptor superfamily [title/abstract] or fas antigens 
[title/abstract] or fas receptors [title/abstract] or cd95 antigen [title/abstract] or tnfrsf6 receptor 
[title/abstract] or fas antigen [title/abstract] or fas receptor [title/abstract] or basic isoferritin 
[title/abstract] OR ferritin [Title/Abstract] OR isoferritin [Title/Abstract] OR fibrinopeptide 
[Title/Abstract] OR cold-insoluble globulins [Title/Abstract] OR lets proteins [Title/Abstract] OR 
fibronectin [Title/Abstract] OR opsonic glycoprotein [Title/Abstract] OR opsonic alpha 2 sb 
glycoprotein [Title/Abstract] OR alpha 2-surface binding glycoprotein [Title/Abstract] OR activin-
binding protein [Title/Abstract] OR follistatin [Title/Abstract] OR fatty acids [Title/Abstract] OR free 
fatty acids [Title/Abstract] OR nefa [Title/Abstract] OR glial fibrillary acidic protein [Title/Abstract] 
OR GFAP [Title/Abstract] OR glial intermediate filament protein [Title/Abstract] OR astroprotein 
[Title/Abstract] OR gfa-protein [Title/Abstract] OR glial fibrillary acid protein [Title/Abstract] OR 
glutathione s-alkyltransferase [Title/Abstract] OR glutathione s-aryltransferase [Title/Abstract] OR 
glutathione s-epoxidetransferase [Title/Abstract] OR ligandins [Title/Abstract] OR glutathione organic 
nitrate ester reductase [Title/Abstract] OR glutathione s-transferase [Title/Abstract] OR glutathione s-
transferase 3 [Title/Abstract] OR glutathione s-transferase a [Title/Abstract] OR glutathione s-
transferase b [Title/Abstract] OR glutathione s-transferase c [Title/Abstract] OR glutathione s-
transferase iii [Title/Abstract] OR glutathione s-transferase p [Title/Abstract] OR glutathione 
transferase e [Title/Abstract] OR glutathione transferase mu [Title/Abstract] OR glutathione 
transferases [Title/Abstract] OR heme transfer protein [Title/Abstract] OR ligandin [Title/Abstract] 
OR csf-gm [Title/Abstract] OR colony-stimulating factor [Title/Abstract] OR gm-csf [Title/Abstract] 
OR histamine-producing cell-stimulating factor [Title/Abstract] OR csf-2 [Title/Abstract] OR 
granulocyte macrophage colony stimulating factor [Title/Abstract] OR cd62p [Title/Abstract] OR 
cd62p antigens [Title/Abstract] OR gmp-140 [Title/Abstract] OR p selectin [Title/Abstract] OR 
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platelet -granule membrane protein [Title/Abstract] OR cd62p antigen [Title/Abstract] OR padgem 
[Title/Abstract] OR cd62l [Title/Abstract] OR cd62l antigens [Title/Abstract] OR lecam-1 
[Title/Abstract] OR cd62l antigen [Title/Abstract] OR l selectin [Title/Abstract] OR lam-1 
[Title/Abstract] OR leu-8 antigen [Title/Abstract] OR leukocyte adhesion molecule [Title/Abstract] OR 
mel-14 antigen [Title/Abstract] OR tq1 antigen [Title/Abstract] OR cd62e [Title/Abstract] OR cd62e 
antigen [Title/Abstract] OR e selectin [Title/Abstract] OR endothelial leukocyte adhesion molecule-1 
[Title/Abstract] OR lecam-2 [Title/Abstract] OR cd62e antigen [Title/Abstract] OR endothelial 
leukocyte adhesion molecule 1 [Title/Abstract] OR gp130 [Title/Abstract] OR sgp130 [Title/Abstract] 
OR interleukin 11 receptor [Title/Abstract] OR gpiib-iiia receptors [Title/Abstract] OR integrin 
alphaiibbeta3 [Title/Abstract] OR glycoproteins iib-iiia [Title/Abstract] OR pituitary growth hormone 
[Title/Abstract] OR somatotropin [Title/Abstract] OR growth hormone [Title/Abstract] OR 
haptoglobin [Title/Abstract] OR hemopexin [Title/Abstract] OR hemopexin [Title/Abstract] OR 
heparin cofactor ii [Title/Abstract] OR cd54 [Title/Abstract] OR cd54 antigens [Title/Abstract] OR 
icam-1 [Title/Abstract] OR cd54 antigen [Title/Abstract] OR intercellular adhesion molecule 1 
[Title/Abstract] OR gamma globulin 7s [Title/Abstract] OR igg [Title/Abstract] OR allerglobuline 
[Title/Abstract] OR igg t [Title/Abstract] OR igg1 [Title/Abstract] OR igg2 [Title/Abstract] OR igg2a 
[Title/Abstract] OR igg2b [Title/Abstract] OR igg3 [Title/Abstract] OR igg4 [Title/Abstract] OR 
immunoglobulin [Title/Abstract] OR polyglobin [Title/Abstract] OR immunoglobulin g 
[Title/Abstract] OR insulin [Title/Abstract] OR ischemia modified albumin [Title/Abstract] OR 
merosin [Title/Abstract] OR glycoprotein gp-2 [Title/Abstract] OR laminin m [Title/Abstract] OR 
laminin m chain [Title/Abstract] OR laminin [Title/Abstract] OR leptin [Title/Abstract] OR ob protein 
[Title/Abstract] OR obese protein [Title/Abstract] OR ob gene product [Title/Abstract] OR obese gene 
product [Title/Abstract] OR lipoprotein associated phospholipase [Title/Abstract] OR lipoprotein 
lipase [Title/Abstract] OR csf-1 [Title/Abstract] OR csf-m [Title/Abstract] OR colony-stimulating factor 
1 [Title/Abstract] OR colony-stimulating factor [Title/Abstract] OR m-csf [Title/Abstract] OR 
macrophage colony stimulating factor [Title/Abstract] OR malonaldehyde [Title/Abstract] OR 
propanedial [Title/Abstract] OR malonylaldehyde [Title/Abstract] OR malonyldialdehyde 
[Title/Abstract] OR sodium malondialdehyde [Title/Abstract] OR Malondialdehyde [Title/Abstract] 
OR interstitial collagenase [Title/Abstract] OR mmp-1 [Title/Abstract] OR mmp1 metalloproteinase 
[Title/Abstract] OR matrix metalloproteinase-1 [Title/Abstract] OR promatrix metalloproteinase-1 
[Title/Abstract] OR promatrixmetalloproteinase-1 [Title/Abstract] OR prommp-1 [Title/Abstract] OR 
matrix metalloproteinase 1 [Title/Abstract] OR gelatinase a [Title/Abstract] OR 72-kda gelatinase 
[Title/Abstract] OR 72-kda type iv collagenase [Title/Abstract] OR mmp2 [Title/Abstract] OR mmp2 
metalloproteinase [Title/Abstract] OR matrix metalloproteinase-2 [Title/Abstract] OR matrix 
metalloproteinase 2 [Title/Abstract] OR stromelysin 1 [Title/Abstract] OR transin [Title/Abstract] OR 
mmp-3 metalloproteinase [Title/Abstract] OR stromelysin [Title/Abstract] OR matrix 
metalloproteinase 3 [Title/Abstract] OR gelatinase b [Title/Abstract] OR 92-kda gelatinase 
[Title/Abstract] OR 92-kda type iv collagenase [Title/Abstract] OR mmp-9 metalloproteinase 
[Title/Abstract] OR mmp9 metalloproteinase [Title/Abstract] OR matrix metalloproteinase-9 
[Title/Abstract] OR matrix metalloproteinase 9 [Title/Abstract] OR metallopeptidase 9 
[Title/Abstract] OR monocyte chemoattractant protein-1 [Title/Abstract] OR myelin basic protein 
[Title/Abstract] OR encephalitogenic basic proteins [Title/Abstract] OR encephalitogenic basic protein 
[Title/Abstract] OR neuritogenic protein [Title/Abstract] OR myeloperoxidase [Title/Abstract] OR 
hemi-myeloperoxidase [Title/Abstract] OR Peroxidase [Title/Abstract] OR antigen s 100 
[Title/Abstract] OR nerve tissue protein s 100 [Title/Abstract] OR s-100 protein [Title/Abstract] OR 
s100 protein family [Title/Abstract] OR s 100 [Title/Abstract] OR ngf-2 [Title/Abstract] OR nerve 
growth factor 2 [Title/Abstract] OR neurotrophin 3 [Title/Abstract] OR neutrophil gelatinase 
associated lipocalin [Title/Abstract] OR neutrophil protease 4 [Title/Abstract] OR gdp kinase 
[Title/Abstract] OR nucleoside diphosphokinases [Title/Abstract] OR nucleoside-diphosphate kinases 
[Title/Abstract] OR oxidized ldl [Title/Abstract] OR osteoprotogerin [Title/Abstract] OR aryl-dialkyl 
phosphatase [Title/Abstract] OR homocysteine thiolactone hydrolase [Title/Abstract] OR opa 
anhydrase [Title/Abstract] OR oph enzyme [Title/Abstract] OR organophosphorus acid anhydrase 
[Title/Abstract] OR organophosphorus acid anhydrolase [Title/Abstract] OR organophosphorus acid 
hydrolase [Title/Abstract] OR organophosphorus hydrolase [Title/Abstract] OR paraoxonase 
[Title/Abstract] OR paraoxonase-1 [Title/Abstract] OR paraoxonase-2 [Title/Abstract] OR 
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phosphoglyceromutase [Title/Abstract] OR phosphoglycerate phosphomutase [Title/Abstract] OR 
phosphoglycerate mutase [Title/Abstract] OR papp-a [Title/Abstract] OR igfbp-4 metalloproteinase 
[Title/Abstract] OR igfbp-4 protease [Title/Abstract] OR insulin-like-growth factor binding protein-4 
protease [Title/Abstract] OR pregnancy associated alpha plasma protein [Title/Abstract] OR 
pregnancy-associated -plasma protein [Title/Abstract] OR pregnancy associated plasma protein a 
[Title/Abstract] OR profibrinolysin [Title/Abstract] OR glu-plasminogen [Title/Abstract] OR glutamic 
acid 1-plasminogen [Title/Abstract] OR glutamyl plasminogen [Title/Abstract] OR agepc 
[Title/Abstract] OR acetyl glyceryl ether phosphorylcholine [Title/Abstract] OR paf-acether 
[Title/Abstract] OR platelet aggregating factor [Title/Abstract] OR platelet aggregation enhancing 
factor [Title/Abstract] OR platelet-activating substance [Title/Abstract] OR thrombocyte aggregating 
activity [Title/Abstract] OR platelet activating factor [Title/Abstract] OR cd31 antigens 
[Title/Abstract] OR pecam-1 [Title/Abstract] OR platelet endothelial cell adhesion molecule-1 
[Title/Abstract] OR cd31 antigen [Title/Abstract] OR platelet derived microvesicles [Title/Abstract] 
OR platelet derived growth factor [Title/Abstract] OR antiheparin factor [Title/Abstract] OR pf 4 
[Title/Abstract] OR heparin neutralizing protein [Title/Abstract] OR pf4 [Title/Abstract] OR -
thromboglobulin [Title/Abstract] OR prorenin [Title/Abstract] OR Protein C [Title/Abstract] OR 
Protein S [Title/Abstract] OR Protein Z [Title/Abstract] OR coagulation factor ii [Title/Abstract] OR 
factor ii [Title/Abstract] OR blood coagulation factor ii [Title/Abstract] OR differentiation reversal 
factor [Title/Abstract] OR prothrombin [Title/Abstract] OR resistin [Title/Abstract] OR RAGE 
[Title/Abstract] OR secretagogin [Title/Abstract] OR plasminogen activator inhibitors [Title/Abstract] 
OR bae-pai [Title/Abstract] OR endothelial plasminogen activator inhibitor [Title/Abstract] OR 
plasminogen activator inhibitor [Title/Abstract] OR platelet activation [Title/Abstract] OR PARK 
[Title/Abstract] OR SCD40L [Title/Abstract] OR Tau [Title/Abstract] OR thrombase [Title/Abstract] 
OR thrombinar [Title/Abstract] OR thrombostat [Title/Abstract] OR -thrombin [Title/Abstract] OR 
thrombin [Title/Abstract] OR thrombin-antithrombin complex [Title/Abstract] OR Thrombomodulin 
[Title/Abstract] OR cd142 [Title/Abstract] OR coagulation factor iii[Title/Abstract] OR factor iii 
[Title/Abstract] OR tissue factor [Title/Abstract] OR tissue thromboplastin [Title/Abstract] OR blood 
coagulation factor [Title/Abstract] OR coagulin [Title/Abstract] OR glomerular procoagulant activity 
[Title/Abstract] OR prothrombinase [Title/Abstract] OR tissue factor procoagulant [Title/Abstract] OR 
urothromboplastin [Title/Abstract] OR thromboplastin [Title/Abstract] OR tissue factor pathway 
inhibitor [Title/Abstract] OR tissue inhibitor of metalloproteinase [Title/Abstract] OR cachectin 
[Title/Abstract] OR tnf-alpha [Title/Abstract] OR tumor necrosis factor ligand superfamily 
[Title/Abstract] OR cachectin-tumor necrosis factor [Title/Abstract] OR tnf superfamily 
[Title/Abstract] OR tumor necrosis factor [Title/Abstract] OR bone-derived transforming growth 
factor [Title/Abstract] OR platelet transforming growth factor [Title/Abstract] OR tgf-beta 
[Title/Abstract] OR milk growth factor [Title/Abstract] OR tgfbeta [Title/Abstract] OR Transforming 
Growth Factor beta [Title/Abstract] OR ubiquitin fusion degradation protein 1 [Title/Abstract] OR 
Vascular Endothelial Growth Factor A [Title/Abstract] OR vascular endothelial growth factor 
[Title/Abstract] OR vascular endothelial growth factor-a [Title/Abstract] OR gd-vegf [Title/Abstract] 
OR glioma-derived vascular endothelial cell growth factor [Title/Abstract] OR vegf [Title/Abstract] OR 
vegf-a [Title/Abstract] OR vascular permeability factor [Title/Abstract] OR vasculotropin 
[Title/Abstract] OR vitronectin [Title/Abstract] OR factor viii-related antigen [Title/Abstract] OR f viii-
vwf [Title/Abstract] OR factor viiir-ag [Title/Abstract] OR factor viiir-rco [Title/Abstract] OR plasma 
factor viii complex [Title/Abstract] OR ristocetin cofactor [Title/Abstract] OR ristocetin-willebrand 
factor [Title/Abstract] OR vwf ag [Title/Abstract] OR von willebrand protein [Title/Abstract] OR von 
Willebrand Factor 
  
11. DIAGNOSIS: Diagnos* [Title/Abstract] OR sensitivity [Title/Abstract] OR specificity 
[Title/Abstract] OR odds ratio [Title/Abstract] OR likelihood ratio [Title/Abstract] OR LR 
[Title/Abstract] 
11. PROGNOSIS: Incidence [Title/Abstract] OR mortality [MeSH term] OR follow up studies OR 
mortality OR prognos* [Title/Abstract] OR predict* [Title/Abstract] OR course [Title/Abstract] OR 
rankin [Title/Abstract] OR Glasgow outcome scale [Title/Abstract] OR NIHSS [Title/Abstract] 
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12. #5 OR #6 OR #7 OR #8 OR #9 OR #10 
  
13. #4 AND #11 AND #12 
  
14. Limit #13 to humans 
  
 256 
Biomarkers for Prognosis After Thrombolysis 
 
1.thrombolytic therapy [Title/Abstract] OR thromboly* [Title/Abstract]  OR fibrinoly* [Title/Abstract] 
OR fibrinolytic agents [Title/Abstract] OR plasmin [Title/Abstract] OR plasminogen [Title/Abstract] 
OR tPA [Title/Abstract]  OR t-PA [Title/Abstract] OR rtPA [Title/Abstract] OR rt-PA [Title/Abstract] 
OR recanalisation [Title/Abstract]  OR clot lysis [Title/Abstract]   
 
2. plasminogen activators [MeSH Term] 
 
3. intracranial embolism [MeSH Term] OR thrombosis [MeSH Term] OR Thromboembolism [MeSH 
Term] 
 
4. 1 OR 2 OR 3 
 
5. "biological markers" [MeSH Term] 
  
6. biomarker* [Title/Abstract] 
  
7. (biochemical [Title/Abstract] OR clinical [Title/Abstract] OR immun* [Title/Abstract] OR laboratory 
[Title/Abstract] OR biological* [Title/Abstract] OR [Title/Abstract] serum [Title/Abstract] OR 
[Title/Abstract] surrogate [Title/Abstract] OR viral [Title/Abstract]) AND (marker* [Title/Abstract]) 
  
8. (blood [Title/Abstract] OR plasma [Title/Abstract]) AND (marker [Title/Abstract]) 
 
9. incidence [Title/Abstract] OR mortality [MeSH term] OR follow up studies OR mortality OR 
prognos* [Title/Abstract] OR predict* [Title/Abstract] OR course [Title/Abstract] OR rankin 
[Title/Abstract] OR Glasgow outcome scale [Title/Abstract] OR NIHSS [Title/Abstract] 
 
10. #5 OR #6 OR #7 OR #8  
  
11. #4 AND #9 AND #10 
  
12. Limit #11 to humans 
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Putative Biomarkers Identified from the Pilot Study (Chapter 3) 
 
 
 
 
 
 
Appendix 2: Box and whisker plots of putative diagnostic biomarkers identified from the pilot study. Six protein ions 
from the pilot study were selected as ‘putative markers’ from the pilot study. Protein ions were captured using binding 
conditions of pH4 (m/z 4163, m/z 6640), pH6 (m/z 3888, m/z 3208, m/z 3416) and pH8 (m/z 7019), on CM10 ProteinArray 
chips with SPA matrix. The putative markers were selected based upon visual inspection of their ability to distinguish 
between study groups, as well as degree of significance (Wilcoxon Signed Rank test p-value) and fold difference between 
study groups. Box and whisker plots depict mean relative ion intensity +/- two standard deviations. Associated data is 
detailed in Table 3.2. 
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PCA Analysis of Training Set Data (Chapter 3) 
 
 
 
Appendix 3: Unsupervised analysis of Training Set data by principal component analysis (PCA).  Unsupervised analysis 
of all protein ions obtained at pH4 binding conditions from the Training Set data (comprising 20 AIS patients, 10 TIA patients 
and 10 stroke mimics) performed on a number of demographic variables (admission NIHSS, time of blood sampling,, history 
of MI, stroke or TIA and gender) did not demonstrate an ability for classification exhibited by diagnosis (Figure 3,5). This 
indicated that differential protein ion expression can be useful for patient diagnostic classification, independent of other 
confounding variables. 
  
 
